0000950170-24-12233110-Q MYOMO, INC. 20241106202411061615231615241615241524 0 0000950170-24-122331 10-Q 59 20240930 20241106 20241106 MYOMO, INC. 0001369290 3842 000000000 DE 1231 10-Q 34 001-38109 241431153 137 PORTLAND STREET 4TH FLOOR BOSTON MA 02114 617-996-9058 137 PORTLAND STREET 4TH FLOOR BOSTON MA 02114 MYOMO INC 20060718 10-Q 1 myo-20240930.htm 10-Q 10-Q false0001369290--12-31Q3nono00013692902023-01-172023-01-170001369290us-gaap:GeographicConcentrationRiskMemberstpr:DEus-gaap:SalesRevenueProductLineMember2024-01-012024-09-300001369290myo:ATMFacilityMember2022-08-022022-08-020001369290us-gaap:RetainedEarningsMember2024-09-300001369290us-gaap:CommonStockMember2023-06-3000013692902024-09-300001369290us-gaap:SalesRevenueProductLineMemberstpr:DEus-gaap:GeographicConcentrationRiskMember2023-07-012023-09-300001369290myo:AccumulatedComprehensiveIncomeMember2024-09-300001369290us-gaap:LicenseMembercountry:USus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2023-01-012023-09-300001369290myo:ATMFacilityMember2024-07-012024-09-300001369290us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001369290us-gaap:SellingAndMarketingExpenseMember2023-01-012023-09-300001369290us-gaap:CommonStockMember2023-07-012023-09-300001369290myo:ATMFacilityMember2023-01-012023-09-300001369290us-gaap:RevolvingCreditFacilityMembermyo:LoanAndSecurityAgreementMembersrt:MaximumMember2024-07-110001369290srt:MaximumMember2024-09-3000013692902024-01-012024-09-300001369290myo:LicenseRevenueMember2023-01-012023-09-300001369290myo:AccumulatedComprehensiveIncomeMember2024-07-012024-09-300001369290us-gaap:SalesRevenueNetMembermyo:PatientsWithMedicareAdvantageInsurancePlansMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300001369290us-gaap:RetainedEarningsMember2024-06-300001369290myo:AccumulatedComprehensiveIncomeMember2024-06-300001369290us-gaap:LicenseMember2023-01-012023-09-300001369290myo:BeijingMedicalInvestmentCoLtdMember2024-01-012024-09-300001369290us-gaap:TreasuryStockCommonMember2023-03-310001369290us-gaap:FairValueInputsLevel1Member2024-09-300001369290us-gaap:AccountsReceivableMember2023-01-012023-12-310001369290us-gaap:DirectorsAndOfficersLiabilityInsuranceMember2023-04-012023-06-300001369290us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001369290myo:LoanAndSecurityAgreementMembersrt:MaximumMember2024-07-112024-07-110001369290myo:LicenseRevenueMember2024-07-012024-09-300001369290myo:DirectToPatientMember2024-07-012024-09-300001369290us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001369290us-gaap:RetainedEarningsMember2023-06-3000013692902022-12-310001369290us-gaap:RevolvingCreditFacilityMembermyo:LoanAndSecurityAgreementMember2024-07-110001369290us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-07-012024-09-300001369290us-gaap:SalesRevenueNetMembermyo:PatientsWithMedicareAdvantageInsurancePlansMemberus-gaap:CustomerConcentrationRiskMember2024-07-012024-09-300001369290us-gaap:CommonStockMember2024-07-012024-09-300001369290us-gaap:MoneyMarketFundsMember2024-09-300001369290myo:OneInsurerMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001369290us-gaap:CommonStockMember2022-12-310001369290us-gaap:MoneyMarketFundsMember2023-12-310001369290us-gaap:SalesRevenueProductLineMemberus-gaap:GeographicConcentrationRiskMembercountry:US2024-07-012024-09-300001369290us-gaap:RetainedEarningsMember2023-01-012023-03-310001369290us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2023-12-310001369290us-gaap:ProductMember2024-01-012024-09-300001369290us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001369290us-gaap:RetainedEarningsMember2024-01-012024-03-310001369290us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-3000013692902023-08-292023-08-290001369290myo:TwoThousandAndEighteenStockOptionAndIncentivePlanMember2024-01-012024-09-300001369290country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2023-01-012023-09-300001369290us-gaap:AdditionalPaidInCapitalMember2024-03-310001369290us-gaap:RetainedEarningsMember2024-07-012024-09-300001369290myo:PreFundedWarrantsMember2024-01-012024-03-310001369290us-gaap:CommonStockMember2023-09-300001369290us-gaap:ThirdPartyPayorMember2023-01-012023-09-300001369290us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-09-300001369290us-gaap:ThirdPartyPayorMember2024-01-012024-09-3000013692902023-01-170001369290myo:OtherInternationalLocationsMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2024-01-012024-09-300001369290myo:LoanAndSecurityAgreementMember2024-07-110001369290srt:MaximumMembermyo:ATMFacilityMember2022-08-022022-08-020001369290myo:ATMFacilityMember2023-07-012023-09-300001369290myo:LicenseRevenueMember2024-01-012024-09-300001369290myo:AccumulatedComprehensiveIncomeMember2023-03-310001369290myo:LicenseRevenueMember2023-07-012023-09-300001369290us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001369290us-gaap:AdditionalPaidInCapitalMember2022-12-310001369290us-gaap:TreasuryStockCommonMember2024-06-300001369290us-gaap:SalesRevenueNetMembermyo:PatientsWithMedicareAdvantageInsurancePlansMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-3000013692902024-03-310001369290us-gaap:SalesRevenueNetMember2024-07-012024-09-3000013692902024-11-010001369290us-gaap:CostOfSalesMember2024-01-012024-09-300001369290us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2024-09-300001369290us-gaap:LicenseMember2023-07-012023-09-300001369290us-gaap:ProductMember2023-07-012023-09-300001369290us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-3000013692902023-03-310001369290us-gaap:SalesRevenueNetMembermyo:PatientsWithMedicarePartBCoverageMemberus-gaap:CustomerConcentrationRiskMember2024-07-012024-09-300001369290us-gaap:LicenseMember2024-01-012024-09-300001369290us-gaap:ProductMember2024-07-012024-09-300001369290us-gaap:DirectorsAndOfficersLiabilityInsuranceMember2024-06-300001369290myo:AccumulatedComprehensiveIncomeMember2023-04-012023-06-300001369290us-gaap:SalesRevenueNetMembermyo:PatientsWithMedicarePartBCoverageMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300001369290us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001369290us-gaap:SalesRevenueNetMember2024-01-012024-09-300001369290us-gaap:CommonStockMember2024-04-012024-06-300001369290myo:LoanAndSecurityAgreementMember2024-07-112024-07-110001369290us-gaap:SalesRevenueNetMembermyo:OneUSInsurancePayerMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300001369290myo:AccumulatedComprehensiveIncomeMember2023-07-012023-09-300001369290us-gaap:AdditionalPaidInCapitalMember2023-12-310001369290myo:PreFundedWarrantsMember2023-09-300001369290us-gaap:RetainedEarningsMember2023-03-3100013692902023-09-300001369290myo:AccumulatedComprehensiveIncomeMember2024-01-012024-03-3100013692902023-07-012023-09-300001369290myo:ATMFacilityMember2024-01-012024-09-3000013692902023-06-300001369290us-gaap:TreasuryStockCommonMember2023-09-300001369290us-gaap:CashMember2023-12-310001369290myo:JiangxiMyomoMedicalAssistiveApplianceCoLtdMember2022-03-282022-03-280001369290us-gaap:AccountsReceivableMember2024-01-012024-09-300001369290us-gaap:SalesRevenueNetMember2023-07-012023-09-300001369290us-gaap:AdditionalPaidInCapitalMember2023-09-3000013692902023-12-310001369290myo:OtherWarrantsMember2024-01-012024-09-300001369290myo:PreFundedWarrantsMember2023-07-012023-09-300001369290us-gaap:AdditionalPaidInCapitalMember2023-01-012024-03-310001369290us-gaap:SalesRevenueNetMembermyo:OneUSInsurancePayerMemberus-gaap:CustomerConcentrationRiskMember2024-07-012024-09-300001369290us-gaap:LicenseMember2024-07-012024-09-300001369290us-gaap:SalesRevenueNetMember2023-01-012023-09-300001369290us-gaap:ThirdPartyPayorMember2024-07-012024-09-300001369290us-gaap:CashMember2024-09-300001369290us-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-3000013692902024-07-012024-09-300001369290us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2023-12-310001369290us-gaap:LicenseMemberstpr:DEus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2023-01-012023-09-300001369290us-gaap:ThirdPartyPayorMember2023-07-012023-09-3000013692902023-08-290001369290myo:AccumulatedComprehensiveIncomeMember2023-09-300001369290country:CNus-gaap:SalesRevenueProductLineMemberus-gaap:GeographicConcentrationRiskMember2023-07-012023-09-3000013692902024-06-300001369290myo:PreFundedWarrantsMember2023-01-012023-03-310001369290us-gaap:AdditionalPaidInCapitalMember2024-06-300001369290us-gaap:CommonStockMember2023-04-012023-06-300001369290us-gaap:CostOfSalesMember2023-01-012023-09-300001369290us-gaap:TreasuryStockCommonMember2023-06-300001369290myo:LoanAndSecurityAgreementMember2024-01-012024-09-300001369290us-gaap:SellingAndMarketingExpenseMember2024-01-012024-09-300001369290us-gaap:RetainedEarningsMember2022-12-310001369290us-gaap:CommonStockMember2023-03-310001369290myo:UnderwriterWarrantsMember2024-01-012024-09-300001369290us-gaap:CommercialPaperMember2024-09-300001369290us-gaap:SalesRevenueProductLineMemberus-gaap:GeographicConcentrationRiskMemberstpr:DE2024-07-012024-09-300001369290myo:ClinicalAndMedicalProvidersMember2024-07-012024-09-300001369290us-gaap:RetainedEarningsMember2023-09-300001369290us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300001369290myo:PreFundedWarrantsMember2024-03-310001369290us-gaap:RetainedEarningsMember2023-07-012023-09-3000013692902024-01-012024-03-3100013692902024-01-192024-01-190001369290us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-3000013692902024-07-110001369290us-gaap:TreasuryStockCommonMember2024-03-310001369290us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001369290us-gaap:DirectorsAndOfficersLiabilityInsuranceMember2023-06-300001369290us-gaap:CostOfSalesMember2024-07-012024-09-300001369290us-gaap:DirectorsAndOfficersLiabilityInsuranceMember2024-04-012024-06-300001369290myo:AccumulatedComprehensiveIncomeMember2023-01-012023-03-310001369290us-gaap:TreasuryStockCommonMember2022-12-310001369290us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001369290us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001369290myo:OtherInternationalLocationsMemberus-gaap:SalesRevenueProductLineMemberus-gaap:GeographicConcentrationRiskMember2023-01-012023-09-300001369290us-gaap:GeographicConcentrationRiskMembercountry:USus-gaap:SalesRevenueProductLineMember2024-01-012024-09-300001369290us-gaap:FairValueInputsLevel2Member2023-12-310001369290myo:DirectToPatientMember2023-01-012023-09-300001369290us-gaap:TreasuryStockCommonMember2024-09-300001369290us-gaap:CommonStockMember2024-09-3000013692902024-01-190001369290us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001369290myo:JiangxiMyomoMedicalAssistiveApplianceCoLtdMember2022-03-280001369290us-gaap:CommercialPaperMember2023-12-310001369290us-gaap:AdditionalPaidInCapitalMember2023-03-310001369290myo:AccumulatedComprehensiveIncomeMember2024-04-012024-06-300001369290myo:PreFundedWarrantsMember2023-03-310001369290us-gaap:RetainedEarningsMember2023-12-310001369290us-gaap:CommonStockMember2023-12-310001369290us-gaap:MoneyMarketFundsMember2023-12-310001369290us-gaap:AdditionalPaidInCapitalMember2024-09-300001369290us-gaap:SalesRevenueNetMembermyo:PatientsWithMedicareAdvantageInsurancePlansMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300001369290us-gaap:ProductMember2024-01-012024-09-300001369290myo:DirectToPatientMember2024-01-012024-09-300001369290us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001369290myo:AccumulatedComprehensiveIncomeMember2022-12-310001369290us-gaap:SellingAndMarketingExpenseMember2023-07-012023-09-300001369290us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001369290myo:AccumulatedComprehensiveIncomeMember2023-06-300001369290us-gaap:CommercialPaperMember2023-12-310001369290myo:ClinicalAndMedicalProvidersMember2023-01-012023-09-300001369290us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001369290us-gaap:LicenseMembermyo:OtherInternationalLocationsMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2023-01-012023-09-300001369290us-gaap:CommonStockMember2024-01-012024-03-310001369290myo:AccumulatedComprehensiveIncomeMember2023-12-310001369290us-gaap:CommonStockMember2024-06-300001369290us-gaap:SellingAndMarketingExpenseMember2024-07-012024-09-300001369290stpr:DEus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2023-01-012023-09-300001369290country:USus-gaap:SalesRevenueProductLineMemberus-gaap:GeographicConcentrationRiskMember2023-07-012023-09-300001369290myo:RestrictedCashMember2024-09-300001369290us-gaap:SalesRevenueNetMembermyo:OneUSInsurancePayerMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-3000013692902024-04-012024-06-3000013692902024-08-310001369290myo:ClinicalAndMedicalProvidersMember2023-07-012023-09-300001369290us-gaap:AdditionalPaidInCapitalMember2023-06-300001369290us-gaap:EmployeeStockOptionMember2024-09-300001369290us-gaap:TreasuryStockCommonMember2023-12-310001369290myo:OtherWarrantsMember2023-01-012023-09-300001369290myo:RestrictedCashMember2023-12-310001369290us-gaap:CostOfSalesMember2023-07-012023-09-300001369290us-gaap:RetainedEarningsMember2023-04-012023-06-300001369290country:CNus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueProductLineMember2023-01-012023-09-300001369290us-gaap:MoneyMarketFundsMember2024-09-3000013692902023-01-012023-09-300001369290myo:OneInsurerMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300001369290myo:TwoThousandAndEighteenStockOptionAndIncentivePlanMember2024-09-300001369290us-gaap:RetainedEarningsMember2024-04-012024-06-300001369290myo:DirectToPatientMember2023-07-012023-09-300001369290us-gaap:CommonStockMember2023-01-012023-03-310001369290us-gaap:RevolvingCreditFacilityMembermyo:LoanAndSecurityAgreementMember2024-07-112024-07-110001369290us-gaap:SalesRevenueNetMembermyo:OneUSInsurancePayerMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-3000013692902023-01-012023-03-310001369290myo:AccumulatedComprehensiveIncomeMember2024-03-3100013692902023-04-012023-06-300001369290us-gaap:RetainedEarningsMember2024-03-310001369290us-gaap:CommonStockMember2024-03-310001369290us-gaap:RestrictedStockUnitsRSUMember2024-09-300001369290myo:ClinicalAndMedicalProvidersMember2024-01-012024-09-30xbrli:purexbrli:sharesiso4217:USDxbrli:sharesmyo:Insurermyo:Customeriso4217:USD 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Â FORM 10-Q Â (Mark One) â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 Â MYOMO, INC. (Exact name of Registrant as Specified in its Charter) Â Â Delaware 47-0944526 (State or Other Jurisdiction of (I.R.S. Employer Incorporation or Organization) Â Identification No.) Â Â 137 Portland St., 4th Floor, Boston, Massachusetts 02114 (Address of principal executive offices) (Zip Code) (617) 996-9058 Registrantâ€™s Telephone Number, Including Area Code Securities registered pursuant to Section 12(b) of the Act: Â Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share MYO NYSE American Â Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes: â˜’ No: â˜ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ No â˜ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large accelerated filer â˜ Accelerated filer â˜ Non-accelerated filer â˜’ Smaller reporting company â˜’ Emerging growth company â˜ Â Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes â˜ No â˜’ At November 1, 2024, the registrant has 30,245,870 shares of common stock, par value $0.0001 per share, outstanding. Â Â Â Â Summary of the Material Risks Associated with Our Business Â â€¢We have a history of operating losses. Factors both within and outside of our control could result in a delay in our ability to achieve cash flow breakeven on a quarterly basis. â€¢Our direct billing revenues are concentrated with a small number of payers, including the Centers for Medicare & Medicaid Services, or (â€œCMSâ€). Adverse changes in these payers' reimbursement policies regarding the MyoPro could have an adverse effect on our business. â€¢We currently rely, and in the future will rely, on sales of our MyoPro products for our revenue, and we may not be able to achieve or maintain market acceptance. â€¢We may not be able to maintain adequate levels of third-party payer reimbursement, including reimbursement by Medicare, for our products. â€¢We depend on a single third-party to manufacture key subassemblies for the MyoPro, and a

limited number of third-party suppliers for certain components of the MyoPro. â€¢We sell to orthotics and prosthetics providers and distributors who are free to market products that compete with the MyoPro, and we rely on these distributors to market and promote our products in accordance with their U.S. Food and Drug Administration, or FDA, listings, select appropriate patients and provide adequate follow-on care. â€¢The market for myoelectric braces is new and the rate of adoption is uncertain, and important assumptions about the potential market for our products may be inaccurate. â€¢Defects in our products or the software that drives them could adversely affect the results of our operations. â€¢ We are subject to extensive governmental regulations relating to the design, development, manufacturing, labeling and marketing of our products, and a failure to comply with such regulations could lead to withdrawal or recall of our products from the market. â€¢Our internal computer systems, or those of our customers, collaborators or other contractors, may be subject to cyber-attacks or security breaches, which could result in a material disruption of our product development programs. â€¢ Our success depends in part on our ability to obtain and maintain protection for the intellectual property relating to or incorporated into our products. â€¢ The market price of our common stock has been and may continue to be volatile. â€¢ Since we sell products in several overseas markets, we are subject to foreign currency fluctuations in value, which may reduce our revenue per unit in dollars. Â Â CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q constitutes forward-looking statements. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar matters that are not historical facts. In some cases, you can identify forward-looking statements by terms such as â€œanticipate,â€ â€œbelieve,â€ â€œcould,â€ â€œestimate,â€ â€œexpect,â€ â€œintend,â€ â€œmay,â€ â€œplan,â€ â€œpotential,â€ â€œshould,â€ â€œwillâ€ and â€œwouldâ€ or the negatives of these terms or other comparable terminology. You should not place undue reliance on forward looking statements. The cautionary statements set forth in this Quarterly Report on Form 10-Q, including in â€œRisk Factorsâ€ and elsewhere, identify important factors which you should consider in evaluating our forward-looking statements. These factors include, among other things: â€¢our ability to achieve reimbursement from third-party payers for our products; â€¢our dependence upon external sources for the financing of our operations; â€¢our ability to obtain and maintain our strategic collaborations and to realize the intended benefits of such collaborations; â€¢our ability to effectively execute our business plan; â€¢our ability to maintain and grow our reputation and to achieve and maintain the market acceptance of our products; â€¢our expectations as to our clinical research program and clinical results; â€¢our ability to improve our products and develop new products; â€¢our ability to manage the growth of our operations over time; â€¢our ability to maintain adequate protection of our intellectual property and to avoid violation of the intellectual property rights of others; â€¢our ability to gain and maintain regulatory approvals; â€¢our ability to maintain relationships with existing customers and develop relationships with new customers; â€¢our ability to compete and succeed in a highly competitive and evolving industry; and â€¢other risks and uncertainties, including those listed under the captain â€œRisk Factorsâ€ in this Quarterly Report on Form 10-Q. Although the forward-looking statements in this Quarterly Report on Form 10-Q, are based on our beliefs, assumptions and expectations, taking into account all information currently available to us, we cannot guarantee future transactions, results, performance, achievements or outcomes. No assurance can be made to any investor by anyone that the expectations reflected in our forward-looking statements will be attained, or that deviations from them will not be material and adverse. We undertake no obligation, other than as may be required by law, to re-issue this Quarterly Report on Form 10-Q, or otherwise make public statements updating our forward-looking statements. Â TABLE of CONTENTS PART I. FINANCIAL INFORMATION Â Â Â Â Â Item 1. Financial Statements (interim periods unaudited) Â 1 Â Â Â Condensed Consolidated Balance Sheets at September 30, 2024 and December 31, 2023 (audited) 1 Â Â Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and 2023 2 Â Â Â Â Â Â Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2024 and 2023 Â Â 3 Â Â Â Condensed Consolidated Statements of Changes in Stockholdersâ€™ Equity for the three and nine months ended September 30, 2024 and 2023 4 Â Â Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2024 and 2023 5 Â Â Notes to Unaudited Condensed Consolidated Financial Statements 6 Â Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 17 Â Â Item 3. Quantitative and Qualitative Disclosures About Market Risk 23 Â Â Item 4. Controls and Procedures 23 Â Â PART II. OTHER INFORMATION Â Â Â Â Item 1. Legal Proceedings 24 Â Â Item 1A. Risk Factors 24 Â Â Item 2. Unregistered Sales of Equity Securities and Use of Proceeds from Registered Securities 44 Â Â Item 5 Other Information Â Â 44 Â Â Â Â Item 6. Exhibits 45 Â Â Signatures Â Â 46 Â Â Â Â Part 1. FINANCIAL INFORMATION Item 1. Financial statements MYOMO, INC. CONDENSED CONSOLIDATED BALANCE SHEETS Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Â Â (unaudited) Â Â Â Â ASSETS Â Â Â Â Â Â Current Assets: Â Â Â Â Â Â Cash and cash equivalents Â $ 6,622,675 Â Â $ 6,871,306 Â Short-term investments Â Â â€” Â Â Â 1,994,662 Â Accounts receivable, net Â Â 3,729,387 Â Â Â 2,382,658 Â Inventories, net Â Â 3,383,513 Â Â Â 1,803,507 Â Prepaid expenses and other current assets Â Â 968,569 Â Â Â 598,850 Â Total Current Assets Â Â 14,704,144 Â Â Â 13,650,983 Â Restricted cash Â Â 375,000 Â Â Â â€” Â Operating lease assets with right of use, net Â Â 466,962 Â Â Â 663,554 Â Equipment, net Â Â 561,325 Â Â Â 175,794 Â Other assets Â Â 205,440 Â Â Â 91,237 Â Total Assets Â $ 16,312,871 Â Â $ 14,581,568 Â LIABILITIES AND STOCKHOLDERSâ€™ EQUITY Â Â Â Â Â Â Current Liabilities: Â Â Â Â Â Â Accounts payable and accrued expenses Â Â 6,448,076 Â Â Â 4,885,944 Â Current operating lease liability Â Â 205,464 Â Â Â 486,143 Â Income taxes payable Â Â 305,861 Â Â Â 96,461 Â Deferred revenue Â Â 31,971 Â Â Â 8,510 Â Total Current Liabilities Â Â 6,991,372 Â Â Â 5,477,058 Â Non-current operating lease liability Â Â 29,165 Â Â Â 115,160 Â Total Liabilities Â Â 7,020,537 Â Â Â 5,592,218 Â Commitments and Contingencies Â Â â€” Â Â Â â€” Â Stockholdersâ€™ Equity: Â Â Â Â Â Â Preferred stock, $0.0001Â par value; 10,000,000Â shares authorized; noÂ shares issued or outstanding Â Â â€” Â Â Â â€” Â Common stock par value $0.0001Â per share, 65,000,000Â shares authorized;30,244,182Â and 27,135,061Â shares issued as of September 30, 2024and December 31, 2023, respectively; and 30,244,155Â and 27,135,034shares outstanding at September 30, 2024 and December 31, 2023, respectively Â Â 3,026 Â Â Â 2,715 Â Additional paid-in capital Â Â 111,754,495 Â Â Â 105,840,239 Â Accumulated other comprehensive income Â Â 395,734 Â Â Â 83,669 Â Accumulated deficit Â Â (102,854,457) Â Â (96,930,809) Treasury stock, 27Â shares at cost Â Â (6,464) Â Â (6,464) Total Stockholdersâ€™ Equity Â Â 9,292,334 Â Â Â 8,989,350 Â Total Liabilities and Stockholdersâ€™ Equity Â $ 16,312,871 Â Â $ 14,581,568 Â The accompanying notes are an integral part of the condensed consolidated unaudited financial statements. 1 Â MYOMO, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) Â Â Â For the Three Months ended Â Â For the Nine Months Ended Â Â Â September 30, Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Revenue Â Â Â Â Â Â Â Â Â Â Â Product revenue Â $ 9,207,586 Â Â $ 5,029,523 Â Â $ 20,482,742 Â Â $ 12,719,855 Â License revenue Â Â â€” Â Â Â 50,000 Â Â Â â€” Â Â Â 1,764,920 Â Â Â Â 9,207,586 Â Â Â 5,079,523 Â Â Â 20,482,742 Â Â Â 14,484,775 Â Â Â Â Â Â Â Â Â Â Â Â Cost of revenue Â Â 2,262,031 Â Â Â 1,590,675 Â Â Â 5,912,632 Â Â Â 4,407,270 Â Gross profit Â Â 6,945,555 Â Â Â 3,488,848 Â Â Â 14,570,110 Â Â Â 10,077,505 Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Research and development Â Â 1,248,870 Â Â Â 717,256 Â Â Â 3,212,309 Â Â Â 1,758,480 Â Selling, clinical and marketing Â Â 3,401,182 Â Â Â 2,387,090 Â Â Â 8,540,161 Â Â Â 6,689,578 Â General and administrative Â Â 3,253,056 Â Â Â 2,408,871 Â Â Â 8,779,024 Â Â Â 7,427,818 Â Â Â Â 7,903,108 Â Â Â 5,513,217 Â Â Â 20,531,494 Â Â Â 15,875,876 Â Â Â Â Â Â Â Â Â Â Â Loss from operations Â Â (957,553) Â Â (2,024,369) Â Â (5,961,384) Â Â (5,798,371) Â Â Â Â Â Â Â Â Â Â Â Other (income) expense, net Â Â Â Â Â Â Â Â Â Â Â Interest income, net Â Â (76,020) Â Â (112,300) Â Â (318,555) Â Â (302,053) Other expense, net Â Â â€” Â Â Â 467 Â Â Â â€” Â Â Â 6,098 Â Loss on equity investment Â Â â€” Â Â Â 70,124 Â Â Â â€” Â Â Â 99,840 Â Â Â Â (76,020) Â Â (41,709) Â Â (318,555) Â Â (196,115) Loss before income taxes Â Â (881,533) Â Â (1,982,660) Â Â (5,642,829) Â Â (5,602,256) Income tax expense Â Â 84,876 Â Â Â 46,356 Â Â Â 280,819 Â Â Â 85,204 Â Net loss Â $ (966,409) Â $ (2,029,016) Â $ (5,923,648) Â $ (5,687,461) Â Â Â Â Â Â Â Â Â Â Â Weighted average number of common shares outstanding: Â Â Â Â Â Â Â Â Â Â Â Basic and diluted Â Â 37,950,515 Â Â Â 35,266,361 Â Â Â 37,359,366 Â Â Â 27,537,357 Â Net loss per share attributable to common stockholders Â Â Â Â Â Â Â Â Â Â Â Basic and diluted Â $ (0.03) Â $ (0.06) Â $ (0.16) Â $ (0.21) The accompanying notes are an integral part of the condensed consolidated unaudited financial statements. 2 Â MYOMO, INC. CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (unaudited) Â Â Â For the Three Months Ended Â Â For the Nine Months Ended Â Â Â September 30, Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net loss Â $ (966,409) Â $ (2,029,016) Â $ (5,923,648) Â $ (5,687,461) Other comprehensive income (loss), net of tax: Â Â Â Â Â Â Â Â Â Â Â Foreign currency translation adjustments Â Â 256,354 Â Â Â (47,072) Â Â 311,939 Â Â Â (52,640) Unrealized gain (loss) on short-term investments Â Â 492 Â Â Â (774) Â Â 126 Â Â Â 860 Â Other comprehensive income (loss) Â Â 256,846 Â Â Â (47,846) Â Â 312,065 Â Â Â (51,780) Comprehensive loss Â $ (709,563) Â $ (2,076,862) Â $ (5,611,583) Â $ (5,739,241) Â The accompanying notes are an integral part of the condensed consolidated unaudited financial statements. Â 3 Â MYOMO, INC. CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERSâ€™ EQUITY (unaudited) Â Â For the Three and Nine Months Ended September 30, 2024 and 2023 Â Common stock AdditionalPaid-in Accumulated Comprehensive Accumulated Treasury Stock TotalStockholdersâ€™ Â Shares Amount Capital Income (Loss) Deficit Shares Amount Equity Balance, January 1, 2024 27,135,061 $2,715 $105,840,239 $83,669 $(96,930,809) 27 $(6,464) $8,989,350 Proceeds from sale of common stock in registered direct offering, net of offering costs of $547,257 1,354,218 135 4,598,636 â€” â€” â€” â€” 4,598,771 Proceeds from sale of 224,730Â pre-funded warrants in registered direct offering, net of offering costs of $90,814 â€” â€” 763,138 â€” â€” â€” â€” 763,138 Common stock issued upon vesting of restricted stock units 300,544 31 (31) â€” â€” â€” â€” Stock-based compensation â€” â€” 320,288 â€” â€” â€” â€” 320,288 Other comprehensive income â€” â€” â€” 63,842 â€” â€” â€” 63,842 Net loss â€” â€” â€” â€” (3,835,632) â€” â€” (3,835,632) Balance, March 31, 2024 28,789,823 $2,881 $111,522,270 $147,511 $(100,766,441) 27 $(6,464) $10,899,757 Common stock issued upon vesting of restricted stock units 636,801 63 (63) â€” â€” â€” â€” Stock-based compensation â€” â€” (91,893) â€” â€” â€” (91,893) Exercise of pre-funded warrants 774,730 77 â€” â€” â€” â€” 77 Other comprehensive loss â€” â€” â€” (8,623) â€” â€” â€” (8,623) Net loss â€” â€” â€” â€” (1,121,607) â€” â€” (1,121,607) Balance, June 30, 2024 30,201,354 $3,021 $111,430,314 $138,888 $(101,888,048) 27 $(6,464) $9,677,711 Common stock issued upon vesting of restricted stock units 42,828 4 (4) â€” â€” â€” â€” â€” Stock-based compensation â€” â€” 324,185 â€” â€” â€” â€” 324,185 Other comprehensive income â€” â€” â€” 256,846 â€” â€” â€” 256,846 Net loss â€” â€” â€” â€” (966,409) â€” â€” (966,409) Balance, September 30, 2024 30,244,182 $3,025 $111,754,495 $395,734 $(102,854,457) 27 $(6,464) $9,292,334 Â Â Â Â Â Â Â Â Â Â Balance, January 1, 2023 7,750,635 $775 $95,105,071 $43,227 $(88,783,244) 27 $(6,464) $6,359,365 Common stock issued upon vesting of restricted stock units 2,821 â€” â€” â€” â€” â€” â€” Proceeds from sale of common stock in public offering, net of offering costs of $663,856 13,169,074 1,317 3,614,777 â€” â€” â€” â€” 3,616,094 Proceeds from sale of 6,830,926Â pre-funded warrants, net of offering costs of $155,356 â€” â€” 2,064,012 â€” â€” â€” â€” 2,064,012 Stock-based compensation â€” â€” 171,027 â€” â€” â€” â€” 171,027 Other comprehensive income â€” â€” â€” 65,788 â€” â€” â€” 65,788 Net loss â€” â€” â€” â€” (2,644,295) â€” â€” (2,644,295) Balance, March 31, 2023 20,922,530 $2,092 $100,954,887 $109,015 $(91,427,539) 27 $(6,464) $9,631,991 Common stock issued upon vesting of restricted stock units, net of 16,744Â shares withheld for employee taxes 169,499 18 $(8,165) â€” â€” â€” â€” (8,147) Stock-based compensation â€” â€” 280,061 â€” â€” â€” â€” 280,061 Unrealized loss on foreign currency â€” â€” â€” (71,357) â€” â€” â€” (71,357) Other comprehensive income â€” â€” â€” 1,634 â€” â€” â€” 1,634 Net loss â€” â€” â€” â€” (1,014,150) â€” â€” (1,014,150) Balance, June 30, 2023 21,092,029 $2,110 $101,226,783 $39,292 $(92,441,689) 27 $(6,464) $8,820,032 Proceeds from sale of common stock in public offering , net of offering costs of $332,413 5,413,334 541 2,915,047 â€” â€” â€” â€” 2,915,588 Proceeds from sales of 1,920,000Â pre-funded warrants, net of offering cost of $117,880 â€” â€” 1,033,928 â€” â€” â€” â€” 1,033,928 Common stock issued upon vesting of restricted stock units 10,099 1 30 â€” â€” â€” â€” 31 Stock-based compensation â€” â€” 330,394 â€” â€” â€” â€” 330,394 Other comprehensive loss â€” â€” â€” (47,846) â€” â€” â€” (47,846) Net loss â€” â€” â€” â€” (2,029,016) â€” â€” (2,029,016) Balance, September 30, 2023 26,515,462 $2,652 $105,506,182 $(8,554) $(94,470,705) 27 $(6,464) $11,023,111 Â Â Â The accompanying notes are an integral part of the consolidated unaudited financial statements. 4 Â MYOMO, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) Â For the Nine Months Ended September 30, Â 2024 Â Â 2023 Â CASH FLOWS FROM OPERATING ACTIVITIES Â Â Â Â Â Â Net loss Â $ (5,923,648) Â $ (5,687,461) Adjustments to reconcile net loss to net cash used in operations: Â Â Â Â Â Â Depreciation Â Â 114,346 Â Â Â 136,416 Â Stock-based compensation Â Â 552,580 Â Â Â 781,513 Â Accretion of discount on short-term investments Â Â (118,520) Â Â â€” Â Â Credit losses Â Â 5,257 Â Â Â 12,626 Â Loss on equity investment Â Â â€” Â Â Â 99,840 Â Amortization of right-of-use assets Â Â 196,592 Â Â Â 301,053 Â Other non-cash charges Â Â 84,180 Â Â Â (49,271) Changes in operating assets and liabilities: Â Â Â Â Â Â Accounts receivable Â Â (1,116,352) Â Â (625,596) Inventories Â Â (1,573,193) Â Â (90,100) Prepaid expenses and other current assets Â Â (614,951) Â Â (439,584) Other assets Â Â (16,640) Â Â 19,797 Â Accounts payable and accrued expenses Â Â 1,895,795 Â Â Â 2,141,978 Â Income taxes payable Â Â 202,137 Â Â Â (74,944) Operating lease liabilities Â Â (366,675) Â Â (352,820) Deferred revenue Â Â 23,460 Â Â Â 9,533 Â Net cash used in operating activities Â Â (6,655,632) Â Â (3,817,020) CASH FLOWS FROM INVESTING ACTIVITIES Â Â Â Â Â Â Purchases of short-term investments Â Â (5,482,757) Â Â (5,209,866) Maturities of short-term investments Â Â 7,595,814 Â Â Â 1,000,000 Â Purchases of equipment Â Â (499,877) Â Â (114,151) Net cash provided by (used in) investing activities Â Â 1,613,180 Â Â Â (4,324,017) CASH FLOWS FROM FINANCING ACTIVITIES Â Â Â Â Â Â Net proceeds from common stock offering Â Â 4,598,771 Â Â Â 6,623,633 Â Proceeds from sale of pre-funded warrants, net of offering costs Â Â 763,138 Â Â Â 3,097,940 Â Net settlement of vested restricted stock units to fund related employee statutory tax withholding Â Â - Â Â Â (8,147) Deferred offering costs Â Â (199,500) Â Â â€” Â Net cash provided by financing activities Â Â 5,162,409 Â Â Â 9,713,426 Â Â Â Â Â Â Effect of foreign exchange rate changes on cash Â Â 6,412 Â Â Â (6,610) Â Â Â Â Â Â Net (decrease) increase in cash, cash equivalents and restricted cash Â Â 126,369 Â Â Â 1,565,780 Â Â Â Â Â Â Cash, cash equivalents and restricted cash, beginning of period Â Â 6,871,306 Â Â Â 5,345,967 Â Â Â Â Â Â Â Â Cash, cash equivalents and restricted cash, end of period Â $ 6,997,675 Â Â $ 6,911,747 Â Â Â Â Â Â Â Â SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTINGÂ Â AND FINANCING ACTIVITIES Â Â Â Â Â Â Right of use assets obtained in exchange for lease liabilities Â $ â€” Â Â $ 508,186 Â Deferred offering costs incurred in a prior period to additional paid-in capital Â $ â€” Â Â $ (91,952) Unrealized (gain) loss from mark to market on short-term investments Â $ 126 Â Â $ 860 Â Â The accompanying notes are an integral part of the condensed consolidated unaudited financial statements. 5 Â MYOMO, INC. NOTES TO CONDENSED CONSOLIDATED UNAUDITED FINANCIAL STATEMENTS Note 1 â€” Description of BusinessMyomo Inc. (â€œMyomoâ€ or the Companyâ€) is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro Â® myoelectric upper limb orthosis product is registered with the U.S. Food and Drug Administration as a Class II medical device. The Company sells its products directly to patients, to Orthotics and Prosthetics ("O&P") providers around the world, the Veterans Health Administration, and distributors in Europe and Australia. The Company was incorporated in the State of Delaware on September 1, 2004 and is headquartered in Boston, Massachusetts. Note 2 â€” LiquidityÂ The Company incurred net losses of approximately $5,923,600 and $5,687,500 during the nine months ended September 30, 2024 and 2023, respectively, and has an accumulated deficit of approximately $102,850,000 at September 30, 2024. Cash used in operating activities was approximately $6,660,000 and $3,817,000 for the nine months ended September 30, 2024 and 2023, respectively. The Company's historical losses and cash used in operations are indicators of substantial doubt regarding the Company's ability to continue as a going concern.Â Based upon its current cash and cash equivalents, as well as the availability under its credit line (see below) and the future expected cash flows, the Company believes that its available cash and cash equivalents will fund its operations for at least the next twelve months from the issuance date of these financial statements. Â The Company has historically funded its operations through financing activities, including raising equity and debt. On July 11, 2024, the Company entered into a Loan and Security Agreement with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, which provides the Company the ability to borrow up to $4.0 million against eligible accounts receivable. Availability under the credit line, which is undrawn as of the issuance date of these financial statements, is approximately $0.9 million. See Note 7 - Line of Credit for further discussion. On January 19, 2024, the Company completed a registered direct equity offering, selling 1,354,218 shares of common stock and 224,730 pre-funded warrants to purchase common stock at $3.80 per share, or $3.7999 per pre-funded warrant, generating net proceeds after fees and expenses of approximately $5.4 million. On August 29, 2023, the Company completed a public equity offering, generating proceeds after fees and expenses of approximately $3.9 million, selling 5,413,334 shares of common stock and 1,920,000 pre-funded warrants to purchase common stock at $0.60 per share or at $0.5999 per pre-funded warrant. On January 17, 2023, the Company completed a public equity offering, generating proceeds after fees and expenses of approximately $5.7 million, selling 13,169,074 shares of common stock and 6,830,926 to pre-funded warrants to purchase common stock at $0.325 per share or at $0.3249 per pre-funded warrant. See Note 8 - Common Stock and Warrants for further discussion. Financing activities, such as the line of credit and the recently completed registered direct equity offering, are enabling the Company to sustain its operations. Â Management's operating plans are primarily focused on growing revenues in its direct billing channel by serving an increasing number of Medicare patients and training O&P providers in the United States,

which will enable them to provide the MyoPro to their patients, which is expected to result in further revenue growth in 2025 and beyond. Based on the final fees published by the Centers for Medicare and Medicaid Services (â€œCMSâ€) for the Companyâ€™s products, which became effective on April 1, 2024, if its supply chain is able to meet its volume requirements without disruption, the Company is able to compensate for additional advertising spending in the second half of 2024 above its original plan, expected payments are received and there is no increase in days sales outstanding in the fourth quarter, the Company believes it can achieve operating cash flow breakeven on a quarterly basis in the fourth quarter of 2024. In addition, the Company believes that it has access to capital resources through the use of its line of credit, possible public or private equity offerings, exercises of outstanding warrants, or other means. Based on the Companyâ€™s latitude as to the timing and amount of certain expenses, its current cash position, availability under its line of credit and operating plans, the Company believes that the substantial doubt is alleviated as of the issuance date of these financial statements. However, there can be no assurance that the Company will be successful in implementing its operating plans. Â Note 3 â€” Summary of Significant Accounting PoliciesInterim Financial StatementsThe accompanying unaudited condensed consolidated financial statements and notes are representations of the Companyâ€™s management, who are responsible for their integrity and objectivity. These statements have been prepared in accordance with United States generally accepted accounting principles (â€œU.S. GAAPâ€) for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) that are considered necessary for a fair presentation of the condensed consolidated financial statements of the Company as of September 30, 2024 and for the three and nine months ended September 30, 2024 and 2023. The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the operating results for the fiscal year ending December 31, 2024, or any other period. These condensed consolidated financial statements should be read in conjunction 6 Â with the audited financial statements and related disclosures of the Company as of December 31, 2023 and 2022 and for the years then ended, included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023.Basis of ConsolidationThe condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary Myomo Europe GmbH. All significant intercompany balances and transactions are eliminated. Comprehensive Income (Loss)Comprehensive loss includes all changes in equity during a period, except those resulting from investments by stockholders and distributions to stockholders. The Company's comprehensive loss includes changes in foreign currency translation adjustments and unrealized gains and losses on short term investments. There was a reclassification, which management does not consider to be material, out of accumulated other comprehensive income (loss) to other (income) expense related to realized gains or losses on short-term investments in the three and nine months ended September 30, 2024. There were no reclassifications in the three and nine months ended September 30, 2023. Use of EstimatesThe preparation of financial statements in conformity with accounting principles generally accepted in the United States of America require management to make estimates and assumptions that affect certain reported amounts and disclosures. These estimates and assumptions are reviewed on an on-going basis and updated as appropriate. Actual results could differ from these estimates. The Companyâ€™s significant estimates include deferred tax valuation allowances, valuation of stock-based compensation, warranty obligations and reserves for slow-moving inventory.Cash, Cash Equivalents and Short-Term InvestmentsThe Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents consist principally of deposit accounts and money market accounts at September 30, 2024 and December 31, 2023. The Company considers all investments with an original maturity of greater than three months but less than one year to be short-term investments. There were no instruments classified as short-term investments as of September 30, 2024. Short-term investments as of December 31, 2023 consists of commercial paper, U.S. Treasury Bills and short-term corporate debt securities, which were classified as held-to-maturity, and certificates of deposit totaling approximately $1,994,700 as of December 31, 2023. The Company determines the appropriate balance sheet classification of its investments at the time of purchases and evaluates the classification at each balance sheet date. Under the new lease, the Company's provided a security deposit to the landlord in the form of a letter of credit for $375,000. The Company has collateralized the letter of credit with cash in a separate bank account, which is accounted for as a long-term restricted cash on the condensed consolidated balance sheet as of September 30, 2024. Â Â Â September 30,2024 Â Â December 31,2023 Â Cash, cash equivalents, and restricted cash Â Â Â Â Â Â Cash Â $ 850,544 Â Â $ 1,231,871 Â Money market funds Â Â 5,772,131 Â Â Â 4,893,387 Â Commercial paper Â Â â€” Â Â Â 746,048 Â Restricted Cash Â Â 375,000 Â Â Â â€” Â Â Â $ 6,997,675 Â Â $ 6,871,306 Â Short-term investments Â Â Â Â Â Â US government agency debt securities Â $ â€” Â Â $ 1,497,099 Â Commercial paper Â Â â€” Â Â Â 497,563 Â Â Â $ â€” Â Â $ 1,994,662 Â Â Accounts Receivable and Allowance for Credit LossesThe Company reports accounts receivable at invoiced amounts less an allowance for credit losses. The Company evaluates its accounts receivable on a continuous basis and, if necessary, establishes an allowance for credit losses based on a number of factors, including current credit conditions and customer payment history. The Company does not require collateral or accrue interest on accounts receivable and credit 7 Â terms are generally 30 days. At September 30, 2024, and December 31, 2023, the Company recorded an allowance for credit losses accounts which was immaterial to the condensed consolidated financial statements. Joint VentureOn March 28, 2022, the Company invested cash consideration of $199,000 for a 19.9% ownership stake in Jiangxi Myomo Medical Assistive Appliance Co. Ltd. (the â€œJV Companyâ€), a company headquartered in China that is majority-owned by Beijing Ryzur Medical Investment Co., Ltd. (â€œRyzur Medicalâ€). The JV Company will manufacture and sell the Companyâ€™s current and future products in greater China, including Hong Kong, Macau and Taiwan. The Company accounts for its investment in the JV Company under the equity method because the Company exerts significant influence over its management. The investment was fully written off as of December 31, 2023, due to the recording of the Company's share of the losses of the JV Company in prior periods, which were recorded to other expense (income) in the condensed consolidated statement of operations, the Company has no obligation to fund any losses incurred by the JV Company. Revenue RecognitionÂ The Company accounts for revenue under ASC 606, â€œRevenue from Contracts with Customersâ€ and all of the related amendments (Topic 606). Revenues under Topic 606 are required to be recognized either at a â€œpoint in timeâ€ or â€œover time,â€ depending on the facts and circumstances of the arrangement and are evaluated using a five-step model. Generally, the Company recognizes revenue at a point in time. Â The Company recognizes revenue after applying the following five steps:1)Identification of the contract, or contracts, with a customer,2)Identification of the performance obligations in the contract, including whether they are distinct within the context of the contract,3)Determination of the transaction price, including the constraint on variable consideration,4)Allocation of the transaction price to the performance obligations in the contract, and5)Recognition of revenue when, or as, performance obligations are satisfied.Revenue is recognized when control of these services is transferred to our customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services.Product RevenueIncreasingly, the Company derives its revenue from direct billing. The Company also derives revenue from the sale of its products to O&P providers in the United States and internationally and the Veterans Administration (â€œVAâ€). Under direct billing, the Company recognizes revenue when all of the following criteria are met:(i)The product has been delivered to the patient, including completion of initial instruction on its use,(ii)Collection is deemed probable and it has been determined that a significant reversal of the revenue to be recognized is not deemed probable when the uncertainty associated with the variable consideration is resolved. As an example, the Company will record revenue if it is notified that insurance intends to pay and a payment amount is provided, and(iii)The amount to be collected is estimable using the â€œexpected valueâ€ estimation techniques, or the â€œmost likely amountâ€ as defined in ASC 606.For revenue derived from certain payers, including CMS, where the Company has demonstrated sufficient payment history, the Company recognizes revenue when it receives either a pre-authorization from the payer, or, in the case of Medicare patients, when the Company has gathered appropriate medical documentation from the patient that demonstrates compliance with the Company's inclusion criteria, control passes to the patient upon delivery of the device in an amount that reflects the consideration the Company expects to receive in exchange for the device and the claim has been submitted to the payer. These payers represented 93% and 69% of direct billing channel revenue during the three months ended September 30, 2024 and 2023, respectively. These payers represented 88% and 61% of direct billing channel revenue during the nine months ended September 30, 2024 and September 30, 2023, respectively. During the three months ended September 30, 2024, revenues from patients covered by Medicare Part B were recorded at the time the device was delivered and the claim submitted to CMS for an amount that was expected to be received from CMS and supplemental insurance payers, as applicable.Depending on the timing of product deliveries to customers, which is when cost of revenue must be recorded, and when the Company meets the criteria to record revenue, there may be fluctuations in gross margin. During the three months ended September 30, 2024 and 2023, the Company recognized revenue of approximately $2,440,900 and $1,324,300, respectively, and during the nine months ended September 30, 2024 and 2023, the Company recognized revenue of approximately $2,185,300 and $2,305,500, respectively, from third-party payers for which costs related to the completion of the Companyâ€™s performance obligations were not recorded in the current period. 8 Â Â For revenues derived from O&P providers and the VA, the Company recognizes revenue when control passes to the customer in an amount that reflects the consideration the Company expects to receive in exchange for those services. Revenues may be recognized upon shipment or upon delivery, depending on the terms of the arrangement, provided that persuasive evidence of an arrangement exists, there are no uncertainties regarding customer acceptance and collectability is deemed probable.The Company has elected to record taxes collected from customers on a net basis and does not include tax amounts in revenue or cost of revenue.License RevenueIf a license to the Companyâ€™s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when the license is transferred to the customer, the customer is able to use and benefit from the license, and collectability is deemed probable. Â On January 21, 2021, the Company entered into a definitive agreement with Ryzur Medical to form the JV Company to manufacture and sell the Company's current and future products in greater China, including Hong Kong, Macau and Taiwan (the â€œJV Agreementâ€). Under the JV Agreement, the Company is entitled to receive an upfront license fee of $2.7 million. As of September 30, 2023, the final portion of the initial license fee has been paid in full and recognized as license revenue. In addition, the Company is entitled to receive a guaranteed minimum payment for purchase of MyoPro Control Units for a period of ten years from the effective date of the JV Agreement. The Company will recognize revenue on these amounts upon invoicing of the JV Company as long as the collectability is deemed to be assured. Contract Balances The timing of revenue recognition may differ from the timing of payment by customers. The Company records a receivable when revenue is recognized prior to payment and there is an unconditional right to payment. Alternatively, when payment precedes the provision of the related services, the Company records deferred revenue until the performance obligations are satisfied. The Company had approximately $32,000 of deferred revenue as of September 30, 2024, and approximately $8,500 of deferred revenue as of December 31, 2023, the outstanding deferred revenue is expected to be recognized by the end of the fourth quarter of 2024.Â Disaggregated Revenue from Contracts with CustomersThe following table presents revenue by major source:Â Â Â For the Three MonthsEnded September 30, Â Â For the Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Direct to patient Â $ 7,431,751 Â Â $ 3,501,958 Â Â $ 15,491,584 Â Â $ 9,245,345 Â Clinical/Medical providers Â Â 1,775,835 Â Â Â 1,527,565 Â Â $ 4,991,158 Â Â Â $ 3,474,510 Â License revenue Â Â â€” Â Â Â 50,000 Â Â Â Â â€” Â Â Â 1,764,920 Â Total revenue from contracts with customers Â $ 9,207,586 Â Â $ 5,079,523 Â Â $ 20,482,742 Â Â $ 14,484,775 Â Â Geographic DataThe Company generated 88% of its total revenue from the United States and 12% from Germany for the three months ended September 30, 2024. The Company generated 78% of its total revenue from the United States, 19% from China and 3% from Germany for the three months ended September 30, 2023. Â During the nine months ended September 30, 2024, the Company generated 85% of its total revenues from the United States, 14% from Germany and 1% from other international locations. During the nine months ended September 30, 2023, the Company generated 72% of its total revenues from the United States, 14% from Germany, 13% from China, and 1% from other international locations. Excluding license revenue during the nine months ended September 30, 2023, the Company generated 82% of its product revenues from the United States, 16% from Germany and 2% from other international locations. 9 Â Cost of RevenueIn conjunction with the adoption of ASC 606, there are certain cases in which the Company will expense costs when incurred as required by ASC 340-40-25. In certain cases, the Company ships the MyoPro device to O&P providers, or provides the device directly to patients, pending reimbursement from third-party payers, after which revenue is recognized. For the three and nine months ended September 30, 2024, the Company recorded cost of goods sold of approximately $107,200 and $140,800, respectively, without corresponding revenue. For the three and nine months ended September 30, 2023, the Company recorded cost of goods sold of $32,800 and $76,900, respectively, without corresponding revenue. Direct billing fees paid to O&P providers for services they provide in conjunction with patient evaluations are expensed as incurred as required by ASC 340-40-25, as a cost of obtaining a contract. These costs are recorded as sales and marketing expense. Internal costs incurred and fees paid to O&P providers to measure, fit and deliver the device to patients are expensed to cost of revenue. AdvertisingThe Company charges the costs of advertising to operating expenses as incurred. Advertising expense amounted to approximately $1,043,700 and $822,500 for the three months ended September 30, 2024 and 2023, respectively, and approximately $2,680,600 and $2,360,400 during the nine months ended September 30, 2024 and 2023, respectively.Foreign Currency TranslationÂ The functional currency of the Companyâ€™s foreign subsidiary, Myomo Europe GmbH, is the Euro. Foreign exchange translation gains and losses from the Euro to U.S. dollars are included in other comprehensive (loss) gain. The Company recorded a gain of approximately $256,400 and a loss of approximately $47,100 during the three months ended September 30, 2024 and 2023, respectively, and a gain of approximately $312,000 and a loss of approximately $50,500 during the nine months ended September 30, 2024 and 2023, respectively, which are included in accumulated other comprehensive income in the condensed consolidated balance sheet. Transaction and translation foreign exchange gains and losses from a foreign currency to the functional currency are included in cost of goods sold in the consolidated statements of operations. Such amounts were immaterial for the three and nine months ended September 30, 2024 and 2023, respectively. The balance sheet is translated using the spot rate on the day of reporting and the statement of operations is translated monthly using the average rate for the month. Â Net Loss per ShareBasic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding, plus potentially dilutive common shares. Restricted stock, restricted stock units, stock options and warrants are excluded from the diluted net loss per share calculation when their impact is antidilutive. The Company reported a net loss for the three months ended September 30, 2024 and 2023, and as a result, all potentially dilutive common shares are considered antidilutive for these periods.Potential dilutive common shares issuable consist of the following at:Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Stock options Â Â 23,246 Â Â Â 24,982 Â Restricted stock units Â Â 1,234,357 Â Â Â 1,621,935 Â Other warrants Â Â 668,250 Â Â Â 668,250 Â Total Â Â 1,925,853 Â Â Â 2,315,167 Â Â Due to their nominal exercise price of $0.0001 per share, a total of 7,721,519 and 8,750,926 outstanding pre-funded warrants as of September 30, 2024 and 2023, respectively are considered common stock equivalents and are included in basic weighted average shares outstanding in the accompanying condensed consolidated statements of operations as of the closing dates of the Company's public equity offerings in January 2023, August 2023, and January 2024, respectively.Â Income TaxesÂ The Company reported a net loss for the three and nine months ended September 30, 2024 and 2023, however records a tax expense. The nature of this tax expense is the difference between the effective tax rate and statutory rate due to tax provision for a its wholly-owned foreign Myomo Europe, GmhH. Â Recently Adopted Accounting StandardsÂ 10 Â In September 2022, the Financial Accounting Standards Board (â€œFASBâ€) issued Accounting Standards Update (â€œASUâ€) 2022-04, â€œLiabilities - Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligationsâ€, that requires entities that use supplier finance programs in connection with the purchase of goods and services to disclose the key terms of the programs and information about obligations outstanding at the end of the reporting period, including a rollforward of those obligations. The guidance does not affect the recognition, measurement or financial statement presentation of supplier finance program obligations. The new standardâ€™s requirements to disclose the key terms of the programs and information about obligations outstanding are effective for fiscal years, including interim periods, beginning after December 15, 2022, except for the requirement to disclose a rollforward of obligations outstanding will be effective for fiscal years beginning after December 15, 2023. The Company adopted this new standard on January 1, 2024, which did not have a material impact on its financial position and results of operations.Â In October 2023, the FASB issued ASU 2023-06, â€œDisclosure Improvements, Codification Amendments in Response to the SECâ€™s Disclosure Update and Simplification Initiativeâ€, that adds 14 of the 27 identified disclosure or presentation requirements to the Codification, each amendment in the ASU will only become effective if the SEC removes the related disclosure or presentation from its existing regulations by June 30, 2027. The Company currently complies with these disclosure requirements as applicable under Regulation S-X or Regulation S-K and will adopt these new standards depending on timing of when they become effective, which is not expected to have a material impact on its financial position and results of operations.Â In November 2023, the FASB issued ASU 2023-07 â€œSegmented Reporting - Improvements to Reportable Segment Disclosuresâ€. ASU 2023-

07 focuses on the requirements to disclose its significant segment expense categories and amounts for each reportable segment. ASU 2023-07 will becoming effective in the calendar year 2024 year-end financial statements. The Company will adopt these new standards when they become effective, which is not expected to have a material impact on its financial position and results of the operation. Â In December 2023, the FASB issued ASU 2023-09, â€œAccounting Standards Update, Income Taxes (Topic 740: Improvements to Income Tax Disclosuresâ€. ASU 2023-09 focuses on income tax disclosures around effective tax rates and cash income taxes paid. This amendment in the ASU will become effective for public companies as of December 15, 2024 and effective to all other companies as of December 15, 2025. The Company will adopt these new standards when they become effective, which is not expected to have a material impact on its financial position and results of operations. Â Note 4 â€” InventoriesInventories consist of the following at:Â Â Â September 30,2024 Â Â December 31,2023 Â Finished goods Â $ 1,367,375 Â Â $ 321,484 Â Work in process Â Â 74,859 Â Â Â 6,589 Â Parts and subassemblies Â Â 1,941,279 Â Â Â 1,475,434 Â Inventories, net Â $ 3,383,513 Â Â $ 1,803,507 Â Â Â Note 5 â€” Fair Value of Financial InstrumentsThe Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820, â€œFair Value Measurementâ€ (â€œASC 820â€), which defines fair value, establishes a framework for measuring fair value, and establishes disclosures about fair value measurements.ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:â€¢Level 1 â€” Quoted prices available in active markets for identical assets or liabilities.â€¢Level 2 â€” Observable inputs other than quoted prices included in Level 1, such as quotable prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.â€¢Level 3 â€” Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use significant unobservable inputs. 11 Â The carrying amounts of the Companyâ€™s financial instruments such as cash and cash equivalents, accounts receivable and accounts payable, approximate fair value due to the short-term nature of these instruments. Cash equivalents consist of money market funds that limit their investments to only short-term U.S. Treasury Securities and repurchase agreements related to these securities. Short-term investments primarily consists of commercial paper and U.S. Treasury Bills and are carried on the condensed consolidated balance sheets at amortized cost which approximates fair value. Cash equivalents measured at fair value on a recurring basis at September 30, 2024 were as follows:Â Â Â In ActiveMarkets forIdentical Assetsor Liabilities(Level 1) Â Â SignificantOtherObservableInputs(Level 2) Â Â SignificantUnobservableInputs(Level 3) Â Â Total Â Cash equivalents Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 5,772,131 Â Â $ â€” Â Â $ â€” Â Â $ 5,772,131 Â Â Â $ 5,772,131 Â Â $ â€” Â Â $ â€” Â Â $ 5,772,131 Â Â Cash equivalents and short-term investments measured at fair value on a recurring basis at December 31, 2023 were as follows:Â Â Â In ActiveMarkets forIdentical Assetsor Liabilities(Level 1) Â Â SignificantOtherObservableInputs(Level 2) Â Â SignificantUnobservableInputs(Level 3) Â Â Total Â Money market funds Â $ 4,893,387 Â Â $ â€” Â Â $ â€” Â Â $ 4,893,387 Â Commercial paper Â $ â€” Â Â $ 746,762 Â Â $ â€” Â Â $ 746,762 Â Short-term investments Â $ â€” Â Â $ 1,994,662 Â Â $ â€” Â Â $ 1,994,662 Â Â Â Note 6 â€” Accounts Payable and Other Accrued ExpensesAccounts Payable and Other Accrued Expenses consists of the following at:Â Â Â September 30,2024 Â Â December 31,2023 Â Trade payables Â $ 1,301,550 Â Â $ 1,073,405 Â Accrued compensation and benefits Â Â 2,598,932 Â Â Â 1,964,487 Â Accrued insurance Â Â 240,575 Â Â Â 95,680 Â Accrued professional services Â Â 54,533 Â Â Â 52,202 Â Warranty reserve Â Â 159,531 Â Â Â 231,108 Â Customer deposits Â Â 1,857,565 Â Â Â 1,114,979 Â Other Â Â 235,390 Â Â Â 354,083 Â Â Â $ 6,448,076 Â Â $ 4,885,944 Â Â Â Note 7 â€” Line of CreditÂ On July 11, 2024 (the â€œEffective Dateâ€), the Company, entered into a Loan and Security Agreement (the â€œLoan Agreementâ€) with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (the â€œBankâ€).The Loan Agreement provides for a revolving line of credit whereby the Company may borrow up to $4,000,000 (the â€œRevolving Lineâ€), which Revolving Line may be increased to $5,500,000 at the Bankâ€™s sole discretion upon the occurrence of certain events. Amounts advanced by the Bank are based on 80% of â€œeligible accountsâ€, which includes all receivables in the United States, reduced by aged amounts and customers and insurance payers with concentrations in excess of defined limits, among other deductions. The outstanding principal amount of any advance shall accrue interest at a floating rate per annum equal to the greater of (i) 8.50% and (ii) the â€œprime rateâ€ as published in The Wall Street Journal for the relevant period plus one-half percent (0.50%). The Revolving Line is secured on a first priority basis by all of Companyâ€™s assets other than intellectual property and certain customary exceptions. Any newly formed or acquired subsidiary of the Company or any guarantor under the Loan Agreement, will either join the Loan Agreement as a co-borrower or become a guarantor under the Loan Agreement, 12 Â as determined by the Bank in its sole discretion. The Company intends to use the Revolving Line for working capital and general business purposes.The Revolving Line terminates, and any outstanding principal amount of all advances made thereunder, and any accrued and unpaid interest thereon, become immediately due and payable on the two year anniversary of the Effective Date. The Company must also pay Bank (i) a commitment fee of $20,000, (ii) an â€œAnniversary Feeâ€ of 0.50% of the Revolving Line and (iii) an â€œUnused Revolving Line Facility Feeâ€ of 0.50% per annum of the average unused portion of the Revolving Line. In addition, upon termination of the Loan Agreement or the Revolving Line prior to the two year anniversary of the Effective Date, the Company must pay a termination fee of 1.00% of the Revolving Line, subject to certain exceptions. The Company recorded approximately $199,500 in debt issuance costs during the nine months ended September 30, 2024 in conjunction with entering into the Loan Agreement, which includes the commitment fee and the Anniversary Fee. The Company capitalized the debt issuance costs and is amortizing them on a straight-line basis into interest expense over the term of the Loan Agreement. Debt issuance costs to be amortized over the term of the loan are included in other long-term assets. Approximately $0.9 million was available to be drawn under the Loan Agreement as of September 30, 2024. No amounts were drawn under the Loan Agreement as of September 30, 2024. Â Note 8 â€” Common Stock and WarrantsOn January 17, 2023, the Company completed a public equity offering, selling 13,169,074 shares of common stock and 6,830,926 pre-funded warrants at $0.325 per share or at $0.3249 per warrant, generating proceeds after fees and expenses of approximately $5.7 million. As of September 30, 2024, 5,801,519 pre-funded warrants remain exercisable. Each pre-funded warrant is exercisable for one share of the Companyâ€™s common stock at a nominal exercise price of $0.0001 per share. On August 29, 2023, the Company completed a public equity offering, selling 5,413,334 shares of common stock and 1,920,000 pre-funded warrants at $0.60 per share, or at $0.5999 per warrant, generating proceeds after fees and expenses of approximately $3.9 million. Each pre-funded warrant is exercisable for one share of the Companyâ€™s common stock at a nominal exercise price of $0.0001 per share. All of these pre-funded warrants remain exercisable at September 30, 2024.Â On January 19, 2024, the Company completed a registered direct equity offering, selling 1,354,218 shares of common stock and 224,730 pre-funded warrants at $3.80 per share, or at $3.7999 per pre-funded warrant, generating proceeds after fees and expenses of approximately $5.4 million. Each pre-funded warrant is exercisable for one share of the Companyâ€™s common stock at a nominal exercise price of $0.0001 per share. All of these pre-funded warrants were exercised during the nine months ended September 30, 2024. Â As of September 30, 2024 there were 7,721,519 pre-funded warrants outstanding. Â On August 2, 2022, the Company entered into an ATM Facility with Alliance Global Partners on (â€œAGPâ€). Under the ATM Facility, the Company may sell up to an aggregate of $15 million of the Companyâ€™s common stock from time to time and shall pay to AGP cash commissions of 3.0% of the gross proceeds of sales of common stock under the ATM Facility. There were no sales under the ATM Facility during the three and nine months ended September 30, 2024 and 2023, respectively. In conjunction with the public equity offering in August 2023, the Company reduced the amount available to sell under the ATM Facility to $1,000. In May 2024, the ATM Facility expired and has not been renewed. No shares of common stock were issued through the exercise of stock options during the three and nine months ended September 30, 2024 and September 30, 2023, respectively.Â During the three and nine months ended September 30, 2024, 42,828 and 980,173 restricted stock units vested, respectively. During the three and nine months ended September 30, 2023, 10,099 and 199,163 restricted stock units vested, respectively. Â Note 9 â€” Stock Award Plans and Stock-Based CompensationÂ As of September 30, 2024, there were 491,770 shares available for issuance under the Myomo, Inc. 2018 Stock Option and Incentive Plan (the â€œ2018 Planâ€). On January 1 of each year, the number of shares of common stock reserved and available for issuance under the 2018 Plan will cumulatively increase by 4% of the number shares of common stock outstanding on the immediately preceding December 31 or such lesser number of shares of common stock determined by management in consultation with members of the Board of Directors, including the compensation committee of the Board of Directors. On January 1, 2024, 1,085,401 shares were added to the share reserve under the 2018 Plan.Â Â Recipients of awards of restricted stock units typically sell shares in the open market to cover their individual tax liabilities and remit the proceeds to the Company, which offsets withholding taxes paid by the Company. In certain circumstances, stock awards may be net share 13 Â settled upon vesting to cover the required employee statutory withholding taxes and the remaining amount is converted into shares based upon their share-value on the date the award vests. In such instances, these payments of employee withholding taxes are presented in the statements of cash flows as a financing activity. There were no stock awards that were net share settled during the three and nine months ended September 30, 2024. There were no restricted stock units that were withheld as part of net share settlement transactions during the three months ended September 30, 2023 and 16,744 restricted stock units were withheld during the nine months ended September 30, 2023.Share-Based Compensation ExpenseThe Company accounts for stock awards to employees and non-employees based upon the fair value of the award on the date of grant. The fair value of that award is then ratably recognized as expense over the period during which the recipient is required to provide services in exchange for that award. The Company attributes the value of stock-based compensation to operations on the straight-line method such that the expense associated with awards is evenly recognized over the vesting period.The Company recognized stock-based compensation expense related to the issuance of stock option awards and restricted stock units to employees, non-employees and directors in the statements of operations as follows:Â Â Â For the Three Months Ended Â Â For the Nine Months Ended Â Â Â September 30, Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Cost of goods sold Â $ 22,805 Â Â $ 24,222 Â Â $ 35,601 Â Â $ 66,815 Â Research and development Â Â 30,599 Â Â Â 11,362 Â Â Â 63,562 Â Â Â (24,056) Selling, clinical and marketing Â Â 41,925 Â Â Â 50,984 Â Â Â 95,237 Â Â Â 142,432 Â General and administrative Â Â 228,856 Â Â Â 243,826 Â Â Â 358,180 Â Â Â 596,322 Â Total Â $ 324,185 Â Â $ 330,394 Â Â $ 552,580 Â Â $ 781,513 Â As of September 30, 2024, there was approximately $9,200 of unrecognized compensation cost related to unvested stock options that is expected to be recognized over a weighted-average period of 0.79 years.As of September 30, 2024, there was approximately $2,511,100 of unrecognized compensation expense related to unvested restricted stock units that is expected to be recognized over a weighted-average period of 2.50 years. Note 10 â€” Commitments and ContingenciesLitigationÂ The Company may be involved from time to time in legal proceedings, claims and assessments arising from the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. During 2022, a former employee who was terminated in 2021 brought an age discrimination claim against the Company. During the fourth quarter of 2023, the Company settled the claim with the former employee. The Company deemed it probable that its insurance company would pay its share of the claim. As a result of this assumed gain contingency, the Company reduced its accrual to an amount that is not expected to be covered by insurance, and recorded a liability of approximately $55,000 for severance and legal expenses as of December 31, 2023. The settlement was paid and all insurance proceeds were received during the three months ended March 31, 2024. There is no other material litigation against the Company at this time.Operating LeasesÂ The Company has a non-cancelable sublease agreement for its corporate headquarters in Boston, Massachusetts, which expires in January 2025 and a lease agreement for office space in Fort Worth, TX. which expires in December 2025. In August 2024, the Company entered into a new lease agreement for its new corporate headquarters and manufacturing facility in Burlington, Massachusetts, which the Company expects to begin occupying by the end of 2024, with a term of approximately 88 months following the rent commencement date. The Company has the option to extend the new lease for an additional five years, subject to certain conditions being satisfied. Under the new lease, the Company provided a security deposit to the landlord in the form of a letter of credit for $375,000. The Company has collateralized the letter of credit with cash in a separate bank account, which is accounted for as long-term restricted cash on the condensed consolidated balance sheet. Termination options are either not included, or have expired, for the Companyâ€™s other existing operating leases. Certain arrangements have discounted rent periods or escalating rent payment provisions. Leases with an initial term of twelve months or less are not recorded on the condensed consolidated balance sheets. We recognize rent expense on a straight-line basis over the lease term.Â 14 Â As of September 30, 2024, operating lease assets were approximately $467,000. The amount and the maturity of the Companyâ€™s operating lease liabilities as of September 30, 2024, are as follows: Â Â Â Â Â Â Â Â Â Â Â September 30, 2024 Â 2024 Â Â Â Â Â Â Â Â $ 144,610 Â 2025 Â Â Â Â Â Â Â Â Â 102,841 Â 2026 Â Â Â Â Â Â Â Â Â â€” Â 2027 Â Â Â Â Â Â Â Â Â â€” Â Thereafter Â Â Â Â Â Â Â Â Â â€” Â Total future minimum lease payments Â Â Â Â Â Â Â Â 247,451 Â Less imputed interest Â Â Â Â Â Â Â Â 12,822 Â Total operating lease liabilities Â Â Â Â Â Â Â $ 234,629 Â Included in the condensed consolidated balance sheet: Â Â Â Â Â Â Â Â Â Â Current operating lease liabilities Â Â Â Â Â Â Â Â $ 205,464 Â Non-current operating lease liabilities Â Â Â Â Â Â Â Â 29,165 Â Total operating lease liabilities Â Â Â Â Â Â Â $ 234,629 Â Â For the three and nine months ended September 30, 2024 and 2023, the total lease cost is comprised of the following amounts: Â Â Â For the Three MonthsEnded September 30, Â Â For the Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Operating lease expense Â $ 87,836 Â Â $ 116,314 Â Â $ 263,506 Â Â $ 367,613 Â Short-term lease expense Â Â 1,615 Â Â Â - Â Â Â 4,884 Â Â Â - Â Total lease expense Â $ 89,451 Â Â $ 116,314 Â Â $ 268,390 Â Â $ 367,613 Â Â The following summarizes additional information related to operating leases:Â Â Â Â Â Â Â September 30, 2024 Â Â December 31, 2023 Â Weighted-average remaining lease term (in years) Â Â Â Â Â Â 0.54 Â Â Â Â 1.20 Â Weighted-average discount rate Â Â Â Â Â Â 23.3 % Â Â 23.3 % Major Customers For the three and nine months ended September 30, 2024 and 2023, there were no customers which accounted for more than 10% of product revenues. For the three and nine months ended September 30, 2024 and 2023, a U.S. insurance payer represented 19% and 22% and 36% and 40% of product revenues, respectively. For the three and nine months ended September 30, 2024, patients with Medicare Part B coverage represented 55% and 44% of product revenues, respectively. For the three and nine months ended September 30, 2024, approximately 24% and 27% of the Company's product revenues, respectively, were derived from patients with Medicare Advantage insurance plans. For the three and nine months ended September 30, 2023, approximately 59% and 59% of the Company's product revenues were derived from patients with Medicare advantage plans, respectively. Â At September 30, 2024 and December 31, 2023, one insurance payer and its affiliates accounted for approximately 25% and 56% of accounts receivable, respectively. Supplier Finance Program ObligationsÂ The Company finances its Directors and Officers Insurance policy, which requires the Company to make a down payment, followed by equal payments over a defined term. During the year ended December 31, 2023, the Company completed its payment obligation associated with its 2022-2023 policy and entered into a new policy covering the twelve-month period ending June 2024. Under this financing arrangement, the Company made a down payment of approximately $29,000 during the three months ended June 30, 2023 and made nine equal monthly payments of approximately $27,000, starting in July 2023. During the nine months ended September 30, 2024, the Company completed its payment obligation associated with its 2023-2024 policy and entered into a new policy covering the twelve-month period ending June 2025. Under this new financing arrangement, the Company made a down payment of approximately $39,000 during the three months ended June 30, 15 Â 2024, and is making nine equal monthly payments of approximately $39,000, starting in July 2024. Changes in the Company's supplier finance obligations were as follows: Â Â Â Â Â Â Â For the Nine Months Ended September 30, Â 2024 Â Â 2023 Â Balance January 1 Â $ 142,217 Â Â $ 56,603 Â Increase Â Â â€” Â Â Â 128,692 Â Expensed Â Â (80,109) Â Â (132,988) Balance March 31, Â $ 62,108 Â Â $ 52,307 Â Increase Â Â 349,909 Â Â Â 375,824 Â Expensed Â Â (78,593) Â Â (155,076) Balance June 30, Â $ 333,424 Â Â $ 273,055 Â Increase Â Â 63,478 Â Â Â 29,809 Â Expensed Â Â (121,512) Â Â (80,538) Balance September 30, Â $ 275,390 Â Â $ 222,326 Â Â No assets are pledged as security under this arrangement. Â 16 Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations The following discussion should be read in conjunction with our condensed consolidated financial statements and the related notes contained elsewhere in this Quarterly Report on Form 10-Q and in our other Securities and Exchange Commission filings. The following discussion may contain predictions, estimates, and other forward-looking statements that involve a number of risks and uncertainties, including those discussed under â€œRisk Factorsâ€, â€œCautionary Statement Regarding Forward-Looking Statementsâ€ and elsewhere in this Quarterly Report on Form 10-Q. These risks could cause our actual results to differ materially from any future performance suggested below. Overview We are a wearable medical robotics company, specializing in myoelectric braces, or orthotics, for people with neuromuscular disorders. We develop and market the MyoPro product line, which is a myoelectric-controlled upper limb brace, or orthosis. The orthosis is a rigid brace used for the purpose of supporting a patientâ€™s weak or deformed arm to enable and improve functional activities of daily living (â€œADLsâ€), in the home and community. It is custom constructed by a trained professional during a custom fabrication process for each individual user to meet their

specific needs. Our products are designed to help regain function in individuals with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury and other neurological disorders. Â We have relationships with physicians and therapists who generate patient referrals, and we utilize digital ads on various platforms as well as television ads to reach patients who are potential candidates for our product. Once the prospective patient contacts us or is referred to us, either our trained clinical staff or a trained Orthotics and Prosthetics (â€œO&Pâ€) provider will evaluate the patient for their suitability as a candidate. Initial evaluations by our trained clinical staff are often conducted using telehealth techniques, followed by an in-person clinical evaluation of the candidate. Prior to delivering our device to a Medicare patient or obtaining authorizations from commercial insurance companies, the patientâ€™s medical records are collected and reviewed to make sure the device is appropriate for their condition and a prescription is always obtained from a physician. Once these documents are obtained, a pre-authorization request is submitted to the patientâ€™s commercial insurer. If we receive a pre-authorization, we proceed to measure the patientâ€™s arm, a process we refer to as shape capture. For a Medicare patient, we will commence shape capture once we are in possession of all relevant medical records and have assessed that the patient meets our inclusion criteria. Arm measurements are being done in many cases using a digital measurement kit supplied to the patient. We then use those measurements to 3D print orthotic parts, which are used to fabricate the MyoPro, and then deliver it to the patient. Since we are directly providing the device to the patient and then billing insurance ourselves, we refer to this process as direct billing. We also call on O&P practices in the United States, Europe and Australia that provide our products to their patients as well as generate indirect sales. The MyoPro product line has been approved by the Veterans Administration (â€œVAâ€) for impaired veterans, and nearly 130 VA facilities have ordered devices for their patients. Â Our myoelectric orthoses have been clinically shown in peer reviewed published research studies to help regain the ability to complete functional tasks by supporting the affected joint and enabling individuals to self-initiate and control movement of their partially paralyzed limbs by using their own muscle signals. Our technology was originally developed at MIT in collaboration with medical experts affiliated with Harvard Medical School. Myomo was incorporated in 2004. Other historical milestones include: â€¢In 2012, we introduced the MyoPro. The primary business focus shifted from developing devices that were designed for rehabilitation therapy and sold to hospitals to providing an assistive device through O&P providers to patients who are otherwise impaired for use at home, work, and in the community that facilitates ADLs. â€¢During 2015, we extended our basic MyoPro for the elbow with the introduction of the MyoPro Motion W, a multi-articulated non-powered wrist and the MyoPro Motion G, which includes a powered grasp. The MyoPro Motion W allows the user to use their sound arm to adjust the device and then, for instance, open a refrigerator door, carry a shopping bag, hold a cell phone, or stabilize themselves to avoid a fall and potential injury. The MyoPro Motion G model allows users with severely weakened or clenched hands, such as seen in certain stroke survivors, to open and close their hands and perform a large number of ADLs. â€¢On June 9, 2017, we completed our initial public offering (â€œIPOâ€) and a private offering concurrent with the IPO, generating net proceeds of $6.9 million in the aggregate. â€¢On July 31, 2017, we met the criteria to apply the CE Mark for the MyoPro. This has enabled us to sell the MyoPro to individuals in the European Union (the â€œEUâ€). â€¢In November 2018, we announced that the Centers for Medicare and Medicaid Services (â€œCMSâ€) had published two new codes (L8701, L8702) pursuant to our application for Healthcare Common Procedure Coding System (â€œHCPCSâ€) codes which become effective in early 2019. The assignment of unique L-Codes, if followed by appropriate payment terms, offers greater access to the MyoPro for Medicare beneficiaries. â€¢In 2019, we transitioned our business to become a direct provider of the MyoPro to patients and bill insurance companies directly. â€¢In July 2021, we became accredited as a Medicare provider. 17 Â â€¢In January 2022, we introduced MyoPro 2+ and began in-house fabrication of the device. Â China Joint Venture Â On January 21, 2021, we entered into a definitive agreement with Beijing Ryzur Medical Investment Co., Ltd. (â€œRyzur Medicalâ€), a medical device manufacturer based in Beijing, to form a joint venture (the â€œJVâ€) to manufacture and sell our current and future products in greater China, including Hong Kong, Macau and Taiwan (the â€œJV Agreementâ€). Â Majority ownership in the joint venture, named Jiangxi Myomo Medical Assistive Appliance Co., Ltd. (the "JV Company") is held by Ryzur Medical with minority ownership by Wuxi Chinaleaf Investment Management Limited Partnership, a private fund that invests in growth opportunities in new technologies. We own a minimum 19.9% stake in the JV Company. Ryzur Medical and its partners have committed to invest a minimum of $8 million and up to $20 million in the JV Company over five years. Â The JV Company was established on August 12, 2021. On December 29, 2021, we entered into an amendment to the JV Agreement, as well as a Technology License Agreement and a Trademark License Agreement (collectively, the â€œAgreementsâ€). Under the Agreements, we and the JV Company have entered into a ten-year agreement to license our intellectual property, including recently issued patents in China and Hong Kong, and purchase MyoPro Control System units from us. Pursuant to the Agreements, the JV Company has agreed to an escalating purchase commitment for a minimum of $10.75 million in MyoPro Control System Units during the next ten years, subject to receipt of regulatory approvals necessary to permit sales of the product in the greater China territory. Â In September 2024, the JV Company was notified it received provincial approval to produce and sell two products for use by hospitals in China, an upper limb joint rehabilitation training device and a surface electromyographic instrument, which are based off the functionality of our Mobile Arm Rehabilitation Kit, or MARK. First revenues for the JV Company are expected to be generated from these products in the future. With respect to its version of the MyoPro to be provided to patients, the JV Company is expected to begin enrolling patients in a clinical trial before the end of 2024, which must be completed in order to receive registration from the National Medical Products Administration, or NMPA. Recent Developments Â Equity Offerings On January 19, 2024 we completed a registered direct equity offering, selling 1,354,218 shares of common stock and 224,730 pre-funded warrants to purchase common stock at $3.80 per share, or $3.7999 per pre-funded warrant, generating net proceeds after fees and expenses of approximately $5.4 million. Net proceeds from the offering were used to hire 50 to 60 people through the second quarter of 2024 in order to increase our clinical, reimbursement and manufacturing capacity to serve a growing number of patients, including Medicare Part B beneficiaries. On August 29, 2023, we completed a public equity offering, selling 5,413,334 shares of common stock and 1,920,000 pre-funded warrants to purchase common stock at $0.60 per share, or at $0.5999 per pre-funded warrant, generating net proceeds after fees and expenses of approximately $3.9 million. In January 2023, we completed a public equity offering, whereby we sold 13,169,074 shares of common stock and 6,830,926 pre-funded warrants to purchase common stock at $0.325 per share, or $0.3249 per pre-funded warrant. Each pre-funded warrant in the above offerings entitles the holder to one share of common stock upon exercise at a nominal exercise price of $0.0001 per share. See section titled â€œLiquidityâ€ for further discussion. Â CMS Status On November 1, 2023, CMS issued a final rule that results in a change in the benefit category associated with products billed under the HCPCS codes for our products from durable medical equipment rental to a brace, which would permit reimbursement of MyoPro sales on a lump sum basis. The rule became effective on January 1, 2024. On February 29, 2024, CMS published final average payment determinations for the HCPCS codes describing our products of approximately $33,500 for L8701, the MyoPro Motion W, and approximately $65,900 for L8702, the MyoPro Motion G, which became effective on April 1, 2024. We are being paid by CMS at approximately 80% of the published fees, with the remaining 20% from either the patient directly or their supplemental insurance, if any. Beginning January 1, 2024, we began deliveries to Medicare Part B patients for lump sum reimbursement under the brace benefit category. During the three and nine months ended September 30, 2024, revenues from Medicare Part B beneficiaries represented 55% and 44% of product revenues, respectively. Â Results of Operations Â 18 Â We have been growing revenues while incurring net losses and negative cash flows from operations since inception and anticipate this to continue as we focus our efforts on continuing to expand our sales and marketing efforts by increasing the breadth of our marketing activities, increasing our investment in the German and other international markets, investing in development of the pediatric version of the MyoPro, the MyoPal, and the funding of resources focused on obtaining reimbursement from insurance companies. The following table sets forth our revenue, cost of revenue, gross profit and gross margin for each of the periods presented. Â Â For the Three MonthsEnded September 30, Period-to-PeriodChange For the Nine MonthsEnded September 30, Period-to-PeriodChange Â 2024 2023 $ % 2024 2023 $ % Product revenue $9,207,586 $5,029,523 $4,178,063 83% $20,482,742 $12,719,855 $7,762,887 61% License revenue â€” 50,000 (50,000) (100)% â€” 1,764,920 (1,764,920) (100)% Total revenue 9,207,586 5,079,523 4,128,063 81% 20,482,742 14,484,775 5,997,967 41% Cost of revenue 2,262,031 1,590,675 671,356 42% 5,912,632 4,407,270 1,505,362 34% Gross profit $6,945,555 $3,488,848 $3,456,707 99% $14,570,110 $10,077,505 $4,492,605 45% Gross margin % 75.4% 68.7% Â 6.7% 71.1% 69.6% Â 1.5% Â Revenues We derive revenue primarily from providing devices directly to patients and billing insurance companies or Medicare directly. We also sell our products to O&P providers in the United States, Europe and Australia, to the VA, and to rehabilitation hospitals. Though we increasingly provide devices directly to patients, we sometimes utilize the clinical services of O&P providers for which they are paid a fee. Total revenue increased by approximately $4,128,100 and $5,998,000, or 81% and 41%, for the three and nine months ended September 30, 2024, as compared to the same periods in 2023. Product revenue increased by approximately $4,178,100 and $7,762,900, or 83% and 61%, for the three and nine months ended September 30, 2024 as compared to the same periods in 2023. Higher product revenues in the three and nine months ended September 30, 2024 were due to a higher number of revenue units, driven by deliveries to Medicare Part B patients and a higher average selling price as a result of the recently published fees for the MyoPro by CMS and successfully obtaining reimbursements from CMS and the respective patient's supplemental insurance, as applicable. Cost of Revenue and Gross Margin Cost of revenue consists of direct costs for the manufacturing, printing of orthotic parts, fabrication and fitting of our products, changes in inventory and warranty reserves, and costs for our quality and fulfillment organizations. Gross margin was 75.4% and 71.1% for the three and nine months ended September 30, 2024 respectively, compared to 68.7% and 69.6% for the three and nine months ended September 30, 2023, respectively. Gross margin on product revenue was the same as overall gross margin for the three and nine months ended September 30, 2024, respectively. Gross margin on product revenue was 68.4% and 65.4% for the three and nine months ended September 30,2023, respectively. The increases in gross margin during the three and nine months ended September 30, 2024 were due primarily due to a higher average selling price, fixed cost absorption and a write-down of inventory in the prior year, partially offset by an increased manufacturing overhead as we are adding capacity in support of planned revenue growth in 2024 and higher material costs. Operating expenses The following table sets forth our operating expenses for each of the periods presented. Â Â Â For the Three MonthsEnded September 30, Â Period-to-PeriodChange Â For the Nine MonthsEnded September 30, Period-to-PeriodChange Â Â 2024 Â 2023 Â $ Â % Â 2024 Â 2023 $ Â % Research and development Â $1,248,870 Â $717,256 Â $531,614 Â 74% Â $3,212,309 Â $1,758,480 $1,453,829 Â 83% Selling, clinical and marketing Â 3,401,182 Â 2,387,090 Â 1,014,092 Â 42% Â 8,540,161 Â 6,689,578 1,850,583 Â 28% General and administrative Â 3,253,056 Â 2,408,871 Â 844,185 Â 35% Â 8,779,024 Â 7,427,818 1,351,206 Â 18% Total operating expenses Â $7,903,108 Â $5,513,217 Â $2,389,891 Â 43% Â $20,531,494 Â $15,875,876 $4,655,618 Â 29% Â 19 Â Research and development Research and development (â€œR&Dâ€) expenses consist of costs for our R&D personnel, including salaries, benefits, bonuses and stock-based compensation, product development costs, clinical studies, and the cost of certain third-party contractors and travel expense. R&D costs are expensed as they are incurred. We intend to enhance our existing products in 2024 and expect R&D costs to increase on an annual basis. R&D expenses increased by approximately $531,600 and $1,453,800, or 74% and 83%, during the three and nine months ended September 30, 2024, respectively, as compared to the same periods in 2023. The increases were primarily due to higher costs for payroll as we are adding headcount in order to accelerate our sustaining engineering and product development efforts as a result of coverage by Medicare. Selling, clinical and marketing Selling, clinical, and marketing (â€œSC&Mâ€) expenses consist of costs for our field clinical staff, O&P channel managers, clinical training organization, and marketing personnel, including salaries, benefits, bonuses, stock-based compensation and sales commissions, costs of advertising, marketing and promotional events, corporate communications, product marketing and travel expenses. Variable compensation for personnel engaged in sales and marketing activities is generally earned and recorded as expense in the period in which the measurable work is performed. We expect SC&M expenses to increase in 2024 as we plan to add clinical capacity in support of serving Medicare Part B patients. SC&M expenses increased by approximately $1,014,100 and $1,850,600 or 42% and 28%, during the three and nine months ended September 30, 2024, respectively, as compared to the same periods in 2023. The increases were primarily due to higher payroll costs due to increased headcount in our clinical functions to support higher expected sales volume in 2024, higher advertising and travel costs and the effect on payroll costs from a headcount decrease in the first quarter of 2023. General and administrative General and administrative (â€œG&Aâ€) expenses consist primarily of costs for administrative, reimbursement, and finance personnel, including salaries, benefits, bonuses and stock-based compensation, professional fees associated with legal matters, consulting expenses, costs for pursuing insurance reimbursements for our products and costs required to comply with the regulatory requirements of the SEC, as well as costs associated with accounting systems, insurance premiums and other corporate expenses. We expect that general and administrative expenses will increase in 2024 as we plan to add headcount in our human resources and reimbursement functions in support of serving Medicare Part B patients. G&A increased by approximately $844,200 and $1,351,200, or 35% and 18%, during the three and nine months ended September 30, 2024, respectively, as compared to the same periods in 2023. The increases were primarily due to increased payroll costs due to increased headcount in our clinical, reimbursement and human resource functions as part of our plan to increase our reimbursement capacity in 2024 in order to serve Medicare Part B patients, and the effect on payroll costs from a headcount decrease in the first quarter of 2023, as well as increases in legal fees and other outside services. Other (income), net The following table sets forth our other income, net for each of the periods presented: Â Â Â For the Three MonthsEnded September 30, Â Â Period-to-PeriodChange Â Â For the Nine MonthsEnded September 30, Â Â Period-to-PeriodChange Â Â Â 2024 Â Â 2023 Â Â $ Â Â % Â Â 2024 Â Â 2023 Â Â $ Â Â % Â Interest income, net Â $ (76,020) Â $ (112,300) Â $ 36,280 Â Â Â (32)% Â $ (318,555) Â $ (302,053) Â $ (16,502) Â Â 5 % Other expense, net Â Â â€” Â Â Â 467 Â Â Â (467) Â Â (100)% Â Â â€” Â Â Â 6,098 Â Â Â (6,098) Â Â (100)% Loss on equity investment Â Â â€” Â Â Â 70,124 Â Â Â (70,124) Â Â (100)% Â Â â€” Â Â Â 99,840 Â Â Â (99,840) Â Â (100)% Total other income, net Â $ (76,020) Â $ (41,709) Â $ (34,311) Â 82 % Â $ (318,555) Â $ (196,114) Â $ (122,440) Â 62 % Â Other income, net was approximately $76,000 and $318,600 for the three and nine months ended September 30, 2024, respectively, compared to approximately $41,700 and $196,100 for the same periods in 2023, respectively. The increase in other income, net in the three months ended September 30, 2024 was due the loss on equity investment related to our joint venture in China in prior year period, offset by lower interest income due to a decrease in lower average investment balances compared to the prior year period. The increase in other income, net during the nine months ended September 30, 2024 was due to higher interest income, partially offset by the loss on equity investment in the prior year period. 20 Â Income tax expense Â Income tax expense recorded during the three and nine months ended September 30, 2024 and 2023 represents the provision for income taxes for our wholly-owned subsidiary, Myomo Europe GmbH. Income tax expense increased in the three and nine months ended September 30, 2024 as a result of higher taxable income compared to the same periods in 2023. Adjusted EBITDA We believe that the presentation of Adjusted EBITDA, a non-GAAP financial measure, provides investors with additional information about our financial results. Adjusted EBITDA is an important supplemental measure used by our board of directors and management to evaluate our operating performance from period-to-period on a consistent basis and as a measure for planning and forecasting overall expectations and for evaluating actual results against such expectations. We define Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization adjusted for, stock-based compensation and other unusual items. Adjusted EBITDA is not in accordance with, or an alternative to, measures prepared in accordance with U.S. GAAP. In addition, this non-GAAP measure is not based on any comprehensive set of accounting rules or principles. As a non-GAAP measure, Adjusted EBITDA has limitations in that it does not reflect all of the amounts associated with our results of operations as determined in accordance with U.S. GAAP. In particular: Â â€¢Adjusted EBITDA does not reflect the amounts we paid in taxes or other components of our tax provision; â€¢Adjusted EBITDA does not include interest income; â€¢Adjusted EBITDA does not include depreciation expense from fixed assets; â€¢Adjusted EBITDA does not include the impact of stock-based compensation; â€¢Adjusted EBITDA does not include the loss on investment in minority interest; Because of these limitations, you should consider Adjusted EBITDA alongside other financial performance measures including net income (loss) and our financial results presented in accordance with U.S. GAAP. The following table provides a reconciliation of net loss to Adjusted EBITDA for each of the periods indicated: Â Â Â For the Three MonthsEnded September 30, Â Â For the Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â GAAP net loss Â $ (966,409) Â $ (2,029,016) Â $ (5,923,648) Â $ (5,687,461) Adjustments to reconcile to Adjusted EBITDA: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Interest income Â Â (76,020) Â Â (112,300) Â Â (318,555) Â Â (302,053) Depreciation expense Â Â 48,682 Â Â Â Â 35,794 Â Â Â Â 114,346 Â Â Â Â 136,416 Â Stock-based compensation Â Â 324,185 Â Â Â Â 330,394 Â Â Â Â 552,580 Â Â Â Â 781,513 Â Loss on investment in minority interest Â Â â€” Â Â Â Â 70,124 Â Â Â Â â€” Â Â Â Â 99,840 Â Income tax expense Â Â 84,876 Â Â Â Â 46,356 Â Â Â Â 280,819 Â Â Â Â 85,204 Â Adjusted EBITDA Â $ (584,686) Â $ (1,658,648) Â $ (5,294,458) Â $ (4,886,541) Â Liquidity and Capital Resources Liquidity We measure our liquidity in a number of ways, including the following: Â Â Â September 30,2024 Â Â December 31,2023 Â Cash and cash equivalents Â $ 6,622,675 Â Â $ 6,871,306 Â Short-term investments Â Â - Â Â Â 1,994,662 Â Total Â Â 6,622,675 Â Â Â 8,865,968 Â Working capital Â $ 7,712,772 Â Â $ 8,173,925 Â Â 21 Â As of September 30, 2024, we had working capital of approximately $7.8 million and stockholdersâ€™ equity of approximately $9.3 million. We used approximately $6.7

million in cash for operating activities during the nine months ended September 30, 2024. Our historical losses and cash used in operations are indicators of substantial doubt regarding our ability to continue as a going concern. Considering our balance of cash and cash equivalents, as of September 30, 2024 and our plans to grow our revenues by serving Medicare Part B beneficiaries and availability under our line of credit, we believe there is sufficient cash and cash equivalents to fund our operations and capital expenditures for the next 12 months from the date of this report. Â We have historically funded our operations through financing activities, including raising equity and debt capital. On July 11, 2024, we entered into a Loan and Security Agreement with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, which provides us the ability to borrow up to $4.0 million against eligible accounts receivable. The line of credit is undrawn as of the issuance date of this Quarterly Report on Form 10-Q and availability under the line was approximately $0.9 million as of September 30, 2024. In January 2024, we completed a registered direct equity offering, pursuant to which we sold 1,354,218 shares of common stock and 224,730 pre-funded warrants to purchase common stock at $3.80 per share, or $3.7999 per pre-funded warrant, generating net proceeds after fees and expenses of approximately $5.4 million. In August 2023, we completed a public equity offering pursuant to which we sold 5,413,334 shares of common stock and 1,920,000 pre-funded warrants to purchase common stock at $0.60 per share, or at $0.5999 per warrant, generating proceeds after fees and expenses of approximately $3.9 million. In January 2023, we completed an equity offering under which we sold 13,169,074 shares of common stock and 6,830,926 pre-funded warrants to purchase common stock at $0.325 per share, or at $0.3249 per pre-funded warrant, generating proceeds after fees and expenses of approximately $5.7 million. Â Our business is dependent upon reimbursement of our products by insurance companies and government-controlled health care plans such as Medicare and Medicaid in the United States and by Statutory Health Insurance plans in Germany, which could prevent our revenues from growing to the level necessary to achieve operating cash flow breakeven. We believe that we have access to capital resources, if necessary, through usage of our line of credit, potential public or private equity offerings, exercises of outstanding warrants, debt financings, or other means. If we are unable to obtain adequate funds on reasonable terms, we may be required to significantly curtail or discontinue operations or obtain funds by entering into financing agreements on unattractive terms. We may also explore strategic alternatives for the purpose of maximizing stockholder value. There can be no assurance we will be successful in implementing our plans to sustain our operations and continue to conduct our business. Â Our operating plans are primarily focused on growing revenues in our direct billing channel by serving an increasing number of Medicare patients and training O&P providers in the United States to provide the MyoPro to their patients, which is expected to result in further revenue growth in 2025 and beyond. Based on the final fees published by CMS for our products, which became effective on April 1, 2024, if our supply chain is able to meet our volume requirements without disruption, we are able to compensate for additional advertising spending in the second half of 2024 above our original plan, expected payments are received and there is no increase in days sales outstanding in the fourth quarter, we believe we can achieve operating cash flow breakeven on a quarterly basis in the fourth quarter of 2024. In addition, we believe that we have access to capital resources through the use of our line of credit, possible public or private equity offerings, exercises of outstanding warrants, or other means. Based on our latitude as to the timing and amount of certain expenses, our current cash position, availability under our line of credit and operating plans, we believe that the substantial doubt is alleviated as of the issuance date of these financial statements. Cash Flows Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Net cash used in operating activities Â $ (6,655,632) Â $ (3,817,020) Net cash provided by (used in) investing activities Â Â 1,613,180 Â Â Â (4,324,017) Net cash provided by financing activities Â Â 5,162,409 Â Â Â 9,713,426 Â Effect of foreign change rate changes on cash Â Â 6,412 Â Â Â (6,610) Net (decrease) increase in cash, cash equivalents and restrictedÂ Â Â cash Â $ 126,369 Â Â $ 1,565,780 Â Â Operating Activities. The net cash used in operating activities for the nine months ended September 30, 2024 was primarily used to fund a net loss of approximately $5.9 million, adjusted for non-cash expenses in the aggregate amount of approximately $0.8 million and by approximately $1.8 million of cash used by net changes in the levels of operating assets and liabilities, primarily related to an increase in accounts receivable, inventory and prepaid expenses and other current assets, offset by an increase in accounts payable and accrued expenses. The net cash used in operating activities for the nine months ended September 30, 2023 was primarily used to fund a net loss of approximately $5.7 million, adjusted for non-cash expenses in the aggregate amount of approximately $1.3 million and by approximately $0.6 million of cash generated by net changes in the levels of operating assets and liabilities, primarily related to an increase in accounts payable and accrued expenses, partially offset by an increases in accounts receivable and prepaid expenses and other current assets. 22 Â Investing Activities. During the nine months ended September 30, 2024, and 2023, cash provided by investing activities was $1.6 million and used in investing activities was $4.3 million respectively. These amounts were impacted by the net difference between maturities and purchases of short term investments, in addition to purchases of equipment. Financing Activities. There was $5.4 million and $9.7 million in cash generated from financing activities during the nine months ended September 30, 2024 and 2023, respectively, due entirely to the net proceeds from our equity offerings in January 2024, January 2023 and August 2023. Critical Accounting Policies and Estimates Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America require management to make estimates and assumptions that affect certain reported amounts and disclosures. These estimates and assumptions are reviewed on an on-going basis and updated as appropriate. Actual results could differ from those estimates. Our significant estimates include deferred tax valuation allowances, valuation of stock-based compensation, warranty obligations and reserves for credit losses and slow-moving inventory. Other There have been no material changes to our critical accounting policies from those described in our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023. Recent Accounting Standards Information regarding new accounting standards is included in Note 3 â€" Recently Adopted Accounting Standards to our unaudited condensed consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q. Item 3. Quantitative and Qualitative Disclosures about Market Risk This item is not applicable to us as a smaller reporting company. Item 4. Controls and Procedures Evaluation of Disclosure Controls and Procedures Â The term â€œdisclosure controls and procedures,â€ as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€), refers to controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SECâ€™s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that such information is accumulated and communicated to a companyâ€™s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Â Our management, with the participation of our Chief Executive Officer, our principal executive officer, and our Chief Financial Officer, our principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2024. Based upon such evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of such date. Changes in Internal Control over Financial Reporting There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) identified in connection with the evaluation of our internal control that occurred during the quarter ended September 30, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Â 23 Â Part II. OTHER INFORMATION Item 1. Legal Proceedings Â The Company may be involved in legal proceedings, claims and assessments arising from the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. During the fourth quarter of 2023, the Company settled an age discrimination claim by a former employee. The settlement was paid and all insurance proceeds were received during the three months ended March 31, 2024. There is no material litigation against the Company at this time that is required to be disclosed under Item 103 of Regulation S-K. Item 1A. Risk Factors The following important factors, among others, could cause our actual operating results to differ materially from those indicated or suggested by forward-looking statements made in this Form 10-Q or presented elsewhere by management from time to time. Investors should carefully consider the risks described below before making an investment decision. The risks described below are not the only ones we face. Additional risks not presently known to us or that we currently believe are not material may also significantly impair our business operations. Our business could be harmed by any of these risks. The trading price of our common stock could decline due to any of these risks, and investors may lose all or part of their investment. Â Risks Associated with Our Business Risks Related to Our Operating and Financial Results We have a history of operating losses. Factors both within and outside of our control could result in a delay in our ability to achieve cash flow breakeven on a quarterly basis. We have a history of losses since inception. For the three and nine months ended September 30, 2024, we incurred net losses of $0.9 million and $5.9 million, respectively. For the year ended December 31, 2023, we incurred a net loss of $8.1 million. At September 30, 2024, we had an accumulated deficit of approximately $102.8 million. The extent and duration of future operating and net losses will depend on our ability to grow our revenues and absorb the headcount and additional clinical, reimbursement and manufacturing capacity we added in the first half of 2024, the ability of our supply chain to meet our volume requirements without disruption and our ability to compensate for additional advertising expenditures in the second half of 2024. Additionally, our expected payments must be received and our days sales outstanding in accounts receivable must not increase. Under these assumptions, we believe it is achievable to be operating cash flow breakeven on a quarterly basis in the fourth quarter of 2024. However, there can be no assurance that we can cost effectively grow our revenues without requiring additional capital. Our cash, cash equivalents and restricted cash at September 30, 2024 were approximately $6.9 million. On July 11, 2024, we entered into a Loan and Security Agreement with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (â€œSilicon Valley Bankâ€), which provides us the ability to borrow up to $4.0 million against eligible accounts receivable. The line of credit remains undrawn as of the issuance date of these financial statements. Availability under the line of credit is approximately $0.9 million as of September 30, 2024. On January 19, 2024, we completed a registered direct offering of our common stock and pre-funded warrants, generating net proceeds of approximately $5.4 million. We believe that our existing cash, cash equivalents, and short-term investments at September 30, 2024 will be sufficient to fund our operations for the twelve months from the date of this report. If we encounter obstacles such as those that have been referred to above, the timing of our ability to achieve operating cash flow breakeven could extend beyond the fourth quarter of 2024 and additional capital may be required. Our direct billing revenues are concentrated with a small number of payers, including CMS. Adverse changes in the reimbursement policies of these payers regarding the MyoPro could have an adverse effect on our business. Revenues from providing the MyoPro directly to patients, a sales channel we refer to as direct billing, represented 81% and 76% of revenues for the three and nine months ended September 30, 2024, respectively. In 2024, we began providing the MyoPro to Medicare Part B patients. Revenues from the Centers for Medicare & Medicaid Services (â€œCMSâ€) represented 68% and 58% of direct billing revenues (55% and 44% of total revenues) for the three and nine months ended September 30, 2024, respectively. In order to maximize revenues and minimize cash used for operations, we focus on patients with commercial insurers who have previously reimbursed for the MyoPro. Beginning in September 2021, a large insurer that has historically reimbursed for the MyoPro began denying claims after having granted a pre-authorization and after we delivered the devices to patients, and these post-service denials currently continue. Revenues from patients insured by this payer represented 24% and 29% of direct billing revenues (19% and 22% of total revenue) during the three and nine months ended September 30, 2024, respectively. With a small number of exceptions, appeals filed with the payer have been successful and these claims have ultimately been paid. 24 Â This payer also continues to provide us with pre-authorizations to serve new patients, however denials are increasing with this payer, as with other Medicare Advantage plans. If CMS were to change their coverage criteria for the MyoPro, or the aforementioned commercial payer were to continue to regularly deny appeals on filed claims, reduce the number of MyoProâ€™s that it will authorize for its insured patients, or delays payments pending resolution of the denial and appeals process, our revenues and cash flows would be negatively impacted, which would have an adverse effect on our business. We may experience significant fluctuations in our quarterly and annual results. Fluctuations in our quarterly and annual financial results have resulted and will continue to result from numerous factors, including: â€¢timing, number and dollar value of reimbursements of our products by insurance payers; â€¢changes in the mix of products we sell; â€¢strategic actions by us, such as acquisitions of businesses, products, or technologies; â€¢effects of domestic and foreign economic conditions and exchange rates on our industry and/or customers; â€¢the divestiture or discontinuation of a product line or other revenue generating activity; â€¢the relocation and integration of manufacturing operations and other strategic restructuring; â€¢regulatory actions which may necessitate recalls of our products or warning letters that negatively affect the markets for our products; â€¢costs incurred by us in connection with the termination of contractual and other relationships, including distributorships; â€¢our ability to collect outstanding accounts receivable; â€¢the expiration or exhaustion of deferred tax assets such as net operating loss carryforwards; â€¢increased product and price competition, due to reimbursement of our products by Medicare, the regulatory landscape, market conditions or other factors; â€¢technology changes to enhance individual data privacy that could negatively impact our ability to market our products to prospective candidates and could result in increased advertising costs; â€¢market reception of our new or improved product offerings; and â€¢the loss of any significant customer. Â These factors, some of which are not within our control, may cause the price of our common stock to fluctuate substantially. If our quarterly operating results fail to meet or exceed the expectations of securities analysts or investors, our stock price could drop suddenly and significantly. We believe quarterly comparisons of our financial results are not always meaningful and should not be relied upon as an indication of our future performance. Â Risks related to our Reliance on Third Parties Â We may not be able to obtain third-party payer reimbursement, including reimbursement by Medicare, for our products. Â Sales of our device depend, in part, on the extent to which our products are covered by third-party payers, such as government health programs, commercial insurance and managed healthcare organizations. See section titled â€œBusiness Section â€“ Government Regulation â€“ Health Insurance Reimbursementâ€, in our December 31, 2023 annual report on Form 10-K. Third-party payers are increasingly challenging the prices charged, examining the medical necessity and creating additional restrictions on coverage, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payers may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication. In addition, CMS may issue local or national coverage determinations which could result in more restrictive coverage for our products. The coverage determination process is often a time-consuming and costly process that requires us to provide scientific and clinical support for the use of our products to each payer separately, with no assurance that coverage and adequate reimbursement will be obtained. In addition, the absence of in-network contracts with Medicare Advantage plans or commercial insurers could result in utilization management for out-of-network patients. Currently, we are almost entirely dependent on third parties to cover the cost of our products to patients and rely on their reimbursement for the cost of our products. If CMS, the U.S. Department of Veterans Affairs (the â€œVAâ€) health insurance companies and other third-party payers do not provide adequate coverage or reimbursement for our products, then our sales will be limited to clinical facilities and individuals who can pay for our devices without reimbursement. To our knowledge, from inception through September 30, 2024, fewer than 50 units have been self-paid or funded by non-profit foundations. Some commercial health insurance plans have published statements that they will not cover the cost of the 25 Â MyoPro for their members. In the event we are unsuccessful in obtaining additional coverage and adequate reimbursement for our products from third-party payers, our sales will be significantly constrained. Currently, reimbursement for the cost of our products is obtained primarily on a case-by-case basis until such time, if any, we obtain broad coverage policies with Medicare and third-party payers. There can be no assurance that we will be able to obtain these broad coverage policies or that Medicare or its local administrative billing contractors will not establish more restrictive coverage requirements for the MyPro in the future (for example, in the form of a local or national coverage determination). See section titled â€œBusiness Section â€“ Government Regulation â€“ Health Insurance Reimbursementâ€, in our December 31,2023 annual report on Form 10-K. In connection with Medicare reimbursement, in November 2023 CMS reclassified the MyoPro from the durable medical equipment benefit to the brace benefit category effective January 1, 2024, thereby allowing for lump sum reimbursement. Such lump sum reimbursements based on the fees posted by CMS, are now being made. CMS published final average payment determinations for the MyoPro Motion W (L8701) of approximately $33,500 and the MyoPro Motion G (L8702) of approximately $65,900, effective April 1, 2024. Our claims can be reviewed on a case-by-case basis at any time by CMS. There can be no assurance that the final fees will be sufficient to permit us to generate gross margin required to allow us to operate on a profitable basis. Third-party payers also may continue to deny or limit coverage, limit reimbursement or reduce their levels of payment, or our costs of production may increase faster than increases in reimbursement levels. In addition, we may not obtain coverage and reimbursement approvals in a timely manner. Our failure to operate profitably could negatively impact market acceptance of MyoPro. If CMS amends, restricts, or retracts coverage requirements, its billing contractors and insurers offering Medicare Advantage insurance plans may restrict what they reimburse for the MyoPro, which would have an adverse effect on our business. Revenues from patients who are covered by Medicare Advantage insurance plans have become a significant portion of our overall revenues. Approximately 24% and 27% of our product revenues were derived from patients with Medicare Advantage insurance plans for the three and nine months ended September 30, 2024, respectively. Revenues from Medicare Part B patients represented 55% and 44% of total revenue for the three and nine months ended September 30, 2024, respectively. If CMS amends, restricts, or retracts its November 2023 rule

classifying MyoPro as a brace, amends or retracts any published fees, or establishes more restrictive inclusion criteria for coverage, our Medicare revenues could be negatively impacted and insurers offering Medicare Advantage insurance plans may no longer cover or adequately reimburse for the MyoPro. As a result, our overall revenues and cash flows would be negatively impacted, which could have an adverse effect on our business. See â€œRisks Related to our Reliance on Third Partiesâ€”We may not be able to obtain third-party payer reimbursement, including reimbursement by Medicare, for our productsâ€ for additional information about CMS coverage decisions. We currently rely, and in the future will rely, on sales of our MyoPro products for our revenue, and we may not be able to expand market acceptance or grow revenues in the orthotics and prosthetics channel. We currently rely, and in the future will rely, on sales of our MyoPro products for our revenue. MyoPro products are relatively new products, and continuing market acceptance and adoption will depend on educating people with limited upper extremity mobility and healthcare providers as to the distinct features, ease-of-use, improved quality of life and other benefits of MyoPro systems compared to alternative technologies and treatments. Our products may not be perceived to have sufficient potential benefits compared with these alternatives, which include rehabilitation therapy or amputation with a prosthetic replacement. Also, healthcare providers such as orthotics and prosthetics ("O&P") practices and the VA want to see good outcomes for their patients and certainty of third-party reimbursement. Accordingly, healthcare providers may not recommend the MyoPro until there is sufficient evidence to convince them to alter the treatment methods they typically recommend. This evidence may include prominent healthcare providers or other key opinion leaders in the upper extremity paralysis community recommending the MyoPro as effective in providing identifiable immediate and long-term health benefits, and the publication of additional peer-reviewed clinical studies demonstrating its value. Additionally, because the MyoPro is a prescription device, patients require the prescription of a healthcare provider to access our products and to have the device reimbursed by insurance. Expanding market acceptance of MyoPro products could be negatively impacted by many other factors, including, but not limited to: â€¢patient outcomes not meeting expectations; â€¢lack of sufficient evidence supporting the benefits of MyoPro over competitive products or other available treatment, or lifestyle management to accommodate the disability; â€¢patient resistance to wearing an external device or making required insurance co-payments; â€¢limitations on the ability of patients to complete evaluations and fittings, including adverse changes in their health, or other environmental, social and economic barriers to patient access; â€¢results of clinical studies relating to MyoPro or similar products; â€¢claims that MyoPro, or any component thereof, infringes on patent or other intellectual property rights of third parties; 26 Â â€¢perceived risks associated with the use of MyoPro or similar products or technologies; â€¢the introduction of new competitive products or greater acceptance of competitive products; â€¢adverse regulatory or legal actions relating to MyoPro or similar products or technologies; and â€¢problems arising from the insourcing of our manufacturing capabilities, or our existing manufacturing and supply relationships with third parties. Any factors that negatively impact sales of MyoPro would adversely affect our business, financial condition and operating results. We depend on a single third-party to manufacture key subassemblies for the MyoPro and a limited number of third-party suppliers for certain components of the MyoPro. While we are the manufacturer of record with the U.S. Food and Drug Administration, (the â€œFDAâ€) for the MyoPro device we sell, we have contracted with Cogmedix, Inc. (â€œCogmedixâ€), a contract manufacturer with expertise in the medical device industry, for the contract manufacture of certain subassemblies and the sourcing of some of our components and raw materials. Pursuant to this contract, Cogmedix manufactures subassemblies for the MyoPro pursuant to our specifications at its facility in West Boylston, Massachusetts. As the manufacturer of the MyoPro, we ultimately remain responsible to the FDA for overseeing Cogmedixâ€™s manufacturing activities to ensure that they conform with product specifications and applicable laws and regulations, including FDAâ€™s good manufacturing practice requirements for medical devices. Any failure to effectively oversee the regulatory compliance of the product and contract manufacturing activities by Cogmedix can lead to potential enforcement actions, including civil or criminal liabilities, as well as recalls with the FDA. We may terminate our relationship with Cogmedix at any time upon sixty (60) daysâ€™ written notice. For our business strategy to be successful, Cogmedix must be able to manufacture our subassemblies in sufficient quantities, and to source raw materials and components, in compliance with regulatory requirements and quality control standards, in accordance with agreed upon specifications, at acceptable costs and on a timely basis. Increases in our product sales, whether forecasted or unanticipated, or supply chain constraints that may arise for any number of reasons, could strain the ability of Cogmedix to manufacture an increasingly large supply of our current or future subassemblies in a manner that meets these various requirements. In addition, although we are not restricted from engaging an alternative manufacturer, the process of moving our manufacturing activities would be time consuming and costly, and may limit our ability to meet our sales commitments, which could harm our reputation and could have a material adverse effect on our business. Further, any new contract manufacturer would need to be compliant with FDA regulations and International Organization for Standardization (â€œISOâ€) standard 13485. We also rely on third-party suppliers, including AB Corp, for 3D printed orthotic components. Some third-party suppliers contract directly with Cogmedix, to supply certain components of the MyoPro products. Cogmedix does not have long-term supply agreements with most of their suppliers and, in many cases, makes purchases on a purchase order basis. We do not have any long-term supply agreements directly with Cogmedixâ€™s suppliers. Our ability and Cogmedixâ€™s ability to secure adequate quantities of such products may be limited. Suppliers may encounter problems that limit their ability to manufacture components for our products, including financial difficulties or damage to their manufacturing equipment or facilities. If we, or Cogmedix, fail to obtain sufficient quantities of high-quality components to meet demand on a timely basis, or fail to effectively oversee the regulatory compliance of the supply chain, we could face regulatory enforcement, have to conduct recalls, lose customer orders, our reputation may be harmed, and our business could suffer. Cogmedix generally uses a small number of suppliers for the MyoPro products. Depending on a limited number of suppliers exposes us to risks, including limited control over pricing, availability, quality and delivery schedules. If any one or more of our suppliers ceases to provide sufficient quantities of components in a timely manner or on acceptable terms, Cogmedix would have to seek alternative sources of supply. It may be difficult to engage additional or replacement suppliers in a timely manner. Failure of these suppliers to deliver products at the level our business requires would limit our ability to meet our sales commitments, which could harm our reputation and could have a material adverse effect on our business. Cogmedix also may have difficulty obtaining similar components from other suppliers that are acceptable to the FDA or other regulatory agencies, and the failure of Cogmedixâ€™s suppliers to comply with strictly enforced regulatory requirements could expose us to regulatory action including warning letters, product recalls, termination of distribution, product seizures or civil penalties. It could also require Cogmedix to cease using the components, seek alternative components or technologies and we could be forced to modify our products to incorporate alternative components or technologies, which could result in a requirement to seek additional regulatory approvals. Any disruption of this nature or increased expenses could harm our commercialization efforts and adversely affect our operating results. We also rely on a limited number of suppliers for certain materials and components used by the MyoPro and do not maintain any long-term supply agreement with respect to these materials and components. If we fail to obtain sufficient quantities of these materials and components in a timely manner, our reputation may be harmed and our business could suffer. While we currently believe we have sufficient inventory in our supply chain in the near term, if we, or any third parties in our supply chain for materials which are used in either the manufacture of our products are adversely impacted by infections or restrictions from public heath crises, or other factors, our supply chain may be disrupted and our ability to manufacture and ship our products may be limited. While many 27 Â companies continue to experience shortages of certain electronic components, so far we and our contract manufacturing partners have been able to procure the electronic components necessary for the manufacture of our products, but we are dealing with longer lead times and delivery delays for certain critical components. There can be no assurance that such supplies will become less constrained in the future. Risks Related to Limited Operating History and Capital Requirements Our limited operating history makes it difficult for us to evaluate our future business prospects and make decisions based on those estimates of our future performance. Since inception through September 30, 2024, we have delivered more than 2,800 units for use by patients at home and at clinical facilities. Our latest product line, the MyoPro, was introduced to the market in fiscal year 2012 and we have delivered more than 2,500 units since such time. As a result, we have a limited operating history. It is difficult to forecast our future results based upon our historical data. Because of the uncertainties related to our limited historical operations, we may be hindered in our ability to anticipate and timely adapt to increases or decreases in revenues or expenses. We may not have sufficient funds to meet our future capital requirements. Our cash, cash equivalents and restricted cash at September 30, 2024 was approximately $6.9 million. On July 11, 2024, we entered into a Loan and Security Agreement with Silicon Valley Bank, which provides us the ability to borrow up to $4.0 million against eligible accounts receivable. The line of credit is undrawn as of the issuance date of these financial statements. Availability under the line of credit is approximately $0.9 million as of September 30, 2024. On January 19, 2024, we completed a registered direct offering of our common stock and pre-funded warrants, generating net proceeds of approximately $5.4 million. Our ability to grow our business is dependent on our ability to generate sufficient cash flows from operations or to raise additional capital to meet our obligations, if necessary. We believe that our existing cash and cash equivalents will be sufficient to enable us to achieve operating cash flow breakeven on a quarterly basis, which we believe is achievable in the fourth quarter of 2024, assuming that we are able to grow revenues as planned, our supply chain is able to meet our volume requirements without disruption, we are able to compensate for additional advertising expenditures in the second half of 2024, expected payments are received and our days sales outstanding in accounts receivable does not increase. If additional capital is required to achieve operating cash flow breakeven, we may be unable to obtain additional funds on reasonable terms, or at all. Our ability to secure financing and the cost of raising such capital are dependent on numerous factors, including general economic and capital markets conditions, credit availability from lenders, investor confidence and the existence of regulatory and tax incentives that are conducive to raising capital. Uncertainty in the financial markets has caused banks and financial institutions to decrease the amount of capital available for lending and has significantly increased the risk premium of such borrowings. In addition, such turmoil and uncertainty has significantly limited the ability of companies to raise funds through the sale of equity or debt securities. If we are unable to raise additional funds, we may need to delay, modify or abandon some or all of our business plans or cease operations. If we raise funds through the issuance of debt, the amount of any indebtedness that we may raise in the future may be substantial, and we may be required to secure such indebtedness with our assets and may have substantial interest expenses. If we default on any future indebtedness, our lenders could declare all outstanding principal and interest to be due and payable and our secured lenders may foreclose on the facilities securing such indebtedness. Usage of our line of credit requires us to meet financial and operating covenants, which could place limits on our operations, decrease our liquidity and increase the amount of cash flow required to service our debt. If we raise funds through the issuance of equity securities, such issuance could result in dilution to our stockholders and the newly issued securities may have rights senior to those of the holders of our common stock. Continued inflation may materially impact our financial operations or results of operations. Inflation has and is expected to remain elevated for the near future. Inflationary factors, such as increases in the cost of our raw materials, manufacturing, interest rates and overhead costs may adversely affect our operating results. The price and availability of key components used to manufacture our products has been increasing and may continue to fluctuate significantly. In addition, the cost of labor internally or at our third-party manufacturers could increase significantly due to regulation or inflationary pressures. Additionally, the cost of logistics and transportation fluctuates in large part due to the price of oil, and availability can be limited due to political and economic issues. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, we may experience some effect in the near future, especially if inflation rates continue to rise. Our level of indebtedness and debt service obligations could adversely affect our financial condition and may make it more difficult for us to fund our operations. In July 2024, we entered into a Loan and Security Agreement (the â€œLoan Agreementâ€) with Silicon Valley Bank. Pursuant to the terms of the Loan Agreement, we may request advances on a revolving line of credit whereby we may borrow up to $4 million (the â€œRevolving Lineâ€), which Revolving Line may be increased to $5.5 million at Silicon Valley Bankâ€™s sole discretion upon the occurrence of certain events. The 28 Â Revolving Line is secured on a first priority basis by all of our assets other than intellectual property and certain customary exceptions. To the extent we use the Revolving Line, such indebtedness may create additional financing risk for us, particularly if our business or prevailing financial market conditions are not conducive to paying off or refinancing our outstanding debt obligations at maturity. This indebtedness could also have important negative consequences, including the fact that: â€¢we will need to repay our indebtedness by making payments of interest and principal, which will reduce the amount of money available to finance our operations; and â€¢our failure to comply with the restrictive covenants under the Loan Agreement could result in an event of default that, if not cured or waived, would accelerate our obligation to repay this indebtedness, and Silicon Valley Bank could seek to enforce our security interest in the assets securing such indebtedness. Â Â Risks Related to Competitors and Our Market The industries in which we operate are highly competitive and subject to rapid technological change. If our competitors are better able to develop and market products that are safer, more effective, less costly, easier to use, or are otherwise more attractive, we may be unable to compete effectively with other companies. Industrial and medical robotics is characterized by intense competition and rapid technological change, and we will face competition on the basis of product features, clinical outcomes, price, services and other factors. Publication of fees by CMS under our Healthcare Common Procedures Coding System billing codes L8701 and L8702 is also expected to attract competition. Competitors may include large medical device and other companies, some of which have significantly greater financial and marketing resources than we do, and firms that are more specialized than we are with respect to particular markets. Our competition may respond more quickly to new or emerging technologies, undertake more extensive marketing campaigns, and have greater financial, marketing and other resources than we do or may be more successful in attracting potential customers, employees and strategic partners. Our competitive position will depend on multiple complex factors, including our ability to maintain and grow market acceptance for our products, develop new products, implement production and marketing plans, secure regulatory clearances or approvals, if necessary, for products under development and protect our intellectual property. In some instances, competitors may also offer, or may attempt to develop, alternative therapies for disease states that may be delivered without a medical device. The development of new or improved products, processes or technologies by other companies may render our products or proposed products obsolete or less competitive. The entry into the market of manufacturers located in low-cost manufacturing locations may also create pricing pressure, particularly in developing markets. Our future success depends, among other things, upon our ability to compete effectively against current technology, as well as to respond effectively to technological advances, and upon our ability to successfully implement our marketing strategies and execute our research and development plans. We sell to O&P providers and distributors who are free to market products that compete with the MyoPro, and we rely on these parties to market and promote our products in accordance with their FDA listings, select appropriate patients and provide adequate follow-on care. We rely on our relationships with qualified O&P providers and our distribution arrangements to market and sell our products. We believe that a meaningful percentage of our sales will continue to be generated through these channels in the future. However, none of these partners are required to sell or provide our products exclusively. If a key independent O&P provider were to cease to distribute our products, our sales could be adversely affected. In such a situation, we may need to seek alternative independent providers or increase our reliance on our other independent providers or our direct field representatives, which may not prevent our sales from being adversely affected. Additionally, to the extent that we enter into additional arrangements with independent distributors to perform sales, marketing, or distribution services, the terms of the arrangements could cause our profit margins to be lower than if we directly marketed and sold our products. If these independent O&P providers or distributors do not follow our inclusion/exclusion criteria for patient selection or do not provide adequate follow-on care, then our reputation may be harmed by patient dissatisfaction. This could also lead to product returns and adversely affect our financial condition. When issues with distributors have arisen in the past, we have supplied additional training and documentation and/or ended the distributor relationship. Â The sales and marketing of medical devices is under increased scrutiny by the FDA and other enforcement bodies. If our sales and marketing activities fail to comply with FDA regulations, such as regulations for the labeling and advertising of our products, or other applicable laws, we may be subject to warnings or enforcement actions from the FDA or other enforcement bodies. For example, we are restricted from promoting our products for any use that is beyond the scope of their applicable FDA classification regulation. Such promotion could result in enforcement action by the FDA, which may include, but is not limited to untitled letters or warning letters, injunctions, recall or seizure of our products, and imposition of FDAâ€™s premarket clearance or approval requirements. 29 Â The market for myoelectric braces is new and the rate of adoption is uncertain, and important assumptions about the potential market for our products may be inaccurate. The market for myoelectric braces, or orthotics, is new and the rate of adoption is uncertain. Our estimates of market size are derived from statistics regarding the number of individuals with paralysis, but not necessarily limited to their upper extremities. Accordingly, it is difficult to predict the future size and rate of growth of the market. We cannot be certain whether the market will continue to develop or if orthotics will achieve and sustain a level of market acceptance and demand sufficient for us to continue to generate revenue and achieve profitability. Limited sources exist to obtain reliable market data with respect to the number of mobility-impaired individuals and the occurrence of upper extremity paralysis in our target markets. In addition, there are no third-party reports or studies regarding what percentage of those with upper extremity paralysis

would be able to use orthotics in general, or our current or planned future products in particular. In order to use our current products marketed to those with upper extremity paralysis, users must meet a set of inclusion criteria and not have a medical condition which disqualifies them from being an appropriate candidate. Future products for those with upper extremity paralysis may have the same or other restrictions. Our business strategy is based, in part, on our estimates of the number of upper extremity impaired individuals and the incidence of upper extremity injuries in our target markets and the percentage of those groups that would be able to use our current and future products. Our assumptions and estimates may be inaccurate and may change. If the upper extremity orthotics market fails to develop or develops more slowly than we expect, or if we have relied on sources or made assumptions or estimates that are not accurate, our business could be adversely affected. In addition, because we operate in a new market, the actions of our competitors could adversely affect our business. Adverse events such as product defects or legal claims with respect to competing or similar products could cause reputational harm to the market on the whole. Further, adverse regulatory findings or reimbursement-related decisions with respect to other products could negatively impact the entire market and, accordingly, our business. Risks Related to Our Products We may receive a significant number of warranty claims or our MyoPro may require significant amounts of service after sale. Sales of MyoPro products generally include a three-year warranty for parts and labor, other than for normal wear and tear. As the number and complexity of the features and functionalities of our products increase, we may experience a higher level of warranty claims. If product returns or warranty claims are significant or exceed our expectations, we could incur unanticipated expenditures for parts and services, which could have a material adverse effect on our operating results. Defects in our products or the software that drives them could adversely affect the results of our operations. The design, manufacture and marketing of the MyoPro products involve certain inherent risks. Manufacturing or design defects, unanticipated use of the MyoPro, or inadequate disclosure of risks relating to the use of MyoPro products can lead to injury or other adverse events. In addition, because the manufacturing of our products is outsourced to Cogmedix, we may not always be aware of manufacturing defects that could occur and corrective or preventive actions implemented by Cogmedix may not be effective at resolving such defects. Such adverse events could lead to recalls or safety alerts relating to MyoPro products (either voluntary or required by the FDA or similar governmental authorities in other countries), and could result, in certain cases, in the removal of MyoPro products from the market. A recall could result in significant costs. To the extent any manufacturing defect occurs, our agreement with Cogmedix contains a limitation on Cogmedixâ€™s liability, and therefore we could be required to incur the majority of related costs. A defect in connection with the fabrication of our products may result in significant costs in connection with lawsuits or refunds. Product defects or recalls could also result in negative publicity, damage to our reputation or, in some circumstances, delays in new product approvals. MyoPro users may not use MyoPro products in accordance with safety protocols and training, which could enhance the risk of injury. Any such occurrence could cause delay in market acceptance of MyoPro products, damage to our reputation, additional regulatory filings, product recalls, increased service and warranty costs, product liability claims and loss of revenue relating to such hardware or software defects. The medical device industry has historically been subject to extensive litigation over product liability claims. We have not been subject to such claims to date, but we may become subject to product liability claims alleging defects in the design, manufacture or labeling of our products in the future. A product liability claim, regardless of its merit or eventual outcome, could result in significant legal defense costs and high punitive damage payments. Although we maintain product liability insurance, the coverage is subject to deductibles and limitations, and may not be 30 Â adequate to cover future claims. Additionally, we may be unable to maintain our existing product liability insurance in the future at satisfactory rates or in adequate amounts. While there is long-term clinical data supporting the safety of our existing MyoPro products, updates to our products inherently have uncertain safety risks as they enter the market. While clinical data have established the safety of MyoPro products, our products undergo periodic updates for various reasons, including performance and reliability improvements and cost reductions. For example, in January 2022, we announced the availability of MyoPro2+. Because MyoPro users generally do not have feeling in their upper extremities, they may not immediately notice adverse effects from updates to the MyoPro, which could exacerbate their impact. If MyoPro products are shown to present new risks or to be unsafe or cause such unforeseen effects in the future, our business and reputation could be harmed, including through field corrections, withdrawals, removals, mandatory product recalls, suspension or withdrawal of FDA registration, significant legal liability or harm to our business reputation. Risks Related to Collaborations and Licensing Agreements We may enter into collaborations, licensing arrangements, joint ventures, strategic alliances or partnerships with third parties that may not result in the development of commercially viable products or the generation of significant future revenues. In the ordinary course of our business, in the future we may enter into collaborations, in-licensing arrangements, joint ventures, strategic alliances or partnerships to develop the MyoPro and to pursue new markets. We are selling the MyoPro in several European countries, as well as Australia. In January 2021, we announced that we had entered into a joint venture (the â€œJVâ€) with Beijing Ryzur Medical Investment Co., Ltd. (â€œRyzur Medicalâ€), to manufacture and sell the products containing our technology in China, including Hong Kong, Taiwan and Macau. The company is named Jiangxi Myomo Medical Assistive Appliance Co., Ltd. (the â€œJV Companyâ€). In December 2021, we entered into a technology license agreement and a trademark license agreement with the JV Company, under which we were entitled to receive a license fee of $2.7 million and the JV Company will commit to purchase a minimum of $10.75 million of MyoPro control units over the next ten years. During 2023, we received full payment of the $2.7 million initial license fee and have received payment for MyoPro control units of $50,000. This and any other of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. In addition, proposing, negotiating and implementing collaborations, licensing arrangements, joint ventures, strategic alliances or partnerships may be a lengthy and complex process. We may not identify, secure, or complete any such transactions or arrangements in a timely manner, on a cost-effective basis, on acceptable terms or at all. We have limited institutional knowledge and experience with respect to these business development activities, and we may also not realize the anticipated benefits of any such transaction or arrangement. In particular, these collaborations may not result in the development of products that achieve commercial success or result in significant revenues and could be terminated prior to developing any products. Any delays in entering into new strategic partnership agreements related to our products could delay the development and commercialization of our products in certain geographies, which would harm our business prospects, financial condition and results of operations. If we pursue collaborations, additional licensing arrangements and joint ventures, strategic alliances or partnerships, we may not be able to consummate them, or we may not be in a position to exercise sole decision decision-making authority regarding the transaction or arrangement, which could create the potential risk of creating impasses on decisions, and our collaborators may have economic or business interests or goals that are, or that may become, inconsistent with our business interests or goals. It is possible that conflicts may arise with our collaborators. Our collaborators may act in their self-interest, which may be adverse to our best interest, and they may breach their obligations to us. Any such disputes could result in litigation or arbitration which would increase our expenses and divert the attention of our management. Further, these transactions and arrangements are contractual in nature and may be terminated or dissolved under the terms of the applicable agreements. Risks Related to Our Business Operations and Management We will be moving our operations to a new, larger facility, by the end of 2024. Regulatory requirements in the United States and other countries, compliance with which is included under our certified quality management system, requires us to re-qualify our new manufacturing operation before we can manufacture and deliver our products from our new facility. Delays in completing this qualification could adversely affect our business Â We will be moving our operations to a new, larger facility by the end of 2024. Our lease on our current headquarters and manufacturing facility in Boston expires in January 2025. In August 2024, we entered into a lease for our new corporate headquarters and manufacturing facility in Burlington, Massachusetts. We are required under regulations in the United States. and other countries, which are codified in our certified quality management system, to re-qualify our manufacturing operation before we can manufacture and deliver our products from our new facility. If there are delays in completing this re-qualification, the start up of our manufacturing will be delayed, which would adversely impact the planned growth of our manufacturing capacity. In addition, we would be required remain in our facility in Boston until the re-qualification is completed. If the delay was beyond the expiration date of our lease, we would be required to pay the landlord holdover rental 31 Â payments, which are double our existing lease payment. Payment of holdover rental payments for an extended period of time could negatively affect our cash flows. Â If we fail to properly manage our anticipated growth, including in O&P channel and international markets, our business could suffer. As we grow our revenues from Medicare Part B patients and expand the number of locations which provide the MyoPro products, including O&P practices in the United States, and future planned international distribution, we expect that it will place significant strain on our management team and on our financial resources. Failure to manage our growth effectively could cause us to mis-allocate management or financial resources and result in losses or weaknesses in our infrastructure, systems, processes and controls, which could materially adversely affect our business. Additionally, our anticipated growth will increase the demands placed on our suppliers, resulting in an increased need for us to manage our suppliers and monitor for quality assurance. Moreover, there are significant costs and risks inherent in selling our products, particularly in international markets, including: (a) time and difficulty in building a widespread network of distribution partners; (b) increased shipping and distribution costs, which could increase our expenses and reduce our margins; (c) potentially lower margins in some regions; (d) longer collection cycles in some regions; (e) compliance with foreign laws and regulations; (f) compliance with anti-bribery, anti-corruption, and anti-money laundering laws, such as the Foreign Corrupt Practices Act and the Office of Foreign Assets Control regulations, by us, our employees, and our business partners; (g) currency exchange rate fluctuations and related effects on our results of operations; (h) economic weakness, including inflation, or political instability in foreign economies and markets; (i) compliance with tax, employment, immigration, and labor laws for employees living or traveling abroad; (j) workforce uncertainty in countries where labor unrest is more common than in the United States; (k) business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters, including earthquakes, typhoons, floods and fires; and (l) other costs and risks of doing business internationally, such as new tariffs which may be imposed. For example, we have entered into a joint venture with Beijing Ryzur Medical Investment Co., Ltd., to manufacture and sell the products containing the Companyâ€™s technology in China, including Hong Kong, Taiwan and Macau. In connection with this joint venture, we may encounter challenges in working with our joint venture partners, including with respect to compliance with local laws and domestic laws related to foreign operations. These and other factors could harm our ability to implement planned growth in international operations and, consequently, harm our business, results of operations, and financial condition. Further, we may incur significant operating expenses as a result of our planned expansion activities, and they may not be successful. We have limited experience with regulatory environments and market practices internationally, and we may not be able to penetrate or successfully operate in new markets. We may also encounter difficulty growing the O&P channel while simultaneously being a direct provider to patients in the United States. and expanding into international markets because of limited brand recognition. These factors my lead to delayed or limited acceptance of our products by patients in these markets. Accordingly, if we are unable to expand O&P channel revenues in the United States., expand internationally or manage our international operations successfully, we may not achieve the expected benefits of this expansion and our financial condition and results of operations could be harmed. We depend on the knowledge and skills of our senior management. We have benefited substantially from the leadership and performance of our senior management and other key employees. We do not carry key person insurance. Our success will depend on our ability to retain our current management and key employees. Competition for these key persons in our industry is intense and we cannot guarantee that we will be able to retain our personnel. The loss of the services of certain members of our senior management or key employees could prevent or delay the implementation and completion of our strategic objectives or divert managementâ€™s attention to seeking qualified replacements. We may seek to grow our business through acquisitions of complementary products or technologies, and the failure to manage acquisitions, or the failure to integrate them with our existing business, could have a material adverse effect on our business, financial condition and operating results. From time to time, we may consider opportunities to acquire other products or technologies that may enhance our products or technology or advance our business strategies. Potential acquisitions involve numerous risks, including: â€¢problems assimilating the acquired products or technologies; â€¢issues maintaining uniform standards, procedures, controls and policies; â€¢unanticipated costs associated with acquisitions; â€¢diversion of managementâ€™s attention from our existing business; â€¢risks associated with entering new markets in which we have limited or no experience; and â€¢increased legal and accounting costs relating to the acquisitions or compliance with regulatory matters. 32 Â We have no current commitments with respect to any acquisition and no current plans to seek acquisitions; however, depending on industry and market conditions, we may consider acquisitions in the future. If we do proceed with acquisitions, we do not know if we will be able to identify acquisitions we deem suitable, whether we will be able to successfully complete any such acquisitions on favorable terms or at all, or whether we will be able to successfully integrate any acquired products or technologies. Our potential inability to integrate any acquired products or technologies effectively may adversely affect our business, operating results and financial condition. Â Risks Related to Government Regulation Risks Related to Healthcare Industry We are subject to extensive governmental regulations relating to the design, development, manufacturing, labeling and marketing, delivery and billing of our products, and a failure to comply with such regulations could lead to withdrawal or recall of our products from the market. Our products are regulated as medical devices in the United States under the FFDCA, as implemented and enforced by the FDA. Under the FFDCA, medical devices are classified into one of three classesâ€”Class I, Class II or Class IIIâ€”depending on the degree of risk associated with the medical device, what is known about the type of device, and the extent of control needed to provide reasonable assurance of safety and effectiveness. Classification of a device is important because the class to which a device is assigned determines, among other things, the necessity and type of FDA pre-market review. This determination is required prior to marketing the device. See section titled â€œBusiness â€“ Government Regulationâ€, in our December 31,2023 annual report on Form 10-K. In 2012, we listed the MyoPro device as a Class I, 510(k)-exempt, limb orthosis with the FDA. From time to time, the FDA may disagree with the classification regulation under which a registrant lists their device. For example, the FDA may disagree with a registrantâ€™s determination to classify their device as a Class I medical device. Instead, the FDA may determine the device to be a Class II or Class III device requiring the submission of a premarket notification, or 510(k), or a premarket approval (â€œPMAâ€) application for premarket clearance or approval. As the FDA is now giving more attention to the differentiated performance of myoelectric controlled orthotics, we elected to change our device listing to be under a Class II classification regulation for biofeedback devices. Under the classification regulation, we believe our device remains 510(k)-exempt as a prescription battery powered external limb orthosis that is indicated for functional improvement, a device which is generally 510(k)-exempt under the classification regulation. In the event that the FDA determines that our devices, whether by functionality or marketing claims, exceed the limitations on 510(k)-exemption such that premarket clearance or approval is required (i.e., that our device is intended for a use different from the intended use of a legally marketed device in the generic type of device under the applicable classification regulation or that our modified device operates using a different fundamental scientific technology than such a legally marketed device), should be classified as Class II devices or Class III devices requiring premarket clearance or approval, or should FDA decide to reclassify our device as a Class II or Class III device requiring premarket clearance or approval, we could be precluded from marketing our devices for clinical use within the United States for months or longer depending on the requirements of the classification. Obtaining premarket clearance or approval could significantly increase our regulatory costs, including expense associated with required pre-clinical (animal) and clinical (human) trials, more extensive mechanical and electrical testing and other costs. We are registered with the FDA as a manufacturer for medical devices. We are also subject to regulation by foreign governmental agencies in connection with international sales. The agencies enforce laws and regulations that govern the development, testing, manufacturing, labeling, advertising, marketing and distribution, and market surveillance of our medical device products. Following the introduction of a product, the governmental agencies will periodically review our product development methodology, quality management systems, and product performance. We are under a continuing obligation to ensure that all applicable regulatory requirements, such as the FDAâ€™s medical device good manufacturing practice / Quality System Regulation (â€œQSRâ€) requirements and the FDAâ€™s medical device reporting requirements for certain device-related adverse events and malfunction, continue to be met. Our facilities are subject to periodic and unannounced inspection by U.S. and foreign regulatory agencies to audit compliance with the QSR, and comparable foreign regulations. The process of complying with the applicable QSR, medical device reporting, and other requirements can be costly and time consuming, and could delay or prevent the production, manufacturing or sale of the MyoPro. If the FDA determines that we fail to comply with applicable regulatory requirements, they may issue an inquiry or an untitled or warning letter with one or more citations of non-compliance. These inquiries or letters, if not closed promptly, can result in fines, delays or suspensions of regulatory clearances, closure of manufacturing sites, seizures or recalls of products and damage to our reputation. Similarly, if we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. Recent changes in enforcement practice by the FDA and other agencies have resulted in increased enforcement activity, which increases the compliance risk that we and other companies in our industry are facing. 33 Â In

addition, governmental agencies of the United States or other countries may impose new requirements regarding registration, labeling or prohibited materials that may require us to modify or re-register the MyoPro once it is already on the market or otherwise impact our ability to market the MyoPro in the United States or other countries. For example, on February 2, 2024, the FDA published a final rule to amend its QSR requirements to align more closely with the international consensus standards for medical devices by converging with quality management system (â€œQMSâ€) requirements used by other regulatory authorities from other countries. Specifically, the final rule does so primarily by incorporating by reference the 2016 edition of the ISO 13485 standard. The amended regulation is referred to as the Quality Management System Regulation (â€œQMSRâ€) and is effective February 2, 2026. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing authorization that we may have obtained, which could have a material adverse effect on our business, prospects, results of operations, financial condition and our ability to achieve or sustain profitability. The process of complying with these governmental regulations can be costly and time consuming, and could delay or prevent the production, manufacturing or sale of the MyoPro. For instance, the FDA may issue mandates, known as 522 orders, requiring us to conduct post-market surveillance studies of our devices. Failure to comply could result in enforcement of the FFDCA against us or our products including an agency request that we recall our MyoPro products. Our relationships with healthcare providers and physicians and third-party payers will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings. We are subject to broadly applicable fraud and abuse and other healthcare laws and regulations, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act, which may constrain the business or financial arrangements and relationships through which we sell, market and distribute our products. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry (e.g., healthcare providers, physicians and third-party payers), are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally. We are also subject to patient information and privacy and security regulation by both the federal government and the states and foreign jurisdictions in which we conduct business. See section titled â€œBusiness â€“ Government Regulation â€“ Healthcare Privacy Laws and Regulationsâ€, in our December 31,2023 annual report on Form 10-K. The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal and state enforcement bodies often scrutinize interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a companyâ€™s attention from the business. The failure to comply with any of these laws or regulatory requirements subject entities to possible legal or regulatory action. Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities, could, despite efforts to comply, be subject to challenge under one or more of such laws. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. Depending on the circumstances, failure to meet applicable regulatory requirements can result in civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in federal and state funded healthcare programs, contractual damages, reputational harm and the curtailment or restricting of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Any action for violation of these laws, even if successfully defended, could cause us to incur significant legal expenses and divert managementâ€™s attention from the operation of the business. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect business in an adverse way. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. In addition, the commercialization of any of our products outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. If we or our third-party manufacturers or key suppliers fail to comply with the FDAâ€™s Quality System Regulation, our manufacturing operations could be interrupted. We and our third-party manufacturers and key suppliers are also required to comply with the FDAâ€™s QSR which covers the methods and documentation of the production, control, quality assurance, labeling, packaging, storage and shipping of our products. We, Cogmedix, our electromechanical kit manufacturer, and other key suppliers are also subject to the regulations of foreign jurisdictions regarding the manufacturing process with respect to the market for our products abroad. We continue to monitor our quality management, as well as that of our third-party manufacturers and suppliers to improve our overall level of compliance. Our facilities and those of our third-party manufacturers and key suppliers are subject to periodic and unannounced inspection by 34 Â U.S. and foreign regulatory agencies to audit compliance with the QSR and comparable foreign regulations. If our facilities or the facilities of our third-party manufacturers and suppliers are found to be in violation of applicable laws and regulations, or if we or our third-party manufacturers and suppliers fail to take satisfactory corrective action in response to an adverse inspection, the regulatory authority could take enforcement action, including any of the following sanctions: â€¢untitled letters, warning letters, Form 483 findings (results from quality system inspections), fines, injunctions, consent decrees and civil penalties; â€¢customer notifications or repair, replacement or refunds; â€¢detention, recalls or seizure of our products; â€¢operating restrictions or partial suspension or total shutdown of production; â€¢withdrawing our FDA registration; â€¢refusing to provide certificates to foreign governments with respect to exports; and â€¢pursuing criminal prosecution. Any of these sanctions could impair our ability to produce the MyoPro in a cost-effective and timely manner in order to meet our customersâ€™ demands and could have a material adverse effect on our reputation, business, results of operations and financial condition. We may also be required to bear other costs or take other actions that may have a negative impact on our future sales and our ability to generate profits. Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business, financial condition and results of operations. We face risks in connection with the Affordable Care Act (â€œACAâ€) or its possible replacement or modifications and other ongoing healthcare legislative and regulatory reform measures. The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could affect our ability to profitably sell our products. Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i) changes to our manufacturing arrangements; (ii) additions or modifications to product labeling; (iii) the recall or discontinuation of our products; or (iv) additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. Payers, whether domestic or foreign, or governmental or private, are developing increasingly sophisticated methods of controlling healthcare costs and those methods are not always specifically adapted for new technologies. In the United States, there have been and continue to be a number of legislative and regulatory initiatives and judicial challenges to contain healthcare costs. See section titled â€œBusiness â€“ Government Regulations â€“ Current and Future Legislationâ€, in our December 31,2023 annual report on Form 10-K. We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, lower reimbursement, and new payment methodologies. This could lower the price that we receive for our products. Any denial or narrowing of coverage or reduction in reimbursement from Medicare or other government-funded programs may result in a similar denial or reduction in payments from private payers, including Medicare Advantage plans, which may prevent us from being able to generate sufficient revenue, attain profitability or commercialize our products. Litigation and legislative efforts to change or repeal the ACA are likely to continue, with unpredictable and uncertain results. It is not clear how these developments, or other future potential changes to the ACA, will change the reimbursement model and market outlook for O&P devices such as the MyoPro. We intend to monitor industry trends relative to the ACA to assist in our determination of how the MyoPro can fit into patient care protocols with providers such as rehabilitation hospitals and surgery centers. If reimbursement policies change significantly, the demand for MyoPro products may be impacted. 35 Â Risks Related to Cybersecurity and Data Protection Our internal computer systems, or those of our customers, collaborators or other contractors, may be subject to cyber-attacks, compromises or security breaches, which could result in a material disruption of our product development programs. Despite the implementation of security measures, our internal computer systems and infrastructures and those of our customers, collaborators, contractors, or other third parties are vulnerable to damage, compromise or interruption from computer viruses, unauthorized access, misuse, or other security compromises or breaches. Cyber-attacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyber-attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, wrongful conduct by employees, vendors, or other third parties, hostile foreign governments, industrial espionage, social engineering and business email compromises, and other means to affect service reliability and threaten or compromise the security, confidentiality, integrity and availability of systems and information. Cyber-attacks also could include phishing attempts or e-mail fraud to cause payments or information to be transmitted to an unintended recipient. We have in the past experienced threats and security incidents related to our data and systems, and we may in the future experience other threats, compromises, breaches, or incidents. A cyber-attack or security compromise or breach could cause interruptions in our operations and could result in a material disruption of our business operations, damage to our reputation or a loss of revenues. In the ordinary course of our business, we collect and store confidential and/or proprietary information or other sensitive information, including, among other things, personal information about our employees and patients, intellectual property, and proprietary business information. Any cyber-attack or security compromise or breach that leads to unauthorized access, use, disclosure, loss, corruption or other compromise of confidential and/or proprietary information or other sensitive information could harm our reputation, cause us not to comply with federal and/or state breach notification laws and foreign law equivalents and otherwise subject us to liability under laws and regulations, including those that protect the privacy and security of personal information. In addition, we could be subject to risks caused by misappropriation, misuse, leakage, falsification or intentional or accidental release or loss of information maintained in the information technology systems, infrastructure, and networks of our company and our vendors, including personal information of our employees, and patients, and company and vendor confidential data. In addition, outside parties may attempt to penetrate our systems and infrastructure or those of our vendors or fraudulently induce our personnel or the personnel of our vendors to disclose sensitive information in order to gain access to our data and/or systems. If a breach or compromise of our information technology systems or infrastructure or those of our vendors occurs, the market perception of the effectiveness of our security measures could be harmed and our reputation and credibility could be damaged. We could be required to expend significant amounts of money and other resources to detect, mitigate and respond to these threats, compromises, or breaches and to repair or replace information technology systems infrastructure or networks and could suffer financial loss or the loss of valuable confidential and/or proprietary information. In addition, we could be subject to regulatory actions, inquiries, investigations, orders, penalties, fines, and/or claims made by individuals and groups in private litigation, including those involving privacy and security issues related to data collection and use practices and other data privacy and security laws and regulations, including claims for misuse or inappropriate disclosure of data, as well as unfair or deceptive practices. Although we develop and maintain systems and controls designed to prevent these events from occurring, and we have a process designed to identify and mitigate threats, the development and maintenance of these systems, controls and processes is costly and requires ongoing monitoring and updating as technologies change and efforts to overcome security measures become increasingly sophisticated. Moreover, despite our efforts, instances of unauthorized access to our computer systems have occurred in the past, though these events have not resulted in financial loss or disruption to our operations. The possibility of these events occurring in the future cannot be eliminated entirely. There can be no assurance that any measures we take will prevent or adequately address cyber-attacks or security compromises or breaches that could adversely affect our business. We, our collaborators and our service providers may be subject to a variety of privacy and data protection laws, regulations and contractual obligations, which may require us to incur substantial compliance costs, and any failure or perceived failure by us to comply with them could expose us to fines or other penalties and otherwise harm our business and operations. In the United States, several layers of federal and state data protection laws and regulations may apply to our business, including HIPAA, the Federal Trade Commission (â€œFTCâ€) Act and state consumer privacy and health data privacy laws. For example, the California Consumer Privacy Act (â€œCCPAâ€) is a comprehensive law that creates new individual privacy rights for California consumers (as defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA requires covered companies to provide certain disclosures to consumers about its data collection, use and sharing practices, and to provide affected California residents with ways to opt-out of certain sales or transfers of personal information. The CCPA went into effect on January 1, 2020 and the California State Attorney General became empowered to commence enforcement actions against violators as of July 1, 2020. Further, as of January 1, 2023, the California Privacy Rights Act, created additional obligations with respect to processing and storing personal information. 36 Â Similar consumer privacy laws have passed or come into force in numerous U.S. states. Like the CCPA, these laws grant consumers rights in relation to their personal information and impose new obligations on regulated businesses, including, in some instances, broader data security requirements. In addition, federal and state legislators and regulators have signaled their intention to further regulate health and other sensitive information, and new and strengthened requirements relating to this information could impact our business. At the state level, some states have passed or proposed laws to specifically regulate health information. For example, Washingtonâ€™s My Health My Data Act, which went into effect in March 2024, requires regulated entities to obtain consent to collect health information, grants consumers certain rights, including to request deletion, and provides for robust enforcement mechanisms, including enforcement by the Washington state attorney-general and a private right of action for consumer claims. At the federal level, the FTC has used its authority over â€œunfair or deceptive acts or practicesâ€ to impose stringent requirements on the collection and disclosure of sensitive categories of personal information, including health information. Moreover, the FTCâ€™s expanded interpretation of a â€œbreachâ€ under its Health Breach Notification Rule could impose new disclosure obligations that would apply in the event of a qualifying breach. Â European data collection is governed by restrictive regulations governing the use, processing, and cross-border transfer of personal information. The collection and use of personal data, including personal health data in the European Economic Area (â€œEEAâ€) and the UK is governed by the provisions of the EU General Data Protection Regulation (â€œEU GDPRâ€) (with regards to the EEA) and the UK General Data Protection Regulation (â€œUK GDPRâ€) (with regards to the UK), as well as applicable data protection laws in effect in the member states of the EEA and in the UK (including the UK Data Protection Act 2018). In this Annual Report on Form 10-K, â€œGDPRâ€ refers to both the EU GDPR and the UK GDPR, unless specified otherwise. The GDPR applies to the processing of personal data by any company established in the EEA/UK and to companies established outside the EEA/UK to the extent they process personal data in connection with the offering of goods or services to data subjects in the EEA/UK or the monitoring of the behavior of data subjects in the EEA/UK. The GDPR imposes a broad range of strict requirements on companies subject to the GDPR, such as including requirements relating to having legal bases or conditions for processing personal data relating to identifiable individuals and transferring such information outside the EEA/UK , including to the United States., providing details to those individuals regarding the processing of their personal data, implementing safeguards to keep personal data secure, having data processing agreements with third parties who process personal data, providing information to individuals regarding data processing activities, responding to individualsâ€™ requests to exercise their rights in respect of their personal data, where required obtaining consent of the individuals to whom the personal data relates, reporting security and privacy breaches involving personal data to the competent national data protection authority and affected individuals, appointing data protection officers, conducting data protection impact assessments, and record-keeping. In the event of any non-compliance with the GDPR and any supplemental EEA Member State or UK national data protection laws, we could be subject to warning letters, mandatory audits, orders to cease/change the use of data, and financial penalties, including fines of up to â‚¬20,000,000 (Â£17.5 million for the UK GDPR) or 4% of total annual global revenue, whichever

is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. The GDPR imposes strict rules on the transfer of personal data outside of the EEA or the UK to countries that do not ensure an adequate level of protection, like the United States in certain circumstances unless adequate safeguards (such as the European Commission approved standard contractual clauses (â€œSCCsâ€) or the UK International Data Transfer Agreement/Addendum, (â€œIDTAâ€) and transfer impact assessments carried out when relying on the SCCs and UK IDTA. The international transfer obligations under the EU data protection laws will require significant effort and cost and may result in us needing to make strategic considerations around where EEA and UK personal data is transferred and which service providers we can utilize for the processing of EEA and UK personal data. Any inability to transfer personal data from the EEA and UK to the United States in compliance with data protection laws may impede our ability to conduct trials and may adversely affect our business and financial position. Although the UK is regarded as a third country under the EU GDPR, the European Commission (â€œECâ€) has now issued a decision recognizing the UK as providing adequate protection under the EU GDPR and, therefore, transfers of personal data originating in the EEA to the UK remain unrestricted. Like the EU GDPR, the UK GDPR restricts personal data transfers outside the UK to countries not regarded by the UK as providing adequate protection. The UK government has confirmed that personal data transfers from the UK to the EEA remain free flowing. The UKâ€™s data protection regime is independent from but aligned to the EUâ€™s data protection regime. However, following the UKâ€™s exit (â€œBrexitâ€) from the European Union (â€œEUâ€), there will be increasing scope for divergence in application, interpretation and enforcement of the data protection laws between these territories. For example, the UK Government has announced plans to introduce a Digital Information and Smart Data Bill (â€œData Reform Billâ€) into the UK legislative process to reform the UKâ€™s data protection regime following Brexit. If passed, the final version of the Digital Reform Bill may have the effect of further altering the similarities between the UK and EEA data protection regimes and threaten the UK adequacy decision from the EU Commission, which may lead to additional compliance costs and could increase our overall risk. The respective provisions and enforcement of the EU GDPR and UK GDPR may further diverge in the future and create additional regulatory challenges and uncertainties. This lack of clarity on future UK laws and regulations and their interaction with EU laws and regulations could add legal risk, complexity and cost to our handling of European personal data and our privacy and data security compliance programs, and could require us to implement different compliance measures for the UK and the EEA. 37 Â Compliance with the GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with any European and UK-based activities. Risks Related to Our Intellectual Property Our success depends in part on our ability to obtain and maintain protection for the intellectual property relating to or incorporated into our products. Our success depends in part on our ability to obtain and maintain protection for the intellectual property relating to or incorporated into our products. We seek to protect our intellectual property through a combination of patents, trademarks, confidentiality and assignment agreements with our employees and certain of our contractors and confidentiality agreements with certain of our consultants, scientific advisors and other vendors and contractors. In addition, we rely on trade secrets law to protect our proprietary software and product candidates or products in development. The patent position of myoelectric orthotic inventions can be highly uncertain and involves many new and evolving complex legal, factual and technical issues. Patent laws and interpretations of those laws are subject to change and any such changes may diminish the value of our patents or narrow the scope of protection. In addition, we may fail to apply for or be unable to obtain patents necessary to protect our technology or products or enforce our patents due to lack of information about the exact use of technology or processes by third parties. Also, we cannot be sure that any patents will be granted in a timely manner or at all with respect to any of our patent pending applications or that any patents that are granted will be adequate to protect our intellectual property for any significant period of time or at all. Â Litigation to establish or challenge the validity of patents, or to defend against or assert against others infringement, unauthorized use, enforceability or invalidity claims, can be lengthy and expensive and may result in our patents being invalidated or interpreted narrowly and our not being granted new patents related to our pending patent applications. Even if we prevail, litigation may be time consuming and force us to incur significant costs, and any damages or other remedies awarded to us may not be valuable and managementâ€™s attention could be diverted from managing our business. In addition, U.S. patents and patent applications may be subject to interference proceedings, and U.S. patents may be subject to re-examination and review in the U.S. Patent and Trademark Office. Foreign patents may also be subject to opposition or comparable proceedings in the corresponding foreign patent offices. Any of these proceedings may be expensive and could result in the loss of a patent or denial of a patent application, or the loss or reduction in the scope of one or more of the claims of a patent or patent application. In addition, we seek to protect our trade secrets, know-how and confidential information that is not patentable by entering into confidentiality and assignment agreements with our employees and certain of our contractors and confidentiality agreements with certain of our consultants, scientific advisors and other vendors and contractors. However, we may fail to enter into the necessary agreements, and even if entered into, these agreements may be breached or otherwise fail to prevent disclosure, third-party infringement or misappropriation of our proprietary information, may be limited as to their term and may not provide an adequate remedy in the event of unauthorized disclosure or use of proprietary information. Enforcing a claim that a third-party illegally obtained and is using our trade secrets is expensive and time consuming, and the outcome is unpredictable. We also have taken precautions to initiate reasonable safeguards to protect our information technology systems. However, these measures may not be adequate to safeguard our proprietary information, which could lead to the loss or impairment thereof or to expensive litigation to defend our rights against competitors who may be better funded and have superior resources. In addition, unauthorized parties may attempt to copy or reverse engineer certain aspects of our products that we consider proprietary or our proprietary information may otherwise become known or may be independently developed by our competitors or other third parties. If other parties are able to use our proprietary technology or information, our ability to compete in the market could be harmed. Further, unauthorized use of our intellectual property may have occurred, or may occur in the future, without our knowledge. If we are unable to obtain or maintain adequate protection for intellectual property, or if any protection is reduced or eliminated, competitors may be able to use our technologies, resulting in harm to our competitive position. We are not able to protect our intellectual property rights in all countries. Filing, prosecuting, maintaining and defending patents on each of our products in all countries throughout the world would be prohibitively expensive, and thus our intellectual property rights outside the United States are currently limited to selected countries in the EU, including China, including Hong Kong, and Japan. In addition, the laws of some foreign countries, especially developing countries, do not protect intellectual property rights to the same extent as federal and state laws in the United States. Also, it may not be possible to effectively enforce intellectual property rights in some countries at all or to the same extent as in the United States and other countries. Consequently, we are unable to prevent third parties from using our inventions in all countries, or from selling or importing products made using our inventions in the jurisdictions in which we do not have (or are unable to effectively enforce) patent protection. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop, market or otherwise commercialize their own products, and we may be unable to prevent those competitors from importing those infringing products into territories where we have patent protection, but enforcement 38 Â is not as strong as in the United States. These products may compete with our products and our patents and other intellectual property rights may not be effective or sufficient to prevent them from competing in those jurisdictions. Moreover, competitors or others in the chain of commerce may raise legal challenges against our intellectual property rights or may infringe upon our intellectual property rights, including through means that may be difficult to prevent or detect. Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. Proceedings to enforce our patent rights in the United States or foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert patent infringement or other claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights in the United States and around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license from third parties. We may be subject to patent infringement claims, which could result in substantial costs and liability and prevent us from commercializing our current and future products. The medical device industry is characterized by competing intellectual property and a substantial amount of litigation over patent rights. In particular, our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in competing technologies, have been issued patents and filed patent applications with respect to their products and processes and may apply for other patents in the future. The large number of patents, the rapid rate of new patent issuances, and the complexities of the technology involved increase the risk of patent litigation. Determining whether a product infringes a patent involves complex legal and factual issues and the outcome of patent litigation is often uncertain. Even though we have conducted research of issued patents, no assurance can be given that patents containing claims covering our products, technology or methods do not exist, have not been filed or could not be filed or issued. In addition, because patent applications can take years to issue and because publication schedules for pending applications vary by jurisdiction, there may be applications now pending of which we are unaware and may result in issued patents which our current or future products infringe. Also, because the claims of published patent applications can change between publication and patent grant, published applications may issue with claims that potentially cover our products, technology or methods. Infringement actions and other intellectual property claims brought against us, with or without merit, may cause us to incur substantial costs and could place a significant strain on our financial resources, divert the attention of management and harm our reputation. We cannot be certain that we will successfully defend against any allegations of infringement. If we are found to infringe another partyâ€™s patents, we could be required to pay damages. We could also be prevented from selling our products that infringe, unless we could obtain a license to use the technology covered by such patents or could redesign our products so that they do not infringe. A license may be available on commercially reasonable terms or none at all, and we may not be able to redesign our products to avoid infringement. Further, any modification to our products could require us to conduct clinical trials and revise our filings with the FDA and other regulatory bodies, which would be time consuming and expensive. In these circumstances, we may not be able to sell our products at competitive prices or at all, and our business and operating results could be harmed. We rely on trademark protection to distinguish our products from the products of our competitors. We rely on trademark protection to distinguish our products from the products of our competitors. We have registered the trademarks â€œMyoProâ€ (Registration No. 4,532,331), â€œMYOMOâ€ (Registration No. 4,451,445), â€œMyoPalâ€ (Registration No. 6,086,533) and â€œMyoCareâ€ (Registration No. 6,579,736) in the United States. The MyoPro mark is registered in Canada and in selected EU countries with pending registration. In jurisdictions where we have not yet registered our trademark and are using it, and as permitted by applicable local law, we seek to rely on common law trademark protection where available. Third parties may oppose our trademark applications, or otherwise challenge our use of the trademarks, and may be able to use our trademarks in jurisdictions where they are not registered or otherwise protected by law. If our trademarks are successfully challenged or if a third-party is using confusingly similar or identical trademarks in particular jurisdictions before we do, we could be forced to rebrand our products, which could result in loss of brand recognition, and could require us to devote additional resources to marketing new brands. If others are able to use our trademarks, our ability to distinguish our products may be impaired, which could adversely affect our business. Further, we cannot assure you that competitors will not infringe upon our trademarks, or that we will have adequate resources to enforce our trademarks. We may be subject to damages resulting from claims that our employees or we have wrongfully used or disclosed alleged trade secrets of their former employers. Some of our employees were previously employed at other medical device companies, including our competitors or potential competitors, and we may hire employees in the future that are so employed. We could in the future be subject to claims that these employees, or we, have 39 Â inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. If we fail in defending against such claims, a court could order us to pay substantial damages and prohibit us from using technologies or features that are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. If any of these technologies or features are important to our products, this could prevent us from selling those products and could have a material adverse effect on our business. Even if we are successful in defending against these claims, such litigation could result in substantial costs and divert the attention of management. Risks Related to our Securities Risks Related to Ownership of Our Securities Our stockholders will experience significant dilution upon the issuance of common stock if the shares of our common stock underlying our warrants are exercised or converted. We have a significant number of securities convertible into, or allowing the purchase of, our common stock. Investors could be subject to increased dilution upon the conversion or exercise of these securities. For example, in conjunction with equity offerings in January 2024, August 2023 and January 2023, we issued 224,730, 1,920,000 and 6,830,926 pre-funded warrants, respectively. Each pre-funded warrant is exercisable for one share of common stock at the nominal exercise price of $0.0001 per share. As of September 30, 2024, we had 7,721,519 shares issuable upon the exercise of pre-funded warrants with an exercise price of $0.0001 per share, 668,250 shares issuable upon the exercise of other warrants, with a weighted-average exercise price of $7.50 per share and 1,234,357 unvested restricted stock units outstanding. In addition, we had 23,246 shares issuable upon the exercise of stock options under our equity incentive plans, with a weighted-average exercise price of $42.89 per share. We may not be able to maintain a listing of our common stock on the NYSE American. We must meet certain financial and liquidity criteria to maintain such listing. If we fail to meet any of the NYSE Americanâ€™s listing standards, our common stock may be delisted. In addition, our board may determine that the cost of maintaining our listing on a national securities exchange outweighs the benefits of such listing. A delisting of our common stock from the NYSE American may materially impair our stockholdersâ€™ ability to buy and sell our common stock and could have an adverse effect on the market price of, and the efficiency of the trading market for, our common stock. A delisting of our common stock could significantly impair our ability to raise capital. There is no public market for our warrants or pre-funded warrants to purchase common stock. There is no established public trading market for our warrants or pre-funded warrants and we do not expect a market to develop. In addition, we do not intend to apply for listing of such warrants on any securities exchange. Without an active market, the liquidity of such warrants will be limited. Holders of our warrants and pre-funded warrants have no rights as a common stockholder until such holders exercise their warrants and acquire our common stock. Until holders of our warrants and pre-funded warrants exercise such warrants, they will have no rights with respect to the shares of our common stock underlying such warrants. Upon exercise of such warrants, the holders thereof will be entitled to exercise the rights of a common stockholder only as to matters for which the record date occurs after the exercise date. The market price of our common stock has been and may continue to be volatile. The stock market in general, and the market price of our common stock in particular will likely be subject to fluctuation, whether due to, or irrespective of, our operating results, financial condition and prospects. For example, from September 30, 2023 to September 30, 2024, the high and low sales price of our common stock on the NYSE American has fluctuated from a low of $0.96 to a high of $5.64 per share. During the period from October 1, 2024 to the date of the filing of this report, our stock price has ranged from $3.66 to $4.02. Our financial performance, our industryâ€™s overall performance, changing consumer preferences, technologies, government regulatory action, tax laws and market conditions in general could have a significant impact on the future market price of our common stock. Some of the other factors that could negatively affect our share price or result in fluctuations in our share price include: â€¢actual or anticipated variations in our periodic operating results; â€¢increases in market interest rates that lead purchasers of our common stock to demand a higher investment return; â€¢changes in earnings estimates; 40 Â â€¢changes in market valuations of similar companies; â€¢actions or announcements by our competitors; â€¢adverse market reaction to any increased indebtedness we may incur in the future; â€¢additions or departures of key personnel; â€ ¢actions by stockholders; â€¢speculation in the media, online forums, or investment community; and â€¢our intentions and ability to maintain our common stock on the NYSE American. We do not expect to declare or pay dividends in the foreseeable future. We do not expect to declare or pay dividends in the foreseeable future, as we anticipate that we will invest future earnings in the development and growth of our business. In addition, pursuant to the terms of our Loan Agreement, we are prohibited from paying cash dividends without the prior written consent of Silicon Valley Bank. Therefore, holders of our common stock will not receive any return on their investment unless they sell their securities, and holders may be unable to sell their securities on favorable terms or at all. If securities industry analysts do not publish research reports on us, or publish unfavorable reports on us, then the market price and market trading volume of our common stock could be negatively affected. Any trading market for our common stock will be influenced in part by any research reports that securities industry analysts publish about us. We do not have any control over these analysts. We currently have limited research coverage by securities industry analysts and we may be unable to maintain analyst coverage or have analysts initiate coverage on us. If securities industry analysts cease coverage of us, the market price and market trading volume of our common stock could be negatively affected. In the event we are covered by analysts, and one or more of such analysts downgrade our securities, or otherwise reports on us unfavorably, or discontinues coverage on us, the market price and market trading

volume of our common stock could be negatively affected. Future issuances of our common stock or equity-related securities could cause the market price of our common stock to decline and would result in the dilution of your holdings. Future issuances of our common stock or securities convertible into our common stock could cause the market price of our common stock to decline. We cannot predict the effect, if any, of future issuances of our common stock or securities convertible into our common stock on the price of our common stock. In all events, future issuances of our common stock would result in the dilution of your holdings. In addition, the perception that new issuances of our common stock, or other securities convertible into our common stock, could occur, could adversely affect the market price of our common stock. Future issuances of debt securities, which would rank senior to our common stock upon our bankruptcy or liquidation, and future issuances of preferred stock, which could rank senior to our common stock for the purposes of dividends and liquidating distributions, may adversely affect our common stock price. In the future, we may attempt to increase our capital resources by offering debt securities. Upon bankruptcy or liquidation, holders of our debt securities, and lenders with respect to other borrowings we may make, would receive distributions of our available assets prior to any distributions being made to holders of our common stock. Moreover, if we issue preferred stock, the holders of such preferred stock could be entitled to preferences over holders of common stock in respect of the payment of dividends and the payment of liquidating distributions. Because our decision to issue debt or preferred securities in any future offering, or borrow money from lenders, will depend in part on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of any such future offerings or borrowings. Holders of our common stock must bear the risk that any future offerings we conduct or borrowings we make may adversely affect the level of return they may be able to achieve from an investment in our common stock. If our shares of common stock become subject to the penny stock rules, it would become more difficult to trade our shares. The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or authorized for quotation on certain automated quotation systems, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or system. If we do not retain a listing on the NYSE American or another national securities exchange and if the price of our common stock is less than $5.00, our common stock will be deemed a penny stock. The penny stock rules require a broker-dealer, before a transaction in a penny stock not otherwise exempt from those rules, to deliver a standardized risk disclosure document containing specified information. In addition, the penny stock rules require that before effecting any transaction in a penny stock not otherwise 41 Â exempt from those rules, a broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive (i) the purchaserâ€™s written acknowledgment of the receipt of a risk disclosure statement; (ii) a written agreement to transactions involving penny stocks; and (iii) a signed and dated copy of a written suitability statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our common stock, and therefore stockholders may have difficulty selling their shares. Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us more difficult, limit attempts by our stockholders to replace or remove our current management and limit the market price of our common stock. Provisions in our amended and restated certificate of incorporation and bylaws may have the effect of delaying or preventing a change in control or changes in our management. Our amended and restated certificate of incorporation and bylaws include provisions that: â€¢authorize our board of directors to issue preferred stock, without further stockholder action and with voting liquidation, dividend and other rights superior to our common stock; â€¢establish an advance notice procedure for stockholder proposals to be brought before an annual meeting, including proposed nominations of persons for director nominees; â€¢establish that our board of directors is divided into three classes, with directors in each class serving three-year staggered terms; â€¢require the approval of holders of two-thirds of the shares entitled to vote at an election of directors to adopt, amend or repeal our bylaws or amend or repeal the provisions of our certificate of incorporation regarding the election and removal of directors and the ability of stockholders to take action by written consent or call a special meeting; â€¢prohibit cumulative voting in the election of directors; and â€¢provide that vacancies on our board of directors may be filled only by the vote of a majority of directors then in office, even though less than a quorum or by the holders of at least sixty-six and two-thirds percent (66 2/3%) of the issued and outstanding shares of common stock. These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law (â€œDGCLâ€) which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with any â€œinterestedâ€ stockholder for a period of three years following the date on which the stockholder became an â€œinterestedâ€ stockholder. Any of the foregoing provisions could limit the price that investors might be willing to pay in the future for shares of our common stock, and they could deter potential acquirers of our company, thereby reducing the likelihood that you would receive a premium for your common stock in an acquisition. Risks Related to Internal Controls We are a "smaller reporting companyâ€ under the reporting rules set forth under the Exchange Act. For so long as we remain a â€œsmaller reporting company,â€ we may take advantage of certain exemptions from various reporting requirements that are applicable to other Exchange Act reporting companies that are not â€œsmaller reporting companiesâ€. We are a â€œsmaller reporting company,â€. For as long as we continue to be a smaller reporting company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not â€œsmaller reporting companies,â€ including exemption from compliance with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act (so long as we remain a non-accelerated filer) and reduced disclosure obligations regarding executive compensation in the Annual Report on Form 10-K and our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We are obligated to develop and maintain a system of effective internal control over financial reporting. We may not complete our analysis of our internal control over financial reporting in a timely manner, or these internal controls may not be determined to be effective, which may harm investor confidence in our company and, as a result, the value of our common stock. We are required, pursuant to Section 404 of the Sarbanes-Oxley Act (â€œSection 404â€) to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting in the annual and quarterly reports we file with the SEC. This assessment will need to include disclosure of any material weaknesses identified by our management in our internal control over financial 42 Â reporting. However, our auditors are not required to formally attest to the effectiveness of our internal control over financial reporting pursuant to Section 404 until we are no longer a â€œsmaller reporting companyâ€ as set forth under the Exchange Act. We will need to continue to dedicate internal resources, engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. As we continue to grow as a public company, we may need to add additional finance staff. We may not be able to remediate any future material weaknesses, or to complete our evaluation, testing and any required remediation in a timely fashion. During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal controls are effective. If we are unable to assert that our internal control over financial reporting is effective, or if our auditors are unable to express an opinion on the effectiveness of our internal controls when they are required to issue such opinion, investors could lose confidence in the accuracy and completeness of our financial reports, which could harm our stock price. The preparation of our financial statements involves the use of estimates, judgments and assumptions, and our financial statements may be materially affected if such estimates, judgments or assumptions prove to be inaccurate. Financial statements prepared in accordance with accounting principles generally accepted in the United States typically require the use of estimates, judgments and assumptions that affect the reported amounts. Often, different estimates, judgments and assumptions could reasonably be used that would have a material effect on such financial statements, and changes in these estimates, judgments and assumptions may occur from period to period over time. Significant areas of accounting requiring the application of managementâ€™s judgment include, but are not limited to, determining the fair value of assets and the timing and amount of cash flows from assets. These estimates, judgments and assumptions are inherently uncertain and, if our estimates were to prove to be wrong, we would face the risk that charges to income or other financial statement changes or adjustments would be required. Any such charges or changes could harm our business, including our financial condition and results of operations and the price of our securities. See â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ for a discussion of the accounting estimates, judgments and assumptions that we believe are the most critical to an understanding of our financial statements and our business. We are incurring increased costs as a public company and our management team is required to devote substantial time to new compliance initiatives and corporate governance practices. As a public company, and particularly after we are no longer a â€œsmall reporting company,â€ we will incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the NYSE American and other applicable securities rules and regulations impose various requirements on public companies. Our management and other personnel will need to devote a substantial amount of time to compliance with these requirements. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. Risks Related to Tax Laws We may be subject to adverse legislative or regulatory changes in tax laws that could negatively impact our financial condition. The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the U.S. Internal Revenue Service (â€œIRSâ€) and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect our stockholders or us. In recent years, many such changes have been made and changes are likely to occur in the future. We cannot predict whether, when, in what form, or with what effective dates, tax laws, regulations and rulings may be enacted, promulgated or decided, which could result in an increase in our, or our stockholdersâ€™ tax liability or require changes in the manner in which we operate in order to minimize increases in our tax liability. Our ability to use net operating losses and research and development credits to offset future taxable income may be subject to certain limitations. As of December 31, 2023, we had U.S. federal and state net operating loss (â€œNOLâ€) carryforwards of $77.4 million and $72.7 million, respectively, which begin to expire in the year 2028 and 2024 through 2044, respectively. Additionally, we had U.S. federal and state research and development tax credits (â€œtax creditsâ€) of $0.4 million and $0.2 million, respectively, which begin to expire in the year 2026 and 2033, respectively. These NOL and tax credit carryforwards could expire unused and be unavailable to offset future taxable income or tax liabilities, respectively. In addition, in general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the â€œCodeâ€), and corresponding provisions of state law, a corporation that undergoes an â€œownership changeâ€ is subject to limitations on its ability to utilize its pre-change NOL carryforwards or tax credits, (â€œNOLsâ€) or credits, to offset future taxable income. For these purposes, an ownership change generally occurs where the aggregate stock ownership of one or more stockholders or groups of stockholders who owns at least 5% of a corporationâ€™s stock increases its ownership by more than 50 percentage points over its lowest ownership percentage within a specified testing 43 Â period. We have determined that such ownership changes have occurred in prior years. The result of these ownership changes is that we have a $64,000 annual limitation on our ability to utilize pre-ownership change NOLs and approximately $20.0 million of our federal NOLs and $48.0 million of our state NOLs will expire unutilized. There may have been an ownership change associated with our equity offerings in August 2023 and January 2024. We may undergo an ownership change in connection with future changes in our stock ownership (many of which are outside of our control), whereby our ability to utilize NOLs or credits could be further limited by Sections 382 and 383 of the Code or under corresponding provisions of state law. Furthermore, our ability to utilize our NOLs or tax credits is conditioned upon our attaining profitability and generating U.S. federal and state taxable income. As described above under â€œRisk factorsâ€ Risks Associated with Our Business,â€ we have incurred net losses since our inception and anticipate that we will continue to incur losses for the foreseeable future; and therefore, we do not know whether or when we will generate the U.S. federal or state taxable income necessary to utilize our NOLs or tax credits that are subject to limitation by Sections 382 and 383 of the Code. Under current law, U.S. federal NOL carryforwards generated in taxable years beginning after December 31, 2017 will not be subject to expiration, but the amount of such NOL carryforwards that we are permitted to deduct in a taxable year beginning after December 31, 2020 will be limited to 80% of our taxable income in each such year to which the NOL carryforwards are applied. Â Â Item 2. Unregistered Sales of Equity Securities and Use of Proceeds from Registered Securities None. Â Â Item 5. Other Information None 44 Â Item 6. Exhibits The exhibits filed as part of this Quarterly Report on Form 10-Q are set forth on the Exhibits Index, which is incorporated by reference. Exhibits Index Â Exhibit No. Â Exhibit Description 3.1 Â Eighth Amended and Restated Certificate of Incorporation (Incorporated by reference to Exhibit 2.3 contained in the Registrantâ€™s Form 1-A filed on January 6, 2017) Â Â Â 3.2 Â Amended and Restated Bylaws (Incorporated by reference to Exhibit 2.4 contained in the Registrantâ€™s Form 1-A filed on January 6, 2017) Â Â Â 3.3 Â Certificate of Amendment to the Eighth Amended and Restated Certificate of Incorporation, as amended, of Myomo, Inc., filed with the Secretary of the State of Delaware on January 30, 2020 (Incorporated by reference to Exhibit 3.1 contained in the Registrantâ€™s Form 8-K filed on January 30, 2020) Â Â Â 3.4 Â Second certificate of Amendment to the Eighth Amended and Restated Certificate of Incorporation, as amended, of Myomo, Inc., filed with the Secretary of the State of Delaware on June 10, 2021 (Incorporated by reference to Exhibit 3.1 contained in the Registrantâ€™s Form 8-K filed on June 15, 2021) Â Â Â 10.1 Â Loan and Security Agreement, dated July 11, 2024, between the Registrant and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (Incorporated by reference to Exhibit 10.1 contained in the Registrant's Form 8-K filed on July 15, 2024) Â Â Â 10.2 Â Lease Agreement, dated August 9, 2024, by and between the Registrant and NDB Property Owner 1. L.P. (Incorporated by reference to Exhibit 10.1 contained in the Registrant's Form 8-K filed on August 13, 2024) Â Â Â Â 31.1* Â Certification of Chief Executive Officer, pursuant to Rule 13a-14(a) or 15(d)-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Â Â Â Â 31.2* Â Certification of Chief Financial Officer, pursuant to Rule 13a-14(a) or 15(d)-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Â Â Â Â 32.1+ Â Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Â Â Â Â 32.2+ Â Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Â Â Â 101.INS* Â Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. 101.SCH* Â Inline XBRL Taxonomy Extension Schema Document with embedded linkbase documents. 104* Â Cover Page Interactive Data File (embedded within the Inline XBRL document) Â * Filed herewith. + The certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed â€œfiledâ€ for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference. Such certification will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference. Â 45 Â SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date November 6, 2024 Â Â Myomo, Inc. Â Â Â /s/ David A. Henry Â David A. Henry Â Chief Financial Officer(Principal Financial and Accounting Officer) Â 46 EX-31.1 2 myo-ex31_1.htm EX-31.1 EX-31.1 Â Exhibit 31.1 Certification Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 I, Paul R. Gudonis, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Myomo, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure

controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Date: November 06, 2024 /s/ Paul R. Gudonis Paul R. Gudonis President and Chief Executive Officer(Principal Executive Officer) Â Â EX-31.2 3 myo-ex31_2.htm EX-31.2 EX-31.2 Â Exhibit 31.2 Certification Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 I, David A. Henry, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Myomo, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Date: November 06, 2024 /s/ David A. Henry David A. Henry Chief Financial Officer(Principal Financial Officer) Â Â EX-32.1 4 myo-ex32_1.htm EX-32.1 EX-32.1 Exhibit 32.1 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 I, Paul R. Gudonis, President and Chief Executive Officer of Myomo, Inc. (the â€œCompanyâ€), certify, pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that: (1) the Quarterly Report on Form 10-Q of the Company for the three months ended September 30, 2024 (the â€œReportâ€) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 780(d)); and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: November 06, 2024 Â /s/ Paul R. Gudonis Paul R. Gudonis President and Chief Executive Officer(Principal Executive Officer) Â EX-32.2 5 myo-ex32_2.htm EX-32.2 EX-32.2 Exhibit 32.2 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 I, David A. Henry, Chief Financial Officer of Myomo, Inc. (the â€œCompanyâ€), certify, pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that: (1) the Quarterly Report on Form 10-Q of the Company for the three months ended September 30, 2024 (the â€œReportâ€) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 780(d)); and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: November 06, 2024 Â /s/ David A. Henry David A. Henry Chief Financial Officer(Principal Financial Officer) Â EX-101.SCH 6 myo-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited) link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100070 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100080 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Liquidity link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Accounts Payable and Other Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Line of Credit link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Common Stock and Warrants link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Stock Award Plans and Stock-based Compensation link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Accounts Payable and Other Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Stock Award Plans and Stock-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Description of Business - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Liquidity - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Summary of Cash, Cash Equivalents and Short-Term Investments (Details) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Summary of Significant Accounting Policies - Summary of Revenue by Major Source (Detail) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Summary of Significant Accounting Policies - Summary of Potential Common Shares Issuable (Detail) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Inventories - Schedule of Inventories (Detail) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Fair Value of Financial Instruments - Schedule of Cash Equivalents and Short-term Investments Measured at Fair Value on Recurring Basis (Detail) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Accounts Payable and Other Accrued Expenses - Summary of Accounts Payable and Other Accrued Expenses (Detail) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Line of Credit (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Common Stock and Warrants - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Commitments and Contingencies - Summary of Maturity of Operating Lease Liabilities (Detail) 2 link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Stock Award Plans and Stock-based Compensation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Stock Award Plans and Stock-based Compensation - Schedule of Grant Date Fair Value (Detail) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Stock Award Plans and Stock-based Compensation - Schedule of Stock-based Compensation Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Related Party Transactions - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Commitments and Contingencies - Summary of Maturity of Operating Lease Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Commitments and Contingencies - Summary of Operating Lease Cost (Detail) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Commitments and Contingencies - Summary of Additional Information Related to Operating Leases (Detail) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Commitments and Contingencies - Schedule Of Changes In The Companys Supplier Finance Obligations (Details) link:presentationLink link:calculationLink link:definitionLink Statement [Line Items] Statement [Line Items] Deferred payroll taxes under CARES Act Deferred Payroll Taxes Under C A R E S Act Deferred payroll taxes under CARES Act. Schedule of Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] Restructuring Reserve, Foreign Currency Translation Gain (Loss) Restructuring Reserve, Foreign Currency Translation Gain (Loss) Accounts receivable Increase (Decrease) in Accounts Receivable Other Warrants [Member] Other Warrants [Member] Other Warrants [Member] Plan Name Plan Name [Domain] At Market Sales Facility Member At Market Sales Facility [Member] At market sales facility member. Entity Address, Postal Zip Code Entity Address, Postal Zip Code Summary of Cash, Cash Equivalents and Short-Term Investments Cash, Cash Equivalents and Investments [Table Text Block] Included in the condensed consolidated balance sheet: Assets and Liabilities, Lessee [Abstract] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Cost reduction activities. CostReductionActivities Cost reduction activities Beginning balance, shares Ending balance, shares Shares, Outstanding Other Noncash Income (Expense), Total Other non-cash charges Other Noncash Income (Expense) Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures, Total Investment in Jiangxi Myomo Medical Assistive Appliance Co. Ltd. Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures Significant Other Observable Inputs (Level 2) [Member] Fair Value, Inputs, Level 2 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Description of operating lease agreement for office space Lessee, Operating Lease, Description 2024 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total Common stock issued upon vesting of restricted stock units Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Schedule Of Stock By Class [Table] Stock, Class of Stock [Table] Product and Service Product and Service [Axis] Investment, Name Investment, Name [Domain] Total cost Inventory, Work in Process and Raw Materials Collaborative Arrangement and Arrangement Other than Collaborative [Domain] SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES Noncash Investing and Financing Items [Abstract] Concentration Risk Benchmark Concentration Risk Benchmark [Axis] Common Stock and Warrants Equity [Text Block] Class of Warrant or Right [Axis] The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Net (Loss) Income Net loss Sale of Stock Sale of Stock [Domain] Cash and Cash Equivalents [Domain] Operating Leases, Rent Expense, Net Entity Central Index Key Entity Central Index Key Additional Employees to be Hired Additional Employees to be Hired Additional Employees to be Hired Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Advertising expense Advertising Expense Allowance for doubtful accounts Allowance for Doubtful Accounts, Premiums and Other Receivables Common Stock, Shares, Issued, Total Common stock, shares issued Common Stock, Shares, Issued Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments And Contingencies [Table] Income Statement [Abstract] Entity Address, State or Province Entity Address, State or Province Loss before income taxes Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Exchange Cap [Member] Exchange Cap[Member] Exchange Cap. Rental units Inventory Rental Units Inventory rental units. Comprehensive Loss [Member] Comprehensive Loss Income [Member] Comprehensive loss income. Purchases of short-term investments Payments to Acquire Short-Term Investments Concentration Risk Type Concentration Risk Type [Domain] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Revenue recognized Contract with Customer, Liability, Revenue Recognized Customer Customer [Axis] Customer Concentration Risk [Member] Customer Concentration Risk [Member] Lease, Cost [Abstract] Treasury shares at cost Treasury Stock, Common, Shares Cover [Abstract] Comprehensive Income (Loss) Comprehensive Income, Policy [Policy Text Block] Basic Earnings Per Share, Basic, Total Earnings Per Share, Basic Number of shares entitled to warrant holder Number Of Shares Entitled To Warrant Holder Number of shares entitled to warrant holder. Option to extend lease term Lessee, Operating Lease, Option to Extend Increase (Decrease) in Income Taxes Payable Income taxes payable Operating expenses: Operating Expenses [Abstract] Selling, clinical, and marketing [Member] Selling and Marketing Expense [Member] License revenue License Revenue [Member] License [Member] Expensed Expensed To Supplier Finance Program Obligations Expensed To Supplier Finance Program Obligations Total share based compensation expense Share-Based Payment Arrangement, Expense Advertising Advertising Cost [Policy Text Block] Retained Earnings (Accumulated Deficit), Ending Balance Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Total Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Plan Name Plan Name [Axis] Current Assets: Assets, Current [Abstract] Number of common shares reserved for issuance Common Stock, Capital Shares Reserved for Future Issuance Less: reserve for rental units Inventory Reserve For Rental Units Inventory reserve for rental units. United States [Member] UNITED STATES Defined Benefit Plan [Table] Cash used in operating activities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Entity Address, Country Entity Address, Country Product and Service Product and Service [Domain] Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income Lease term Lessee, Operating Lease, Term of Contract Property, Plant and Equipment, Net, Ending Balance Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Total Equipment, net Property, Plant and Equipment, Net CASH FLOWS FROM OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities [Abstract] Common stock, par value Common Stock, Par or Stated Value Per Share Total Accounts Payable and Other Accrued Liabilities, Current Taxes Payable, Current, Total Taxes Payable, Current Income taxes payable Statement of Cash Flows [Abstract] Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Warrants to purchase common stock Class of Warrant or Right, Number of Securities Called by Warrants or Rights General and Administrative [Member] Selling, General and Administrative Expenses [Member] Entity Entity [Domain] Restricted Stock [Member] Restricted Stock [Member] Equity Components Equity Components [Axis] Entity Address, Address Line One Entity Address, Address Line One Subsequent Event Type Subsequent Event Type [Axis] Summary of Potential Common Shares Issuable Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Amount drawn under loan agreement Line Of Credit Facility Maximum Borrowing Capacity Line of Credit Facility, Maximum Borrowing Capacity Weighted-average risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Payments To Supplier Finance Program Obligations Payments To Supplier Finance Program Obligations Increase Amendment Flag Amendment Flag Operating Lease, Liability, Noncurrent Non-current operating lease liabilities Corporate Debt Securities [Member] Corporate debt securities [Member] Geographic Concentration Risk [Member] Geographic Concentration Risk [Member] Additional Paid in Capital, Common Stock, Ending

Balance Additional Paid in Capital, Common Stock, Beginning Balance Additional paid-in capital Additional Paid in Capital, Common Stock Sale of Stock, Price Per Share Price per share Net loss Net loss Common stock issued for the exercise of common stock options, Shares Exercise of stock options, shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Committed to purchase Research and Development [Member] Research and Development Expense [Member] Customer Customer [Domain] Equity Component Equity Component [Domain] Statistical Measurement [Domain] General and administrative General and Administrative Expense General and Administrative Expense, Total Regulatory Assets [Abstract] Regulatory Assets [Abstract] Loss on equity investment Gain (Loss) on Investments, Total Gain (Loss) on Investments Loss on equity investment Total other expense (income), net Other Nonoperating Income (Expense), Total Other Nonoperating Income (Expense) Treasury Stock [Member] Treasury Stock, Common [Member] Disaggregation Of Revenue [Table] Disaggregation of Revenue [Table] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Preferred Stock, Shares Issued, Total Preferred stock, shares issued Preferred Stock, Shares Issued Credit losses Bad debt expense Accounts Receivable, Credit Loss Expense (Reversal) Payables and Accruals [Abstract] Short-term investments Short-Term Investments Short-Term Investments, Total Deferred Revenue, Noncurrent, Total Deferred Revenue, Noncurrent Deferred revenue, net of current portion Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Offering cost from sale of stock Offering Cost From Sale Of Shares Offering cost from sale of shares. Insurance Type and Tier Identifier [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Class of Stock [Domain] Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Common Stock, Shares, Outstanding, Ending Balance Common Stock, Shares, Outstanding, Beginning Balance Common stock, shares outstanding Common Stock, Shares, Outstanding Subsequent Events Subsequent Events, Policy [Policy Text Block] Short-term investments Short-Term Investments [Abstract] Preferred stock, par value Preferred Stock, Par or Stated Value Per Share Sales Revenue, Net [Member] Revenue Benchmark [Member] Antidilutive Securities Antidilutive Securities [Axis] Short-Term Investments Other Short-Term Investments Stock Warrants [Member] Stock Warrants [Member] Stock warrant. Cash, Ending Balance Cash, Beginning Balance Cash balance Cash Proceeds from sale of common stock in public offering, net of offering costs value Proceeds from sale of common stock in public offering, net of offering costs value Proceeds from sale of common stock in public offering costs, value Upfront license fee Upfront License Fee1 Upfront license fee1. Per Sale Price of warrants Per Sale Price of warrants Per sale price of warrants Entity Interactive Data Current Entity Interactive Data Current Proceeds from sale of pre-funded warrants, net of offering costs Proceeds from issuance under at-market sales facility, net of offering costs Proceeds From At The Market Offering Net Of Offering Costs Proceeds from at the market offering net of offering costs Directors and Officers Liability Insurance [Member] Directors and Officers Insurance Member Product revenue Product [Member] Cost of Goods Sold [Member] Cost of Sales [Member] Accounting Standards Update Accounting Standards Update [Domain] Document Quarterly Report Document Quarterly Report One Insurer [Member] One Insurer [Member] One insurer. Related Party Transactions Related Party Transactions Disclosure [Text Block] Statistical Measurement [Axis] Cost of Goods and Services Sold, Total Cost of goods sold Cost of Goods and Services Sold Operating lease expense Operating Lease, Cost Joint Venture Joint Venture Policy [Text Block] Joint venture. Debt Instrument, Periodic Payment, Principal Equal monthly payment made Related Party Related and Nonrelated Parties [Domain] Total lease expense Lease, Cost Summary of Revenue by Major Source Disaggregation of Revenue [Table Text Block] Selling, clinical and marketing Selling and Marketing Expense Selling and Marketing Expense, Total Summary of Maturity of Operating Lease Liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Beijing Ryzur Medical Investment Co., Ltd Beijing Medical Investment Co Ltd [Member] Beijing Medical Investment Co. Ltd. Commercial Paper [Member] Commercial Paper [Member] Number of shares available for future grant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Pre-funded Warrants [Member] Pre Funded Warrants [Member] Pre-funded warrants. Common Stock Purchase Agreement [Member] Common Stock Purchase Agreement [Member] Common Stock Purchase Agreement [Member] Schedule Of Changes In The Companys Supplier Finance Obligations Schedule Of Changes In The Companys Supplier Finance Obligations [Table Text Block] Schedule Of Changes In The Companys Supplier Finance Obligations [Table Text Block] Accrued compensation and benefits Accrued Employee Benefits, Current Income Statement Location Statement of Income Location, Balance [Axis] Cash and Cash Equivalents [Axis] Total Assets Assets Weighted-average expected option term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Restricted Cash and Cash Equivalents [Abstract] Number of shares, Vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period February 2020 offering. February Two Thousand And Twenty Offering [Member] February 2020 Offering [Member] Recently Adopted Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Entity Address, City or Town Entity Address, City or Town Equity [Abstract] O&P Providers or Third Party Payors [Member] Third-Party Payor [Member] Prepaid expenses and other current assets Increase Decrease In Prepaid Expense And Other Current Assets Increase decrease in prepaid expense and other current assets. Schedule of Stock-based Compensation Expense Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Accounts Receivable and Allowance for Credit Losses [Policy Text Block] Accounts Receivable and Allowance for Credit Losses [Policy Text Block] Accounts Receivable and Allowance for Credit Losses Depreciation, Total Depreciation Depreciation Stock Award Plans and Stock-based Compensation Share-Based Payment Arrangement [Text Block] Percentage of gross proceeds from sales of common stock Percentage Of Gross Proceeds From Sales Of Common Stock Percentage of gross proceeds from sales of common stock. Trade payables Accounts Payable, Trade, Current Other International Locations [Member] Other International Locations [Member] Other international locations. Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Fair Value Disclosures [Abstract] Summary Of Significant Accounting Policies [Line Items] Summary of significant accounting policies. Summary of Significant Accounting Policies [Line Items] Common Stock Equivalents, Pre-Funded Warrants Common Stock Equivalents, Pre-Funded Warrants Common stock equivalents, pre-funded warrants Current Liabilities: Liabilities, Current [Abstract] Accounts Receivable [Member] Accounts Receivable [Member] Document Type Document Type Accounting Standards Update Accounting Standards Update [Axis] US Government Agencies Debt Securities [Member] US government agency debt securities [Member] Title of 12(b) Security Title of 12(b) Security Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Cash and Cash Equivalents, at Carrying Value, Ending Balance Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Summary of Operating Lease Cost Lease, Cost [Table Text Block] Statement of Stockholders' Equity [Abstract] Accumulated Deficit Accumulated Deficit Accumulated deficit Document Fiscal Period Focus Document Fiscal Period Focus Research and Development Expense, Total Research and development Research and Development Expense Impairment charge Equity Method Investment, Other-than-Temporary Impairment Income tax benefit recognized Share-Based Payment Arrangement, Expense, Tax Benefit Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activity. Net Cash Provided by Used in Operating Activity Cash used in operating activities Number of options granted Number of stock options granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Percentage increase in number of shares of common stock reserved and available for issuance Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Warrant, Down Round Feature, Increase (Decrease) in Equity, Amount Deemed dividend on discounting of warrants Basis of Consolidation Consolidation, Policy [Policy Text Block] Subsequent Event Type [Domain] Common stock warrants, exercise price per share Class of Warrant or Right, Exercise Price of Warrants or Rights Warrants exercise price Financial Instruments [Domain] Sales of prefunded warrants. SalesOfPrefundedWarrants Sales of prefunded warrants Accrued Liabilities Customer Deposit Accrued liabilities customer deposit. Customer deposits Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax, Total Unrealized gains (loss) on foreign currency adjustments Type and Tier Identifier [Domain] Sale of Stock Sale of Stock [Axis] CASH FLOWS FROM INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities [Abstract] Proceeds from sale of common stock in public offering, net of offering costs Proceeds from sale of common stock in public offering, net of offering costs Proceeds from sale of common stock in public offering costs, shares Revenue from Contract with Customer, Excluding Assessed Tax, Total Total revenue from contracts with customer Revenue Revenue from Contract with Customer, Excluding Assessed Tax Statement of Comprehensive Income [Abstract] Deferred revenue Deferred Income, Current One U.S. Insurance Payer [Member] One U S Insurance Payer [Member] One U.S. insurance payer. Line of Credit Facility [Line Items] Credit Facility [Domain] Other Other Accrued Liabilities, Current Entity Address, Address Line Two Entity Address, Address Line Two LIABILITIES AND STOCKHOLDERSâ€™ EQUITY Liabilities and Equity [Abstract] Debt Instrument, Debt Default, Amount Amount borrowed against account receivable Document Period End Date Document Period End Date Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Total Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Ownership percentage Equity Method Investment, Ownership Percentage Proceeds from public equity offering Sale of Stock, Consideration Received on Transaction Sale of stock consideration received on transaction Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Deferred Revenue, Total Deferred revenue Deferred Revenue Income tax expense Income Tax Expense (Benefit), Total Income Tax Expense (Benefit) Accumulated Comprehensive Income [Member] Accumulated Comprehensive Income [Member] Accumulated Comprehensive Income [Member] Trading Symbol Trading Symbol Total Stockholdersâ€™ Equity Beginning balance Ending balance Equity, Attributable to Parent Common Stock Issued For Warrants Exercised Shares Common stock issued for warrants exercised shares. Exercise of pre-funded warrants, share Proceeds from sale of pre-funded warrants, value Proceeds from sale of pre-funded warrants, net of offering costs Proceeds from sale of pre-funded warrants, net of offering costs Class of Warrant or Right, Outstanding Warrants Outstanding Investment in Jiangxi Myomo Medical Assistive Appliance Co. Ltd. Cash consideration paid Payments to Acquire Businesses, Gross Restricted Stock Units [Member] Restricted Stock Units (RSUs) [Member] Sale of Stock, Number of Shares Issued in Transaction Sale of stock number of shares issued in transaction Issuance of common stock as commitment fee for future financing Conversion of Stock, Shares Issued Related Party Transactions [Abstract] Deferred revenue Increase (Decrease) in Deferred Revenue Percentage of Amounts advanced Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate Percentage of direct billing channel revenue Payers represent Percentage Of Direct Billing Channel Revenue Payers Represent Percentage Of Direct Billing Channel Revenue Payers Represent Warrants [Member] Warrants [Member] Warrants [Member] Germany [Member] DELAWARE Patients with Medicare Part B coverage. Patients With Medicare Part B Coverage [Member] Patients With Medicare Part B Coverage [Member] Description of Business Nature of Operations [Text Block] Geographical Geographical [Axis] Unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Leases [Abstract] Use of Estimates Use of Estimates, Policy [Policy Text Block] Other Operating Income (Expense), Net Other expense, net Other expense, net Concentration Risk, Percentage Concentration Risk, Percentage Concentration Risk, Percentage Cash, Cash Equivalents and Short-Term Investments Cash and Cash Equivalents, Policy [Policy Text Block] Accrued Insurance, Current Accrued insurance Class of Stock [Line Items] Class of Stock [Line Items] Weighted-average dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Security Exchange Name Security Exchange Name Deferred Offering Costs Deferred Offering Cost Deferred Offering Cost Securities Sold under Agreements to Repurchase, Total Securities Sold under Agreements to Repurchase Purchase agreement requires approval from shareholders Total operating expenses Operating Expenses Class of Stock [Axis] Legal Entity Legal Entity [Axis] Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Accrued professional services Professional Fees Accrued Current Professional fees accrued current. 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three Weighted-average fair value per share of grants Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Subsequent Event [Member] Subsequent Event [Member] Maximum [Member] Maximum [Member] Total Liabilities and Stockholdersâ€™ Equity Liabilities and Equity Gain (Loss) on Extinguishment of Debt, Total Gain (Loss) on Extinguishment of Debt Loss on equity investment Loss on equity investment Operating Lease, Right-of-Use Asset Operating lease assets with right of use, net Number of customers Number Of Customers Number of customers. Diluted Earnings Per Share, Diluted, Total Earnings Per Share, Diluted Entity Ex Transition Period Entity Ex Transition Period Total Liabilities Liabilities Debt and Equity Securities, Realized Gain (Loss), Total Debt and Equity Securities, Realized Gain (Loss) Loss on equity investment Loss on equity investment Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Line of Credit Facility, Commitment Fee Amount Commitment fee Total Current Assets Assets, Current Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Weighted-average expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Stock issued during period Stock Issued During Period, Shares, New Issues Cash [Member] Unrealized (gain) loss from mark to market on short-term investments Unrealized Loss From Mark To Market On Short Term Investments Unrealized Loss From Mark To Market On Short Term Investments Entity Filer Category Entity Filer Category Clinical/Medical Providers [Member] Clinical And Medical Providers [Member] Clinical and medical providers. Other (income) expense, net Nonoperating Income (Expense) [Abstract] Current Fiscal Year End Date Current Fiscal Year End Date Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Share-based Payment Arrangement, Noncash Expense, Total Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Related Party Related and Nonrelated Parties [Axis] Warranty reserve Product Warranty Accrual, Current Entity Registrant Name Entity Registrant Name Number of shares offer and sell Common Stock Amount Reserved For Future Issuance Common stock amount reserved for future issuance. Gross profit Gross Profit Cost of Revenue, Total Cost of revenue Cost of Revenue Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Entity Emerging Growth Company Entity Emerging Growth Company Unrealized gain on short-term investments Unrealized gain on short-term investments Unrealized gain on short-term investments Money market funds [Member] Money Market Funds [Member] Basic Weighted Average Number of Shares Outstanding, Basic, Total Weighted Average Number of Shares Outstanding, Basic Interest Income (Expense), Nonoperating Interest income Interest income Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Pre-Funded Warrant [Member] Pre-Funded Warrant [Member] Pre-Funded Warrants [Member] Common stock, shares authorized Common Stock, Shares Authorized Stock award net share settled paid for withholding taxes Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Proceeds from Issuance of Common Stock Proceeds from issuance of common stock Concentration Risk Type Concentration Risk Type [Axis] In Active Markets for Identical Assets or Liabilities (Level 1) [Member] Fair Value, Inputs, Level 1 [Member] Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Debt Disclosure [Abstract] Net settlement of vested restricted stock units to fund related employee statutory tax withholding Restricted Stock, Value, Shares Issued Net of Tax Withholdings Net settlement of vested restricted stock units to fund related employee statutory tax withholding Financial Instrument [Axis] Net Loss per Share Earnings Per Share, Policy [Policy Text Block] Revenue Recognition Revenue [Policy Text Block] Share-Based Payment Arrangement [Abstract] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Summary of Additional Information Related to Operating Leases Schedule Of Weighted Average Remaining Lease Term And Discount Rate Table [Text Block] Tabular disclosure of weighted average remaining lease term and discount rate related to operating leases. Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture, Total Stock-based compensation Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Accounting Policies [Abstract] Letter of credit Long-Term Line of Credit Long-Term Line of Credit, Total Cash and Cash Equivalents [Line Items] 2018 Stock Option and Incentive Plan [Member] Two Thousand And Eighteen Stock Option And Incentive Plan [Member] Two thousand and eighteen stock option and incentive plan. Stockholdersâ€™ Equity: Equity, Attributable to Parent [Abstract] Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Effect of foreign exchange rate changes on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Inventory, Raw Materials and Supplies, Gross, Total Parts and subassemblies Inventory, Raw Materials and Supplies, Gross Statement [Table] Statement [Table] Weighted-average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Operating Lease Right Of Use Assets Operating Lease Right Of Use Assets Operating Lease Right Of Use Assets Preferred stock, shares authorized Preferred Stock, Shares Authorized Operating lease liabilities Increase Decrease In Operating Lease Liabilities Increase (decrease) in operating lease liabilities. Fair Value Adjustment of Warrants Discounting and repricing of certain warrants Entity File Number Entity File Number Reclassifications out of accumulated other comprehensive loss Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Net (decrease) increase in cash, cash equivalents and restricted cash Cash,

Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Earnings Per Share [Abstract] Net loss per share attributable to common stockholders Inventory Disclosure [Abstract] Statement of Financial Position [Abstract] Loss from operations Operating Income (Loss) Common Stock, No Par Value Nominal Exercise Value Entity Shell Company Entity Shell Company Line of Credit Facility [Table] Deferred offering costs incurred in a prior period to additional paid in capital Deferred offering costs incurred in a prior period to additional paid in capital Deferred offering costs incurred in a prior period to additional paid-in capital Purchase Obligation, Total Purchase Obligation Purchase obligations maximum amount Entity Tax Identification Number Entity Tax Identification Number ASSETS Assets [Abstract] Class of Warrant or Right [Domain] China [Member] CHINA Entity Current Reporting Status Entity Current Reporting Status Common Stock Issued For Warrants Exercised Common stock issued for warrants exercised. Exercise of pre-funded warrants, value Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Schedule of Cash Equivalents and Short-term Investments Measured at Fair Value on Recurring Basis Summary of Accounts Payable and Other Accrued Expenses Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Inventories Inventory Disclosure [Text Block] Geographical Geographical [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Preferred Stock, Value, Issued, Ending Balance Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Total Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding Preferred Stock, Value, Issued Product Revenue [Member] Revenue, Product and Service Benchmark [Member] Cash, cash equivalents, and restricted cash Cash, cash equivalents and restricted cash, end of period Cash, cash equivalents and restricted cash, beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Other Comprehensive Income (Loss), Tax, Total Other Comprehensive Income (Loss), Tax Other comprehensive (loss)/income City Area Code City Area Code Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Total Current Liabilities Liabilities, Current Inventories, net Inventories, net Inventory, Net Inventory, Finished Goods, Gross, Total Finished goods Inventory, Finished Goods, Gross Organization, Consolidation and Presentation of Financial Statements [Abstract] Local Phone Number Local Phone Number Preferred Stock, Shares Outstanding, Ending Balance Preferred Stock, Shares Outstanding, Beginning Balance Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Net proceeds from common stock offering Proceeds from exercise of warrants Proceeds from Warrant Exercises Income Taxes Income Tax, Policy [Policy Text Block] Commitments and Contingencies Disclosure [Abstract] Shares, Issued Share issued Treasury Stock, Value, Ending Balance Treasury Stock, Value, Beginning Balance Treasury Stock, Value, Total Treasury stock, 27 shares at cost Treasury Stock, Value Fair Value By Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Patients with Medicare Advantage Insurance Plans [Member] Patients With Medicare Advantage Insurance Plans [Member] Patients with medicare advantage insurance plans. Operating Lease, Liability, Current Current operating lease liabilities Interim Financial Statements Interim Financial Statements Policy [Text Block] Disclosure of accounting policy for the use of interim financial statements. Investor warrants. Investor Warrants [Member] Investor Warrants [Member] Utilities Operating Expense, Total Utilities Operating Expense Utilities operating expense Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Accumulated Deficit [Member] Retained Earnings [Member] Payments to Acquire Property, Plant, and Equipment, Total Purchases of equipment Payments to Acquire Property, Plant, and Equipment Document Transition Report Document Transition Report Debt Instrument, Date of First Required Payment Date Of first required payment Increase (Decrease) in Other Operating Assets, Total Increase (Decrease) in Other Operating Assets Other assets Other assets 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Minimum [Member] Minimum [Member] Minimum Unrealized gain (loss) on short-term investments Unrealized Gain (Loss) on Investments Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and contingencies. Common Stock Common Stock [Member] Restricted cash Restricted Cash Restricted Cash, Total Underwriter warrants. Underwriter Warrants [Member] Underwriter Warrants [Member] Loss Contingency, Accrual, Current Loss Contingency Investment, Name Investment, Name [Axis] Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Foreign Currency Translation Foreign Currency Transactions and Translations Policy [Policy Text Block] To maintain beneficial ownership limitation Beneficial ownership limitation Beneficial ownership limitation Adjustments to reconcile net loss to net cash used in operations: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Keystone Capital Partners [Member] Keystone Capital Partners [Member] Keystone [Member] Other comprehensive income (loss), net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Income Statement Location Statement of Income Location, Balance [Domain] 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Common Stock Issued Upon Vesting of Restricted Stock Units Common Stock Issued Upon Vesting Of Restricted Stock Units Common stock issued upon vesting of restricted stock units Other Assets, Noncurrent, Total Other assets Other Assets, Noncurrent Germany & Other International Locations [Member] Germany & Other International Locations [Member] Germany & Other International Locations [Member] Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Maturities of short-term investments Proceeds from Maturities, Prepayments and Calls of Short-Term Investments Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Restricted Cash (Member) Restricted Cash (Member) Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Termination fee Percentage Of Termination Fees Percentage Of Termination Fees Warrants exercised Number Of Exercised Warrants Number of exercised warrants. Percentage of direct billing channel revenue insures represent Percentage Of Direct Billing Channel Revenue Insures Represent Percentage of direct billing channel revenue insures represent. Common stock par value $0.0001 per share, 65,000,000 shares authorized; 30,244,182 and 27,135,061 shares issued as of September 30, 2024 and December 31, 2023, respectively; and 30,244,155 and 27,135,034 shares outstanding at September 30, 2024 and December 31, 2023, respectively Common Stock, Value, Issued, Ending Balance Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Total Common Stock, Value, Issued Shares value Amortization of right-of-use assets Finance Lease, Right-of-Use Asset, Amortization Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Cash and Cash Equivalent [Table] Share Repurchase Program, Remaining Authorized, Number of Shares Remaining capacity under its purchase agreement Total operating lease liabilities Total operating lease liabilities Operating Lease, Liability Liquidity Substantial Doubt about Going Concern [Text Block] Commitments and Contingencies Commitments and Contingencies Diluted Weighted Average Number of Shares Outstanding, Diluted, Total Weighted Average Number of Shares Outstanding, Diluted Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Accounts Receivable, after Allowance for Credit Loss, Current, Total Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Total future minimum lease payments Lessee, Operating Lease, Liability, to be Paid Increase (Decrease) in Inventories, Total Inventories Increase (Decrease) in Inventories Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted average number of common shares outstanding: Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Warrants maturity date Warrants and Rights Outstanding, Maturity Date Entity Small Business Entity Small Business Floating Interest Rate Debt Instrument, Basis Spread on Variable Rate Basis spread on variable rate Line of Credit Debt Disclosure [Text Block] ATM facility. A T M Facility [Member] ATM Facility [Member] Credit Facility [Axis] Jiangxi Myomo Medical Assistive Appliance Co. Ltd Jiangxi Myomo Medical Assistive Appliance Co Ltd [Member] Jiangxi Myomo Medical Assistive Appliance Co. Ltd. Revolving Credit Facility [Member] Revolving Credit Facility [Member] Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total Common stock issued upon vesting of restricted stock units, Shares Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Accretion of discount on short-term investments Accretion (Amortization) of Discounts and Premiums, Investments CASH FLOWS FROM FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities [Abstract] Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Accounts Payable and Other Accrued Expenses Direct to Patient [Member] Direct To Patient [Member] Direct to patient. Right of use assets obtained in exchange for lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Anniversary Fee Line of Credit Facility, Commitment Fee Percentage Work in process Inventory, Work in Process, Gross Significant Unobservable Inputs (Level 3) [Member] Fair Value, Inputs, Level 3 [Member] Weighted-average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Loan and Security Agreement [Member] Loan And Security Agreement [Member] Loan And Security Agreement [Member] License Revenue [Member] License Revenue [Member] License Revenue [Member] Ending Opening January 1 Program Rights Obligations, Total Program Rights Obligations Finance program obligations Debt issuance costs Proceeds from Issuance of Secured Debt Short-term lease expense Short-Term Lease, Cost Accounts Payable and Accrued Liabilities, Current, Total Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document and Entity Information - shares 9 Months Ended Sep. 30, 2024 Nov. 01, 2024 Cover [Abstract] Â Â Document Type 10-Q Â Amendment Flag false Â Document Period End Date Sep. 30, 2024 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Trading Symbol MYO Â Entity Registrant Name MYOMO, INC. Â Entity Central Index Key 0001369290 Â Current Fiscal Year End Date --12-31 Â Entity Filer Category Non-accelerated Filer Â Entity Shell Company false Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Common Stock, Shares Outstanding Â 30,245,870 Entity File Number 001-38109 Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Tax Identification Number 47-0944526 Â Entity Address, Address Line One 137 Portland St. Â Entity Address, Address Line Two 4th Floor Â Entity Address, City or Town Boston Â Entity Address, State or Province MA Â Entity Address, Postal Zip Code 02114 Â City Area Code 617 Â Local Phone Number 996-9058 Â Title of 12(b) Security Common Stock, $0.0001 par value per share Â Security Exchange Name NYSEAMER Â Entity Incorporation, State or Country Code DE Â Document Quarterly Report true Â Document Transition Report false Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name:

dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 9 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets - USD ($) Sep. 30, 2024 Dec. 31, 2023 Current Assets: Â Â Cash and cash equivalents $ 6,622,675 $ 6,871,306 Short-term investments 0 1,994,662 Accounts receivable, net 3,729,387 2,382,658 Inventories, net 3,383,513 1,803,507 Prepaid expenses and other current assets 968,569 598,850 Total Current Assets 14,704,144 13,650,983 Restricted cash 375,000 0 Operating lease assets with right of use, net 466,962 663,554 Equipment, net 561,325 175,794 Other assets 205,440 91,237 Total Assets 16,312,871 14,581,568 Current Liabilities: Â Â Accounts payable and accrued expenses 6,448,076 4,885,944 Current operating lease liabilities 205,464 486,143 Income taxes payable 305,861 96,461 Deferred revenue 31,971 8,510 Total Current Liabilities 6,991,372 5,477,058 Non-current operating lease liabilities 29,165 115,160 Total Liabilities 7,020,537 5,592,218 Commitments and Contingencies 0 0 Stockholdersâ€™ Equity: Â Â Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding 0 0 Common stock par value $0.0001 per share, 65,000,000 shares authorized; 30,244,182 and 27,135,061 shares issued as of September 30, 2024 and December 31, 2023, respectively; and 30,244,155 and 27,135,034 shares outstanding at September 30, 2024 and December 31, 2023, respectively 3,026 2,715 Additional paid-in capital 111,754,495 105,840,239 Accumulated other comprehensive income 395,734 83,669 Accumulated deficit (102,854,457) (96,930,809) Treasury stock, 27 shares at cost (6,464) (6,464) Total Stockholdersâ€™ Equity 9,292,334 8,989,350 Total Liabilities and Stockholdersâ€™ Equity $ 16,312,871 $ 14,581,568 X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix:

us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 25 -Paragraph 2 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481174/470-10-25-2 + Details Name: us-gaap_DeferredIncomeCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-

gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_RestrictedCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_TaxesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 10 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares Sep. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] Â Â Preferred stock, par value $ 0.0001 $ 0.0001 Preferred stock, shares authorized 10,000,000 10,000,000 Preferred stock, shares issued 0 0 Preferred stock, shares outstanding 0 0 Common stock, par value $ 0.0001 $ 0.0001 Common stock, shares authorized 65,000,000 65,000,000 Common stock, shares issued 30,244,182 27,135,061 Common stock, shares outstanding 30,244,155 27,135,034 Treasury shares at cost 27 27 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2:

http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockCommonShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant XML 11 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations (Unaudited) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenue $ 9,207,586 $ 5,079,523 $ 20,482,742 $ 14,484,775 Cost of revenue 2,262,031 1,590,675 5,912,632 4,407,270 Gross profit 6,945,555 3,488,848 14,570,110 10,077,505 Operating expenses: Â Â Â Â Research and development 1,248,870 717,256 3,212,309 1,758,480 Selling, clinical and marketing 3,401,182 2,387,090 8,540,161 6,689,578 General and administrative 3,253,056 2,408,871 8,779,024 7,427,818 Total operating expenses 7,903,108 5,513,217 20,531,494 15,875,876 Loss from operations (957,553) (2,024,369) (5,961,384) (5,798,371) Other (income) expense, net Â Â Â Â Interest income (76,020) (112,300) (318,555) (302,053) Other expense, net 0 467 0 6,098 Loss on equity investment 0 70,124 0 99,840 Total other expense (income), net (76,020) (41,709) (318,555) (196,115) Loss before income taxes (881,533) (1,982,660) (5,642,829) (5,602,256) Income tax expense 84,876 46,356 280,819 85,204 Net loss $ (966,409) $ (2,029,016) $ (5,923,648) $ (5,687,461) Weighted average number of common shares outstanding: Â Â Â Â Basic 37,950,515 35,266,361 37,359,366 27,537,357 Diluted 37,950,515 35,266,361 37,359,366 27,537,357 Net loss per share attributable to common stockholders Â Â Â Â Basic $ (0.03) $ (0.06) $ (0.16) $ (0.21) Diluted $ (0.03) $ (0.06) $ (0.16) $ (0.21) Product revenue Â Â Â Â Revenue $ 9,207,586 $ 5,029,523 $ 20,482,742 $ 12,719,855 License revenue Â Â Â Â Revenue $ 0 $ 50,000 $ 0 $ 1,764,920 X - DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B + Details Name: us-gaap_CostOfRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe

aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest income (expense) classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 + Details Name: us-gaap_InterestIncomeExpenseNonoperatingNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards

Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations. + ReferencesNo definition available. + Details Name: us-gaap_OtherOperatingIncomeExpenseNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total amount of expenses directly related to the marketing or selling of products or services. + ReferencesNo definition available. + Details Name: us-gaap_SellingAndMarketingExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_LicenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 12 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Comprehensive Loss (unaudited) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Statement of Comprehensive Income [Abstract] Â Â Â Â Net Income (Loss) $ (966,409) $ (2,029,016) $ (5,923,648) $ (5,687,461) Other comprehensive income (loss), net of tax: Â Â Â Â Foreign currency translation adjustments 256,354 (47,072) 311,939 (52,640) Unrealized gain (loss) on short-term investments 492 (774) 126 860 Other comprehensive income (loss) 256,846 (47,846) 312,065 (51,780) Comprehensive loss $ (709,563) $ (2,076,862) $ (5,611,583) $ (5,739,241) X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -

Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of unrealized gain (loss) on investment. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_UnrealizedGainLossOnInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 13 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) Total Common Stock Additional Paid-in Capital [Member] Accumulated Comprehensive Income [Member] Accumulated Deficit [Member] Treasury Stock [Member] Beginning balance at Dec. 31, 2022 $ 6,359,365 $ 775 $ 95,105,071 $ 43,227 $ (88,783,244) $ (6,464) Beginning balance, shares at Dec. 31, 2022 Â 7,750,635 Â Â Â 27 Proceeds from sale of common stock in public offering costs, value 3,616,094 $ 1,317 3,614,777 Â Â Â Proceeds from sale of common stock in public offering costs, shares Â 13,169,074 Â Â Â Â Proceeds from sale of pre-funded warrants, value 2,064,012 Â 2,064,012 Â Â Â Common stock issued upon vesting of restricted stock units, Shares Â 2,821 Â Â Â Â Stock-based compensation 171,027 Â 171,027 Â Â Â Other comprehensive (loss)/income 65,788 Â Â 65,788 Â Â Net Income (Loss) (2,644,295) Â Â Â (2,644,295) Â Ending balance at Mar. 31, 2023 9,631,991 $ 2,092 100,954,887 109,015 (91,427,539) $ (6,464) Ending balance, shares at Mar. 31, 2023 Â 20,922,530 Â Â Â 27 Beginning balance at Dec. 31, 2022 6,359,365 $ 775 95,105,071 43,227 (88,783,244) $ (6,464) Beginning balance, shares at Dec. 31, 2022 Â 7,750,635 Â Â Â 27 Net Income (Loss) (5,687,461) Â Â Â Â Â Ending balance at Sep. 30, 2023 11,023,111 $ 2,652 105,506,182 (8,554) (94,470,705) $ (6,464) Ending balance, shares at Sep. 30, 2023 Â 26,515,462 Â Â Â 27 Beginning balance at Mar. 31, 2023 9,631,991 $ 2,092 100,954,887 109,015 (91,427,539) $ (6,464) Beginning balance, shares at Mar. 31, 2023 Â 20,922,530 Â Â Â 27 Common stock issued upon vesting of restricted stock units (8,147) $ 18 (8,165) Â Â Â Common stock issued upon vesting of restricted stock units, Shares Â 169,499 Â Â Â Â Stock-based compensation 280,061 Â 280,061 Â Â Â Unrealized gains (loss) on foreign currency adjustments (71,357) Â Â (71,357) Â Â Other comprehensive (loss)/income 1,634 Â Â 1,634 Â Â Net Income (Loss) (1,014,150) Â Â Â (1,014,150) Â Ending balance at Jun. 30, 2023 8,820,032 $ 2,110 101,226,783 39,292 (92,441,689) $ (6,464) Ending balance, shares at Jun. 30, 2023 Â 21,092,029 Â Â Â 27 Proceeds from sale of common stock in public offering costs, value 2,915,588 $ 541 2,915,047 Â Â Â Proceeds from sale of common stock in public offering costs, shares Â 5,413,334 Â Â Â Â Proceeds from sale of pre-funded warrants, value 1,033,928 Â 1,033,928 Â Â Â Common stock issued upon vesting of restricted stock units 31 $ 1 30 Â Â Â Common stock issued upon vesting of restricted stock units, Shares Â 10,099 Â Â Â Â Stock-based compensation 330,394 Â 330,394 Â Â Â Other comprehensive (loss)/income (47,846) Â Â (47,846) (0) Â Net Income (Loss) (2,029,016) Â Â Â (2,029,016) Â Ending balance at Sep. 30, 2023 11,023,111 $ 2,652 105,506,182 (8,554) (94,470,705) $ (6,464) Ending balance, shares at Sep. 30, 2023 Â 26,515,462 Â Â Â 27 Beginning balance at Dec. 31, 2023 8,989,350 $ 2,715 105,840,239 83,669 (96,930,809) $ (6,464) Beginning balance, shares at Dec. 31, 2023 Â 27,135,061 Â Â Â 27 Proceeds from sale of common stock in public offering costs, value 4,598,771 $ 135 4,598,636 Â Â Â Proceeds from sale of common stock in public offering costs, shares Â 1,354,218 Â Â Â Â Proceeds from sale of pre-funded warrants, value 763,138 Â 763,138 Â Â Â Common stock issued upon vesting of restricted stock units Â $ 31 (31) Â Â Â Common stock issued upon vesting of restricted stock units, Shares Â 300,544 Â Â Â Â Stock-based compensation 320,288 Â 320,288 Â Â Â Other comprehensive (loss)/income 63,842 Â Â 63,842 Â Â Net Income (Loss) (3,835,632) Â Â Â (3,835,632) Â Ending balance at Mar. 31, 2024 10,899,757 $ 2,881 111,522,270 147,511 (100,766,441) $ (6,464) Ending balance, shares at Mar. 31, 2024 Â 28,789,823 Â Â Â 27 Beginning balance at Dec. 31, 2023 8,989,350 $ 2,715 105,840,239 83,669 (96,930,809) $ (6,464) Beginning balance, shares at Dec. 31, 2023 Â 27,135,061 Â Â Â 27 Net Income (Loss) (5,923,648) Â Â Â Â Â Ending balance at Sep. 30, 2024 9,292,334 $ 3,025 111,754,495 395,734 (102,854,457) $ (6,464) Ending balance, shares at Sep. 30, 2024 Â 30,244,182 Â Â Â 27 Beginning balance at Mar. 31, 2024 10,899,757 $ 2,881 111,522,270 147,511 (100,766,441) $ (6,464) Beginning balance, shares at Mar. 31, 2024 Â 28,789,823 Â Â Â 27 Exercise of pre-funded warrants, value 77 $ 77 Â Â Â Â Exercise of pre-funded warrants, share Â 774,730 Â Â Â Â Common stock issued upon vesting of restricted stock units Â $ 63 (63) Â Â Â Common stock issued upon vesting of restricted stock units, Shares Â 636,801 Â Â Â Â Stock-based compensation (91,893) Â (91,893) Â Â Â Other comprehensive (loss)/income (8,623) Â Â (8,623) Â Â Net Income (Loss) (1,121,607) Â Â Â (1,121,607) Â Ending balance at Jun. 30, 2024 9,677,711 $ 3,021 $ 111,430,314 138,888 (101,888,048) $ (6,464) Ending balance, shares at Jun. 30, 2024 Â 30,201,354 Â Â Â 27 Common stock issued upon vesting of restricted stock units Â $ 4 Â Â Â Â Common stock issued upon vesting of restricted stock units, Shares Â 42,828 (4) Â Â Â Stock-based compensation 324,185 Â $ 324,185 Â Â Other comprehensive (loss)/income 256,846 Â Â 256,846 Â Â Net Income (Loss) (966,409) Â Â Â (966,409) Â Ending balance at Sep. 30, 2024 $ 9,292,334 $ 3,025 $ 111,754,495 $ 395,734 $ (102,854,457) $ (6,464) Ending balance, shares at Sep. 30, 2024 Â 30,244,182 Â Â Â 27 X - DefinitionCommon stock issued for warrants exercised. + ReferencesNo definition available. + Details Name: myo_CommonStockIssuedForWarrantsExercised Namespace Prefix: myo_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCommon stock issued for warrants exercised shares. + ReferencesNo definition available. + Details Name: myo_CommonStockIssuedForWarrantsExercisedShares Namespace Prefix: myo_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionProceeds from sale of common stock in public offering, net of offering costs + ReferencesNo definition available. + Details Name: myo_ProceedsFromSaleOfCommonStockInPublicOfferingNetOfOfferingCosts Namespace Prefix: myo_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionProceeds from sale of common stock in public offering, net of offering costs value + ReferencesNo definition available. + Details Name: myo_ProceedsFromSaleOfCommonStockInPublicOfferingNetOfOfferingCostsValue Namespace Prefix: myo_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionProceeds from sale of pre-funded warrants, net of offering costs + ReferencesNo definition available. + Details Name: myo_ProceedsFromSaleOfPreFundedWarrantsNetOfOfferingCosts Namespace Prefix: myo_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -

Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of tax expense (benefit) allocated to other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2 + Details Name: us-gaap_OtherComprehensiveIncomeLossTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C + Details Name: us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 14 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) - USD ($) 3 Months Ended Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Common stock issued upon vesting of restricted stock units Â Â Â 16,744 Â Pre-funded Warrants [Member] Â Â Â Â Offering cost from sale of stock $ 90,814 $ 117,880 Â $ 155,356 Warrants Outstanding 224,730 1,920,000 Â 6,830,926 Common Stock Â Â Â Â Offering cost from sale of stock $ 547,257 $ 332,413 Â $ 663,856 X - DefinitionCommon Stock Issued Upon Vesting of Restricted Stock Units + ReferencesNo definition available. + Details Name: myo_CommonStockIssuedUponVestingOfRestrictedStockUnits Namespace Prefix: myo_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionOffering cost from sale of shares. + ReferencesNo definition available. + Details Name: myo_OfferingCostFromSaleOfShares Namespace Prefix: myo_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=myo_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 15 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 CASH FLOWS FROM OPERATING ACTIVITIES Â Â Net loss $ (5,923,648) $ (5,687,461) Adjustments to reconcile net loss to net cash used in operations: Â Â Depreciation 114,346 136,416 Stock-based compensation 552,580 781,513 Accretion of discount on short-term investments (118,520) 0 Credit losses 5,257 12,626 Loss on equity investment 0 99,840 Amortization of right-of-use assets 196,592 301,053 Other non-cash charges 84,180 (49,271) Changes in operating assets and liabilities: Â Â Accounts receivable (1,116,352) (625,596) Inventories (1,573,193) (90,100) Prepaid expenses and other current assets (614,951) (439,584) Other assets (16,640) 19,797 Accounts payable and accrued expenses 1,895,795 2,141,978 Income taxes payable 202,137 (74,944) Operating lease liabilities (366,675) (352,820) Deferred revenue 23,460 9,533 Net cash used in operating activities (6,655,632) (3,817,020) CASH FLOWS FROM INVESTING ACTIVITIES Â Â Purchases of short-term investments (5,482,757) (5,209,866) Maturities of short-term investments 7,595,814 1,000,000 Purchases of equipment (499,877) (114,151) Net cash provided by (used in) investing activities 1,613,180 (4,324,017) CASH FLOWS FROM FINANCING ACTIVITIES Â Â Net proceeds from common stock offering 4,598,771 6,623,633 Proceeds from sale of pre-funded warrants, net of offering costs 763,138 3,097,940 Net settlement of vested restricted stock units to fund related employee statutory tax withholding 0 (8,147) Net cash provided by financing activities 5,162,409 9,713,426 Deferred Offering Costs (199,500) Â Effect of foreign exchange rate changes on cash 6,412 (6,610) Net (decrease) increase in cash, cash equivalents and restricted cash 126,369 1,565,780 Cash, cash equivalents and restricted cash, beginning of period 6,871,306 5,345,967 Cash, cash equivalents and restricted cash, end of period 6,997,675 6,911,747 SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES Â Â Right of use assets obtained in exchange for lease liabilities 0 508,186 Deferred offering costs incurred in a prior period to additional paid-in capital 0 (91,952) Unrealized (gain) loss from mark to market on short-term investments $ 126 $ 860 X - DefinitionDeferred Offering Cost + ReferencesNo definition available. + Details Name: myo_DeferredOfferingCost Namespace Prefix: myo_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDeferred offering costs incurred in a prior period to additional paid in capital + ReferencesNo definition available. + Details Name: myo_DeferredOfferingCostsIncurredInAPriorPeriodToAdditionalPaidInCapital Namespace Prefix: myo_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease (decrease) in operating lease liabilities. + ReferencesNo definition available. + Details Name: myo_IncreaseDecreaseInOperatingLeaseLiabilities Namespace Prefix: myo_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease decrease in prepaid expense and other current assets. + ReferencesNo definition available. + Details Name: myo_IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets Namespace Prefix: myo_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionProceeds from at the market offering net of offering costs + ReferencesNo definition available. + Details Name: myo_ProceedsFromAtTheMarketOfferingNetOfOfferingCosts Namespace Prefix: myo_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionUnrealized Loss From Mark To Market On Short Term Investments + ReferencesNo definition available. + Details Name: myo_UnrealizedLossFromMarkToMarketOnShortTermInvestments Namespace Prefix: myo_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings.

This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of realized gain (loss) on investment in debt and equity securities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column C)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column C)(Footnote 6)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column C)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_DebtAndEquitySecuritiesRealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of amortization expense attributable to right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseRightOfUseAssetAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInDeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in operating assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (expense) included in net income that results in no cash inflow (outflow), classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OtherNoncashIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_ProvisionForDoubtfulAccounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionValue, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation. + ReferencesNo definition available. + Details Name: us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 16 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Â Â Â Â Net Income (Loss) $ (966,409) $ (1,121,607) $ (3,835,632) $ (2,029,016) $ (1,014,150) $ (2,644,295) $ (5,923,648) $ (5,687,461) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 17 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1:

http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 18 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Description of Business Note 1 â€” Description of BusinessMyomo Inc. (â€œMyomoâ€ or the Companyâ€) is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro Â® myoelectric upper limb orthosis product is registered with the U.S. Food and Drug Administration as a Class II medical device. The Company sells its products directly to patients, to Orthotics and Prosthetics ("O&P") providers around the world, the Veterans Health Administration, and distributors in Europe and Australia. The Company was incorporated in the State of Delaware on September 1, 2004 and is headquartered in Boston, Massachusetts. X - DefinitionThe entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 275 -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_NatureOfOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 19 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Liquidity 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Liquidity Note 2 â€” LiquidityÂ The Company incurred net losses of approximately $5,923,600 and $5,687,500 during the nine months ended September 30, 2024 and 2023, respectively, and has an accumulated deficit of approximately $102,850,000 at September 30, 2024. Cash used in operating activities was approximately $6,660,000 and $3,817,000 for the nine months ended September 30, 2024 and 2023, respectively. The Company's historical losses and cash used in operations are indicators of substantial doubt regarding the Company's ability to continue as a going concern.Â Based upon its current cash and cash equivalents, as well as the availability under its credit line (see below) and the future expected cash flows, the Company believes that its available cash and cash equivalents will fund its operations for at least the next twelve months from the issuance date of these financial statements. Â The Company has historically funded its operations through financing activities, including raising equity and debt. On July 11, 2024, the Company entered into a Loan and Security Agreement with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, which provides the Company the ability to borrow up to $4.0 million against eligible accounts receivable. Availability under the credit line, which is undrawn as of the issuance date of these financial statements, is approximately $0.9 million. See Note 7 - Line of Credit for further discussion. On January 19, 2024, the Company completed a registered direct equity offering, selling 1,354,218 shares of common stock and 224,730 pre-funded warrants to purchase common stock at $3.80 per share, or $3.7999 per pre-funded warrant, generating net proceeds after fees and expenses of approximately $5.4 million. On August 29, 2023, the Company completed a public equity offering, generating proceeds after fees and expenses of approximately $3.9 million, selling 5,413,334 shares of common stock and 1,920,000 pre-funded warrants to purchase common stock at $0.60 per share or at $0.5999 per pre-funded warrant. On January 17, 2023, the Company completed a public equity offering, generating proceeds after fees and expenses of approximately $5.7 million, selling 13,169,074 shares of common stock and 6,830,926 to pre-funded warrants to purchase common stock at $0.325 per share or at $0.3249 per pre-funded warrant. See Note 8 - Common Stock and Warrants for further discussion. Financing activities, such as the line of credit and the recently completed registered direct equity offering, are enabling the Company to sustain its operations. Â Management's operating plans are primarily focused on growing revenues in its direct billing channel by serving an increasing number of Medicare patients and training O&P providers in the United States, which will enable them to provide the MyoPro to their patients, which is expected to result in further revenue growth in 2025 and beyond. Based on the final fees published by the Centers for Medicare and Medicaid Services (â€œCMSâ€) for the Companyâ€™s products, which became effective on April 1, 2024, if its supply chain is able to meet its volume requirements without disruption, the Company is able to compensate for additional advertising spending in the second half of 2024 above its original plan, expected payments are received and there is no increase in days sales outstanding in the fourth quarter, the Company believes it can achieve operating cash flow breakeven on a quarterly basis in the fourth quarter of 2024. In addition, the Company believes that it has access to capital resources through the use of its line of credit, possible public or private equity offerings, exercises of outstanding warrants, or other means. Based on the Companyâ€™s latitude as to the timing and amount of certain expenses, its current cash position, availability under its line of credit and operating plans, the Company believes that the substantial doubt is alleviated as of the issuance date of these financial statements. However, there can be no assurance that the Company will be successful in implementing its operating plans. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 40 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-40/tableOfContent + Details Name: us-gaap_SubstantialDoubtAboutGoingConcernTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Summary of Significant Accounting Policies Note 3 â€” Summary of Significant Accounting PoliciesInterim Financial StatementsThe accompanying unaudited condensed consolidated financial statements and notes are representations of the Companyâ€™s management, who are responsible for their integrity and objectivity. These statements have been prepared in accordance with United States generally accepted accounting principles (â€œU.S. GAAPâ€) for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) that are considered necessary for a fair presentation of the condensed consolidated financial statements of the Company as of September 30, 2024 and for the three and nine months ended September 30, 2024 and 2023. The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the operating results for the fiscal year ending December 31, 2024, or any other period. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and related disclosures of the Company as of December 31, 2023 and 2022 and for the years then ended, included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023.Basis of ConsolidationThe condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary Myomo Europe GmbH. All significant intercompany balances and transactions are eliminated. Comprehensive Income (Loss)Comprehensive loss includes all changes in equity during a period, except those resulting from investments by stockholders and distributions to stockholders. The Company's comprehensive loss includes changes in foreign currency translation adjustments and unrealized gains and losses on short term investments. There was a reclassification, which management does not consider to be material, out of accumulated other comprehensive income (loss) to other (income) expense related to realized gains or losses on short-term investments in the three and nine months ended September 30, 2024. There were no reclassifications in the three and nine months ended September 30, 2023. Use of EstimatesThe preparation of financial statements in conformity with accounting principles generally accepted in the United States of America require management to make estimates and assumptions that affect certain reported amounts and disclosures. These estimates and assumptions are reviewed on an on-going basis and updated as appropriate. Actual results could differ from these estimates. The Companyâ€™s significant estimates include deferred tax valuation allowances, valuation of stock-based compensation, warranty obligations and reserves for slow-moving inventory.Cash, Cash Equivalents and Short-Term InvestmentsThe Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents consist principally of deposit accounts and money market accounts at September 30, 2024 and December 31, 2023. The Company considers all investments with an original maturity of greater than three months but less than one year to be short-term investments. There were no instruments classified as short-term investments as of September 30, 2024. Short-term investments as of December 31, 2023 consists of commercial paper, U.S. Treasury Bills and short-term corporate debt securities, which were classified as held-to-maturity, and certificates of deposit totaling approximately $1,994,700 as of December 31, 2023. The Company determines the appropriate balance sheet classification of its investments at the time of purchases and evaluates the classification at each balance sheet date. Under the new lease, the Company's provided a security deposit to the landlord in the form of a letter of credit for $375,000. The Company has collateralized the letter of credit with cash in a separate bank account, which is accounted for as a long-term restricted cash on the condensed consolidated balance sheet as of September 30, 2024. Â Â Â September 30,2024 Â Â December 31,2023 Â Cash, cash equivalents, and restricted cash Â Â Â Â Â Â Cash Â $ 850,544 Â Â $ 1,231,871 Â Money market funds Â Â 5,772,131 Â Â Â 4,893,387 Â Commercial paper Â Â â€” Â Â Â 746,048 Â Restricted Cash Â Â 375,000 Â Â Â â€” Â Â Â $ 6,997,675 Â Â $ 6,871,306 Â Short-term investments Â Â Â Â Â Â US government agency debt securities Â $ â€” Â Â $ 1,497,099 Â Commercial paper Â Â â€” Â Â Â 497,563 Â Â Â $ â€” Â Â $ 1,994,662 Â Â Accounts Receivable and Allowance for Credit LossesThe Company reports accounts receivable at invoiced amounts less an allowance for credit losses. The Company evaluates its accounts receivable on a continuous basis and, if necessary, establishes an allowance for credit losses based on a number of factors, including current credit conditions and customer payment history. The Company does not require collateral or accrue interest on accounts receivable and credit terms are generally 30 days. At September 30, 2024, and December 31, 2023, the Company recorded an allowance for credit losses accounts which was immaterial to the condensed consolidated financial statements. Joint VentureOn March 28, 2022, the Company invested cash consideration of $199,000 for a 19.9% ownership stake in Jiangxi Myomo Medical Assistive Appliance Co. Ltd. (the â€œJV Companyâ€), a company headquartered in China that is majority-owned by Beijing Ryzur Medical Investment Co., Ltd. (â€œRyzur Medicalâ€). The JV Company will manufacture and sell the Companyâ€™s current and future products in greater China, including Hong Kong, Macau and Taiwan. The Company accounts for its investment in the JV Company under the equity method because the Company exerts significant influence over its management. The investment was fully written off as of December 31, 2023, due to the recording of the Company's share of the losses of the JV Company in prior periods, which were recorded to other expense (income) in the condensed consolidated statement of operations, the Company has no obligation to fund any losses incurred by the JV Company. Revenue RecognitionÂ The Company accounts for revenue under ASC 606, â€œRevenue from Contracts with Customersâ€ and all of the related amendments (Topic 606). Revenues under Topic 606 are required to be recognized either at a â€œpoint in timeâ€ or â€œover time,â€ depending on the facts and circumstances of the arrangement and are evaluated using a five-step model. Generally, the Company recognizes revenue at a point in time. Â The Company recognizes revenue after applying the following five steps:1)Identification of the contract, or contracts, with a customer,2)Identification of the performance obligations in the contract, including whether they are distinct within the context of the contract,3)Determination of the transaction price, including the constraint on variable consideration,4)Allocation of the transaction price to the performance obligations in the contract, and5)Recognition of revenue when, or as, performance obligations are satisfied.Revenue is recognized when control of these services is transferred to our customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services.Product RevenueIncreasingly, the Company derives its revenue from direct billing. The Company also derives revenue from the sale of its products to O&P providers in the United States and internationally and the Veterans Administration (â€œVAâ€). Under direct billing, the Company recognizes revenue when all of the following criteria are met:(i)The product has been delivered to the patient, including completion of initial instruction on its use,(ii)Collection is deemed probable and it has been determined that a significant reversal of the revenue to be recognized is not deemed probable when the uncertainty associated with the variable consideration is resolved. As an example, the Company will record revenue if it is notified that insurance intends to pay and a payment amount is provided, and(iii)The amount to be collected is estimable using the â€œexpected valueâ€ estimation techniques, or the â€œmost likely amountâ€ as defined in ASC 606.For revenue derived from certain payers, including CMS, where the Company has demonstrated sufficient payment history, the Company recognizes revenue when it receives either a pre-authorization from the payer, or, in the case of Medicare patients, when the Company has gathered appropriate medical documentation from the patient that demonstrates compliance with the Company's inclusion criteria, control passes to the patient upon delivery of the device in an amount that reflects the consideration the Company expects to receive in exchange for the device and the claim has been submitted to the payer. These payers represented 93% and 69% of direct billing channel revenue during the three months ended September 30, 2024 and 2023, respectively. These payers represented 88% and 61% of direct billing channel revenue during the nine months ended September 30, 2024 and September 30, 2023, respectively. During the three months ended September 30, 2024, revenues from patients covered by Medicare Part B were recorded at the time the device was delivered and the claim submitted to CMS for an amount that was expected to be received from CMS and supplemental insurance payers, as applicable.Depending on the timing of product deliveries to customers, which is when cost of revenue must be recorded, and when the Company meets the criteria to record revenue, there may be fluctuations in gross margin. During the three months ended September 30, 2024 and 2023, the Company recognized revenue of approximately $2,440,900 and $1,324,300, respectively, and during the nine months ended September 30, 2024 and 2023, the Company recognized revenue of approximately $2,185,300 and $2,305,500, respectively, from third-party payers for which costs related to the completion of the Companyâ€™s performance obligations were not recorded in the current period.Â For revenues derived from O&P providers and the VA, the Company recognizes revenue when control passes to the customer in an amount that reflects the consideration the Company expects to receive in exchange for those services. Revenues may be recognized upon shipment or upon delivery, depending on the terms of the arrangement, provided that persuasive evidence of an arrangement exists, there are no uncertainties regarding customer acceptance and collectability is deemed probable.The Company has elected to record taxes collected from customers on a net basis and does not include tax amounts in revenue or cost of revenue.License RevenueIf a license to the Companyâ€™s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when the license is transferred to the customer, the customer is able to use and benefit from the license, and collectability is deemed probable. Â On January 21, 2021, the Company entered into a definitive agreement with Ryzur Medical to form the JV Company to manufacture and sell the Company's current and future products in greater China, including Hong Kong, Macau and Taiwan (the â€œJV Agreementâ€). Under the JV Agreement, the Company is entitled to receive an upfront license fee of $2.7 million. As of September 30, 2023, the final portion of the initial license fee has been paid in full and recognized as license revenue. In addition, the Company is entitled to receive a guaranteed minimum payment for purchase of MyoPro Control Units for a period of ten years from the effective date of the JV Agreement. The Company will recognize revenue on these amounts upon invoicing of the JV Company as long as the collectability is deemed to be assured. Contract Balances The timing of revenue recognition may differ from the timing of payment by customers. The Company records a receivable when revenue is recognized prior to payment and there is an unconditional right to payment. Alternatively, when payment precedes the provision of the related services, the Company records deferred revenue until the performance obligations are satisfied. The Company had approximately $32,000 of deferred revenue as of September 30, 2024, and approximately $8,500 of deferred revenue as of December 31, 2023, the outstanding deferred revenue is expected to be recognized by the end of the fourth quarter of 2024.Â Disaggregated Revenue from Contracts with CustomersThe following table presents revenue by major source:Â Â Â For the Three MonthsEnded September 30, Â Â For the Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Direct to patient Â $ 7,431,751 Â Â $ 3,501,958 Â Â $ 15,491,584 Â Â $ 9,245,345 Â Clinical/Medical providers Â Â 1,775,835 Â Â Â 1,527,565 Â Â $ 4,991,158 Â Â $ 3,474,510 Â License revenue Â Â â€” Â Â Â 50,000 Â Â Â â€” Â Â Â 1,764,920 Â Total revenue from contracts with customers Â $ 9,207,586 Â Â $ 5,079,523 Â Â $ 20,482,742 Â Â $ 14,484,775 Â Â Geographic DataThe Company generated 88% of its total revenue from the United States and 12% from Germany for the three months ended September 30, 2024. The Company generated 78% of its total revenue from the United States, 19% from China and 3% from Germany

for the three months ended September 30, 2023. Â During the nine months ended September 30, 2024, the Company generated 85% of its total revenues from the United States, 14% from Germany and 1% from other international locations. During the nine months ended September 30, 2023, the Company generated 72% of its total revenues from the United States, 14% from Germany, 13% from China, and 1% from other international locations. Excluding license revenue during the nine months ended September 30, 2023, the Company generated 82% of its product revenues from the United States, 16% from Germany and 2% from other international locations.Cost of RevenueIn conjunction with the adoption of ASC 606, there are certain cases in which the Company will expense costs when incurred as required by ASC 340-40-25. In certain cases, the Company ships the MyoPro device to O&P providers, or provides the device directly to patients, pending reimbursement from third-party payers, after which revenue is recognized. For the three and nine months ended September 30, 2024, the Company recorded cost of goods sold of approximately $107,200 and $140,800, respectively, without corresponding revenue. For the three and nine months ended September 30, 2023, the Company recorded cost of goods sold of $32,800 and $76,900, respectively, without corresponding revenue. Direct billing fees paid to O&P providers for services they provide in conjunction with patient evaluations are expensed as incurred as required by ASC 340-40-25, as a cost of obtaining a contract. These costs are recorded as sales and marketing expense. Internal costs incurred and fees paid to O&P providers to measure, fit and deliver the device to patients are expensed to cost of revenue. AdvertisingThe Company charges the costs of advertising to operating expenses as incurred. Advertising expense amounted to approximately $1,043,700 and $822,500 for the three months ended September 30, 2024 and 2023, respectively, and approximately $2,680,600 and $2,360,400 during the nine months ended September 30, 2024 and 2023, respectively.Foreign Currency TranslationÂ The functional currency of the Companyâ€™s foreign subsidiary, Myomo Europe GmbH, is the Euro. Foreign exchange translation gains and losses from the Euro to U.S. dollars are included in other comprehensive (loss) gain. The Company recorded a gain of approximately $256,400 and a loss of approximately $47,100 during the three months ended September 30, 2024 and 2023, respectively, and a gain of approximately $312,000 and a loss of approximately $50,500 during the nine months ended September 30, 2024 and 2023, respectively, which are included in accumulated other comprehensive income in the condensed consolidated balance sheet. Transaction and translation foreign exchange gains and losses from a foreign currency to the functional currency are included in cost of goods sold in the consolidated statements of operations. Such amounts were immaterial for the three and nine months ended September 30, 2024 and 2023, respectively. The balance sheet is translated using the spot rate on the day of reporting and the statement of operations is translated monthly using the average rate for the month. Â Net Loss per ShareBasic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding, plus potentially dilutive common shares. Restricted stock, restricted stock units, stock options and warrants are excluded from the diluted net loss per share calculation when their impact is antidilutive. The Company reported a net loss for the three months ended September 30, 2024 and 2023, and as a result, all potentially dilutive common shares are considered antidilutive for these periods.Potential dilutive common shares issuable consist of the following at:Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Stock options Â Â 23,246 Â Â Â 24,982 Â Restricted stock units Â Â 1,234,357 Â Â Â 1,621,935 Â Other warrants Â Â 668,250 Â Â Â 668,250 Â Total Â Â 1,925,853 Â Â Â 2,315,167 Â Â Due to their nominal exercise price of $0.0001 per share, a total of 7,721,519 and 8,750,926 outstanding pre-funded warrants as of September 30, 2024 and 2023, respectively are considered common stock equivalents and are included in basic weighted average shares outstanding in the accompanying condensed consolidated statements of operations as of the closing dates of the Company's public equity offerings in January 2023, August 2023, and January 2024, respectively.Â Income TaxesÂ The Company reported a net loss for the three and nine months ended September 30, 2024 and 2023, however records a tax expense. The nature of this tax expense is the difference between the effective tax rate and statutory rate due to tax provision for a its wholly-owned foreign Myomo Europe, GmbH. Â Recently Adopted Accounting StandardsÂ In September 2022, the Financial Accounting Standards Board (â€œFASBâ€) issued Accounting Standards Update (â€œASUâ€) 2022-04, â€œLiabilities - Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligationsâ€, that requires entities that use supplier finance programs in connection with the purchase of goods and services to disclose the key terms of the programs and information about obligations outstanding at the end of the reporting period, including a rollforward of those obligations. The guidance does not affect the recognition, measurement or financial statement presentation of supplier finance program obligations. The new standardâ€™s requirements to disclose the key terms of the programs and information about obligations outstanding are effective for fiscal years, including interim periods, beginning after December 15, 2022, except for the requirement to disclose a rollforward of obligations outstanding will be effective for fiscal years beginning after December 15, 2023. The Company adopted this new standard on January 1, 2024, which did not have a material impact on its financial position and results of operations.Â In October 2023, the FASB issued ASU 2023-06, â€œDisclosure Improvements, Codification Amendments in Response to the SECâ€™s Disclosure Update and Simplification Initiativeâ€, that adds 14 of the 27 identified disclosure or presentation requirements to the Codification, each amendment in the ASU will only become effective if the SEC removes the related disclosure or presentation from its existing regulations by June 30, 2027. The Company currently complies with these disclosure requirements as applicable under Regulation S-X or Regulation S-K and will adopt these new standards depending on timing of when they become effective, which is not expected to have a material impact on its financial position and results of operations.Â In November 2023, the FASB issued ASU 2023-07 â€œSegmented Reporting - Improvements to Reportable Segment Disclosuresâ€. ASU 2023-07 focuses on the requirements to disclose its significant segment expense categories and amounts for each reportable segment. ASU 2023-07 will becoming effective in the calendar year 2024 year-end financial statements. The Company will adopt these new standards when they become effective, which is not expected to have a material impact on its financial position and results of the operation. Â In December 2023, the FASB issued ASU 2023-09, â€œAccounting Standards Update, Income Taxes (Topic 740: Improvements to Income Tax Disclosuresâ€. ASU 2023-09 focuses on income tax disclosures around effective tax rates and cash income taxes paid. This amendment in the ASU will become effective for public companies as of December 15, 2024 and effective to all other companies as of December 15, 2025. The Company will adopt these new standards when they become effective, which is not expected to have a material impact on its financial position and results of operations. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Inventories 9 Months Ended Sep. 30, 2024 Inventory Disclosure [Abstract] Â Inventories Note 4 â€” InventoriesInventories consist of the following at:Â Â Â September 30,2024 Â Â December 31,2023 Â Finished goods Â $ 1,367,375 Â Â $ 321,484 Â Work in process Â Â 74,859 Â Â Â 6,589 Â Parts and subassemblies Â Â 1,941,279 Â Â Â 1,475,434 Â Inventories, net Â $ 3,383,513 Â Â $ 1,803,507 Â X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContent + Details Name: us-gaap_InventoryDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value of Financial Instruments Note 5 â€” Fair Value of Financial InstrumentsThe Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820, â€œFair Value Measurementâ€ (â€œASC 820â€), which defines fair value, establishes a framework for measuring fair value, and establishes disclosures about fair value measurements.ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:â€¢Level 1 â€” Quoted prices available in active markets for identical assets or liabilities.â€¢Level 2 â€” Observable inputs other than quoted prices included in Level 1, such as quotable prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.â€¢Level 3 â€” Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use significant unobservable inputs.The carrying amounts of the Companyâ€™s financial instruments such as cash and cash equivalents, accounts receivable and accounts payable, approximate fair value due to the short-term nature of these instruments. Cash equivalents consist of money market funds that limit their investments to only short-term U.S. Treasury Securities and repurchase agreements related to these securities. Short-term investments primarily consists of commercial paper and U.S. Treasury Bills and are carried on the condensed consolidated balance sheets at amortized cost which approximates fair value. Cash equivalents measured at fair value on a recurring basis at September 30, 2024 were as follows:Â Â Â In ActiveMarkets forIdentical Assetsor Liabilities(Level 1) Â Â SignificantOtherObservableInputs(Level 2) Â Â SignificantUnobservableInputs(Level 3) Â Â Total Â Cash equivalents Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 5,772,131 Â Â $ â€” Â Â $ â€” Â Â $ 5,772,131 Â Â Â Â $ 5,772,131 Â Â $ â€” Â Â $ â€” Â Â $ 5,772,131 Â Â Cash equivalents and short-term investments measured at fair value on a recurring basis at December 31, 2023 were as follows:Â Â Â In ActiveMarkets forIdentical Assetsor Liabilities(Level 1) Â Â SignificantOtherObservableInputs(Level 2) Â Â SignificantUnobservableInputs(Level 3) Â Â Total Â Money market funds Â $ 4,893,387 Â Â $ â€” Â Â $ â€” Â Â $ 4,893,387 Â Commercial paper Â $ â€” Â Â $ 746,762 Â Â $ â€” Â Â $ 746,762 Â Short-term investments Â $ â€” Â Â $ 1,994,662 Â Â $ â€” Â Â $ 1,994,662 Â X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Accounts Payable and Other Accrued Expenses 9 Months Ended Sep. 30, 2024 Payables and Accruals [Abstract] Â Accounts Payable and Other Accrued Expenses Note 6 â€” Accounts Payable and Other Accrued ExpensesAccounts Payable and Other Accrued Expenses consists of the following at:Â Â Â September 30,2024 Â Â December 31,2023 Â Trade payables Â $ 1,301,550 Â Â $ 1,073,405 Â Accrued compensation and benefits Â Â 2,598,932 Â Â Â 1,964,487 Â Accrued insurance Â Â 240,575 Â Â Â 95,680 Â Accrued professional services Â Â 54,533 Â Â Â 52,202 Â Warranty reserve Â Â 159,531 Â Â Â 231,108 Â Customer deposits Â Â 1,857,565 Â Â Â 1,114,979 Â Other Â Â 235,390 Â Â Â 354,083 Â Â Â $ 6,448,076 Â Â $ 4,885,944 Â X - DefinitionThe entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1 + Details Name: us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 24 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Line of Credit 9 Months Ended Sep. 30, 2024 Debt Disclosure [Abstract] Â Line of Credit Note 7 â€” Line of CreditÂ On July 11, 2024 (the â€œEffective Dateâ€), the Company, entered into a Loan and Security Agreement (the â€œLoan Agreementâ€) with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (the â€œBankâ€).The Loan Agreement provides for a revolving line of credit whereby the Company may borrow up to $4,000,000 (the â€œRevolving Lineâ€), which Revolving Line may be increased to $5,500,000 at the Bankâ€™s sole discretion upon the occurrence of certain events. Amounts advanced by the Bank are based on 80% of â€œeligible accountsâ€, which includes all receivables in the United States, reduced by aged amounts and customers and insurance payers with concentrations in excess of defined limits, among other deductions. The outstanding principal amount of any advance shall accrue interest at a floating rate per annum equal to the greater of (i) 8.50% and (ii) the â€œprime rateâ€ as published in The Wall Street Journal for the relevant period plus one-half percent (0.50%). The Revolving Line is secured on a first priority basis by all of Companyâ€™s assets other than intellectual property and certain customary exceptions. Any newly formed or acquired subsidiary of the Company or any guarantor under the Loan Agreement, will either join the Loan Agreement as a co-borrower or become a guarantor under the Loan Agreement, as determined by the Bank in its sole discretion. The Company intends to use the Revolving Line for working capital and general business purposes.The Revolving Line terminates, and any outstanding principal amount of all advances made thereunder, and any accrued and unpaid interest thereon, become immediately due and payable on the

two year anniversary of the Effective Date. The Company must also pay Bank (i) a commitment fee of $20,000, (ii) an â€œAnniversary Feeâ€ of 0.50% of the Revolving Line and (iii) an â€œUnused Revolving Line Facility Feeâ€ of 0.50% per annum of the average unused portion of the Revolving Line. In addition, upon termination of the Loan Agreement or the Revolving Line prior to the two year anniversary of the Effective Date, the Company must pay a termination fee of 1.00% of the Revolving Line, subject to certain exceptions. The Company recorded approximately $199,500 in debt issuance costs during the nine months ended September 30, 2024 in conjunction with entering into the Loan Agreement, which includes the commitment fee and the Anniversary Fee. The Company capitalized the debt issuance costs and is amortizing them on a straight-line basis into interest expense over the term of the Loan Agreement. Debt issuance costs to be amortized over the term of the loan are included in other long-term assets. Approximately $0.9 million was available to be drawn under the Loan Agreement as of September 30, 2024. No amounts were drawn under the Loan Agreement as of September 30, 2024. X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Common Stock and Warrants 9 Months Ended Sep. 30, 2024 Equity [Abstract] Â Common Stock and Warrants Note 8 â€” Common Stock and WarrantsOn January 17, 2023, the Company completed a public equity offering, selling 13,169,074 shares of common stock and 6,830,926 pre-funded warrants at $0.325 per share or at $0.3249 per warrant, generating proceeds after fees and expenses of approximately $5.7 million. As of September 30, 2024, 5,801,519 pre-funded warrants remain exercisable. Each pre-funded warrant is exercisable for one share of the Companyâ€™s common stock at a nominal exercise price of $0.0001 per share. On August 29, 2023, the Company completed a public equity offering, selling 5,413,334 shares of common stock and 1,920,000 pre-funded warrants at $0.60 per share, or at $0.5999 per warrant, generating proceeds after fees and expenses of approximately $3.9 million. Each pre-funded warrant is exercisable for one share of the Companyâ€™s common stock at a nominal exercise price of $0.0001 per share. All of these pre-funded warrants remain exercisable at September 30, 2024.Â On January 19, 2024, the Company completed a registered direct equity offering, selling 1,354,218 shares of common stock and 224,730 pre-funded warrants at $3.80 per share, or at $3.7999 per pre-funded warrant, generating proceeds after fees and expenses of approximately $5.4 million. Each pre-funded warrant is exercisable for one share of the Companyâ€™s common stock at a nominal exercise price of $0.0001 per share. All of these pre-funded warrants were exercised during the nine months ended September 30, 2024. Â As of September 30, 2024 there were 7,721,519 pre-funded warrants outstanding. Â On August 2, 2022, the Company entered into an ATM Facility with Alliance Global Partners on (â€œAGPâ€). Under the ATM Facility, the Company may sell up to an aggregate of $15 million of the Companyâ€™s common stock from time to time and shall pay to AGP cash commissions of 3.0% of the gross proceeds of sales of common stock under the ATM Facility. There were no sales under the ATM Facility during the three and nine months ended September 30, 2024 and 2023, respectively. In conjunction with the public equity offering in August 2023, the Company reduced the amount available to sell under the ATM Facility to $1,000. In May 2024, the ATM Facility expired and has not been renewed. No shares of common stock were issued through the exercise of stock options during the three and nine months ended September 30, 2024 and September 30, 2023, respectively.Â During the three and nine months ended September 30, 2024, 42,828 and 980,173 restricted stock units vested, respectively. During the three and nine months ended September 30, 2023, 10,099 and 199,163 restricted stock units vested, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Stock Award Plans and Stock-based Compensation 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Stock Award Plans and Stock-based Compensation Note 9 â€” Stock Award Plans and Stock-Based CompensationÂ As of September 30, 2024, there were 491,770 shares available for issuance under the Myomo, Inc. 2018 Stock Option and Incentive Plan (the â€œ2018 Planâ€). On January 1 of each year, the number of shares of common stock reserved and available for issuance under the 2018 Plan will cumulatively increase by 4% of the number shares of common stock outstanding on the immediately preceding December 31 or such lesser number of shares of common stock determined by management in consultation with members of the Board of Directors, including the compensation committee of the Board of Directors. On January 1, 2024, 1,085,401 shares were added to the share reserve under the 2018 Plan.Â Â Recipients of awards of restricted stock units typically sell shares in the open market to cover their individual tax liabilities and remit the proceeds to the Company, which offsets withholding taxes paid by the Company. In certain circumstances, stock awards may be net share settled upon vesting to cover the required employee statutory withholding taxes and the remaining amount is converted into shares based upon their share-value on the date the award vests. In such instances, these payments of employee withholding taxes are presented in the statements of cash flows as a financing activity. There were no stock awards that were net share settled during the three and nine months ended September 30, 2024. There were no restricted stock units that were withheld as part of net share settlement transactions during the three months ended September 30, 2023 and 16,744 restricted stock units were withheld during the nine months ended September 30, 2023.Share-Based Compensation ExpenseThe Company accounts for stock awards to employees and non-employees based upon the fair value of the award on the date of grant. The fair value of that award is then ratably recognized as expense over the period during which the recipient is required to provide services in exchange for that award. The Company attributes the value of stock-based compensation to operations on the straight-line method such that the expense associated with awards is evenly recognized over the vesting period.The Company recognized stock-based compensation expense related to the issuance of stock option awards and restricted stock units to employees, non-employees and directors in the statements of operations as follows:Â Â Â For the Three Months Ended Â Â For the Nine Months Ended Â Â Â September 30, Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Cost of goods sold Â $ 22,805 Â Â $ 24,222 Â Â $ 35,601 Â Â $ 66,815 Â Research and development Â Â 30,599 Â Â Â 11,362 Â Â Â 63,562 Â Â Â (24,056) Selling, clinical and marketing Â Â 41,925 Â Â Â 50,984 Â Â Â 95,237 Â Â Â 142,432 Â General and administrative Â Â 228,856 Â Â Â 243,826 Â Â Â 358,180 Â Â Â 596,322 Â Total Â $ 324,185 Â Â $ 330,394 Â Â $ 552,580 Â Â $ 781,513 Â Â As of September 30, 2024, there was approximately $9,200 of unrecognized compensation cost related to unvested stock options that is expected to be recognized over a weighted-average period of 0.79 years.As of September 30, 2024, there was approximately $2,511,100 of unrecognized compensation expense related to unvested restricted stock units that is expected to be recognized over a weighted-average period of 2.50 years. X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 27 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Commitments and Contingencies Note 10 â€” Commitments and ContingenciesLitigationÂ The Company may be involved from time to time in legal proceedings, claims and assessments arising from the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. During 2022, a former employee who was terminated in 2021 brought an age discrimination claim against the Company. During the fourth quarter of 2023, the Company settled the claim with the former employee. The Company deemed it probable that its insurance company would pay its share of the claim. As a result of this assumed gain contingency, the Company reduced its accrual to an amount that is not expected to be covered by insurance, and recorded a liability of approximately $55,000 for severance and legal expenses as of December 31, 2023. The settlement was paid and all insurance proceeds were received during the three months ended March 31, 2024. There is no other material litigation against the Company at this time.Operating LeasesÂ The Company has a non-cancelable sublease agreement for its

corporate headquarters in Boston, Massachusetts, which expires in January 2025 and a lease agreement for office space in Fort Worth, TX. which expires in December 2025. In August 2024, the Company entered into a new lease agreement for its new corporate headquarters and manufacturing facility in Burlington, Massachusetts, which the Company expects to begin occupying by the end of 2024, with a term of approximately 88 months following the rent commencement date. The Company has the option to extend the new lease for an additional five years, subject to certain conditions being satisfied. Under the new lease, the Company provided a security deposit to the landlord in the form of a letter of credit for $375,000. The Company has collateralized the letter of credit with cash in a separate bank account, which is accounted for as long-term restricted cash on the condensed consolidated balance sheet. Termination options are either not included, or have expired, for the Companyâ€™s other existing operating leases. Certain arrangements have discounted rent periods or escalating rent payment provisions. Leases with an initial term of twelve months or less are not recorded on the condensed consolidated balance sheets. We recognize rent expense on a straight-line basis over the lease term.Â As of September 30, 2024, operating lease assets were approximately $467,000. The amount and the maturity of the Companyâ€™s operating lease liabilities as of September 30, 2024, are as follows: Â Â Â Â Â Â Â Â Â September 30, 2024 Â 2024 Â Â Â Â Â Â Â $ 144,610 Â 2025 Â Â Â Â Â Â Â Â 102,841 Â 2026 Â Â Â Â Â Â Â Â â€” Â 2027 Â Â Â Â Â Â Â Â â€” Â Thereafter Â Â Â Â Â Â Â Â â€” Â Total future minimum lease payments Â Â Â Â Â Â Â Â 247,451 Â Less imputed interest Â Â Â Â Â Â Â Â 12,822 Â Total operating lease liabilities Â Â Â Â Â Â Â $ 234,629 Â Included in the condensed consolidated balance sheet: Â Â Â Â Â Â Â Â Â Current operating lease liabilities Â Â Â Â Â Â Â $ 205,464 Â Non-current operating lease liabilities Â Â Â Â Â Â Â Â 29,165 Â Total operating lease liabilities Â Â Â Â Â Â Â $ 234,629 Â Â For the three and nine months ended September 30, 2024 and 2023, the total lease cost is comprised of the following amounts: Â Â Â For the Three MonthsEnded September 30, Â Â For the Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Operating lease expense Â $ 87,836 Â Â $ 116,314 Â Â $ 263,506 Â Â $ 367,613 Â Short-term lease expense Â Â 1,615 Â Â Â - Â Â Â 4,884 Â Â Â - Â Total lease expense Â $ 89,451 Â Â $ 116,314 Â Â $ 268,390 Â Â $ 367,613 Â Â The following summarizes additional information related to operating leases:Â Â Â Â Â Â Â September 30, 2024 Â Â December 31, 2023 Â Weighted-average remaining lease term (in years) Â Â Â Â Â Â 0.54 Â Â Â Â 1.20 Â Weighted-average discount rate Â Â Â Â Â Â 23.3 % Â Â 23.3 % Major Customers For the three and nine months ended September 30, 2024 and 2023, there were no customers which accounted for more than 10% of product revenues. For the three and nine months ended September 30, 2024 and 2023, a U.S. insurance payer represented 19% and 22% and 36% and 40% of product revenues, respectively. For the three and nine months ended September 30, 2024, patients with Medicare Part B coverage represented 55% and 44% of product revenues, respectively. For the three and nine months ended September 30, 2024, approximately 24% and 27% of the Company's product revenues, respectively, were derived from patients with Medicare Advantage insurance plans. For the three and nine months ended September 30, 2023, approximately 59% and 59% of the Company's product revenues were derived from patients with Medicare advantage plans, respectively. Â At September 30, 2024 and December 31, 2023, one insurance payer and its affiliates accounted for approximately 25% and 56% of accounts receivable, respectively. Supplier Finance Program ObligationsÂ The Company finances its Directors and Officers Insurance policy, which requires the Company to make a down payment, followed by equal payments over a defined term. During the year ended December 31, 2023, the Company completed its payment obligation associated with its 2022-2023 policy and entered into a new policy covering the twelve-month period ending June 2024. Under this financing arrangement, the Company made a down payment of approximately $29,000 during the three months ended June 30, 2023 and made nine equal monthly payments of approximately $27,000, starting in July 2023. During the nine months ended September 30, 2024, the Company completed its payment obligation associated with its 2023-2024 policy and entered into a new policy covering the twelve-month period ending June 2025. Under this new financing arrangement, the Company made a down payment of approximately $39,000 during the three months ended June 30, 2024, and is making nine equal monthly payments of approximately $39,000, starting in July 2024. Changes in the Company's supplier finance obligations were as follows: Â Â Â Â Â Â For the Nine Months Ended September 30, Â 2024 Â Â 2023 Â Balance January 1 Â $ 142,217 Â Â $ 56,603 Â Increase Â Â â€” Â Â Â 128,692 Â Expensed Â Â (80,109) Â Â (132,988) Balance March 31, Â $ 62,108 Â Â $ 52,307 Â Increase Â Â 349,909 Â Â Â 375,824 Â Expensed Â Â (78,593) Â Â (155,076) Balance June 30, Â $ 333,424 Â Â $ 273,055 Â Increase Â Â 63,478 Â Â Â 29,809 Â Expensed Â Â (121,512) Â Â (80,538) Balance September 30, Â $ 275,390 Â Â $ 222,326 Â Â No assets are pledged as security under this arrangement. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Interim Financial Statements Interim Financial StatementsThe accompanying unaudited condensed consolidated financial statements and notes are representations of the Companyâ€™s management, who are responsible for their integrity and objectivity. These statements have been prepared in accordance with United States generally accepted accounting principles (â€œU.S. GAAPâ€) for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) that are considered necessary for a fair presentation of the condensed consolidated financial statements of the Company as of September 30, 2024 and for the three and nine months ended September 30, 2024 and 2023. The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the operating results for the fiscal year ending December 31, 2024, or any other period. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and related disclosures of the Company as of December 31, 2023 and 2022 and for the years then ended, included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023. Basis of Consolidation Basis of ConsolidationThe condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary Myomo Europe GmbH. All significant intercompany balances and transactions are eliminated. Comprehensive Income (Loss) Comprehensive Income (Loss)Comprehensive loss includes all changes in equity during a period, except those resulting from investments by stockholders and distributions to stockholders. The Company's comprehensive loss includes changes in foreign currency translation adjustments and unrealized gains and losses on short term investments. There was a reclassification, which management does not consider to be material, out of accumulated other comprehensive income (loss) to other (income) expense related to realized gains or losses on short-term investments in the three and nine months ended September 30, 2024. There were no reclassifications in the three and nine months ended September 30, 2023. Use of Estimates Use of EstimatesThe preparation of financial statements in conformity with accounting principles generally accepted in the United States of America require management to make estimates and assumptions that affect certain reported amounts and disclosures. These estimates and assumptions are reviewed on an on-going basis and updated as appropriate. Actual results could differ from these estimates. The Companyâ€™s significant estimates include deferred tax valuation allowances, valuation of stock-based compensation, warranty obligations and reserves for slow-moving inventory. Cash, Cash Equivalents and Short-Term Investments Cash, Cash Equivalents and Short-Term InvestmentsThe Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents consist principally of deposit accounts and money market accounts at September 30, 2024 and December 31, 2023. The Company considers all investments with an original maturity of greater than three months but less than one year to be short-term investments. There were no instruments classified as short-term investments as of September 30, 2024. Short-term investments as of December 31, 2023 consists of commercial paper, U.S. Treasury Bills and short-term corporate debt securities, which were classified as held-to-maturity, and certificates of deposit totaling approximately $1,994,700 as of December 31, 2023. The Company determines the appropriate balance sheet classification of its investments at the time of purchases and evaluates the classification at each balance sheet date. Under the new lease, the Company's provided a security deposit to the landlord in the form of a letter of credit for $375,000. The Company has collateralized the letter of credit with cash in a separate bank account, which is accounted for as a long-term restricted cash on the condensed consolidated balance sheet as of September 30, 2024. Â Â Â September 30,2024 Â Â December 31,2023 Â Cash, cash equivalents, and restricted cash Â Â Â Â Â Â Cash Â $ 850,544 Â Â $ 1,231,871 Â Money market funds Â Â 5,772,131 Â Â Â 4,893,387 Â Commercial paper Â Â â€” Â Â Â 746,048 Â Restricted Cash Â Â 375,000 Â Â Â â€” Â Â Â $ 6,997,675 Â Â $ 6,871,306 Â Short-term investments Â Â Â Â Â Â US government agency debt securities Â $ â€” Â Â $ 1,497,099 Â Commercial paper Â Â â€” Â Â Â 497,563 Â Â Â $ â€” Â Â $ 1,994,662 Â Â Accounts Receivable and Allowance for Credit Losses Accounts Receivable and Allowance for Credit LossesThe Company reports accounts receivable at invoiced amounts less an allowance for credit losses. The Company evaluates its accounts receivable on a continuous basis and, if necessary, establishes an allowance for credit losses based on a number of factors, including current credit conditions and customer payment history. The Company does not require collateral or accrue interest on accounts receivable and credit terms are generally 30 days. At September 30, 2024, and December 31, 2023, the Company recorded an allowance for credit losses accounts which was immaterial to the condensed consolidated financial statements. Joint Venture Joint VentureOn March 28, 2022, the Company invested cash consideration of $199,000 for a 19.9% ownership stake in Jiangxi Myomo Medical Assistive Appliance Co. Ltd. (the â€œJV Companyâ€), a company headquartered in China that is majority-owned by Beijing Ryzur Medical Investment Co., Ltd. (â€œRyzur Medicalâ€). The JV Company will manufacture and sell the Companyâ€™s current and future products in greater China, including Hong Kong, Macau and Taiwan. The Company accounts for its investment in the JV Company under the equity method because the Company exerts significant influence over its management. The investment was fully written off as of December 31, 2023, due to the recording of the Company's share of the losses of the JV Company in prior periods, which were recorded to other expense (income) in the condensed consolidated statement of operations, the Company has no obligation to fund any losses incurred by the JV Company. Revenue Recognition Revenue RecognitionÂ The Company accounts for revenue under ASC 606, â€œRevenue from Contracts with Customersâ€ and all of the related amendments (Topic 606). Revenues under Topic 606 are required to be recognized either at a â€œpoint in timeâ€ or â€œover time,â€ depending on the facts and circumstances of the arrangement and are evaluated using a five-step model. Generally, the Company recognizes revenue at a point in time. Â The Company recognizes revenue after applying the following five steps:1)Identification of the contract, or contracts, with a customer,2)Identification of the performance obligations in the contract, including whether they are distinct within the context of the contract,3)Determination of the transaction price, including the constraint on variable consideration,4)Allocation of the transaction price to the performance obligations in the contract, and5)Recognition of revenue when, or as, performance obligations are satisfied.Revenue is recognized when control of these services is transferred to our customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services.Product RevenueIncreasingly, the Company derives its revenue from direct billing. The Company also derives revenue from the sale of its products to O&P providers in the United States and internationally and the Veterans Administration (â€œVAâ€). Under direct billing, the Company recognizes revenue when all of the following criteria are met: (i)The product has been delivered to the patient, including completion of initial instruction on its use,(ii)Collection is deemed probable and it has been determined that a significant reversal of the revenue to be recognized is not deemed probable when the uncertainty associated with the variable consideration is resolved. As an example, the Company will record revenue if it is notified that insurance intends to pay and a payment amount is provided, and(iii)The amount to be collected is estimable using the â€œexpected valueâ€ estimation techniques, or the â€œmost likely amountâ€ as defined in ASC 606.For revenue derived from certain payers, including CMS, where the Company has demonstrated sufficient payment history, the Company recognizes revenue when it receives either a pre-authorization from the payer, or, in the case of Medicare patients, when the Company has gathered appropriate medical documentation from the patient that demonstrates compliance with the Company's inclusion criteria, control passes to the patient upon delivery of the device in an amount that reflects the consideration the Company expects to receive in exchange for the device and the claim has been submitted to the payer. These payers represented 93% and 69% of direct billing channel revenue during the three months ended September 30, 2024 and 2023, respectively. These payers represented 88% and 61% of direct billing channel revenue during the nine months ended September 30, 2024 and September 30, 2023, respectively. During the three months ended September 30, 2024, revenues from patients covered by Medicare Part B were recorded at the time the device was delivered and the claim submitted to CMS for an amount that was expected to be received from CMS and supplemental insurance payers, as applicable.Depending on the timing of product deliveries to customers, which is when cost of revenue must be recorded, and when the Company meets the criteria to record revenue, there may be fluctuations in gross margin. During the three months ended September 30, 2024 and 2023, the Company recognized revenue of approximately $2,440,900 and $1,324,300, respectively, and during the nine months ended September 30, 2024 and 2023, the Company recognized revenue of approximately $2,185,300 and $2,305,500, respectively, from third-party payers for which costs related to the completion of the Companyâ€™s performance obligations were not recorded in the current period.Â For revenues derived from O&P providers and the VA, the Company recognizes revenue when control passes to the customer in an amount that reflects the consideration the Company expects to receive in exchange for those services. Revenues may be recognized upon shipment or upon delivery, depending on the terms of the arrangement, provided that persuasive evidence of an arrangement exists, there are no uncertainties regarding customer acceptance and collectability is deemed probable.The Company has elected to record taxes collected from customers on a net basis and does not include tax amounts in revenue or cost of revenue.License RevenueIf a license to the Companyâ€™s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when the license is transferred to the customer, the customer is able to use and benefit from the license, and collectability is deemed probable. Â On January 21, 2021, the Company entered into a definitive agreement with Ryzur Medical to form the JV Company to manufacture and sell the Company's current and future products in greater China, including Hong Kong, Macau and Taiwan (the â€œJV Agreementâ€). Under the JV Agreement, the Company is entitled to receive an upfront license fee of $2.7 million. As of September 30, 2023, the final portion of the initial license fee has been paid in full and recognized as license revenue. In addition, the Company is entitled to receive a guaranteed minimum payment for purchase of MyoPro Control Units for a period of ten years from the effective date of the JV Agreement. The Company will recognize revenue on these amounts upon invoicing of the JV Company as long as the collectability is deemed to be assured. Contract Balances The timing of revenue recognition may differ from the timing of payment by customers. The Company records a receivable when revenue is recognized prior to payment and there is an unconditional right to payment. Alternatively, when payment precedes the provision of the related services, the Company records deferred revenue until the performance obligations are satisfied. The Company had approximately $32,000 of deferred revenue as of September 30, 2024, and approximately $8,500 of deferred revenue as of December 31, 2023, the outstanding deferred revenue is expected to be recognized by the end of the fourth quarter of 2024.Â Disaggregated Revenue from Contracts with CustomersThe following table presents revenue by major source:Â Â Â For the Three MonthsEnded September 30, Â Â For the Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Direct to patient Â $ 7,431,751 Â Â $ 3,501,958 Â Â $ 15,491,584 Â Â $ 9,245,345 Â Clinical/Medical providers Â Â 1,775,835 Â Â Â 1,527,565 Â Â $ 4,991,158 Â Â $ 3,474,510 Â License revenue Â Â â€” Â Â Â 50,000 Â Â Â â€” Â Â Â 1,764,920 Â Total revenue from contracts with customers Â $ 9,207,586 Â Â $ 5,079,523 Â Â $ 20,482,742 Â Â $ 14,484,775 Â Â Geographic DataThe Company generated 88% of its total revenue from the United States and 12% from Germany for the three months ended September 30, 2024. The Company generated 78% of its total revenue from the United States, 19% from China and 3% from Germany for the three months ended September 30, 2023. Â During the nine months ended September 30, 2024, the Company generated 85% of its total revenues from the United States, 14% from Germany and 1% from other international locations. During the nine months ended September 30, 2023, the Company generated 72% of its total revenues from the United States, 14% from Germany, 13% from China, and 1% from other international locations. Excluding license revenue during the nine months ended September 30, 2023, the Company generated 82% of its product revenues from the United States, 16% from Germany and 2% from other international locations.Cost of RevenueIn conjunction with the

adoption of ASC 606, there are certain cases in which the Company will expense costs when incurred as required by ASC 340-40-25. In certain cases, the Company ships the MyoPro device to O&P providers, or provides the device directly to patients, pending reimbursement from third-party payers, after which revenue is recognized. For the three and nine months ended September 30, 2024, the Company recorded cost of goods sold of approximately $107,200 and $140,800, respectively, without corresponding revenue. For the three and nine months ended September 30, 2023, the Company recorded cost of goods sold of $32,800 and $76,900, respectively, without corresponding revenue. Direct billing fees paid to O&P providers for services they provide in conjunction with patient evaluations are expensed as incurred as required by ASC 340-40-25, as a cost of obtaining a contract. These costs are recorded as sales and marketing expense. Internal costs incurred and fees paid to O&P providers to measure, fit and deliver the device to patients are expensed to cost of revenue. Advertising AdvertisingThe Company charges the costs of advertising to operating expenses as incurred. Advertising expense amounted to approximately $1,043,700 and $822,500 for the three months ended September 30, 2024 and 2023, respectively, and approximately $2,680,600 and $2,360,400 during the nine months ended September 30, 2024 and 2023, respectively. Foreign Currency Translation Foreign Currency TranslationÂ The functional currency of the Companyâ€™s foreign subsidiary, Myomo Europe GmbH, is the Euro. Foreign exchange translation gains and losses from the Euro to U.S. dollars are included in other comprehensive (loss) gain. The Company recorded a gain of approximately $256,400 and a loss of approximately $47,100 during the three months ended September 30, 2024 and 2023, respectively, and a gain of approximately $312,000 and a loss of approximately $50,500 during the nine months ended September 30, 2024 and 2023, respectively, which are included in accumulated other comprehensive income in the condensed consolidated balance sheet. Transaction and translation foreign exchange gains and losses from a foreign currency to the functional currency are included in cost of goods sold in the consolidated statements of operations. Such amounts were immaterial for the three and nine months ended September 30, 2024 and 2023, respectively. The balance sheet is translated using the spot rate on the day of reporting and the statement of operations is translated monthly using the average rate for the month. Net Loss per Share Net Loss per ShareBasic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding, plus potentially dilutive common shares. Restricted stock, restricted stock units, stock options and warrants are excluded from the diluted net loss per share calculation when their impact is antidilutive. The Company reported a net loss for the three months ended September 30, 2024 and 2023, and as a result, all potentially dilutive common shares are considered antidilutive for these periods.Potential dilutive common shares issuable consist of the following at:Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Stock options Â Â 23,246 Â Â Â 24,982 Â Restricted stock units Â Â 1,234,357 Â Â Â 1,621,935 Â Other warrants Â Â 668,250 Â Â Â 668,250 Â Total Â Â 1,925,853 Â Â Â 2,315,167 Â Â Due to their nominal exercise price of $0.0001 per share, a total of 7,721,519 and 8,750,926 outstanding pre-funded warrants as of September 30, 2024 and 2023, respectively are considered common stock equivalents and are included in basic weighted average shares outstanding in the accompanying condensed consolidated statements of operations as of the closing dates of the Company's public equity offerings in January 2023, August 2023, and January 2024, respectively.Â Income TaxesÂ The Company reported a net loss for the three and nine months ended September 30, 2024 and 2023, however records a tax expense. The nature of this tax expense is the difference between the effective tax rate and statutory rate due to tax provision for a its wholly-owned foreign Myomo Europe, GmbH. Income Taxes Income TaxesÂ The Company reported a net loss for the three and nine months ended September 30, 2024 and 2023, however records a tax expense. The nature of this tax expense is the difference between the effective tax rate and statutory rate due to tax provision for a its wholly-owned foreign Myomo Europe, GmbH. Recently Adopted Accounting Standards Recently Adopted Accounting StandardsÂ In September 2022, the Financial Accounting Standards Board (â€œFASBâ€) issued Accounting Standards Update (â€œASUâ€) 2022-04, â€œLiabilities - Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligationsâ€, that requires entities that use supplier finance programs in connection with the purchase of goods and services to disclose the key terms of the programs and information about obligations outstanding at the end of the reporting period, including a rollforward of those obligations. The guidance does not affect the recognition, measurement or financial statement presentation of supplier finance program obligations. The new standardâ€™s requirements to disclose the key terms of the programs and information about obligations outstanding are effective for fiscal years, including interim periods, beginning after December 15, 2022, except for the requirement to disclose a rollforward of obligations outstanding will be effective for fiscal years beginning after December 15, 2023. The Company adopted this new standard on January 1, 2024, which did not have a material impact on its financial position and results of operations.Â In October 2023, the FASB issued ASU 2023-06, â€œDisclosure Improvements, Codification Amendments in Response to the SECâ€™s Disclosure Update and Simplification Initiativeâ€, that adds 14 of the 27 identified disclosure or presentation requirements to the Codification, each amendment in the ASU will only become effective if the SEC removes the related disclosure or presentation from its existing regulations by June 30, 2027. The Company currently complies with these disclosure requirements as applicable under Regulation S-X or Regulation S-K and will adopt these new standards depending on timing of when they become effective, which is not expected to have a material impact on its financial position and results of operations.Â In November 2023, the FASB issued ASU 2023-07 â€œSegmented Reporting - Improvements to Reportable Segment Disclosuresâ€. ASU 2023-07 focuses on the requirements to disclose its significant segment expense categories and amounts for each reportable segment. ASU 2023-07 will becoming effective in the calendar year 2024 year-end financial statements. The Company will adopt these new standards when they become effective, which is not expected to have a material impact on its financial position and results of the operation. Â In December 2023, the FASB issued ASU 2023-09, â€œAccounting Standards Update, Income Taxes (Topic 740: Improvements to Income Tax Disclosuresâ€. ASU 2023-09 focuses on income tax disclosures around effective tax rates and cash income taxes paid. This amendment in the ASU will become effective for public companies as of December 15, 2024 and effective to all other companies as of December 15, 2025. The Company will adopt these new standards when they become effective, which is not expected to have a material impact on its financial position and results of operations. X - DefinitionAccounts Receivable and Allowance for Credit Losses [Policy Text Block] + ReferencesNo definition available. + Details Name: myo_AccountsReceivableAndAllowanceForCreditLossesPolicyTextBlock Namespace Prefix: myo_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of interim financial statements. + ReferencesNo definition available. + Details Name: myo_InterimFinancialStatementsPolicyTextBlock Namespace Prefix: myo_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionJoint venture. + ReferencesNo definition available. + Details Name: myo_JointVenturePolicyTextBlock Namespace Prefix: myo_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for advertising cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 35 -Topic 720 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1 + Details Name: us-gaap_AdvertisingCostsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for comprehensive income. + ReferencesNo definition available. + Details Name: us-gaap_ComprehensiveIncomePolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/830/tableOfContent + Details Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(h)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1 + Details Name: us-gaap_IncomeTaxPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 3: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4 + Details Name: us-gaap_RevenueRecognitionPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Tables) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Summary of Cash, Cash Equivalents and Short-Term Investments The Company has collateralized the letter of credit with cash in a separate bank account, which is accounted for as a long-term restricted cash on the condensed consolidated balance sheet as of September 30, 2024. Â Â Â September 30,2024 Â Â December 31,2023 Â Cash, cash equivalents, and restricted cash Â Â Â Â Â Â Cash Â $ 850,544 Â Â $ 1,231,871 Â Money market funds Â Â 5,772,131 Â Â Â 4,893,387 Â Commercial paper Â Â â€” Â Â 746,048 Â Restricted Cash Â Â 375,000 Â Â Â â€” Â Â Â $ 6,997,675 Â Â $ 6,871,306 Â Short-term investments Â Â Â Â Â US government agency debt securities Â $ â€” Â Â $ 1,497,099 Â Commercial paper Â Â â€” Â Â Â 497,563 Â Â Â Â $ â€” Â Â $ 1,994,662 Â Summary of Revenue by Major Source The following table presents revenue by major source:Â Â Â For the Three MonthsEnded September 30, Â Â For the Nine MonthsEnded September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Direct to patient Â $ 7,431,751 Â Â $ 3,501,958 Â Â $ 15,491,584 Â Â $ 9,245,345 Â Clinical/Medical providers Â Â 1,775,835 Â Â Â 1,527,565 Â Â $ 4,991,158 Â Â $ 3,474,510 Â License revenue Â Â â€” Â Â Â 50,000 Â Â Â â€” Â Â Â 1,764,920 Â Total revenue from contracts with customers Â $ 9,207,586 Â Â $ 5,079,523 Â Â $ 20,482,742 Â Â $ 14,484,775 Â Summary of Potential Common Shares Issuable Potential dilutive common shares issuable consist of the following at:Â Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Stock options Â Â 23,246 Â Â Â 24,982 Â Restricted stock units Â Â 1,234,357 Â Â Â 1,621,935 Â Other warrants Â Â 668,250 Â Â Â 668,250 Â Total Â Â 1,925,853 Â Â Â 2,315,167 Â X - ReferencesNo definition

available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details Name: us-gaap_DisaggregationOfRevenueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of cash, cash equivalents, and investments. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Inventories (Tables) 9 Months Ended Sep. 30, 2024 Inventory Disclosure [Abstract] Â Schedule of Inventories Inventories consist of the following at:Â Â Â September 30,2024 Â Â December 31,2023 Â Finished goods Â $ 1,367,375 Â Â $ 321,484 Â Work in process Â Â 74,859 Â Â Â 6,589 Â Parts and subassemblies Â Â 1,941,279 Â Â Â 1,475,434 Â Inventories, net Â $ 3,383,513 Â Â $ 1,803,507 Â X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1 + Details Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments (Tables) 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Schedule of Cash Equivalents and Short-term Investments Measured at Fair Value on Recurring Basis Cash equivalents measured at fair value on a recurring basis at September 30, 2024 were as follows:Â Â Â In ActiveMarkets forIdentical Assetsor Liabilities(Level 1) Â Â SignificantOtherObservableInputs(Level 2) Â Â SignificantUnobservableInputs(Level 3) Â Â Total Â Cash equivalents Â Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 5,772,131 Â Â $ â€” Â Â $ â€” Â Â $ 5,772,131 Â Â Â Â $ 5,772,131 Â Â Â $ â€” Â Â $ â€” Â Â $ 5,772,131 Â Â Cash equivalents and short-term investments measured at fair value on a recurring basis at December 31, 2023 were as follows:Â Â Â In ActiveMarkets forIdentical Assetsor Liabilities(Level 1) Â Â SignificantOtherObservableInputs(Level 2) Â Â SignificantUnobservableInputs(Level 3) Â Â Total Â Money market funds Â $ 4,893,387 Â Â $ â€” Â Â $ â€” Â Â $ 4,893,387 Â Commercial paper Â $ â€” Â Â $ 746,762 Â Â $ â€” Â Â $ 746,762 Â Short-term investments Â $ â€” Â Â $ 1,994,662 Â Â $ â€” Â Â $ 1,994,662 Â X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Accounts Payable and Other Accrued Expenses (Tables) 9 Months Ended Sep. 30, 2024 Payables and Accruals [Abstract] Â Summary of Accounts Payable and Other Accrued Expenses Accounts Payable and Other Accrued Expenses consists of the following at:Â Â Â September 30,2024 Â Â December 31,2023 Â Trade payables Â $ 1,301,550 Â Â $ 1,073,405 Â Accrued compensation and benefits Â Â 2,598,932 Â Â Â 1,964,487 Â Accrued insurance Â Â 240,575 Â Â Â 95,680 Â Accrued professional services Â Â 54,533 Â Â Â 52,202 Â Warranty reserve Â Â 159,531 Â Â Â 231,108 Â Customer deposits Â Â 1,857,565 Â Â Â 1,114,979 Â Other Â Â Â 235,390 Â Â Â 354,083 Â Â Â Â $ 6,448,076 Â Â $ 4,885,944 Â X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Stock Award Plans and Stock-based Compensation (Tables) 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Schedule of Stock-based Compensation Expense The Company recognized stock-based compensation expense related to the issuance of stock option awards and restricted stock units to employees, non-employees and directors in the statements of operations as follows:Â Â Â For the Three Months Ended Â Â For the Nine Months Ended Â Â Â September 30, Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Cost of goods sold Â $ 22,805 Â Â $ 24,222 Â Â $ 35,601 Â Â $ 66,815 Â Research and development Â Â 30,599 Â Â Â 11,362 Â Â Â 63,562 Â Â Â (24,056) Selling, clinical and marketing Â Â 41,925 Â Â Â 50,984 Â Â Â 95,237 Â Â Â 142,432 Â General and administrative Â Â 228,856 Â Â Â 243,826 Â Â Â 358,180 Â Â Â 596,322 Â Total Â $ 324,185 Â Â $ 330,394 Â Â $ 552,580 Â Â $ 781,513 Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies (Tables) 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Summary of Maturity of Operating Lease Liabilities The amount and the maturity of the Companyâ€™s operating lease liabilities as of September 30, 2024, are as follows: Â Â Â Â Â Â Â Â Â Â Â Â Â

Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 36 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) 3 Months Ended 9 Months Ended Mar. 28, 2022 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Aug. 31, 2024 Dec. 31, 2023 Summary of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Percentage of direct billing channel revenue Payers represent Â 93.00% 69.00% 88.00% 61.00% Â Â Revenue Â $ 9,207,586 $ 5,079,523 $ 20,482,742 $ 14,484,775 Â Â Deferred revenue Â 32,000 Â 32,000 Â Â $ 8,500 Cost of goods sold Â 107,200 32,800 140,800 76,900 Â Â Advertising expense Â 1,043,700 822,500 2,680,600 2,360,400 Â Â Restructuring Reserve, Foreign Currency Translation Gain (Loss) Â $ 256,400 $ 47,100 $ 312,000 $ 50,500 Â Â Warrants exercise price Â $ 0.0001 Â $ 0.0001 Â Â Â Common stock equivalents, pre-funded warrants Â 7,721,519 8,750,926 7,721,519 8,750,926 Â Â Letter of credit Â Â Â Â Â $ 375,000 Â Short-Term Investments Â $ 0 Â $ 0 Â Â 1,994,700 Short-term investments Â $ 0 Â $ 0 Â Â $ 1,994,662 Product Revenue [Member] | Geographic Concentration Risk [Member] | United States [Member] Â Â Â Â Â Â Â Summary of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Concentration Risk, Percentage Â 88.00% 78.00% 85.00% 72.00% Â Â Product Revenue [Member] | Geographic Concentration Risk [Member] | China [Member] Â Â Â Â Â Â Â Summary of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Concentration Risk, Percentage Â Â 19.00% Â 13.00% Â Â Product Revenue [Member] | Geographic Concentration Risk [Member] | Germany [Member] Â Â Â Â Â Â Â Summary of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Concentration Risk, Percentage Â 12.00% 3.00% 14.00% 14.00% Â Â Product Revenue [Member] | Geographic Concentration Risk [Member] | Other International Locations [Member] Â Â Â Â Â Â Â Summary of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Concentration Risk, Percentage Â Â Â 1.00% 1.00% Â Â Beijing Ryzur Medical Investment Co., Ltd Â Â Â Â Â Â Â Summary of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Upfront license fee Â Â Â $ 2,700,000 Â Â Â License revenue Â Â Â Â Â Â Summary of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Revenue Â $ 0 $ 50,000 0 $ 1,764,920 Â Â License revenue | Product Revenue [Member] | Geographic Concentration Risk [Member] | United States [Member] Â Â Â Â Â Â Â Summary of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Concentration Risk, Percentage Â Â Â Â 82.00% Â Â License revenue | Product Revenue [Member] | Geographic Concentration Risk [Member] | Germany [Member] Â Â Â Â Â Â Â Summary of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Concentration Risk, Percentage Â Â Â Â 16.00% Â Â License revenue | Product Revenue [Member] | Geographic Concentration Risk [Member] | Other International Locations [Member] Â Â Â Â Â Â Â Summary of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Concentration Risk, Percentage Â Â Â Â 2.00% Â Â O&P Providers or Third Party Payors [Member] Â Â Â Â Â Â Â Summary of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Revenue recognized Â $ 2,440,900 $ 1,324,300 $ 2,185,300 $ 2,305,500 Â Â Jiangxi Myomo Medical Assistive Appliance Co. Ltd Â Â Â Â Â Â Â Summary of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Cash consideration paid $ 199,000 Â Â Â Â Â Â Ownership percentage 19.90% Â Â Â Â Â Â X - DefinitionCommon Stock Equivalents, Pre-Funded Warrants + ReferencesNo definition available. + Details Name: myo_CommonStockEquivalentsPreFundedWarrants Namespace Prefix: myo_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPercentage Of Direct Billing Channel Revenue Payers Represent + ReferencesNo definition available. + Details Name: myo_PercentageOfDirectBillingChannelRevenuePayersRepresent Namespace Prefix: myo_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionSummary of significant accounting policies. + ReferencesNo definition available. + Details Name: myo_SummaryOfSignificantAccountingPoliciesLineItems Namespace Prefix: myo_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionUpfront license fee1. + ReferencesNo definition available. + Details Name: myo_UpfrontLicenseFee1 Namespace Prefix: myo_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 720 -SubTopic 35 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483385/720-35-55-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 35 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1 + Details Name: us-gaap_AdvertisingExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerLiabilityRevenueRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details Name: us-gaap_EquityMethodInvestmentOwnershipPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_LineOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of short-term investments classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(g)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_OtherShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireBusinessesGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringReserveTranslationAdjustment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, excluding

tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_CN Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=stpr_DE Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=myo_OtherInternationalLocationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=myo_BeijingMedicalInvestmentCoLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_LicenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ThirdPartyPayorMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=myo_JiangxiMyomoMedicalAssistiveApplianceCoLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 37 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Cash, Cash Equivalents and Short-Term Investments (Details) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Dec. 31, 2022 Restricted Cash and Cash Equivalents [Abstract] Â Â Â Â Cash, cash equivalents, and restricted cash $ 6,997,675 $ 6,871,306 $ 6,911,747 $ 5,345,967 Short-term investments Â Â Â Â Short-Term Investments, Total 0 1,994,662 Â Â Cash [Member] Â Â Â Â Restricted Cash and Cash Equivalents [Abstract] Â Â Â Â Cash, cash equivalents, and restricted cash 850,544 1,231,871 Â Â Money Market Funds [Member] Â Â Â Â Restricted Cash and Cash Equivalents [Abstract] Â Â Â Â Cash, cash equivalents, and restricted cash 5,772,131 4,893,387 Â Â Commercial Paper [Member] Â Â Â Â Restricted Cash and Cash Equivalents [Abstract] Â Â Â Â Cash, cash equivalents, and restricted cash 0 746,048 Â Â Short-term investments Â Â Â Â Short-Term Investments, Total 0 497,563 Â Â Restricted Cash (Member) Â Â Â Â Restricted Cash and Cash Equivalents [Abstract] Â Â Â Â Cash, cash equivalents, and restricted cash 375,000 0 Â Â US Government Agencies Debt Securities [Member] Â Â Â Â Short-term investments Â Â Â Â Short-Term Investments, Total $ 0 $ 1,497,099 Â Â X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_RestrictedCashAndCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShortTermInvestmentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=myo_RestrictedCashMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 38 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Summary of Revenue by Major Source (Detail) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Disaggregation of Revenue [Line Items] Â Â Â Â Total revenue from contracts with customer $ 9,207,586 $ 5,079,523 $ 20,482,742 $ 14,484,775 Direct to Patient [Member] Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenue from contracts with customer 7,431,751 3,501,958 15,491,584 9,245,345 Clinical/Medical Providers [Member] Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenue from contracts with customer 1,775,835 1,527,565 4,991,158 3,474,510 License Revenue [Member] Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenue from contracts with customer $ 0 $ 50,000 $ 0 $ 1,764,920 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_MajorCustomersAxis=myo_DirectToPatientMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=myo_ClinicalAndMedicalProvidersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=myo_LicenseRevenueMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Summary of Potential Common Shares Issuable (Detail) - shares 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total 1,925,853 2,315,167 Employee Stock Option Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total 23,246 24,982 Restricted Stock Units [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total 1,234,357 1,621,935 Other Warrants [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total 668,250 668,250 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=myo_OtherWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Inventories - Schedule of Inventories (Detail) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Inventory Disclosure [Abstract] Â Â Finished goods $ 1,367,375 $ 321,484 Work in process 74,859 6,589 Parts and

subassemblies 1,941,279 1,475,434 Inventories, net $ 3,383,513 $ 1,803,507 X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryFinishedGoods Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionGross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryRawMaterialsAndSupplies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryWorkInProcess Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 41 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments - Schedule of Cash Equivalents and Short-term Investments Measured at Fair Value on Recurring Basis (Detail) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Â Â Cash equivalents $ 5,772,131 Â Short-term investments 0 $ 1,994,662 Money market funds [Member] Â Â Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Â Â Cash equivalents 5,772,131 4,893,387 Commercial Paper [Member] Â Â Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Â Â Cash equivalents Â 746,762 In Active Markets for Identical Assets or Liabilities (Level 1) [Member] Â Â Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Â Â Cash equivalents 5,772,131 Â In Active Markets for Identical Assets or Liabilities (Level 1) [Member] | Money market funds [Member] Â Â Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Â Â Cash equivalents $ 5,772,131 4,893,387 Significant Other Observable Inputs (Level 2) [Member] Â Â Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Â Â Short-term investments Â 1,994,662 Significant Other Observable Inputs (Level 2) [Member] | Commercial Paper [Member] Â Â Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Â Â Cash equivalents Â $ 746,762 X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Accounts Payable and Other Accrued Expenses - Summary of Accounts Payable and Other Accrued Expenses (Detail) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Payables and Accruals [Abstract] Â Â Trade payables $ 1,301,550 $ 1,073,405 Accrued compensation and benefits 2,598,932 1,964,487 Accrued insurance 240,575 95,680 Accrued professional services 54,533 52,202 Warranty reserve 159,531 231,108 Customer deposits 1,857,565 1,114,979 Other 235,390 354,083 Total $ 6,448,076 $ 4,885,944 X - DefinitionAccrued liabilities customer deposit. + ReferencesNo definition available. + Details Name: myo_AccruedLiabilitiesCustomerDeposit Namespace Prefix: myo_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionProfessional fees accrued current. + ReferencesNo definition available. + Details Name: myo_ProfessionalFeesAccruedCurrent Namespace Prefix: myo_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8 + Details Name: us-gaap_AccountsPayableTradeCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedEmployeeBenefitsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedInsuranceCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8 + Details Name: us-gaap_ProductWarrantyAccrualClassifiedCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 43 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Line of Credit (Additional Information) (Details) - USD ($) 9 Months Ended Jul. 11, 2024 Sep. 30, 2024 Aug. 31, 2024 Line of Credit Facility [Line Items] Â Â Â Letter of credit Â Â $ 375,000 Amount drawn under loan agreement $ 900,000 Â Â Loan and Security Agreement [Member] Â Â Â Line of Credit Facility [Line Items] Â Â Â Percentage of Amounts advanced 80.00% Â Â Floating Interest Rate 0.50% Â Â Commitment fee $ 20,000 Â Â Anniversary Fee 0.50% Â Â Termination fee 0.01 Â Â Debt issuance costs Â $ 199,500 Â Maximum [Member] Â Â Â Line of Credit Facility [Line Items] Â Â Â Amount drawn under loan agreement Â $ 900,000 Â Maximum [Member] | Loan and Security Agreement [Member] Â Â Â Line of Credit Facility [Line Items] Â Â Â Floating Interest Rate 8.50% Â Â Revolving Credit Facility [Member] | Loan and Security Agreement [Member] Â Â Â Line of Credit Facility [Line Items] Â Â Â Letter of credit $ 4,000,000 Â Â Anniversary Fee 0.50% Â Â Revolving Credit Facility [Member] | Maximum [Member] | Loan and Security Agreement [Member] Â Â Â Line of Credit Facility [Line Items] Â Â Â Letter of credit $ 5,500,000 Â Â X - DefinitionPercentage Of Termination Fees + ReferencesNo definition available. + Details Name: myo_PercentageOfTerminationFees Namespace Prefix: myo_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_LineOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of the fee for available but unused credit capacity under the credit facility. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityCommitmentFeeAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used. + ReferencesNo definition available. + Details Name: us-gaap_LineOfCreditFacilityCommitmentFeePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtPercentageBearingVariableInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-

types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfSecuredDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=myo_LoanAndSecurityAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Common Stock and Warrants - Additional Information (Details) 3 Months Ended 9 Months Ended Jan. 19, 2024 USD ($) $ / shares shares Aug. 29, 2023 USD ($) $ / shares shares Jan. 17, 2023 USD ($) $ / shares shares Aug. 02, 2022 USD ($) Sep. 30, 2024 USD ($) $ / shares shares Sep. 30, 2023 shares Sep. 30, 2024 USD ($) $ / shares shares Sep. 30, 2023 shares Dec. 31, 2023 USD ($) shares Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Sale of stock number of shares issued in transaction 1,354,218 5,413,334 13,169,074 Â Â Â Â Â Â Â Â Sales of prefunded warrants 224,730 1,920,000 6,830,926 Â Â Â Â Â Â Â Per Sale Price of warrants | $ / shares $ 3.7999 $ 0.5999 $ 0.3249 Â Â Â Â Â Â Â Â Proceeds from public equity offering | $ $ 5,400,000 $ 3,900,000 $ 5,700,000 Â Â Â Â Â Â Â Nominal Exercise Value | $ / shares $ 0.0001 $ 0.0001 $ 0.0001 Â Â Â Â Â Â Â Common stock equivalents, pre-funded warrants Â Â Â Â 7,721,519 8,750,926 7,721,519 8,750,926 Â Common stock, shares outstanding Â Â Â Â 30,244,155 Â 30,244,155 Â 27,135,034 Shares value | $ Â Â Â Â Â $ 3,026 Â $ 3,026 Â $ 2,715 Price per share | $ / shares $ 3.8 $ 0.6 $ 0.325 Â Â Â Â Â Â Â Common stock warrants, exercise price per share | $ / shares Â Â Â Â Â $ 0.0001 Â $ 0.0001 Â Â Number of shares, Vested Â Â Â Â Â 42,828 10,099 980,173 199,163 Â A T M Facility [Member] Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Number of shares offer and sell | $ Â Â Â Â $ 1,000 Â Â Â Â Â Â Percentage of gross proceeds from sales of common stock Â Â Â 0.03 Â Â Â Â Â Â Stock issued during period Â Â Â Â 0 0 0 0 Â Common stock issued for the exercise of common stock options, Shares Â Â Â Â 0 0 0 0 Â A T M Facility [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Proceeds from issuance of common stock | $ Â Â Â $ 15,000,000 Â Â Â Â Â Underwriter Warrants [Member] Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Sales of prefunded warrants Â Â Â Â Â Â 5,801,519 Â Â X - DefinitionCommon stock amount reserved for future issuance. + ReferencesNo definition available. + Details Name: myo_CommonStockAmountReservedForFutureIssuance Namespace Prefix: myo_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCommon Stock Equivalents, Pre-Funded Warrants + ReferencesNo definition available. + Details Name: myo_CommonStockEquivalentsPreFundedWarrants Namespace Prefix: myo_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer Sale Price of warrants + ReferencesNo definition available. + Details Name: myo_PerSalePriceOfWarrants Namespace Prefix: myo_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionPercentage of gross proceeds from sales of common stock. + ReferencesNo definition available. + Details Name: myo_PercentageOfGrossProceedsFromSalesOfCommonStock Namespace Prefix: myo_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionSales of prefunded warrants. + ReferencesNo definition available. + Details Name: myo_Salesofprefundedwarrants Namespace Prefix: myo_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionFace amount per share of no-par value common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockNoParValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=myo_ATMFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=myo_UnderwriterWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Stock Award Plans and Stock-based Compensation - Additional Information (Detail) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Stock award net share settled paid for withholding taxes 0 0 0 16,744 Employee Stock Option Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Unrecognized compensation cost $ 9,200 Â $ 9,200 Â Weighted-average remaining contractual term Â Â 9 months 14 days Â Restricted Stock Units [Member] Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Unrecognized compensation cost $ 2,511,100 Â $ 2,511,100 Â Weighted-average remaining contractual term Â Â 2 years 6 months Â 2018 Stock Option and Incentive Plan [Member] Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Number of shares available for future grant 491,770 Â 491,770 Â Number of common shares reserved for issuance 1,085,401 Â 1,085,401 Â Percentage increase in number of shares of common stock reserved and available for issuance Â Â 4.00% Â X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of cost to be recognized for option under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType

Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionMaximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=myo_TwoThousandAndEighteenStockOptionAndIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Stock Award Plans and Stock-based Compensation - Schedule of Stock-based Compensation Expense (Detail) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Total share based compensation expense $ 324,185 $ 330,394 $ 552,580 $ 781,513 Cost of Goods Sold [Member] Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Total share based compensation expense 22,805 24,222 35,601 66,815 Research and Development [Member] Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Total share based compensation expense 30,599 11,362 63,562 (24,056) Selling, clinical, and marketing [Member] Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Total share based compensation expense 41,925 50,984 95,237 142,432 General and Administrative [Member] Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Total share based compensation expense $ 228,856 $ 243,826 $ 358,180 $ 596,322 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Related Party Transactions - Additional Information (Detail) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Related Party Transactions [Abstract] Â Â Â Â Cost of goods sold $ 107,200 $ 32,800 $ 140,800 $ 76,900 X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 48 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Additional Information (Detail) 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 USD ($) Customer Jun. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Customer Jun. 30, 2023 USD ($) Sep. 30, 2024 USD ($) Insurer Customer Sep. 30, 2023 USD ($) Customer Dec. 31, 2023 USD ($) Insurer Aug. 31, 2024 USD ($) Mar. 31, 2024 USD ($) Mar. 31, 2023 USD ($) Dec. 31, 2022 USD ($) Commitments And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Description of operating lease agreement for office space Â Â Â Â The Company has a non-cancelable sublease agreement for its corporate headquarters in Boston, Massachusetts, which expires in January 2025 and a lease agreement for office space in Fort Worth, TX. which expires in December 2025. In August 2024, the Company entered into a new lease agreement for its new corporate headquarters and manufacturing facility in Burlington, Massachusetts, which the Company expects to begin occupying by the end of 2024, with a term of approximately 88 months following the rent commencement date. The Company has the option to extend the new lease for an additional five years, subject to certain conditions being satisfied. Under the new lease, the Company provided a security deposit to the landlord in the form of a letter of credit for $375,000. The Company has collateralized the letter of credit with cash in a separate bank account, which is accounted for as long-term restricted cash on the condensed consolidated balance sheet. Termination options are either not included, or have expired, for the Companyâ€™s other existing operating leases. Certain arrangements have discounted rent periods or escalating rent payment provisions. Leases with an initial term of twelve months or less are not recorded on the condensed consolidated balance sheets. We recognize rent expense on a straight-line basis over the lease term. Â Â Â Â Â Â Operating Lease Right Of Use Assets $ 467,000 Â Â Â $ 467,000 Â Â Â Â Â Â Finance program obligations $ 275,390 $ 333,424 $ 222,326 $ 273,055 $ 275,390 $ 222,326 $ 142,217 Â $ 62,108 $ 52,307 $ 56,603 Loss Contingency Â Â Â Â Â Â $ 55,000 Â Â Â Â Lease term Â Â Â Â Â Â Â 88 months Â Â Â Option to extend lease term Â Â Â Â The Company has the option to extend the new lease for an additional five years, subject to certain conditions being satisfied. Â Â Â Â Â Â Letter of credit Â Â Â Â Â Â Â $ 375,000 Â Â Â Directors and Officers Insurance Member Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Finance program obligations Â 39,000 Â 29,000 Â Â Â Â Â Â Â Equal monthly payment made Â $ 39,000 Â $ 27,000 Â Â Â Â Â Â Â Â Sales Revenue, Net [Member] Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Number of customers | Customer 0 Â 0 Â 0 0 Â Â Â Â Â Accounts Receivable [Member] Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Number of customers | Insurer Â Â Â Â 1 Â 1 Â Â Â Â Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | One U.S. Insurance Payer [Member] Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Concentration Risk, Percentage 19.00% Â 36.00% Â 22.00% 40.00% Â Â Â Â Â Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Patients with Medicare Advantage Insurance Plans [Member] Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Concentration Risk, Percentage 24.00% Â 59.00% Â 27.00% 59.00% Â Â Â Â Â Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Patients With Medicare Part B Coverage [Member] Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Concentration Risk, Percentage 55.00% Â Â Â 44.00% Â Â Â Â Â Â Customer Concentration Risk [Member] | Accounts Receivable [Member] | One Insurer [Member] Â Â Â Â Â Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Concentration Risk, Percentage Â Â Â 25.00% Â 56.00% Â Â Â Â X - DefinitionCommitments and contingencies. + ReferencesNo definition available. + Details Name: myo_CommitmentsAndContingenciesLineItems Namespace Prefix: myo_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of customers. + ReferencesNo definition available. + Details Name: myo_NumberOfCustomers Namespace Prefix: myo_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionOperating Lease Right Of Use Assets + ReferencesNo definition available. + Details Name: myo_OperatingLeaseRightOfUseAssets Namespace Prefix: myo_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of the required periodic payments applied to principal. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentPeriodicPaymentPrincipal Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDescription of lessee's operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseDescription Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDescription of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseOptionToExtend Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionThe carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_LineOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingencyAccrualCarryingValueCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal amount of obligations related to rights to programming, including, but not limited to, feature films and episodic series, acquired under license agreements. + ReferencesNo definition available. + Details Name: us-gaap_ProgramRightsObligations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis=us-gaap_DirectorsAndOfficersLiabilityInsuranceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=myo_OneUSInsurancePayerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=myo_PatientsWithMedicareAdvantageInsurancePlansMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=myo_PatientsWithMedicarePartBCoverageMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=myo_OneInsurerMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Summary of Maturity of Operating Lease Liabilities (Detail) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Â Â 2024 $ 144,610 Â 2025 102,841 Â 2026 0 Â 2027 0 Â Thereafter 0 Â Total future minimum lease payments 247,451 Â Less imputed interest 12,822 Â Total operating lease liabilities 234,629 Â Included in the condensed consolidated balance sheet: Â Â Current operating lease liabilities 205,464 $ 486,143 Non-current operating lease liabilities 29,165 $ 115,160 Total operating lease liabilities $ 234,629 Â X - ReferencesNo definition available. + Details Name: us-gaap_AssetsAndLiabilitiesLesseeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 50 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Summary of Operating Lease Cost (Detail) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Lease, Cost [Abstract] Â Â Â Â Operating lease expense $ 87,836 $ 116,314 $ 263,506 $ 367,613 Short-term lease expense 1,615 0 4,884 0 Total lease expense $ 89,451 $ 116,314 $ 268,390 $ 367,613 X - DefinitionAmount of lease cost recognized by lessee for lease contract. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -

Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeaseCostAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of short-term lease cost, excluding expense for lease with term of one month or less. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_ShortTermLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 51 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Summary of Additional Information Related to Operating Leases (Detail) Sep. 30, 2024 Dec. 31, 2023 Leases [Abstract] Â Â Weighted-average remaining lease term (in years) 6 months 14 days 1 year 2 months 12 days Weighted-average discount rate 23.30% 23.30% X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining lease term calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: instant X - DefinitionWeighted average remaining lease term expressed in terms of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant XML 52 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Schedule Of Changes In The Companys Supplier Finance Obligations (Details) - USD ($) 3 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Commitments and Contingencies Disclosure [Abstract] Â Â Â Â Â Â Opening January 1 $ 333,424 $ 62,108 $ 142,217 $ 273,055 $ 52,307 $ 56,603 Increase 63,478 349,909 0 29,809 375,824 128,692 Expensed (121,512) (78,593) (80,109) (80,538) (155,076) (132,988) Ending $ 275,390 $ 333,424 $ 62,108 $ 222,326 $ 273,055 $ 52,307 X - DefinitionExpensed To Supplier Finance Program Obligations + ReferencesNo definition available. + Details Name: myo_ExpensedToSupplierFinanceProgramObligations Namespace Prefix: myo_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPayments To Supplier Finance Program Obligations + ReferencesNo definition available. + Details Name: myo_PaymentsToSupplierFinanceProgramObligations Namespace Prefix: myo_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTotal amount of obligations related to programs, including, but not limited to, feature films and episodic series, acquired under license agreements. + ReferencesNo definition available. + Details Name: us-gaap_ProgramObligations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: instant EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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z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}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

MKM,HF1UWPX'19^+/[2'.IRO*_WZJ/1"E&0!O MY+'QY9),/+;.327;HHMVU\B6/"QKE- II^T]3.@E^H>VA8_7H MX+Y3HRKXNCLONOK07[VZ=5TP5G.BK<$VJ83";>*'ZFUSW M8F3C;D\K:>@NYAY+NORBL@+T?2WI4+U]L09VU^G%WU!+ P04 " #H@699 M:C4%>A8' "9$0 &0 'AL+W=OC:S>2EJ;J>Z M$0HK6VUJ[O!H=C/;&,$++U17LV0^7\Y]+M7D]MK//9C;:]VZ2BKQ8)AMZYJ; MX[VH].%F$D_ZB0]R5SJ:F-U>-WPG/@KWU^;!X&DV:"ED+9256C$CMC>3N_CU M?
4K[_8:_27&PHS$<)ANM/]/#K\7-9$Z 1"5R1QHX?C;E4N2[3*_>^[@LN%O-75WV7ARIO):L(*L>5MY3[HPY%QRC5A>6N=KCMA(*BE"K \L?/#2& U?T8@Z002CSL8\BC?
<<=OKXT^,$.[H8T& MG]J7!CBI*"@?G<&JA)R[_>AT_IG=';@IV$/%E65<%LL0+22JC3!#R"+F2H%R9@>!?^DZCJZNYLR6#&&-MRCV7%=]4@J'?,&EMRU4N6(OD,5[P_5'7.F*_JGP*=?
&J@_5[$VHN6O0C%A-@P?.2'04W :=J/7@LV-(# MQ"C7=0U;UAONPEIXT]]$/P! E5<6ZKMN*TY8JR.3*D=7M8)MCBQE?R)+(P3/ MF$>;M0ZFI=HQ3)* K&M12.Y()
[(N%W[Q'08A#J!)31DT*V$! ML<"-&$0>\! M2V"KN>)=-;4B%CWMV!{_O::$P<,{"3!.&QL1U:KUL&A'/DX, M,BR=$^)Y^=-.@]5D51__5%J7SN&?A\XL7Z#K,;: _*+_01.Q>5*?L@!KG3-
5;EB$0='#"6^8SCE8@R/4^V)-(M#41L+XN65\SQ1U9)OI&5=%*$HC("/O Z&J-S(8"AHT EQM4Q8H=2(H)ZN[4"_M.,CQI:Z"2_DCU#1<^FB-A*8H#98+XSC%3!ID'^5.+A"10*KC6_,CVR#S@#NX
M##9IM@PCMX0IO9T0)B/]H$9^"B;JI]!'A@VK7(ES',^"(8Y"B:P/\-UJW-ME%"6$@I*R=%2P43GTM#/O/W@03]_N>=5*_K$+Y#S?N!I>)S6<_,)+M5 %GM0 M9DUH]CZ\ ^HS6 U% 0(J8
J9!')BD,XYVM<6UQOOJA-;2@5+'GA;=..:2#ZS^5 MHN]Y21^ZVY7<=2M//%ZTIB\35QH)-?!8X+5X5@5=*R>:;,?6WPN@<0?t,GKFH M"J+0<..(V-=X?-'C,$2Q^CN5?8KO95+3]>1E=I^ARD4S0C
-\!{<64C<_S MDP/IIT<:"_)+7Q&(3TYY9WV_/@V*!(BY*O2ZO++S&D^LBU'2G;)N!WEX#@$ ML;"#ZYR/S!,)A"&(2 H*&H?!;6Z#QH*FIW=*_DOXR(B.Q%!XC3!2#VX*72&4 M5M?
(2.%0G6'%CH+.0Q$U>YF';B4>\Y(N/-X-7[!,3WWE$*U-ZX0'^ 6[5TX M3EHYC*$%&AXR1?>58SA=E"\K'TWA2J#W!>KMTI:>((=6YW20%>%@Z2(#/F(O
MU*EK!G_TW2GXY93!./^SH'OC1E3>^GWS5C>_8K%_ZC3P\7KDXK9>3IPMJ&J%$ MA]'%6VU']AI#8X6?9&]8DD2K>89#=(H21(,%EFTQ+G[BBV7T2K.+CZ@6W*#
MD'IZ"%:E&\Z8"=,KUD<1XMEPI.+*,//#Z1HGBW9C\!7(2UV$KUQ". M4 I]&D?K)&/9/%JO4K,.HF1QQ>(TB=)%G(?9X;O#77C=_M_K(]?+1XS\T..PMEX+AYT@:L;S7> MLKH',C!\C;G]-U!+ P04 "
#H@69970,/,+(* #[' &0 'AL+W=O MMG6Y7V>ZD MIE/II>)>]JFY@$B(OEDIE (T&[-U\^Y%Z!$6,+3G>5%X@+<]>#<" #YO6D^
MV)523GRLRMJ^.%TYMWYV<6'SE:JD'9BUJO%F89I*.MPVRPN[,I0L>%)57J1Q M/+ZHI*Y/+Y_SLW?·Y7/3NE+7ZETC,%M5LME=]._9=_@REU;=F/*]
M+MSJQ>GT5!1J(=O2_63N_ZF"/R.2EYO2\]^X]V-'Z;G(6^M,%2;#@DK7_E]^ M#"!H39C&CTQ(PX24[?:*V,J7TLG+YXVY%PV-AC2Z8%=Y HS3-27EUC5XJS'/ M7=Z8JM(.4796R+H0-Z9VNEZJ.M?
*/K]P4$$#+_(@[MJ+2Q\1-Q.O(6!EQ7=U MH8K]^1=G6WXSE97_$7_%2V[PTMFV4 M^._5W+H&H/GOL2AX)7DE?9SRM%@]>RW@"F&S%*7 M0M=WIKQ3A5@TIA(.2UHXX_]U+4JUE*58-R07JH!
(&XF\E+KR>J2URMJ@M]$6 M X(8Z#$-)H!)1&[.QN)^(>8MAF#&0-RV^0H6.*<.FJI ._?006DNR+KVCI7 MC0-M.,@0L3:05FXJY0Z1&=1?[RPRKD2>NF9E\H^^.E[U@[V\E8H M59&YY+^9L_
N)1T>6/@0 H"@^]'WIBT+L4:NZ;U=4>Q@SE;I0%PAH"!P"Z+T M;[3E0)(2.DPB/6M)86*+I?DO5:ZJ.<*:)K!KBJ/+\JXE?Q6C9 >5 W9'68S/$0!G,.6@&JT;"U MW*W1(@2TOF\T+(VT@3HD5NH:
6$*2N#:H;W4$-ZR5^:JE2&$YIWJ\TO$)P-4!#XWZ0 M=4OK'$Z.?.C$,65FL="()),934Q9=N(}?E:1^/G?@T.YVX21X(%X58NK=HF: MR]'<1R7]T,)I %X:\1{OQF+_T[A&?R7:03[M-7?
&)Q97"X6C;4#.R\=#LF<0 MH]UZL"\QV^1YN]Z03""">1BIBM$7PQ;,7L]%#J&_$=-K!.F%*M&D=XAIR"^L< M[N7>QP(3!@=H8#)>,[9@COKH2#4]W(6)@D/+MB@TC0,@%\"WV"C9P+T>-P=2
M)D[P0RW\(X,L &D76A4#\0O W^PKV,\6G+O3?H5;E2/2CEAM;.QF'32T1*Y* MT %OF $C@SDN4"I.=& _3^R9R":>#0[=1P]6TC*3I?Y?H-L#&1S_7-H5Z2.K MU1+A,9?
U!Z(V8K,NS=IV3ZAH4N"L*$V]/.?L ,NNT4QT+,]X^RE>1$8%75E3 MZH)KSER63"_<(<+T4(TH53YCOM@IS6Q!.*KKO&P1NXA8;R61)+]B\(!LZ869 MFX//MS90C?JH+7.&V,
(!IP,%^"8D538@NZ7R]9QE4_$+GC+:,%4;L" T*9O# M>);C7\D-8Y"32YL"" [TY-%=PW9 AFI$@+F[5^@\.G!#9HG>8%O=MW7@,T((.MG>^9GLVR1K:]9:$.D!RD%ETC;07.J=&B'0/22:4HX((6
YG'91$FHL%UH6J$ M+C=Z&$#N@ERH#/LK]TP,QY,>+$ 9E&']890'?RC(!XE[H*@KAWI,TXZ91_&3 M'5?89R>'8T[H!\8EPV$T3N(3)NXD3J/I,*&;<==8TLUD>\/E2RYHY6P?&4=<
MT3KJR0%=7,55,#;@P8IT.(F&H^3D1TJNKM:M;[:(L,'E":2F:1#TE,-(G{LU@ M;CH[>1660,<-GP*,9RVW"8,QZX:R(=* 1j. !#)WRGUEYV UV M#]^0'?Z9APCI$}NKD[,H2PAN1.!
#:#H=BO,0S0,=,X+1 QW3*)O%.QV\RG9N^[,,$('M MES9=^],2?W!1RM"4/N3%8ROGL(D\><\G"ZHXE]2!+HESZ+1E%R5V^&M@E:OI M-R(>C(8B&:3QX=2.;@47'W2HF?BR^WLM?
T6:,;OC,@9J5/PDCP3C"JF7:0D.: M;R7[,K=?XRK3\#:C!D]\2?@"S:'Y)Y:^4W5+5>1/XUJ*7P:W@W[3+3<8V2C> M^+(IR0R1X!EIN #J_,4P%D<-BZ@D4S.&AJ;<_%$S(QB##=4Q\QM7L->T\B6G?
MH7<4UWEX[X[._LW8TZRP_-KVV[5>==-@%:>+5]FK+/^SO&!%V*"#T]M#@4=< MORKN9.W(Z5[*P+.E_% O90T=&7;;YXG<=^73+Y=9RMO=&]!Z8T-J6/[H!FIU M
%D:RIMB,'E0!)PZ:!GW$};A9#3V?H;!-FPT:0OWT;,;=KTN-71]CX:1-+]K MS+*1E7@[+\.1 M2/>54ZU#%Q\'[K>TVQ]IZ;,Y}JYG7-/P^@PZ)S)S[O'SA_9.H:WO*:WVWON M5<\9P:$>)DOI]0\M(.!W^-
W6!]78QYN+[ZZMWG>$8N^E'B^A6.LR3W2=6C%NY,B[N*&:81M#IWCC:.QG%%, MWW##U)UJ)^DT&L_2D^]\"UB(K\4TCI)X)K[!99*ET6PZ%=]LI>^.V\[$.,7 M*0E/HRR>
[(1GPUDT@P@Z+YAB*]03/IE&HUGFA=/9XF3<$[[$*<9=&0-U#1 M)(OBT6@G'3WO<#*E%3N-9WW929I$HR1EX7!BE/4-WP\;B1V%MC9-83[V8V],
MM\NDH\H555"SI^,3N5D2/%N$5.W+W!3SDC.G(<3##V:.8K%I;W M:E^4%?"R0!=!C(:7?V]-.NEV#:,,@C!&8>2,P.ZNV7TF0)=SEM4<\H+\/_%-9^= MI]}4]4]. /L8BCM-
4%DK4O=)'%!"PV/0*!@+XN[<&8S]1JD7J.LOST462&^ MJTO@8O%##MOX1M"$H%A.X*Z17K8T")RU%.*Y/Q M)Z 2:&/C+$M5ZG7-Z 6S%;[!VLY2^6]&Q"> 15@#.$%^P)4&U0#V0.7Q@4EH
M;6%H31"_@=-DNI_ L=L(03AAS@U:H0<%OZ()_!&:RL$&+#"'2@)B98GE<80 M*^$;Z&IHL&> @0-3"].AEG6V"+<*6@QL+"!1J @ZPK9&E8\SFI63PLVYO6 MEGHI40\FX9>>\O-
G0(Lj2I972LD"\^D"W."ME'0Y;L _<.$.6]+N[C9B#69/?/.PXG%!@2'2TI%\XR4?V. M7X^:!'6]B1AH:L,N":6SA<+.0T(GLE/H*4\H(AHH$,=[:V0D5^TV8"#*V)5 M5L 5Z$X#(Z!/FK&&[7A]SE:?
GI4]ZN(>9%ST6V$/R^W!6YR3:: I&W/JA[E M9K\'20S,7RET3JN:?#CV+6*R\HD&(9O6(U5[^99F\#8U5.@-I,Z"0*2M2G0"-M*WDO,F5:6X60IL4=J?LH> I()DUTB0%[0D((%>7AG-
E>>>F9>GK<8TNPB@7^*[X#^ -+379C7.&%"KMN2"2O^=BL[/1V!YR>:I@H:>D>EA"@0*FW($\IZLB: M C.R^J@ZK,9 308N*VA,1:$/F ##*@\T:XQ@J@;,, 0..P'9_$C:H<,)(,@B+ M)2 41E>-
VXVT(G3)0?E+A+]4IK_W(9.T M*+TI0SM(?@[,6"$'(Z5!*<,(U)E?B(GB@,Y]E(B+]K.022Y8OW:U4^0L2P@,,00O86LZ&T6PZ)?8;PQS+Q>CB;:BA-G6> M&#&+%HNPQ-)J,Q#!:KB;19+FXN.[(ER
S.OY:+*;S:#A=7KQOEJ35'&7L>Q=?:MB3FP_"*.+V8"/\-T60XO^B7^8N/-V);W*HR)S<%W!7TS#M2"O,X*!'4YA] MN%J=!A52F,TG%^UA*(2S^?B.07_'@@%%,&<(9+CRCD-Q#C7
MS'P_DUO=9VS/+MO)O;+]@Y9;L=G&A-5!O @O'M;Z#AP^,AFR, =HOFM6'' MT!:,)1K'H$\N@@D$A 4>W+FK3N(&1T)LF%!>AKP8# (C.YT 0{{{1S'E-DH_^ M-X3G16E7&UY\,0=\>
+=7O2Y$U.]$M#0Q&0#J%HEY M'GD>/&+,04OIS(6@3F, (CES-C0,#9L"TO"LD/T$04(H9@(=3HK0R='=\O M/ZU)Q2^Y>"O!+(KQDA X,B)&R]J3,XG\P87E,IJ1;J/L\.CU6 E_D @>GJDT M.
[U'E'Q"3A_:9EO{[7-.+U5F$9-Q96AG#6${U?[?;}.M?%0/Q<)0/Q% &Q M.?^??@UC&DSZ1R1"U@@JF?Q>R]>2MN)PO0.B<#RGL=;Q6X$FV.:_UN B*2T; M"L/[PS_KTD/3-.@(1&2AL!"T7G5
L%@TP(&93=$?S6N4/,0ON6$*O:E.ITL M4L*TIO?!W76"O,GP*R66.?"I)G_5WO!9H5R'.V MH-3>PGG]$A2H1V?URWL%P3<@%BQI 70\E>,^/TN_ENF9^C1GEO9E9L"KFVLQ
M'\XC)_MN*DIW7/(5Q+JQ+0.OK;TR5B(Y^]+4ZURV3P]*$ELI^U#L=8PK@/C: MN8U=VO]DLS:VH,(,3!D5I$U(-IPT!2E^YE$ G^*W&\0 M#]RRLD^ M&&+%HNPQ-)J,Q#!:KB;19+FXN.[(ER78KE%JQN2S:)6;
MPMY$I0/Q@S.HQY:1-F,\]FDWK6T,.H[3\9 -ZB<(T5*J7W,<@W:6TMRHUQ$4 M\T*,GHDW("Q5*URS0D3TI$*8^X(224&^]T= #9R: 22,:K*D>(*T4R.E=H%& M?][M%-&/BKV(QX0JS&'2<% =5\=
SIY!@J*8]06($$]!/5+K,(E[138]((MAE=N)3@7Z->UK&HDIL_(E8W/S^V4X8-WCRPS>],21YC;$1(S15R+!-R?FA,Q MA9D^@PD"+SMH80/1H)P3+5LX*<0> =-*&ID97J-]N(PCZ$ PJX[,Y*F2LT;. M-
UOP4FVPTFXQ@HX# _$8(VYF*=.8 TN=>UIP'.) L69 MX.)K'WOH%A VZ938*D#+L\'[ED8&5H7W?V07-(=%W=4(SBPSFU=-,MIC"EB M3\UYB=MT=\.S0J(%/]"7.+O+8W_4CF#=$01,5Z$0-L
M'_#(8"E,6/I&\U@4 89YM31+SIZ%8JR^:,O!#.Y\BZMNCICR0B5,@P1S+ MI8-H]%B(!MR*=5RE[H+W^'[C!P\ACG2,3A0C*T&!$>>^]_)LA*O.H%<6 4(M*'U'TNQL3YON+7*#-
K!=2"WVP_%>CWE+H!K]@N,H_*.'!/R;-G6V6U,M-[7#% M-X4-@*H$_'3#@@J;:BC6=-;30JU9@ +?R:?OK1-FJM#'R^!%9Z]*K\F/U$2F ME),I0\19-*K0NJ-RNL'G!'B?
BQ3>\]S6V('2B;+KUO@K!JARW#3XC_\U .V(P*<%+(,'!"8,A;E-3O&4;:,5 M'8?UG-L^#N*CIDI(NP$4FUI2+Y/"QT2C#>TYB/S5/9:!G?QQBVK@5FI"ZE:6 M-M=O<<=],T1VRB^PFR9!\V.:
[]@-/JXQJM0K.JL**GFO3.#QL4_EE)&M1*@J MZ"Q90/?NBCO?9F%>FVL[)1=W340/P-A, GG8S2JE-J'EE6ZW(Z>+4&''33H M[JC2[;,Q]DEQ^_C?.SV^'[<_NK:9B$906H3}7**%P_M&<-
T^O"VV#XZCY5 D-MHHZ);1VX-W,%N+&%^K'#SB8%MVXNBA//!++GZ2>8V]HF/.Q8[-VU.Y2[K# ML1(=<$T9?;DM%?,L^8;M5#MF.[@W3YW_XE;?-NL>'* =^_D"W
M_O=.N<2T$@].W<#\]1YHD%>>LANEN(R'BQ$AAY8D5-LUU<=M^9F0]TN6+T, M5+P+AL.)O=NZE]1#(EV6RWWB@S><6.\E+W!-E"N!SYL8V(+O $ALH+GF&/(MZLR'0JA87+H<)]B"?
M[XG05E<^"];-EHEM[DHIW%(<7.Y-R@F!-R(&$*6D<["G! 7UB'8\U=B@.Y2 MU.*5ZY,^T'+C'$!ED(I#.]/IZ@L=/XM1<'6]@CW.S9.)[;EU!592)V5OEH[K-M'QSR^XPRVQ12UFA27&48VP_Q %
(P.K:)YQ3>RS<.6;GVB,,B6VL(2-G H9U-M3HNSMQT56]/T#):U@4JG9U.>G?1DVX(E1^[89$R%2U!$QXN=ZE)AO=F=-4E. M7'%RGA-%ZJ'N,,5/JNEHI.X++ASU;#T(\U9-ZJTN0
M532>@E,]G5U<0Q"+MN6YLS&-)PJS+&;1W#Z!1Y",7$U]TI@2Q_']C:+ M7!T#U)\W'HUA$/W^@T)Y.G1.2GTN&!KT0I.(Q2.!B<1HY2#ARCU"_DCP$U.
M8>=#0KNV&FHVLYR=V(PYO9MI%W3"MGO(KF4K:2]]Z#SC>YZ2QZPJ0[2.GN,ID.KR$_\8S?N]OLK &Y''G;HYT0GF(LMM48",88HTZ4TCC4!+CYLDTG08+7L2-4AN
M/\)$<_/A:,MSZTY_$>"G6MCZ 2<_9ND!7Z[\$1){6) YF]CX02S-F5*/AF*.O,U-#(\[>_@=G45ID M*PEL]-]JCRI0"S".M5"@N)# IW9L Q'&F.?Q@4$KM=Y#6(W^ M*(!0 &0 'AL+W=O=7 M$-XP;(!1?
^9SB8&F7;$>"@3-MAZ&'12;B87*DB8D5,U>J1DDW:Z4K9LG5F\#4&EG1)%4B MB,-P$%2,2R^,-F<+G4W5U@HN<:';*N*Z=9%W/'CDF]*Z@R";UFR# M2[3?ZX4F+^A0"EZA-
%Q)T+B>>=?19)ZZ^";@!\>],:!=;)2ZMDY]\7,"QTA M%)A;A\#HM<,;%,(!$8W?!TRO*^D23^TC^EW3._6R8@9OE'CBA2UGWLB# M=L M*^RCVG_%0S]]AY4I=5TRRG/9O=RA]{JS='
QV]L M)=!$F@:6D-UJD!)0YBU*_,*&!Z4M*6!+[+ XM_\@!AUM.(CK7E\$7")]14D MH0]Q&*<7\)*NS:3!2_[3YBO<?zUREA-,\6O5B:E9
MCC./Q&!0[]#+/KR+!N'G"W33CFYZ"3U;DO:*K4!0:SB9T#F:%X'.TSR=>:Y(M7\:Z0K9$6"M!,N5R \Q.>C0%B]4*=3.*6\P/3N3W[KCD]-<5L%&J,/ >(C\9 M#/UDV"<[B2,_':6]}Q(D<
FU5CD: \/4'_7',/#[HW%OP,0UP&1!"X%T90A; M.$:1/TXC/QZ.R4]"?3]-TMX)8Q\DK2JJX2>CQ.]'25-[%)(=#N'4&EX-^Q[H5O>M8U7=:&VE M++"FW,4M:E:A= -VOE;)'QQ7HEF_V!U!+
P04 "_#H@699+)777 (# !Z M!P &0 'AL+W=ON?11L@'E2}J>,H85V,OU3H?^KZ'4LR(.A$Y"-!%5E&Y/,,F=B,O,:WV[BEJU3;#7\BRLD* M%ZB_YS?2K/P*):89MXWS"M-MZ 8[NK/@(.
"\Q,(6TT(6D'G %Y8R0\=7OAW^>=414RH0J*"G].ED6_^,;_V M:2XA._LA;1<-54XB"NF313*-7J3XZ-VMW5V@'"G(MPYA#Y9F*Z,"^:J-2$2"FN7<4EI:"=3&%UI@M45;5A@U*!*
(@$6,NL@REFQLYR0VCNENOTVWVNL&^O<9B?R+JKNWF8-!I M=M\ O.SNZRF_-@\-L96;^@HB47!=CL9JMWI8IN4\?7$O7Z5K(E>4*V"8F-#6 M2>_4
UE.^G*A1>ZFZU)H,ZN=F9K'$:5U,.>)$'JWL!=4S^WD-U!+ P04 M" #H@699F+3E4_L" !Q!@ &0 'AL+W=O,'_/>O,U#9AS D\,&7=!>NE7{O5ZZ7:VZ;N(%:#V;>MU(_7
MV*C#*HB"X*7>KNS;B%<+WNYQ3NT7_M;3;-P8BGK%CM3JPXT5Q@*KJ\3EV\ M#_A6X\$\&8-SLE'JAYO\4ZX"[@1A@X5U#)+^?N(--HTC(AG_CYS!E-(!GXZ/
M[!^]=_*RD09O5/.]+NUN%60!E%C)?6._J,/?./H1CJJ0C?&_97OI97KI58'T"Z:V-S 6_5H$E=W MKBAW5M-N33B[OBH*M>^L@5OY*#<-@NQ*^&QWJ{&V]!Y+^/! -\"@@;_N781Y
MNPPM97;XL!BS7 J9X>RY/!)=79GX$-78ODG/B3%D^SX*/LZ/DMXA_T%))Q! MS./T#%\R'4/B^9)G^$;WQMOWQF5CX-^KC;&.+LY_IRP/C.EI10+8+DTO"UP% M]%H,ZI\8K-
^\BN;\W1F]Z:0W/<>^OAO>$*@*7E#!4R[.YCGMXB5WIE#T?@W% MDE**@$HUU ?J;@O27LZHC!;,#0%=+=]C,4XB-KO7LD3HCW5Y#1%+>,2$X'[,
M%PE+N9@=$Q:J=1GE\-1)SP8[K&I*'#.19RQ/8D+E\Y2EV6)"U9W9:]D5"'!* MF5@(R 6,9WP*Z+6JT+@.)!MP]NN"Q(B4B20!$3.Z?K/O4A.'?83Q@" 2.>U'
M$)./B&>S&_^,R5>)O3).4\0RL6!B+F@412G+%_EL., X$2S).224@V?)[+7, M69IFY'=.OE.698+E:0JG[E#XI U0NJUO=JX$5*RA(TRK4S^]&MK([_"A&7^2 M>DN' PU6!.47"VI?
>FAPP\2JWC>5C,+DS0JW]$U [0)HOU+*'B@$, $,' 9 >&PO=V]R.W-H965T&' XG>Z6?38-HX;43TDR#QMK^/HI,
MUG#'S:WJ4=+*1NF.6QKJ,61ZC,SV09V(6!P74<=;&:.1M$)I6X[E*95$C1NIL$\ MN5]DSM\[_-'BWIS9X#)9*_7L!K_6TR!V@E!@91T"I]\+/J 0#HAD_'/ #$Z4 M+O#S@#+^((=
IC7/1!YE3]RRV<3K?:@G3>A.<.G MZJ-)7"O=H:RLIM66XNQL957U#/,]US4L!9<&N*S!S]ZX;&MX4!U5@.%^$S_M\;5 \V4262)W$%%U(%H,1.P#HC%\4}
(V!K[*&NOW\1&)/BEG1^4+=A5PA?TM M!$(+&;9%;STM!.IQTL_PFNXQIN$WG)WZCP+,RUYG*+9ZOXQO7964Q7]?2GY M_3N[C.UNUKW1>8743@*Z:0
V"P>S[[Y(B_N&*\NRD/+N&/EO13:UW D%M/CZY MKZ_.QDO:KZ)?UO{4H(?G\HVN9J6VLOV7&,T9>W7.C@,[^0IN:=$JL 31&K/C MLO+*?2RH?KBLKB"'6B1.J]O*'N%A)UMK'
)VO5!OB"8$J>3-:>C#ZI9T6:4- MM-)S&4O,[B2-8Z.NIKTT\C:P48*ZD[D?T4WWSD^-1GQ7L7!<^HWVY]W*B"J1 MD->H?
3F^&XU<<;H*3>%PC1Z4L4[#5BG*T2A1PR=@+"SCW!E9R!@€(\W#(D[{M*QP3/+1(VT^UU4SI(&8Y9#'X;C;8>Y,&]+-TGZ"7J -6QI$*E?
DH85L&R,C3JFFBB;LC.V M9@\M4VB8D##R1^^XUB#*NC$\!U$A#-<&?-1*:0=TS.&G0 ,TETY';ZJL:'(' MXHXMDY@O0Q+[E0XQO)SX^@ -+.TGZ"7J-6QI$*E?
O976:_80$ MG1(_COZ+^7"$Q5'/XNAG67S(W+G49HBR1P&'*8LEW)VO62O.'6DK%(.R+5+< M%]D! KJ-. A(*^Q.ICV/#&T#H?%=UDK8@'7$;[EJG6@S!%F[57[OE'>%<;OX
MWMK1KK57[@8Z4!%-OI^,8^^:>!?'/LN J MXG6XL=&:-U7;=MC[^R,O7"H8>'[*OJ++\BB.D[9EV<74A>HYEX{$I4_.XM"\,^ H M][UHCK>3*[YH",=*BP\BQD"XFM\5 M=0UW35T7
OU[+2I7F&X7A5BYLQJ,QE&-PQF[5=T5QD[UKQJCU>E>=KKE3C=L M^,&-,9!F;4\RE.XN4M==K7W+JL92TK$-]1 3O,1Q%,8F]P-9MY<+6W1Y8^U,2 M3^GH59LZ.3R'U".^-
X43'/H!)=,TA9,>_8:I;.WH\11BBAM3"TY)X"4[\""< MDBE"!F-TNX#YZD))H&+7@4$2^)]\#?-NBL]0IS- A(Z&Y{F@3$BZ(=.M:* M,$EMV4^]Z3ZV3WT2^=2!HQ-
1L&_XXV.SL%%7#BA%_''>+@9*]%+;E:N4;< M5D^D<=NM]JM]KW_5MKB[[>V/ I[<2F"H"[Y$4>\LP>M M\+<% !] M(P &0 'AL+W=OU4Y&/',OR1@7.RL%\5E^[9_,9K42>E>2>

**(5X5!69/MR2G^^N!/7B^ M\#G;;(6Z,)K/=GA#'HCXLKMG\FQTH*1904J>T1(QLKX>W-A7L>TKA]KB[XSL M^6ZA')22(4 LNO1[(@>:Y(LA_?6^C@T*9R/#U^IB_K MPSV8#E!*UKC*Q6>Z_YVT YHH7D)S7G^B?6/K!P.45%S0 MHG66/2BRLOG&/]H?XL3!'K_@X+0.SEL=W-;!?:O#N'48GSM,7G"8M Z3M[;@ MM0[>6QW\UJ%6?]3\NK4T(19X/F-TCYBREC1U4.M,>TM%LE*%XH-@\FXF_<3\ M4_;]RM),/*$/Z":5!S(^<(X^EDV4JVAY%Q*!L_R]M/CR$*)W/[^?C81L6@%& M2=M,U#3CO-!,@<B+85<165*TT[_2':YT&_GN=^WCA'X!RZ'R Y^18[EC#7] M69C=;ZK-$#F-NZMQ#]_2NO^B>V1V?R"[(7*M%SN_?+N[KO7XERV\K6N] M(X5[""&WYKDO=6>+&?EP*]>#%"UH(1=)W@3.#6.XW!"Y< FT>D*G=O?XJ;Y\ ML\(T/X34VT>=_RN=Q3CG7!8;1\}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}ZW_TE'+AUQ7Z*MYM*VI\6BW1QI#_?Y(1}1ND,P#O%@V2%H, M1>N*>ZQIV>:BUO-,_WI'U9)6\0V(RZ~W2 U+5!:!$I;@M)B*%HW4(ZU+]O[M&^KL4%+9:"T$)06@=*6H+08BM8-1VIS3;7WH S*%%!G<4>?2PF%=OD->K<VXXQ] M]WQ*]LWLP-%,R;Z=-W6MP/'.M#..X5+M(&Q*RCG6T=]^S6*TMKEA D'YW- M--0IUA*"T^5Q>#[9-$;6\$R$L#527R=6KC,Y$\OG\(C.U>O;6<-)SR[4VKG..#@7T#B(BP6$I,50 MM*Z SE% Q[QI*6BEBAB425>Y5N(-SDHN9-*:U#<824CVB%>Y?BX:X9=FKZ"T M$)06@=*6H+2XI9TF@DU>>7PZ=:/C6/^RC?6/>5V]^FN-%HRDF4!+G&2YRG+O M\(^L] IT6X>-VN0LL.ROO*6-$M J%R@M!*5%H+0E*"UN::=1$IB"Y%C%LLUE MK&XBG="29VF]}ZW_TE'+AUQ7Z*MYM*VI\6BW1QI#_?Y(1}1ND,P#O%@V2%H, M1>N*>ZQIV>:BUO-,_WI'U9)6\0V(RZ~W2&+]}WO[M&^KL4%+9:"T$)06@=*6H+08BM8-1VIS3;7WH S*%%!G<4>?2PF%=OD->K<VXXQ] M]WQ*]LWLP-%,R;Z=-W6MP/'.M#..X5+M(&Q*RCG6T=]^S6*TMKEA D'YW- M--0IUA*"T^5Q>#[9-$;6\$R$L#527R=6KC,Y$\OG\(C.U>O;6<-)SR[4VKG..#@7T#B(BP6$I,50 MM*Z/M9Q[@JKTK!O6$O8:.];G1B:8X]'C<"VQ]F:,[&-A@"\]CA#L\:&8QF-+#'MZI8UMAS';H04N;L4!)-".MJ%=*0,J@;VQ)F[WW%IB_ M:(W((EUZ1[GTD2X#)(R.6JHZUD}(V\TP]#KCE&*_3M8:8Q;H[R.F"6UAKFMX!YG17)FW]9BZM[Y@U9"^H9UW!%6RW1:<6V/&QN&W0IL>Y@Q&FNC M5F0[QIDCS6K%%KFO% 238CO9Q7;R2O+--((S%M/ZUTF%?'4S:2=8>M>+AMH=9CMY207N4 MJ7<0B_#FF?AUBQ/S.&-DS>.H\T>N M)O6-;D5SI#=-$9#&N:X+]>H=Z=6'>@V@-{JBR8K9JYOIKR3ZU4H<";(\C;X2 M]NZPY]J,,2J,=FU\H8#0R#BB@K@/JZD+@/4^G8BI"JH(@ M^?V.K;XP_@?YFP0LG?-PO8@CV8EW.1CW'V=7_@YR3.Q:G'0Q[F14>C M^D.GBJ#%12C-A=(*,V'T@(HC:)HLH#KJJ<^.E6O38>61Z$T%TKSH#0?2@N@ M-{JBR>JL:[/Z:\79YH'S#:D;<9TBA%9J*]HKW2^W>Y@S;D[0NFEV,Y-VTXSF MY Q:K$71Y$#7Y5I=7:]%Y-&;19R$ZOP)K?="::2Z4YD%/I060&D419.%6]>B M]T"@VEN5":IZ7Y4%H I5$435X15U?)#765O'_^5 -/[BA!*U*E_P&EC944 =4I1-%DV=:G<4)?0*$=DX8*P5)L_*?*S>C-YB0}<*,V#MTGPH+8#2*(HF2[>N\AO&J?*Q 6T&0&DNE.9!:3Z4%D!I%$63U5FW# QUR^ [M\C&T=5#1FLFL,;5TNX=IS=6$!VA68SY[W+ NJ<419,#77<&C%=6"P,RZ(=\ MP3AYG^2,)V%U%<=M&FU?JNO$ZHWK+1HDS872/"C-A{("*(VB:+*@ZT:'89\L MKT*[&%":"Z5Y4)H/I050&D719'7670Q#O7C[._(JM%D!I;E0FE?1FLF\N7+L MN&$!=-LHBB;+IFXO&.KVPC6+_[==0_K\UX:3.S85![7EWF(.D:#/WI#;O'-) MN)K=6T%(F@NE>5":#Z4%4!I%T60]UET08WRR) MM=4:I+I3F06D^E!9 :11%MD]59MSH,];K[S^L93X4W4^U&T MI5$43,;[2N^9UF.I#Q%E)L55=VI"7T%!:2Z4YD%/I060&D419-55SE^5!: *51%$U6 M9]VH,-579/00!:N\04U{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}&/C\QO]G:MW?.[I[_SRT9,UOGP2YEW(Y&&2D26;"5Z:F2/. M$7CY<,GRN3ZNMX\J_)+F>;K:OERP4!PCBP'B[[,TS5_>% YVC_B_#)02P,$ M% @ Z(%F66]XCOG2! EB, !D !X;"]W;W)K&LUM9=CYLX%(;_BL6N5JTT'3"?83.)- UTMQ,]X_EFE*!ON=944Z,M1";&],L MDS7-27G--K201U.,YT3(7?YDEAM.R,)*RC/3MBS?S$E:&--Q]=D]GX[95F1I M0>\Y*K=Y3OB/CS1C^XF!C9U\WDY,2PU(YK11"@$D6\[.J-9 MIDAR'M\;J-&.J1(/MU_HGZJ3ER>S("6=L>S?="G6$V-DH"5=D6TF'MC^,]J< MD*=X"366> MF,[K:l8+8"LU(N;ZJ7E\;9ON2$8+42)2+-%\S;C%\(R7"TN=K04>77H740% M2;/R/?J 'N<1>O?[^[$IY*P4VTR:&7RL9V"_-@.ZN4:.=85LRW8'TF?Z]([@F M,AU7ZO3VT8?2X[>/;O?33:E$*X?=RF%7/.<5WH.L+4\309>U$*KX)XI\ MO5W(*/D5^V^HVO4 [O JN_*T8GG9I#G?J*_2%"9(-:5+CO(-%81TMP],('(:N[!M' MRU [L7-K 3M:=!O:^C_].N-OM{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{6F_]+4,4> ME>SB%^8P"QS+]\:CB7DXC_VEG6?Y@5>4U[E=>&GG6'CL^-AI&T:7AC;&8^S[M7F/8"H?7A,;;#$=(N?I!0I*AA:I64,+V90[9"GAO?0ZR7EN?.F&A3EBD"=9* MR*A)R.A*XC'2F1R=L% G+-($:R7';Y+C7U$*K9W]@[V+5]S^Z(QZ6=ZUEV MX(T[XG%I9WLXL+TQ[HC'I6P=A[,]E&PO=Y[R:W>[E=_%SVC'N(G&># :#ZI#?0REYAS6Q14M.#0O M-7 Q*"+R-7 6J4Y8J!,6:8*U,A,TF0FN)"*!SN3HA(4Z89$F6"LYMG7:45A7 ME)$:WGKOU7? V/4Z.M)GZ#F^-^H8ACV&. ALNZLX48^ABWWLV5:_DMAGFRQ[M,"0?::SVUG"JTP$!&4.]MDBUTD*MM$@7K9T4YY04YTHR4H-UI4@G+=+1*BW31 MVBDZ;37MP[&ML+HBJO*R'_28IZ3&Q_A-4&JB,>YMEAC9IX M4IZ2"52>MU2[!*:W.8F[*\^?.OWW]NV#W=,?%B=WY>'0"5\=^\T)3V@N4 H; M-91UXRNIX]5)6M60;%<>%:V85%$M;[= U#=/8:">;QB33XUB@.8\<_8O4$L# M!!0 (_.B!9EF1L<*F@(_L& 9 >&PO=V]R:W-H965TG?[Y!2%,M5U*;00UYLD9QS=.,,0!C.#D+>]3V)@\9S]70474F"LCQ9"MD1C4NYXD,[NWE,E,E)JS'):2MJ#++J/QV"5PFPTWF15T!RO0GXJEQ)7;L&Q8!KEB(B<2MG/G MPC]?^^$!V(C/# [JZ)F85-9"W)G%]6;N>$81<$BUH:#X=P\+X-PPH8[_:E*G M>:0M%1:9#48%60LK_[I0VW$$0!YN@%!#0A. :-G &$-L_ZYE3*;UCNJ:3*3 MXD"DB48V\V"]L6C,AN6FC"LM\90A3B>KJGQ$;,F*[7*V92G--;E(4U'FFN4[MLA2A:J9*N.9W[T!3QM\B3-FCF:M1 MKWFKF];.+BMMP3/:IN1&Y'JOR%6^@4T;[V*>3;+!8[*702_A"HHS$GI_D, + M1AUZ%C\/#WODA(WWH>4+G^&[0,WC)>FDDAYB1F3K129\;W"2WW_S8^^O+HL&(FL9-FH,&_6Q)Q^%IKPKPPH669CY<-TG_C2()A%6Z?Y8 M_/=Q0>A'?CQNXEJZHD97U*OK*BNX^981"W2. .*A,,7JTME+\|)*#$36RCAN M,HY?1>O&0QHV$%G+L%\C/C76G?@E?6H^!R%JY3YOUU1Q({6U=3:[#97H@M[$3C9OS17)3OO/]%4]ZP;*GR!-.)YO!4[R]<*\H+E)O\#4$L#M!!0 (_.B!9EF1L<*F@(_L& 9 >&PO=V]R:W-H965TG?[Y!2%,M5U*;00UYLD9QS=.,,0!C.#D+>]3V)@\9S]70474F"LCQ9"MD1C4NYXD,[NWE,E,E)JS'):2MJ#++J/QV"5PFPTWF15T!RO0GXJEQ)7;L&Q8!KEB(B<2MG/G MPC]?^^$!V(C/# [JZ)F85-9"W)G%]6;N>$81<$BUH:#X=P\+X-PPH8[_:E*G M>:0M%1:9#48%60LK_[I0VW$$0!YN@%!#0A. :-G &$-L_ZYE3*;UCNJ:3*3 MXD"DB48V\V"]L6C,AN6FC"LM\90A3B>KJGQ$;,F*[7*V92G--;E(4U'FFN4[MLA2A:J9*N.9W[T!3QM\B3-FCF:M1 MKWFKF];.+BMMP3/:IN1&Y'JOR%6^@4T;[V*>3;+!8[*702_A"HHS$GI_D, + M1AUZ%C\/#WODA(WWH>4+G^&[0,WC)>FDDAYB1F3K129\;W"2WW_S8^^O+HL&(FL9-FH,&_6Q)Q^%IKPKPPH669CY<-TG_C2()A%6Z?Y8 M_/=Q0>A'?CQNXEJZHD97U*OK*BNX^981"W2. .*A,,7JTME+\|)*#$36RCAN M,HY?1>O&0QHV$%G+L%\C/C76G?@E?6H^!R%JY3YOUU1Q({6U=3:[#97H@M[$3C9OS17)3OO/]%4]ZP;*GR!-.)YO!4[R]<*\H+E)O\#4$L#M!!0 (_.B!9EF1L<*F@(_L& 9 >&PO=V]R:W-H965TG?[Y!2%,M5U*;00UYLD9QS=.,,0!C.#D+>]3V)@\9S]70474F"LCQ9"MD1C4NYXD,[NWE,E,E)JS'):2MJ#++J/QV"5PFPTWF15T!RO0GXJEQ)7;L&Q8!KEB(B<2MG/G MPC]?^^$!V(C/# [JZ)F85-9"W)G%]6;N>$81<$BUH:#X=P\+X-PPH8[_:E*G M>:0M%1:9#48%60LK_[I0VW$$0!YN@%!#0A. :-G &$-L_ZYE3*;UCNJ:3*3 MXD"DB48V\V"]L6C,AN6FC"LM\90A3B>KJGQ$;,F*[7*V92G--;E(4U'FFN4[MLA2A:J9*N.9W[T!3QM\B3-FCF:M1 MKWFKF];.+BMMP3/:IN1&Y'JOR%6^@4T;[V*>3;+!8[*702_A"HHS$GI_D, + M1AUZ%C\/#WODA(WWH>4+G^&[0,WC)>FDDAYB1F3K129\;W"2WW_S8^^O+HL&(FL9-FH,&_6Q)Q^%IKPKPPH669CY<-TG_C2()A%6Z?Y8 M_/=Q0>A'?CQNXEJZHD97U*OK*BNX^981"W2. .*A,,7JTME+\|)*#$36RCAN M,HY?1>O&0QHV$%G+L%\C/C76G?@E?6H^!R%JY3YOUU1Q({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|)*#$36RCAN M,HY?1>O&0QHV$%G+L%\C/C76G?@E?6H^!R%JY3YOUU1Q({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¥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}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}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|)G+'8ED9$JVH,]A.M-+ M-_[9]!@ME8VBA:,0FDP=JF77_^@4TUFOGTVE2;3 *%IH"JU)Y.'B=[M+_M\V MZG-"=%F<>7"$MSA)\2(%?>*QW(@- [22M+,GF_ZK+>SMJS95N9N&79?3%SJ*LZ4$LXW6,.X5NL.7I_R.%=]WW&/S6NT M_#Y5;6A*;=.^A^+:[:ZNY\!4;E!Y/"$1 QEG9 .18Y>N$:"S2V5_E5^:_M{) MALFR>V84+2C17+=^9'CI^,>$&:WC[=K]2@9VIR^VN+3UWFB8+WJK2[/O25 MT5'_K7L]&aPCO=V]R:W-H965T]);<F1Z%+(K6!]_:D5:J:O>W#M\N.DJX,QVFO:_GPV4!.*B=O53OS3@ MG'MLWW-SRC63'67W?$V((JE4?&IM19B6;-)/7;#9A.Z%45>D1L&^+8L,7NZ(@7=32UH/0_< MYJNU4 /V;++!*[(@XOOFALD[NV/)\I)4/*<58&0YM2[A10(#%5 C_LS)CA]< M [65.TKOU;E M9NXP)W-:_)5G8CVU0@MD9(FWA;BEN]}(NR%?\:6TX/5?L&NQC@72+1>T;(/E M"LJ\:C[Q8YN(@P#)HP] ;0 :!G@O!+AM@/O:&;PVP'OM#'X;4&_=;O9>)R[& M-I L\FC.X 4VC]J[>1.2]Y!0IE(9C\-I=Q8K80-+T'ESO.,G!3X(H#7&6@ M-'CU5 F1@3DM9E1S7NIZ"A2S5,%L00)?9=SW10P^_?QY M8@NY:C6WG;8KO&I6B%Y8H0NN:276'"151C)-?#P>'XW$VS);7^>O#7=UVWC=[\K]G[R7#[>K'K?G?G[EHQ=\@U,RM:11 MB#7[Y2<8.+_JI#%)%HLD2PR1]43T.A&],?;9'U3@ G

E$6@D2@^E),VO62=.`MPQO4O.I_TL/,11X,_8G]<)AV#5"F=I72C,.%K20I7E-RCO"M&4Y2O;6LC1)%ILD2PR1|10).D6" M#_:6P*2()LEBDV2)(;*>B.>=B.<_R%L:7O_@9XY0Z RM18/R$${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{]+$]Y#4R?K+BHL-*]6/NR%H +"ZJH'P9!WZ\P85Z: M6-M.P `53SX76_):E M(14P23A# E8C;]P;SF+C;QV^$=C) QF93):&J(**4^/<Y>;N\YEB25,.?U."E6.O',/%;#"&ZJN^>X+-/F< M&;Z<4VE_T<[Y#G3&?",5KQJPUBO"W!??-74X &B>;D#8 ,+'@/@90-0 HI=&<MB!M_-(9PW INZ[W&WA,JQPF@B^0)X:S8CV.L,M*X78:9/%DKH4ZQ)*KT& MBA44:(Z%ND=?!682VR>4Z",,%P4Q,J;HDKF>-(]{DH''A+[7'C>++#)V\?9_X M2M_%,/IY$W? BXH;/Q(W0%6>JE&C&"B@Z\-EQ_,41O*]KT!8BW!=B$AXE7$!] MBJ+@ PJ#,.ZXS_3E*@KG?^+/OOGZ_^*$;5=$5F^Z.^[XL=X*970VL^N1W>T M<3>MF7E#6>, <1IX>:A+$%KSTW9M>/_C45?'7),M>DVSV2F0/WB9NWR8^QIY. MN52(K]":\T(BR6G7OV?B./J6P^R*;=H+!GIY)/[VL,1/W:+P_+%7UD$6!T_< M9D_=!OV+ R^7KG\PK"H0: {LE),KYABG7H:WU741C.W\?V2>]X,378<_TXG)[MU7+4<:8WUZ6)MM@H6V**K: ,QHV"+#)\13NT!EA,.QHDZ_!>6Z(@'J'!-.";NKS\SL]!"WKRS7!>6$* M(+]? 4BJ>;]0$W4N>V7]02P,$% @ Z(%F68?B$FF2 @ V@< !D !X M;"]W;W)K&ULK57?,]HP$/Y7K&R:.FEK0I)"RT(D M(@SK0R54UNUAVH-)#F+5L3/,0/O?SS]"1ML4=5M?R-WYON]\Y^,NV7%Q*TL MA>XJRN3(*Y6JA[XO\Q{]+$]Y#4R?K+BHL-*]6/NR%H +"ZJH'P9!WZ\P85Z: M6-M.P `53SX76_):E M(14P23A# E8C;]P;SF+C;QV^$=C) QF93):&J(**4^/<Y>;N\YEB25,.?U."E6.O',/%;#"&ZJN^>X+-/F< M&;Z<4VE_T<[Y#G3&?",5KQJPUBO"W!??-74X &B>;D#8 ,+'@/@90-0 HI=&<MB!M_-(9PW INZ[W&WA,JQPF@B^0)X:S8CV.L,M*X78:9/%DKH4ZQ)*KT& MBA44:(Z%ND=?!682VR>4Z",,%P4Q,J;HDKF>-(]{DH''A+[7'C>++#)V\?9_X M2M_%,/IY$W? BXH;/Q(W0%6>JE&C&"B@Z\-EQ_,41O*]KT!8BW!=B$AXE7$!] MBJ+@ PJ#,.ZXS_3E*@KG?^+/OOGZ_^*$;5=$5F^Z.^[XL=X*970VL^N1W>T M<3>MF7E#6>, <1IX>:A+$%KSTW9M>/_C45?'7),M>DVSV2F0/WB9NWR8^QIY. MN52(K]":\T(BR6G7OV?B./J6P^R*;=H+!GIY)/[VL,1/W:+P_+%7UD$6!T_< M9D_=!OV+ R^7KG\PK"H0: {LE),KYABG7H:WU741C.W\?V2>]X,378<_TXG)[MU7+4<:8WUZ6)MM@H6V**K: ,

Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 100040 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited) Sheet http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited Condensed Consolidated Statements of Comprehensive Loss (unaudited) Statements 5 false false R6.htm 100050 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) Sheet http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 100060 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) Sheet http://myomo.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) Statements 7 false false R8.htm 100070 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 8 false false R9.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 9 false false R10.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 10 false false R11.htm 995455 - Disclosure - Description of Business Sheet http://myomo.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusiness Description of Business Notes 11 false false R12.htm 995465 - Disclosure - Liquidity Sheet http://myomo.com/20240930/taxonomy/role/DisclosureLiquidity Liquidity Notes 12 false false R13.htm 995475 - Disclosure - Summary of Significant Accounting Policies Sheet http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 13 false false R14.htm 995485 - Disclosure - Inventories Sheet http://myomo.com/20240930/taxonomy/role/Role_DisclosureInventories Inventories Notes 14 false false R15.htm 995495 - Disclosure - Fair Value of Financial Instruments Sheet http://myomo.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments Fair Value of Financial Instruments Notes 15 false false R16.htm 995505 - Disclosure - Accounts Payable and Other Accrued Expenses Sheet http://myomo.com/20240930/taxonomy/role/DisclosureAccountsPayableAndOtherAccruedExpenses1 Accounts Payable and Other Accrued Expenses Notes 16 false false R17.htm 995515 - Disclosure - Line of Credit Sheet http://myomo.com/20240930/taxonomy/role/DisclosureLineOfCredit Line of Credit Notes 17 false false R18.htm 995525 - Disclosure - Common Stock and Warrants Sheet http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommonStockAndWarrants Common Stock and Warrants Notes 18 false false R19.htm 995535 - Disclosure - Stock Award Plans and Stock-based Compensation Sheet http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensation Stock Award Plans and Stock-based Compensation Notes 19 false false R20.htm 995555 - Disclosure - Commitments and Contingencies Sheet http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 20 false false R21.htm 995565 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies 21 false false R22.htm 995575 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies 22 false false R23.htm 995585 - Disclosure - Inventories (Tables) Sheet http://myomo.com/20240930/taxonomy/role/Role_DisclosureInventoriesTables Inventories (Tables) Tables http://myomo.com/20240930/taxonomy/role/Role_DisclosureInventories 23 false false R24.htm 995595 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://myomo.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://myomo.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments 24 false false R25.htm 995605 - Disclosure - Accounts Payable and Other Accrued Expenses (Tables) Sheet http://myomo.com/20240930/taxonomy/role/DisclosureAccountsPayableAndOtherAccruedExpensesTables Accounts Payable and Other Accrued Expenses (Tables) Tables http://myomo.com/20240930/taxonomy/role/DisclosureAccountsPayableAndOtherAccruedExpenses1 25 false false R26.htm 995615 - Disclosure - Stock Award Plans and Stock-based Compensation (Tables) Sheet http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationTables Stock Award Plans and Stock-based Compensation (Tables) Tables http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensation 26 false false R27.htm 995625 - Disclosure - Commitments and Contingencies (Tables) Sheet http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies 27 false false R28.htm 995645 - Disclosure - Liquidity - Additional Information (Detail) Sheet http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail Liquidity - Additional Information (Detail) Details 28 false false R29.htm 995655 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 29 false false R30.htm 995665 - Disclosure - Summary of Cash, Cash Equivalents and Short-Term Investments (Details) Sheet http://myomo.com/20240930/taxonomy/role/DisclosureSummaryOfCashCashEquivalentsAndShorttermInvestmentsDetails Summary of Cash, Cash Equivalents and Short-Term Investments (Details) Details 30 false false R31.htm 995675 - Disclosure - Summary of Significant Accounting Policies - Summary of Revenue by Major Source (Detail) Sheet http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueByMajorSourceDetail Summary of Significant Accounting Policies - Summary of Revenue by Major Source (Detail) Details 31 false false R32.htm 995685 - Disclosure - Summary of Significant Accounting Policies - Summary of Potential Common Shares Issuable (Detail) Sheet http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentialCommonSharesIssuableDetail Summary of Significant Accounting Policies - Summary of Potential Common Shares Issuable (Detail) Details 32 false false R33.htm 995695 - Disclosure - Inventories - Schedule of Inventories (Detail) Sheet http://myomo.com/20240930/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoriesDetail Inventories - Schedule of Inventories (Detail) Details 33 false false R34.htm 995705 - Disclosure - Fair Value of Financial Instruments - Schedule of Cash Equivalents and Short-term Investments Measured at Fair Value on Recurring Basis (Detail) Sheet http://myomo.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCashEquivalentsAndShorttermInvestmentsMeasuredAtFairValueOnRecurring Fair Value of Financial Instruments - Schedule of Cash Equivalents and Short-term Investments Measured at Fair Value on Recurring Basis (Detail) Details 34 false false R35.htm 995715 - Disclosure - Accounts Payable and Other Accrued Expenses - Summary of Accounts Payable and Other Accrued Expenses (Detail) Sheet http://myomo.com/20240930/taxonomy/role/DisclosureAccountsPayableAndOtherAccruedExpensesSummaryOfAccountsPayableAndOtherAccruedExpensesDetail Accounts Payable and Other Accrued Expenses - Summary of Accounts Payable and Other Accrued Expenses (Detail) Details 35 false false R36.htm 995725 - Disclosure - Line of Credit (Additional Information) (Details) Sheet http://myomo.com/20240930/taxonomy/role/DisclosureLineOfCreditAdditionalInformationDetails Line of Credit (Additional Information) (Details) Details http://myomo.com/20240930/taxonomy/role/DisclosureLineOfCredit 36 false false R37.htm 995735 - Disclosure - Common Stock and Warrants - Additional Information (Details) Sheet http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails Common Stock and Warrants - Additional Information (Details) Details 37 false false R38.htm 995755 - Disclosure - Stock Award Plans and Stock-based Compensation - Additional Information (Detail) Sheet http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationAdditionalInformationDetail Stock Award Plans and Stock-based Compensation - Additional Information (Detail) Details 38 false false R39.htm 995775 - Disclosure - Stock Award Plans and Stock-based Compensation - Schedule of Stock-based Compensation Expense (Detail) Sheet http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail Stock Award Plans and Stock-based Compensation - Schedule of Stock-based Compensation Expense (Detail) Details 39 false false R40.htm 995785 - Disclosure - Related Party Transactions - Additional Information (Detail) Sheet http://myomo.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail Related Party Transactions - Additional Information (Detail) Details 40 false false R41.htm 995795 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 41 false false R42.htm 995805 - Disclosure - Commitments and Contingencies - Summary of Maturity of Operating Lease Liabilities (Detail) Sheet http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail Commitments and Contingencies - Summary of Maturity of Operating Lease Liabilities (Detail) Details 42 false false R43.htm 995815 - Disclosure - Commitments and Contingencies - Summary of Operating Lease Cost (Detail) Sheet http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfOperatingLeaseCostDetail Commitments and Contingencies - Summary of Operating Lease Cost (Detail) Details 43 false false R44.htm 995825 - Disclosure - Commitments and Contingencies - Summary of Additional Information Related to Operating Leases (Detail) Sheet http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfAdditionalInformationRelatedToOperatingLeasesDetail Commitments and Contingencies - Summary of Additional Information Related to Operating Leases (Detail) Details 44 false false R45.htm 995835 - Disclosure - Commitments and Contingencies - Schedule Of Changes In The Companys Supplier Finance Obligations (Details) Sheet http://myomo.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfChangesInTheCompanysSupplierFinanceObligationsDetails Commitments and Contingencies - Schedule Of Changes In The Companys Supplier Finance Obligations (Details) Details 45 false false All Reports Book All Reports myo-20240930.htm myo-20240930.xsd http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 false false JSON 60 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "myo-20240930.htm": { "nsprefix": "myo", "nsuri": "http://myomo.com/20240930", "dts": { "inline": { "local": ["myo-20240930.htm"] }, "schema": { "local": ["myo-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] } }, "keyStandard": 218, "keyCustom": 35, "axisStandard": 22, "axisCustom": 0, "memberStandard": 30, "memberCustom": 18, "hidden": { "total": 7, "http://fasb.org/us-gaap/2024": 3, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 219, "entityCount": 1, "segmentCount": 51, "elementCount": 574, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 626, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_82cc0d2a-d51a-483a-9d5c-3785253b2d12", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_82cc0d2a-d51a-483a-9d5c-3785253b2d12", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R3": { "role": "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical", "longName": "100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_82cc0d2a-d51a-483a-9d5c-3785253b2d12", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us-gaap:PreferredStockParOrStatedValuePerShare", "span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm",

```
"first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_82cc0d2a-d51a-483a-9d5c-3785253b2d12", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R4": { "role": "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "longName": "100030 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_037f2dd1-9b53-430f-ae7b-5368f80c84b1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_037f2dd1-9b53-430f-ae7b-5368f80c84b1", "name": "us-gaap:CostOfRevenue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "unique": true } }, "R5": { "role": "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited", "longName": "100040 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited)", "shortName": "Condensed Consolidated Statements of Comprehensive Loss (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_037f2dd1-9b53-430f-ae7b-5368f80c84b1", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_037f2dd1-9b53-430f-ae7b-5368f80c84b1", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "unique": true } }, "R6": { "role": "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited", "longName": "100050 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_a56f64f5-4350-4648-b13d-1d0600e12d4d", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_781efd9d-ad75-4624-97b2-08189d2eeaa1", "name": "myo:ProceedsFromSaleOfCommonStockInPublicOfferingNetOfOfferingCostsValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "unique": true } }, "R7": { "role": "http://myomo.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical", "longName": "100060 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)", "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "C_794b94d8-55ee-49ab-b6bd-4bea08ed283b", "name": "myo:CommonStockIssuedUponVestingOfRestrictedStockUnits", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_794b94d8-55ee-49ab-b6bd-4bea08ed283b", "name": "myo:CommonStockIssuedUponVestingOfRestrictedStockUnits", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R8": { "role": "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "longName": "100070 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R9": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_037f2dd1-9b53-430f-ae7b-5368f80c84b1", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true }, "uniqueAnchor": null }, "R10": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_037f2dd1-9b53-430f-ae7b-5368f80c84b1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_037f2dd1-9b53-430f-ae7b-5368f80c84b1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://myomo.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusiness", "longName": "995455 - Disclosure - Description of Business", "shortName": "Description of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://myomo.com/20240930/taxonomy/role/DisclosureLiquidity", "longName": "995465 - Disclosure - Liquidity", "shortName": "Liquidity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995475 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://myomo.com/20240930/taxonomy/role/Role_DisclosureInventories", "longName": "995485 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://myomo.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments", "longName": "995495 - Disclosure - Fair Value of Financial Instruments", "shortName": "Fair Value of Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://myomo.com/20240930/taxonomy/role/DisclosureAccountsPayableAndOtherAccruedExpenses1", "longName": "995505 - Disclosure - Accounts Payable and Other Accrued Expenses", "shortName": "Accounts Payable and Other Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://myomo.com/20240930/taxonomy/role/DisclosureLineOfCredit", "longName": "995515 - Disclosure - Line of Credit", "shortName": "Line of Credit", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommonStockAndWarrants", "longName": "995525 - Disclosure - Common Stock and Warrants", "shortName": "Common Stock and Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensation", "longName": "995535 - Disclosure - Stock Award Plans and Stock-based Compensation", "shortName": "Stock Award Plans and Stock-based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "longName": "995555 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "995565 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "myo:InterimFinancialStatementsPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "myo:InterimFinancialStatementsPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables", "longName": "995575 -
```

Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://myomo.com/20240930/taxonomy/role/Role_DisclosureInventoriesTables", "longName": "995585 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://myomo.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables", "longName": "995595 - Disclosure - Fair Value of Financial Instruments (Tables)", "shortName": "Fair Value of Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://myomo.com/20240930/taxonomy/role/DisclosureAccountsPayableAndOtherAccruedExpensesTables", "longName": "995605 - Disclosure - Accounts Payable and Other Accrued Expenses (Tables)", "shortName": "Accounts Payable and Other Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationTables", "longName": "995615 - Disclosure - Stock Award Plans and Stock-based Compensation (Tables)", "shortName": "Stock Award Plans and Stock-based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables", "longName": "995625 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail", "longName": "995645 - Disclosure - Liquidity - Additional Information (Detail)", "shortName": "Liquidity - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "myo:NetLossIncome", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "myo:NetLossIncome", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "longName": "995655 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "C_037f2dd1-9b53-430f-ae7b-5368f80c84b1", "name": "myo:PercentageOfDirectBillingChannelRevenuePayersRepresent", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "us-gaap:RevenueRecognitionPolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_037f2dd1-9b53-430f-ae7b-5368f80c84b1", "name": "myo:PercentageOfDirectBillingChannelRevenuePayersRepresent", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "us-gaap:RevenueRecognitionPolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://myomo.com/20240930/taxonomy/role/DisclosureSummaryOfCashCashEquivalentsAndShorttermInvestmentsDetails", "longName": "995665 - Disclosure - Summary of Cash, Cash Equivalents and Short-Term Investments (Details)", "shortName": "Summary of Cash, Cash Equivalents and Short-Term Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "C_82cc0d2a-d51a-483a-9d5c-3785253b2d12", "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_02234738-2360-4322-a79e-aca196a768cc", "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm", "unique": true } }, "R31": { "role": "http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueByMajorSourceDetail", "longName": "995675 - Disclosure - Summary of Significant Accounting Policies - Summary of Revenue by Major Source (Detail)", "shortName": "Summary of Significant Accounting Policies - Summary of Revenue by Major Source (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "C_037f2dd1-9b53-430f-ae7b-5368f80c84b1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_a1b52835-102d-441c-8c0b-78dc1b2ef99b", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm", "unique": true } }, "R32": { "role": "http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentialCommonSharesIssuableDetail", "longName": "995685 - Disclosure - Summary of Significant Accounting Policies - Summary of Potential Common Shares Issuable (Detail)", "shortName": "Summary of Significant Accounting Policies - Summary of Potential Common Shares Issuable (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://myomo.com/20240930/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoriesDetail", "longName": "995695 - Disclosure - Inventories - Schedule of Inventories (Detail)", "shortName": "Inventories - Schedule of Inventories (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "C_82cc0d2a-d51a-483a-9d5c-3785253b2d12", "name": "us-gaap:InventoryFinishedGoods", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_82cc0d2a-d51a-483a-9d5c-3785253b2d12", "name": "us-gaap:InventoryFinishedGoods", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://myomo.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCashEquivalentsAndShorttermInvestmentsMeasuredAtFairValueOnRecurri "longName": "995705 - Disclosure - Fair Value of Financial Instruments - Schedule of Cash Equivalents and Short-term Investments Measured at Fair Value on Recurring Basis (Detail)", "shortName": "Fair Value of Financial Instruments - Schedule of Cash Equivalents and Short-term Investments Measured at Fair Value on Recurring Basis (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "C_82cc0d2a-d51a-483a-9d5c-3785253b2d12", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_82cc0d2a-d51a-483a-9d5c-3785253b2d12", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://myomo.com/20240930/taxonomy/role/DisclosureAccountsPayableAndOtherAccruedExpensesSummaryOfAccountsPayableAndOtherAccruedExpensesDetail", "longName": "995715 - Disclosure - Accounts Payable and Other Accrued Expenses - Summary of Accounts Payable and Other Accrued Expenses (Detail)", "shortName": "Accounts Payable and Other Accrued Expenses - Summary of Accounts Payable and Other Accrued Expenses (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_82cc0d2a-d51a-483a-9d5c-3785253b2d12", "name": "us-gaap:AccountsPayableTradeCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_82cc0d2a-d51a-483a-9d5c-3785253b2d12", "name": "us-gaap:AccountsPayableTradeCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "myo-20240930.htm", "first":

```
true, "unique": true } }, "R36": { "role": "http://myomo.com/20240930/taxonomy/role/DisclosureLineOfCreditAdditionalInformationDetails", "longName": "995725 - Disclosure - Line of Credit (Additional Information) (Details)", "shortName": "Line of Credit (Additional Information) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_6441e328-c7cd-465e-8d68-7ee244aa4962", "name": "us-gaap:LineOfCredit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_c293660e-30ee-4194-9dc7-37f8a0c86918", "name": "us-gaap:LongTermDebtPercentageBearingVariableInterestRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "unique": true } }, "R37": { "role": "http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails", "longName": "995735 - Disclosure - Common Stock and Warrants - Additional Information (Details)", "shortName": "Common Stock and Warrants - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_25be1378-93a8-47de-85d1-dd7e4c58b437", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_40214afb-4783-45b1-8f7b-bbb9162b8fc9", "name": "us-gaap:CommonStockNoParValue", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "unique": true } }, "R38": { "role": "http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationAdditionalInformationDetail", "longName": "995755 - Disclosure - Stock Award Plans and Stock-based Compensation - Additional Information (Detail)", "shortName": "Stock Award Plans and Stock-based Compensation - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_ee5157fd-a2ec-4671-bddb-dc9528dcd33a", "name": "us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ee5157fd-a2ec-4671-bddb-dc9528dcd33a", "name": "us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R39": { "role": "http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail", "longName": "995775 - Disclosure - Stock Award Plans and Stock-based Compensation - Schedule of Stock-based Compensation Expense (Detail)", "shortName": "Stock Award Plans and Stock-based Compensation - Schedule of Stock-based Compensation Expense (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_037f2dd1-9b53-430f-ae7b-5368f80c84b1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_037f2dd1-9b53-430f-ae7b-5368f80c84b1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R40": { "role": "http://myomo.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail", "longName": "995785 - Disclosure - Related Party Transactions - Additional Information (Detail)", "shortName": "Related Party Transactions - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_037f2dd1-9b53-430f-ae7b-5368f80c84b1", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true }, "uniqueAnchor": null }, "R41": { "role": "http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "longName": "995795 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:LesseeOperatingLeaseDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9203e84c-ef7b-49cc-95fb-8d6b32b6d81c", "name": "us-gaap:LesseeOperatingLeaseDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R42": { "role": "http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail", "longName": "995805 - Disclosure - Commitments and Contingencies - Summary of Maturity of Operating Lease Liabilities (Detail)", "shortName": "Commitments and Contingencies - Summary of Maturity of Operating Lease Liabilities (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_82cc0d2a-d51a-483a-9d5c-3785253b2d12", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_82cc0d2a-d51a-483a-9d5c-3785253b2d12", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R43": { "role": "http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfOperatingLeaseCostDetail", "longName": "995815 - Disclosure - Commitments and Contingencies - Summary of Operating Lease Cost (Detail)", "shortName": "Commitments and Contingencies - Summary of Operating Lease Cost (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_037f2dd1-9b53-430f-ae7b-5368f80c84b1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_037f2dd1-9b53-430f-ae7b-5368f80c84b1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R44": { "role": "http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfAdditionalInformationRelatedToOperatingLeasesDetail", "longName": "995825 - Disclosure - Commitments and Contingencies - Summary of Additional Information Related to Operating Leases (Detail)", "shortName": "Commitments and Contingencies - Summary of Additional Information Related to Operating Leases (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_82cc0d2a-d51a-483a-9d5c-3785253b2d12", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "td", "tr", "table", "myo:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_82cc0d2a-d51a-483a-9d5c-3785253b2d12", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "td", "tr", "table", "myo:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true, "unique": true } }, "R45": { "role": "http://myomo.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfChangesInTheCompanysSupplierFinanceObligationsDetails", "longName": "995835 - Disclosure - Commitments and Contingencies - Schedule Of Changes In The Companys Supplier Finance Obligations (Details)", "shortName": "Commitments and Contingencies - Schedule Of Changes In The Companys Supplier Finance Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_0c678e63-c283-46a2-ab8f-3705ab8bb9e9", "name": "us-gaap:ProgramRightsObligations", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_037f2dd1-9b53-430f-ae7b-5368f80c84b1", "name": "myo:PaymentsToSupplierFinanceProgramObligations", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "myo-20240930.htm", "unique": true } } }, "tag": { "myo_ATMFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://myomo.com/20240930", "localname": "ATMFacilityMember", "presentation": [ "http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails", "http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail", "http://myomo.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "ATM facility.", "label": "A T M Facility [Member]", "terseLabel": "ATM Facility [Member]" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": [ "http://myomo.com/20240930/taxonomy/role/DisclosureAccountsPayableAndOtherAccruedExpenses1" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "Accounts Payable and Other Accrued Expenses", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": [ "r386" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Accounts Payable and Accrued Liabilities, Current, Total", "terseLabel": "Accounts payable and accrued expenses", "label": "Accounts Payable and Accrued Liabilities, Current", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r61", "r62" ] }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://myomo.com/20240930/taxonomy/role/DisclosureAccountsPayableAndOtherAccruedExpensesSummaryOfAccountsPayableAndOtherAccruedExpensesDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Accounts Payable and Other Accrued Liabilities, Current", "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableTradeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableTradeCurrent", "crdr": "credit", "presentation": [ "http://myomo.com/20240930/taxonomy/role/DisclosureAccountsPayableAndOtherAccruedExpensesSummaryOfAccountsPayableAndOtherAccruedExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables", "label": "Accounts Payable, Trade, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r12", "r59" ] }, "myo_AccountsReceivableAndAllowanceForCreditLossesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://myomo.com/20240930", "localname": "AccountsReceivableAndAllowanceForCreditLossesPolicyTextBlock", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Accounts Receivable and Allowance for Credit Losses [Policy Text Block]", "label": "Accounts Receivable and Allowance for Credit Losses [Policy Text Block]", "terseLabel": "Accounts Receivable and Allowance for Credit Losses" } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": [
```

"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable [Member]", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } } }, "auth_ref": ["r744"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total", "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r967"] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Accretion of discount on short-term investments", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r96"] }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedEmployeeBenefitsCurrent", "crdr": "credit", "presentation": ["http://myomo.com/20240930/taxonomy/role/DisclosureAccountsPayableAndOtherAccruedExpensesSummaryOfAccountsPayableAndOtherAccruedExpensesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation and benefits", "label": "Accrued Employee Benefits, Current", "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r62"] }, "us-gaap_AccruedInsuranceCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedInsuranceCurrent", "crdr": "credit", "presentation": ["http://myomo.com/20240930/taxonomy/role/DisclosureAccountsPayableAndOtherAccruedExpensesSummaryOfAccountsPayableAndOtherAccruedExpensesDetail"], "lang": { "en-us": { "role": { "label": "Accrued Insurance, Current", "terseLabel": "Accrued insurance", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r62"] }, "myo_AccruedLiabilitiesCustomerDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://myomo.com/20240930", "localname": "AccruedLiabilitiesCustomerDeposit", "crdr": "credit", "presentation": ["http://myomo.com/20240930/taxonomy/role/DisclosureAccountsPayableAndOtherAccruedExpensesSummaryOfAccountsPayableAndOtherAccruedExpensesDetail"], "lang": { "en-us": { "role": { "label": "Accrued Liabilities Customer Deposit", "documentation": "Accrued liabilities customer deposit.", "terseLabel": "Customer deposits" } } }, "auth_ref": [] }, "myo_AccumulatedComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://myomo.com/20240930", "localname": "AccumulatedComprehensiveIncomeMember", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Comprehensive Income [Member]", "label": "Accumulated Comprehensive Income [Member]", "documentation": "Accumulated Comprehensive Income [Member]" } } }, "auth_ref": [] }, "myo_AccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://myomo.com/20240930", "localname": "AccumulatedDeficit", "crdr": "credit", "presentation": ["http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Accumulated Deficit", "label": "Accumulated Deficit", "terseLabel": "Accumulated deficit" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r14", "r15", "r80", "r150", "r599", "r631", "r635"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r870"] }, "myo_AdditionalEmployeesToBeHired": { "xbrltype": "integerItemType", "nsuri": "http://myomo.com/20240930", "localname": "AdditionalEmployeesToBeHired", "presentation": ["http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Additional Employees to be Hired", "label": "Additional Employees to be Hired", "documentation": "Additional Employees to be Hired" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance", "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": ["r72"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital [Member]", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r649", "r957", "r958", "r959", "r960", "r1023", "r1083"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r883"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r883"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r883"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r883"] }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Accounting Standards Update", "label": "Accounting Standards Update [Axis]", "documentation": "Information by amendment to accounting standards." } } }, "auth_ref": ["r135", "r136", "r137", "r138", "r139", "r140", "r180", "r181", "r182", "r183", "r193", "r220", "r221", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r277", "r278", "r286", "r397", "r398", "r399", "r400", "r401", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r419", "r420", "r421", "r422", "r423", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r475", "r476", "r488", "r489", "r490", "r506", "r507", "r508", "r509", "r510", "r511", "r552", "r553", "r554", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operations:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Advertising", "label": "Advertising Cost [Policy Text Block]", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": ["r127"] }, "us-gaap_AdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingExpense", "crdr": "debit", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Advertising expense", "label": "Advertising Expense", "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line." } } }, "auth_ref": ["r387", "r789"] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r916"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r842", "r852", "r862", "r894"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r845", "r855", "r865", "r897"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r917"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r883"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r890"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r846", "r856", "r866", "r890", "r898", "r902", "r910"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r908"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail"], "lang": { "en-us": { "role": { "terseLabel": "Total share based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r380", "r384"] }, "us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables", "crdr": "credit", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": {

```
"terseLabel": "Allowance for doubtful accounts", "label": "Allowance for Doubtful Accounts, Premiums and Other Receivables", "documentation": "The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet." } } }, "auth_ref": [ "r968" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentialCommonSharesIssuableDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r202" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentialCommonSharesIssuableDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [
"r25" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentialCommonSharesIssuableDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentialCommonSharesIssuableDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r25" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails",
"http://myomo.com/20240930/taxonomy/role/DisclosureLineOfCreditAdditionalInformationDetails",
"http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r424" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r109", "r122", "r146", "r174", "r205", "r209", "r214", "r215", "r256", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r426", "r430", "r477", "r593", "r688", "r770", "r771", "r804", "r833", "r986", "r987", "r1038" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsAndLiabilitiesLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAndLiabilitiesLesseeAbstract", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Included in the condensed consolidated balance sheet:", "label": "Assets and Liabilities, Lessee [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r142", "r152", "r174", "r256", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r426", "r430", "r477", "r804", "r986", "r987", "r1038" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current Assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "myo_AtMarketSalesFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://myomo.com/20240930", "localname": "AtMarketSalesFacilityMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "At Market Sales Facility Member", "label": "At Market Sales Facility [Member]", "documentation": "At market sales facility member." } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r905" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r906" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r901" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r901" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r901" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r901" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r901" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r901" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentialCommonSharesIssuableDetail",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r904" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r903" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r902" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r902" ] }, "myo_BeijingMedicalInvestmentCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://myomo.com/20240930", "localname": "BeijingMedicalInvestmentCoLtdMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Beijing Ryzur Medical Investment Co., Ltd", "label": "Beijing Medical Investment Co Ltd [Member]", "documentation": "Beijing Medical Investment Co. Ltd." } } }, "auth_ref": [] }, "myo_BeneficialOwnershipLimitation": { "xbrltype": "percentItemType", "nsuri": "http://myomo.com/20240930", "localname": "BeneficialOwnershipLimitation", "presentation": [ "http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "To maintain beneficial ownership limitation", "label": "Beneficial ownership limitation", "terseLabel": "Beneficial ownership limitation" } } }, "auth_ref": [] }, "country_CN": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "CN", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "China [Member]", "label": "CHINA" } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Cash", "crdr": "debit", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "periodEndLabel": "Cash, Ending Balance", "periodStartLabel": "Cash, Beginning Balance", "terseLabel": "Cash balance", "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r125", "r596", "r660", "r683", "r804", "r833", "r938" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r20", "r144", "r762" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://myomo.com/20240930/taxonomy/role/DisclosureSummaryOfCashCashEquivalentsAndShorttermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [
"r144" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCashEquivalentsAndShorttermInvestmentsMeasuredAtFairValueOnRecurri
], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency
```

```
on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1025", "r1026" ] }, "us-gaap_CashAndCashEquivalentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsLineItems", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureSummaryOfCashCashEquivalentsAndShorttermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, Cash Equivalents and Short-Term Investments", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r21" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "lang": { "en-us": {
"role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr":
"debit", "presentation": [ "http://myomo.com/20240930/taxonomy/role/DisclosureSummaryOfCashCashEquivalentsAndShorttermInvestmentsDetails",
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents, and restricted cash", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
"documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r20", "r94", "r170" ] }, "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"crdr": "debit", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": {
"role": { "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r94" ] }, "us-gaap_CashMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashMember", "presentation": [ "http://myomo.com/20240930/taxonomy/role/DisclosureSummaryOfCashCashEquivalentsAndShorttermInvestmentsDetails" ], "lang": { "en-
us": { "role": { "label": "Cash [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits." } } }, "auth_ref": [ "r144" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": {
"role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r881" ] },
"ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label":
"Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r878" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } },
"auth_ref": [ "r876" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ClassOfStockDomain", "presentation": [ "http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails" ],
"lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r134", "r147", "r148", "r149",
"r174", "r196", "r197", "r199", "r201", "r207", "r208", "r256", "r297", "r299", "r300", "r301", "r304", "r305", "r320", "r321", "r324", "r327", "r334", "r477", "r640", "r641",
"r642", "r643", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r661", "r675", "r697", "r717", "r737", "r738", "r739", "r740", "r741",
"r922", "r954", "r961" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems",
"presentation": [ "http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r147", "r148", "r149", "r207", "r320", "r321",
"r322", "r324", "r327", "r332", "r334", "r640", "r641", "r642", "r643", "r776", "r922", "r954" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r48" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } },
"auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Common stock warrants, exercise price per share", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "verboseLabel": "Warrants exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r335" ] }, "us-
gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants to purchase common stock", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r335" ] }, "us-
gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding",
"presentation": [ "http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails",
"http://myomo.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" ], "lang": { "en-us": { "role": {
"label": "Class of Warrant or Right, Outstanding", "terseLabel": "Warrants Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] },
"myo_ClinicalAndMedicalProvidersMember": { "xbrltype": "domainItemType", "nsuri": "http://myomo.com/20240930", "localname": "ClinicalAndMedicalProvidersMember",
"presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueByMajorSourceDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "Clinical/Medical Providers [Member]", "label": "Clinical And Medical Providers [Member]", "documentation": "Clinical and medical providers." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount",
"terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r882" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label":
"Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r882" ] }, "us-gaap_CommercialPaperMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCashEquivalentsAndShorttermInvestmentsMeasuredAtFairValueOnRecurri
"http://myomo.com/20240930/taxonomy/role/DisclosureSummaryOfCashCashEquivalentsAndShorttermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Commercial Paper [Member]", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r102", "r296", "r827", "r828", "r829", "r830" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r68", "r112",
"r595", "r674" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" ],
"lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r100", "r288", "r289", "r745", "r975", "r979" ] }, "myo_CommitmentsAndContingenciesLineItems": {
"xbrltype": "stringItemType", "nsuri": "http://myomo.com/20240930", "localname": "CommitmentsAndContingenciesLineItems", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Commitments And Contingencies [Line Items]", "label": "Commitments And Contingencies [Line Items]", "documentation": "Commitments and contingencies." } } },
"auth_ref": [] }, "myo_CommitmentsAndContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://myomo.com/20240930", "localname":
```

```
"CommitmentsAndContingenciesTable", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Commitments And Contingencies [Table]", "label": "Commitments And Contingencies [Table]", "documentation": "Commitments And Contingencies [Table]" } } }, "auth_ref":
[] }, "myo_CommonStockAmountReservedForFutureIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://myomo.com/20240930", "localname":
"CommonStockAmountReservedForFutureIssuance", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of
shares offer and sell", "label": "Common Stock Amount Reserved For Future Issuance", "documentation": "Common stock amount reserved for future issuance." } } },
"auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Number of common shares reserved for issuance", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number
of common shares reserved for future issuance." } } }, "auth_ref": [ "r71" ] }, "myo_CommonStockEquivalentsPreFundedWarrants": { "xbrltype": "sharesItemType", "nsuri":
"http://myomo.com/20240930", "localname": "CommonStockEquivalentsPreFundedWarrants", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"documentation": "Common Stock Equivalents, Pre-Funded Warrants", "label": "Common Stock Equivalents, Pre-Funded Warrants", "terseLabel": "Common stock equivalents,
pre-funded warrants" } } }, "auth_ref": [] }, "myo_CommonStockIssuedForWarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://myomo.com/20240930",
"localname": "CommonStockIssuedForWarrantsExercised", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": {
"label": "Common Stock Issued For Warrants Exercised", "documentation": "Common stock issued for warrants exercised.", "terseLabel": "Exercise of pre-funded warrants,
value" } } }, "auth_ref": [] }, "myo_CommonStockIssuedForWarrantsExercisedShares": { "xbrltype": "sharesItemType", "nsuri": "http://myomo.com/20240930", "localname":
"CommonStockIssuedForWarrantsExercisedShares", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": {
"label": "Common Stock Issued For Warrants Exercised Shares", "documentation": "Common stock issued for warrants exercised shares.", "terseLabel": "Exercise of pre-
funded warrants, share" } } }, "auth_ref": [] }, "myo_CommonStockIssuedUponVestingOfRestrictedStockUnits": { "xbrltype": "sharesItemType", "nsuri":
"http://myomo.com/20240930", "localname": "CommonStockIssuedUponVestingOfRestrictedStockUnits", "presentation": [
"http://myomo.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" ], "lang": { "en-us": { "role": {
"documentation": "Common Stock Issued Upon Vesting of Restricted Stock Units", "label": "Common Stock Issued Upon Vesting Of Restricted Stock Units", "terseLabel":
"Common stock issued upon vesting of restricted stock units" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited",
"http://myomo.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" ], "lang": { "en-us": { "role": {
"terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r823",
"r824", "r825", "r827", "r828", "r829", "r830", "r957", "r958", "r960", "r1023", "r1082", "r1083" ] }, "us-gaap_CommonStockNoParValue": { "xbrltype": "perShareItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockNoParValue", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock, No
Par Value", "terseLabel": "Nominal Exercise Value", "documentation": "Face amount per share of no-par value common stock." } } }, "auth_ref": [ "r71" ] }, "us-
gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockParOrStatedValuePerShare", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock,
par value", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r71" ] },
"myo_CommonStockPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://myomo.com/20240930", "localname":
"CommonStockPurchaseAgreementMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails",
"http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Common
Stock Purchase Agreement [Member]", "label": "Common Stock Purchase Agreement [Member]", "terseLabel": "Common Stock Purchase Agreement [Member]" } } },
"auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockSharesAuthorized", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ],
"lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of
common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r71", "r675" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "totalLabel": "Common Stock,
Shares, Issued, Total", "terseLabel": "Common stock, shares issued", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity
that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested
by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the
treasury." } } }, "auth_ref": [ "r71" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockSharesOutstanding", "presentation": [ "http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails",
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "periodEndLabel": "Common
Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "terseLabel": "Common stock, shares
outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership
interest in a corporation." } } }, "auth_ref": [ "r9", "r71", "r675", "r694", "r1083", "r1084" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails",
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock par value
$0.0001 per share, 65,000,000 shares authorized; 30,244,182 and 27,135,061 shares issued as of September 30, 2024 and December 31, 2023, respectively; and 30,244,155
and 27,135,034 shares outstanding at September 30, 2024 and December 31, 2023, respectively", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
"periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "totalLabel": "Common Stock, Value, Issued, Total", "label": "Common Stock, Value, Issued",
"verboseLabel": "Shares value", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of
the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure
concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r71", "r598", "r804" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel":
"Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r887" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-
us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r886" ] },
"ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually
Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r888" ] },
"ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation
Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r885" ] }, "us-
gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr":
"credit", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited" ], "lang": { "en-
us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase
(decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes
in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r16", "r157", "r159", "r165", "r587", "r609", "r610" ] }, "us-
gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive
Income (Loss)", "label": "Comprehensive Income, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref":
[] }, "myo_ComprehensiveLossIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://myomo.com/20240930", "localname": "ComprehensiveLossIncomeMember",
"presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "lang": { "en-
us": { "role": { "terseLabel": "Comprehensive Loss [Member]", "label": "Comprehensive Loss Income [Member]", "documentation": "Comprehensive loss income." } } },
"auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ConcentrationRiskBenchmarkDomain", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Concentration Risk Benchmark", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed
concentration risk percentage." } } }, "auth_ref": [ "r27", "r29", "r55", "r56", "r219", "r744" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Concentration Risk Benchmark", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } },
"auth_ref": [ "r27", "r29", "r55", "r56", "r219", "r637", "r744" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Concentration Risk Type", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited
to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r27", "r29", "r55", "r56", "r219", "r744", "r929" ] }, "us-
gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation":
[ "http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label":
"Concentration Risk, Percentage", "terseLabel": "Concentration Risk, Percentage", "verboseLabel": "Concentration Risk, Percentage", "documentation": "For an entity that
```

discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": ["r27", "r29", "r55", "r56", "r219"] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": ["r27", "r29", "r55", "r56", "r219", "r744"] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Basis of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": ["r52", "r764"] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": ["r340"] }, "us-gaap_ConversionOfStockSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockSharesIssued1", "presentation": ["http://myomo.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock as commitment fee for future financing", "label": "Conversion of Stock, Shares Issued", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r22", "r23", "r24"] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember", "presentation": ["http://myomo.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCashEquivalentsAndShorttermInvestmentsMeasuredAtFairValueOnRecurri], "lang": { "en-us": { "role": { "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": ["r784", "r786", "r793", "r805", "r821", "r1079"] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail", "http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "totalLabel": "Cost of Goods and Services Sold, Total", "terseLabel": "Cost of goods sold", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": ["r83", "r85", "r551"] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Cost of Revenue, Total", "terseLabel": "Cost of revenue", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": ["r86", "r174", "r256", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r477", "r770", "r986"] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail"], "lang": { "en-us": { "role": { "terseLabel": "Cost of Goods Sold [Member]", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "myo_Costreductionactivities": { "xbrltype": "percentItemType", "nsuri": "http://myomo.com/20240930", "localname": "Costreductionactivities", "presentation": ["http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail", "http://myomo.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Cost reduction activities.", "label": "CostReductionActivities", "terseLabel": "Cost reduction activities" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": ["http://myomo.com/20240930/taxonomy/role/DisclosureLineOfCreditAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r296", "r984"] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": ["http://myomo.com/20240930/taxonomy/role/DisclosureLineOfCreditAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r296", "r984", "r985"] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk [Member]", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": ["r98", "r219"] }, "stpr_DE": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "DE", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Germany [Member]", "label": "DELAWARE" } } }, "auth_ref": [] }, "us-gaap_DebtAndEquitySecuritiesRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtAndEquitySecuritiesRealizedGainLoss", "crdr": "credit", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Debt and Equity Securities, Realized Gain (Loss), Total", "label": "Debt and Equity Securities, Realized Gain (Loss)", "terseLabel": "Loss on equity investment", "negatedLabel": "Loss on equity investment", "documentation": "Amount of realized gain (loss) on investment in debt and equity securities." } } }, "auth_ref": ["r703", "r704", "r733", "r734", "r735", "r949", "r950"] }, "us-gaap_DebtDefaultLongtermDebtAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDefaultLongtermDebtAmount", "crdr": "credit", "presentation": ["http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Debt Default, Amount", "terseLabel": "Amount borrowed against account receivable", "documentation": "Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured." } } }, "auth_ref": ["r172"] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": ["http://myomo.com/20240930/taxonomy/role/DisclosureLineOfCredit"], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": ["r101", "r172", "r280", "r281", "r282", "r283", "r284", "r295", "r296", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r314", "r315", "r316", "r318", "r487"] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": ["http://myomo.com/20240930/taxonomy/role/DisclosureLineOfCreditAdditionalInformationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Floating Interest Rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentDateOfFirstRequiredPayment1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentDateOfFirstRequiredPayment1", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Date of First Required Payment", "terseLabel": "Date Of first required payment", "documentation": "Date the debt agreement requires the first payment to be made, in YYYY-MM-DD format." } } }, "auth_ref": ["r11", "r57"] }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPaymentPrincipal", "crdr": "debit", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Periodic Payment, Principal", "terseLabel": "Equal monthly payment made", "documentation": "Amount of the required periodic payments applied to principal." } } }, "auth_ref": ["r11"] }, "us-gaap_DeferredIncomeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeCurrent", "crdr": "credit", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Deferred Income, Current", "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": ["r926"] }, "myo_DeferredOfferingCost": { "xbrltype": "monetaryItemType", "nsuri": "http://myomo.com/20240930", "localname": "DeferredOfferingCost", "crdr": "debit", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Deferred Offering Costs", "label": "Deferred Offering Cost", "documentation": "Deferred Offering Cost" } } }, "auth_ref": [] }, "myo_DeferredOfferingCostsIncurredInAPriorPeriodToAdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://myomo.com/20240930", "localname": "DeferredOfferingCostsIncurredInAPriorPeriodToAdditionalPaidInCapital", "crdr": "debit", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "documentation": "Deferred offering costs incurred in a prior period to additional paid in capital", "label": "Deferred offering costs incurred in a prior period to additional paid in capital", "terseLabel": "Deferred offering costs incurred in a prior period to additional paid-in capital" } } }, "auth_ref": [] }, "myo_DeferredPayrollTaxesUnderCARESAct": { "xbrltype": "monetaryItemType", "nsuri": "http://myomo.com/20240930", "localname": "DeferredPayrollTaxesUnderCARESAct", "crdr": "credit", "presentation": ["http://myomo.com/20240930/taxonomy/role/DisclosureAccountsPayableAndOtherAccruedExpensesSummaryOfAccountsPayableAndOtherAccruedExpensesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Deferred payroll taxes under CARES Act", "label": "Deferred Payroll Taxes Under C A R E S Act", "documentation": "Deferred payroll taxes under CARES Act." } } }, "auth_ref": [] }, "us-gaap_DeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenue", "crdr": "credit", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "totalLabel": "Deferred Revenue, Total", "terseLabel": "Deferred revenue", "label": "Deferred Revenue", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r940"] }, "us-gaap_DeferredRevenueNoncurrent": {

```
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueNoncurrent", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred Revenue, Noncurrent, Total", "label": "Deferred Revenue, Noncurrent", "terseLabel": "Deferred revenue, net of current portion", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r940" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Depreciation, Total", "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r6", "r33" ] },
"myo_DirectToPatientMember": { "xbrltype": "domainItemType", "nsuri": "http://myomo.com/20240930", "localname": "DirectToPatientMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueByMajorSourceDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Direct to Patient [Member]", "label": "Direct To Patient [Member]", "documentation": "Direct to patient." } } }, "auth_ref": [] }, "us-gaap_DirectorsAndOfficersLiabilityInsuranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DirectorsAndOfficersLiabilityInsuranceMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Directors and Officers Liability Insurance [Member]", "terseLabel": "Directors and Officers Insurance Member", "documentation": "Professional liability coverage for legal expenses and liability to shareholders, bondholders, creditors or others due to actions or omissions by a director or officer of a corporation or nonprofit organization." } } }, "auth_ref": [] },
"us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems",
"presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueByMajorSourceDetail" ], "lang": {
"en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
} } }, "auth_ref": [ "r339", "r777", "r778", "r779", "r780", "r781", "r782", "r783" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueByMajorSourceDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation Of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r339", "r777", "r778", "r779", "r780", "r781", "r782", "r783" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Revenue by Major Source", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r989" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Award Plans and Stock-based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement."
} } }, "auth_ref": [ "r350", "r353", "r381", "r382", "r383", "r788" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": {
"label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus",
"label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus",
"label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": {
"xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date",
"label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported, for the EDGAR submission types of Form N-1A: the filing date, for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." }
} }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport",
"presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r837" ]
}, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report",
"label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r869" ] },
"dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label":
"Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r880" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "EarningsPerShareAbstract", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net loss per share attributable to common stockholders" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Basic", "totalLabel": "Earnings Per Share, Basic, Total", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r166", "r184", "r185", "r186", "r187", "r188", "r189", "r194", "r196", "r199", "r200",
"r201", "r204", "r413", "r423", "r454", "r455", "r588", "r611", "r767" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r166", "r184", "r185", "r186", "r187",
"r188", "r189", "r196", "r199", "r200", "r201", "r204", "r413", "r423", "r454", "r455", "r588", "r611", "r767" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r25", "r26", "r203" ] }, "us-
gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit",
"presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": {
"totalLabel": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total", "terseLabel": "Effect of foreign exchange rate changes on cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1033" ] }, "us-
gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr":
"debit", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationAdditionalInformationDetail" ], "lang": {
"en-us": { "role": { "verboseLabel": "Unrecognized compensation cost", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r1018" ] }, "us-
gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Income tax benefit recognized", "label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement." } } }, "auth_ref": [ "r380" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentialCommonSharesIssuableDetail",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option",
"documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityAddressAddressLine1", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us":
{ "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityAddressAddressLine2", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": {
```

```
"terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } },
"auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown",
"presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address,
City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype":
"countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label":
"Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code",
"label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype":
"stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province",
"label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype":
"centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label":
"Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as
CIK." } } }, "auth_ref": [ "r835" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityCommonStockSharesOutstanding", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": {
"role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or
other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where
multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest
[Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status",
"label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of
the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject
to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } },
"auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Entity", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct
activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not
include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] },
"dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation":
[ "http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth
Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r835" ] },
"dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period",
"label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any
new or revised financial accounting standards." } } }, "auth_ref": [ "r920" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity
File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8
digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype":
"filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label":
"Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions
of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related
disclosure." } } }, "auth_ref": [ "r835" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang":
{ "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character
EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current",
"label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to
be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } },
"auth_ref": [ "r919" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName",
"presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity
Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms
filed with the SEC." } } }, "auth_ref": [ "r835" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityShellCompany", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": {
"terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule
12b-2 of the Exchange Act." } } }, "auth_ref": [ "r835" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntitySmallBusiness", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": {
"terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } },
"auth_ref": [ "r835" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityTaxIdentificationNumber", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role":
{ "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an
Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r835" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang":
{ "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r874" ] },
"ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity
Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation
Table" } } }, "auth_ref": [ "r915" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]",
"terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r915" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": {
"en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant
Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r915" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited",
"http://myomo.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" ], "lang": { "en-us": { "role": {
"terseLabel": "Equity Component", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that
which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r9", "r137", "r161", "r162", "r163", "r177", "r178", "r179", "r181", "r188",
"r190", "r192", "r206", "r260", "r266", "r278", "r337", "r397", "r398", "r409", "r410", "r411", "r414", "r422", "r423", "r435", "r437", "r438", "r439", "r440", "r442", "r453",
"r479", "r481", "r482", "r483", "r484", "r485", "r489", "r491", "r511", "r607", "r626", "r627", "r628", "r649", "r717" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Investment, Name", "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r253", "r254", "r255", "r405", "r923", "r924", "r925", "r1019", "r1020", "r1021",
"r1022" ] }, "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EquityMethodInvestmentOtherThanTemporaryImpairment", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Impairment charge", "label": "Equity Method Investment, Other-than-Temporary Impairment", "documentation": "Amount of other-than-temporary decline in
value that has been recognized against investment accounted for under equity method of accounting." } } }, "auth_ref": [ "r973" ] }, "us-
gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EquityMethodInvestmentOwnershipPercentage", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Ownership percentage", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or
equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r253" ] },
"ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation
Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r884" ] },
"ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous
Compensation Analysis" } } }, "auth_ref": [ "r842", "r852", "r862", "r894" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label":
"Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r839", "r849", "r859", "r891" ] },
"myo_ExchangeCapMember": { "xbrltype": "domainItemType", "nsuri": "http://myomo.com/20240930", "localname": "ExchangeCapMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange Cap
[Member]", "label": "Exchange Cap[Member]", "documentation": "Exchange Cap." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label":
"Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r890" ] }, "myo_ExpensedToSupplierFinanceProgramObligations": { "xbrltype":
"monetaryItemType", "nsuri": "http://myomo.com/20240930", "localname": "ExpensedToSupplierFinanceProgramObligations", "crdr": "debit", "presentation": [
```

```
"http://myomo.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfChangesInTheCompanysSupplierFinanceObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expensed", "label": "Expensed To Supplier Finance Program Obligations", "documentation": "Expensed To Supplier Finance Program Obligations" } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value Adjustment of Warrants", "terseLabel": "Discounting and repricing of certain warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r0", "r6" ] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCashEquivalentsAndShorttermInvestmentsMeasuredAtFairValueOnRecurri
], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCashEquivalentsAndShorttermInvestmentsMeasuredAtFairValueOnRecurri
], "lang": { "en-us": { "role": { "terseLabel": "Fair Value By Balance Sheet Grouping [Table]", "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r53", "r54" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCashEquivalentsAndShorttermInvestmentsMeasuredAtFairValueOnRecurri
], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r313", "r342", "r343", "r344", "r345", "r346", "r347", "r456", "r457", "r458", "r459", "r460", "r466", "r467", "r469", "r522", "r523", "r524", "r774", "r775", "r784", "r785", "r786", "r793", "r796" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Instruments", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate), (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r462", "r464", "r465", "r466", "r469", "r470", "r471", "r472", "r473", "r585", "r793", "r797" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCashEquivalentsAndShorttermInvestmentsMeasuredAtFairValueOnRecurri
], "lang": { "en-us": { "role": { "terseLabel": "In Active Markets for Identical Assets or Liabilities (Level 1) [Member]", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r313", "r342", "r347", "r457", "r467", "r522", "r784", "r785", "r786", "r793" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCashEquivalentsAndShorttermInvestmentsMeasuredAtFairValueOnRecurri
], "lang": { "en-us": { "role": { "terseLabel": "Significant Other Observable Inputs (Level 2) [Member]", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r313", "r342", "r347", "r457", "r458", "r467", "r523", "r774", "r775", "r784", "r785", "r786", "r793" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCashEquivalentsAndShorttermInvestmentsMeasuredAtFairValueOnRecurri
], "lang": { "en-us": { "role": { "terseLabel": "Significant Unobservable Inputs (Level 3) [Member]", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r313", "r342", "r343", "r344", "r345", "r346", "r347", "r457", "r458", "r459", "r460", "r467", "r524", "r774", "r775", "r784", "r785", "r786", "r793", "r796" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Cash Equivalents and Short-term Investments Measured at Fair Value on Recurring Basis", "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset." } } }, "auth_ref": [ "r1025", "r1026" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCashEquivalentsAndShorttermInvestmentsMeasuredAtFairValueOnRecurri
], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r313", "r342", "r343", "r344", "r345", "r346", "r347", "r456", "r457", "r458", "r459", "r460", "r466", "r467", "r469", "r522", "r523", "r524", "r774", "r775", "r784", "r785", "r786", "r793", "r796" ] }, "myo_FebruaryTwoThousandAndTwentyOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://myomo.com/20240930", "localname": "FebruaryTwoThousandAndTwentyOfferingMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "February 2020 offering.", "label": "February Two Thousand And Twenty Offering [Member]", "terseLabel": "February 2020 Offering [Member]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of right-of-use assets", "label": "Finance Lease, Right-of-Use Asset, Amortization", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": [ "r494", "r498", "r803" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCashEquivalentsAndShorttermInvestmentsMeasuredAtFairValueOnRecurri
], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r267", "r268", "r270", "r271", "r272", "r273", "r274", "r275", "r317", "r332", "r443", "r474", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r608", "r773", "r793", "r794", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r805", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r969", "r970", "r971", "r972", "r1024", "r1027", "r1028", "r1029", "r1030", "r1031" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r478" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r846", "r856", "r866", "r898" ] },
"ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r846", "r856", "r866", "r898" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r846", "r856", "r866", "r898" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r846", "r856", "r866", "r898" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r846", "r856", "r866", "r898" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r879" ] }, "us-gaap_GainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnInvestments", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on equity investment", "totalLabel": "Gain (Loss) on Investments, Total", "label": "Gain (Loss) on Investments", "terseLabel": "Loss on equity
```

```
investment", "documentation": "Amount of realized and unrealized gain (loss) on investment." } } }, "auth_ref": [ "r89", "r90", "r921" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total", "label": "Gain (Loss) on Extinguishment of Debt", "terseLabel": "Loss on equity investment", "negatedLabel": "Loss on equity investment", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r6", "r34", "r35" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense", "totalLabel": "General and Administrative Expense, Total", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r88", "r699" ] }, "us-gaap_GeographicConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeographicConcentrationRiskMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Geographic Concentration Risk [Member]", "label": "Geographic Concentration Risk [Member]", "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa)." } } }, "auth_ref": [ "r28", "r744" ] },
"myo_GermanyOtherInternationalLocationsMember": { "xbrltype": "domainItemType", "nsuri": "http://myomo.com/20240930", "localname":
"GermanyOtherInternationalLocationsMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"documentation": "Germany & Other International Locations [Member]", "label": "Germany & Other International Locations [Member]", "terseLabel": "Germany & Other International Locations [Member]" } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GrossProfit", "crdr": "credit", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ],
"lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r81", "r86", "r121", "r174", "r256", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r477", "r769", "r770", "r962", "r963", "r964", "r965", "r966", "r986" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss before income taxes", "totalLabel": "Loss before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
"documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r82", "r116", "r121", "r589", "r604", "r769", "r770", "r962", "r963", "r964", "r965", "r966" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": {
"en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r279", "r285", "r287", "r461", "r463", "r468", "r621", "r623", "r702", "r757", "r795", "r1052" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeStatementLocationDomain", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r285", "r287", "r461", "r463", "r468", "r621", "r623", "r702", "r757", "r795", "r1052" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit",
"presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": {
"terseLabel": "Income tax expense", "totalLabel": "Income Tax Expense (Benefit), Total", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r124", "r132", "r191", "r192", "r205", "r212", "r215", "r391", "r392", "r402", "r612", "r790" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ],
"lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r160", "r389", "r390", "r393", "r394", "r395", "r396", "r639" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total", "terseLabel": "Accounts payable and accrued expenses", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel":
"Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Income taxes payable", "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": {
"role": { "terseLabel": "Deferred revenue", "label": "Increase (Decrease) in Deferred Revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r758" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr":
"credit", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Inventories, Total", "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "myo_IncreaseDecreaseInOperatingLeaseLiabilities": {
"xbrltype": "monetaryItemType", "nsuri": "http://myomo.com/20240930", "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel":
"Operating lease liabilities", "label": "Increase Decrease In Operating Lease Liabilities", "documentation": "Increase (decrease) in operating lease liabilities." } } }, "auth_ref":
[] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Other Operating Assets, Total", "label": "Increase (Decrease) in Other Operating Assets", "terseLabel": "Other assets", "negatedLabel": "Other assets",
"documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r5" ] },
"myo_IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://myomo.com/20240930", "localname":
"IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel":
"Prepaid expenses and other current assets", "label": "Increase Decrease In Prepaid Expense And Other Current Assets", "documentation": "Increase decrease in prepaid expense and other current assets." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel":
"Individual:" } } }, "auth_ref": [ "r846", "r856", "r866", "r890", "r898", "r902", "r910" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel":
"Insider Trading Arrangements:" } } }, "auth_ref": [ "r908" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r838", "r914" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype":
"booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel":
"Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r838", "r914" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
"terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r838", "r914" ] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "label": "Interest Income (Expense), Nonoperating", "terseLabel": "Interest income", "negatedLabel": "Interest income", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth_ref": [ "r770", "r951", "r963" ] }, "myo_InterimFinancialStatementsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://myomo.com/20240930", "localname": "InterimFinancialStatementsPolicyTextBlock", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Interim Financial Statements", "label": "Interim Financial Statements Policy [Text Block]", "documentation": "Disclosure of accounting policy for the use of interim financial statements." } } },
"auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract",
"lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType",
```

```
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureInventories" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory Disclosure [Text
Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the
classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r276" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoriesDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Inventory, Finished Goods,
Gross, Total", "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Gross", "documentation": "Amount before valuation and LIFO reserves of completed
merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r941" ] }, "us-gaap_InventoryNet": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoriesDetail",
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Inventories, net",
"terseLabel": "Inventories, net", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within
one year or operating cycle, if longer." } } }, "auth_ref": [ "r151", "r763", "r804" ] }, "us-gaap_InventoryRawMaterialsAndSupplies": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsAndSupplies", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoriesDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Inventory, Raw Materials
and Supplies, Gross, Total", "terseLabel": "Parts and subassemblies", "label": "Inventory, Raw Materials and Supplies, Gross", "documentation": "Gross amount of unprocessed
materials to be used in manufacturing or production process and supplies that will be consumed." } } }, "auth_ref": [ "r943" ] }, "myo_InventoryRentalUnits": { "xbrltype":
"monetaryItemType", "nsuri": "http://myomo.com/20240930", "localname": "InventoryRentalUnits", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoriesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Rental units", "label":
"Inventory Rental Units", "documentation": "Inventory rental units." } } }, "auth_ref": [] }, "myo_InventoryReserveForRentalUnits": { "xbrltype": "monetaryItemType", "nsuri":
"http://myomo.com/20240930", "localname": "InventoryReserveForRentalUnits", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoriesDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: reserve for rental
units", "label": "Inventory Reserve For Rental Units", "documentation": "Inventory reserve for rental units." } } }, "auth_ref": [] }, "us-gaap_InventoryWorkInProcess": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcess", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoriesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Work in process", "label":
"Inventory, Work in Process, Gross", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be
completed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r942" ] }, "us-gaap_InventoryWorkInProcessAndRawMaterials": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcessAndRawMaterials", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureInventoriesScheduleOfInventoriesDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Total cost", "label":
"Inventory, Work in Process and Raw Materials", "documentation": "The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially
completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. Includes supplies used
directly or indirectly in the manufacturing or production process. This element may be used when the reporting entity combines work in process and raw materials into an
aggregate amount." } } }, "auth_ref": [ "r943" ] }, "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Investments in and Advance
to Affiliates, Subsidiaries, Associates, and Joint Ventures, Total", "terseLabel": "Investment in jiangxi Myomo Medical Assistive Appliance Co. Ltd.", "label": "Investments in
and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures", "documentation": "Amount of investment in equity method investee and investment in and advance to
affiliate." } } }, "auth_ref": [ "r939" ] }, "myo_InvestorWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://myomo.com/20240930", "localname":
"InvestorWarrantsMember", "presentation": [ "http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails" ], "lang": {
"en-us": { "role": { "documentation": "Investor warrants.", "label": "Investor Warrants [Member]", "terseLabel": "Investor Warrants [Member]" } } }, "auth_ref": [] },
"myo_JiangxiMyomoMedicalAssistiveApplianceCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://myomo.com/20240930", "localname":
"JiangxiMyomoMedicalAssistiveApplianceCoLtdMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Jiangxi Myomo Medical Assistive Appliance Co. Ltd", "label": "Jiangxi Myomo Medical Assistive Appliance Co Ltd [Member]", "documentation": "Jiangxi Myomo
Medical Assistive Appliance Co. Ltd." } } }, "auth_ref": [] }, "myo_JointVenturePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://myomo.com/20240930",
"localname": "JointVenturePolicyTextBlock", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
], "lang": { "en-us": { "role": { "terseLabel": "Joint Venture", "label": "Joint Venture Policy [Text Block]", "documentation": "Joint venture." } } }, "auth_ref": [] },
"myo_KeystoneCapitalPartnersMember": { "xbrltype": "domainItemType", "nsuri": "http://myomo.com/20240930", "localname": "KeystoneCapitalPartnersMember",
"presentation": [ "http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails",
"http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Keystone
Capital Partners [Member]", "label": "Keystone Capital Partners [Member]", "terseLabel": "Keystone [Member]" } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfOperatingLeaseCostDetail" ], "lang": { "en-us": { "role": {
"totalLabel": "Total lease expense", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r497", "r803" ]
}, "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostAbstract", "lang": { "en-us": { "role": { "label":
"Lease, Cost [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LeaseCostTableTextBlock", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role":
{ "terseLabel": "Summary of Operating Lease Cost", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not
limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease
income." } } }, "auth_ref": [ "r1035" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract",
"lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "LegalEntityAxis", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Legal Entity", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-
gaap_LesseeOperatingLeaseDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseDescription",
"presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Description of operating lease agreement for office space", "label": "Lessee, Operating Lease, Description", "documentation": "Description of lessee's operating
lease." } } }, "auth_ref": [ "r495" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Maturity of
Operating Lease Liabilities", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash
flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of
financial position." } } }, "auth_ref": [ "r1036" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail" ], "lang": { "en-us": {
"role": { "totalLabel": "Total future minimum lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted
obligation for lease payment for operating lease." } } }, "auth_ref": [ "r504" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail" ], "lang": { "en-us": {
"role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for
lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current
statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r504" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail" ], "lang": { "en-us": {
"role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease
payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current
statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r504" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail" ], "lang": { "en-us": {
"role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease
payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current
statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r504" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail" ], "lang": { "en-us": {
"role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease
payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current
statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r504" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail" ], "lang": { "en-us": {
"role": { "terseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation
for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r1036" ] },
"us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail" ], "lang": { "en-us": {
"role": { "terseLabel": "Less imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted
obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r504" ] }, "us-
gaap_LesseeOperatingLeaseOptionToExtend": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseOptionToExtend",
"presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Option to extend lease term", "label": "Lessee, Operating Lease, Option to Extend", "documentation": "Description of terms and conditions of option to extend
lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability." } } }, "auth_ref": [ "r496" ] }, "us-
gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract",
"presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Lease term", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for
```

example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r1034"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r11", "r61", "r62", "r63", "r66", "r67", "r68", "r69", "r174", "r256", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r427", "r430", "r431", "r477", "r673", "r768", "r833", "r986", "r1038", "r1039"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities and Stockholders\u2019 Equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r76", "r113", "r601", "r804", "r956", "r974", "r1032"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total Current Liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r63", "r143", "r174", "r256", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r427", "r430", "r431", "r477", "r804", "r986", "r1038", "r1039"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Current Liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicenseMember", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "License revenue", "verboseLabel": "License Revenue [Member]", "label": "License [Member]", "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark." } } }, "auth_ref": ["r990"] }, "myo_LicenseRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://myomo.com/20240930", "localname": "LicenseRevenueMember", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueByMajorSourceDetail"], "lang": { "en-us": { "role": { "documentation": "License Revenue [Member]", "label": "License Revenue [Member]", "terseLabel": "License Revenue [Member]" } } }, "auth_ref": [] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCredit", "crdr": "credit", "presentation": ["http://myomo.com/20240930/taxonomy/role/DisclosureLineOfCreditAdditionalInformationDetails", "http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Letter of credit", "label": "Long-Term Line of Credit", "totalLabel": "Long-Term Line of Credit, Total", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": ["r11", "r111", "r1049"] }, "us-gaap_LineOfCreditFacilityCommitmentFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCommitmentFeeAmount", "crdr": "debit", "presentation": ["http://myomo.com/20240930/taxonomy/role/DisclosureLineOfCreditAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Commitment Fee Amount", "terseLabel": "Commitment fee", "documentation": "Amount of the fee for available but unused credit capacity under the credit facility." } } }, "auth_ref": ["r60", "r65", "r296"] }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCommitmentFeePercentage", "presentation": ["http://myomo.com/20240930/taxonomy/role/DisclosureLineOfCreditAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Anniversary Fee", "label": "Line of Credit Facility, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityLineItems", "presentation": ["http://myomo.com/20240930/taxonomy/role/DisclosureLineOfCreditAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r296", "r955", "r984"] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": ["http://myomo.com/20240930/taxonomy/role/DisclosureLineOfCreditAdditionalInformationDetails", "http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Amount drawn under loan agreement", "terseLabel": "Line Of Credit Facility Maximum Borrowing Capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": ["r60", "r65"] }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityTable", "presentation": ["http://myomo.com/20240930/taxonomy/role/DisclosureLineOfCreditAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Table]", "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement." } } }, "auth_ref": ["r60", "r65", "r296", "r955", "r984"] }, "myo_LoanAndSecurityAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://myomo.com/20240930", "localname": "LoanAndSecurityAgreementMember", "presentation": ["http://myomo.com/20240930/taxonomy/role/DisclosureLineOfCreditAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Loan and Security Agreement [Member]", "label": "Loan And Security Agreement [Member]", "documentation": "Loan And Security Agreement [Member]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtPercentageBearingVariableInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtPercentageBearingVariableInterestRate", "presentation": ["http://myomo.com/20240930/taxonomy/role/DisclosureLineOfCreditAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of Amounts advanced", "label": "Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate", "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time." } } }, "auth_ref": ["r64"] }, "us-gaap_LossContingencyAccrualCarryingValueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualCarryingValueCurrent", "crdr": "credit", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Loss Contingency, Accrual, Current", "terseLabel": "Loss Contingency", "documentation": "Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r290"] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueByMajorSourceDetail"], "lang": { "en-us": { "role": { "terseLabel": "Customer", "label": "Customer [Axis]" } } }, "auth_ref": ["r219", "r779", "r815", "r819", "r989", "r1051", "r1053", "r1054", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1080", "r1081"] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails", "http://myomo.com/20240930/taxonomy/role/DisclosureLineOfCreditAdditionalInformationDetails", "http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail", "http://myomo.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Maximum [Member]", "label": "Maximum [Member]" } } }, "auth_ref": ["r291", "r292", "r293", "r294", "r349", "r385", "r460", "r550", "r620", "r622", "r636", "r665", "r666", "r725", "r727", "r729", "r730", "r732", "r755", "r756", "r772", "r776", "r787", "r796", "r797", "r801", "r802", "r816", "r988", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r882"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r882"] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails", "http://myomo.com/20240930/taxonomy/role/DisclosureLineOfCreditAdditionalInformationDetails", "http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail", "http://myomo.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Minimum [Member]", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "auth_ref": ["r291", "r292", "r293", "r294", "r349", "r385", "r460", "r550", "r620", "r622", "r636", "r665", "r666", "r725", "r727", "r729", "r730", "r732", "r755", "r756", "r772", "r776", "r787", "r796", "r797", "r801", "r816", "r988", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r901"] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": ["http://myomo.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCashEquivalentsAndShorttermInvestmentsMeasuredAtFairValueOnRecurri "http://myomo.com/20240930/taxonomy/role/DisclosureSummaryOfCashCashEquivalentsAndShorttermInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Money market funds [Member]", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": ["r991"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r909"] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueByMajorSourceDetail"], "lang": { "en-us": { "role": { "terseLabel": "Customer", "label": "Customer [Domain]" } } }, "auth_ref": ["r219", "r779", "r815", "r819", "r989", "r1051", "r1053", "r1054", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077",

```
"r1078", "r1080", "r1081" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers,
Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r883" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusiness" ], "lang": { "en-us": { "role": { "terseLabel": "Description of Business", "label": "Nature of
Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and
the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that
has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding
of what those activities are being directed toward." } } }, "auth_ref": [ "r126", "r133" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash
provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities,
including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their
investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term
credit." } } }, "auth_ref": [ "r169" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "CASH
FLOWS FROM FINANCING ACTIVITIES", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash
provided by (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing
activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and
property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r169" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "CASH
FLOWS FROM INVESTING ACTIVITIES", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInOperatingActivities", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash
used in operating activities", "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of
cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not
defined as investing or financing activities." } } }, "auth_ref": [ "r94", "r95", "r96" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "CASH
FLOWS FROM OPERATING ACTIVITIES", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] },
"myo_NetCashProvidedByUsedInOperatingActivity": { "xbrltype": "monetaryItemType", "nsuri": "http://myomo.com/20240930", "localname":
"NetCashProvidedByUsedInOperatingActivity", "crdr": "debit", "presentation": [ "http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows
include transactions, adjustments, and changes in value not defined as investing or financing activity.", "label": "Net Cash Provided by Used in Operating Activity",
"terseLabel": "Cash used in operating activities" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NetIncomeLoss", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited",
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited",
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang":
{ "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "negatedLabel": "Net loss", "totalLabel": "Net loss", "documentation": "The portion of
profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r87", "r96", "r117", "r141", "r155", "r158", "r163", "r174", "r180",
"r184", "r185", "r186", "r187", "r188", "r191", "r192", "r198", "r256", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r413", "r423", "r455", "r477",
"r606", "r696", "r715", "r716", "r831", "r986" ] }, "myo_NetLossIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://myomo.com/20240930", "localname":
"NetLossIncome", "crdr": "credit", "presentation": [ "http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail" ], "lang": { "en-us": { "role":
{ "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net (Loss) Income", "terseLabel": "Net loss"
} } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Adopted
Accounting Standards", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new
accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref":
[] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description
[Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r882" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-
NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r846", "r856", "r866", "r890", "r898" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO
Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r873" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r872" ] },
"ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r890" ] },
"ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule
10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r909" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule
10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r909" ] }, "us-
gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NoncashInvestingAndFinancingItemsAbstract", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel":
"SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] },
"us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract",
"presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": {
"terseLabel": "Other (income) expense, net", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "myo_NumberOfCustomers": { "xbrltype":
"integerItemType", "nsuri": "http://myomo.com/20240930", "localname": "NumberOfCustomers", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Number of customers", "label": "Number Of Customers", "documentation": "Number of customers." } } }, "auth_ref": [] }, "myo_NumberOfExercisedWarrants": { "xbrltype":
"sharesItemType", "nsuri": "http://myomo.com/20240930", "localname": "NumberOfExercisedWarrants", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants
exercised", "label": "Number Of Exercised Warrants", "documentation": "Number of exercised warrants." } } }, "auth_ref": [] },
"myo_NumberOfSharesEntitledToWarrantHolder": { "xbrltype": "integerItemType", "nsuri": "http://myomo.com/20240930", "localname":
"NumberOfSharesEntitledToWarrantHolder", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of
shares entitled to warrant holder", "label": "Number Of Shares Entitled To Warrant Holder", "documentation": "Number of shares entitled to warrant holder." } } }, "auth_ref":
[] }, "myo_OfferingCostFromSaleOfShares": { "xbrltype": "monetaryItemType", "nsuri": "http://myomo.com/20240930", "localname": "OfferingCostFromSaleOfShares", "crdr":
"debit", "presentation": [ "http://myomo.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" ], "lang": {
"en-us": { "role": { "terseLabel": "Offering cost from sale of stock", "label": "Offering Cost From Sale Of Shares", "documentation": "Offering cost from sale of shares." } } },
"auth_ref": [] }, "myo_OneInsurerMember": { "xbrltype": "domainItemType", "nsuri": "http://myomo.com/20240930", "localname": "OneInsurerMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "One
Insurer [Member]", "label": "One Insurer [Member]", "documentation": "One insurer." } } }, "auth_ref": [] }, "myo_OneUSInsurancePayerMember": { "xbrltype":
"domainItemType", "nsuri": "http://myomo.com/20240930", "localname": "OneUSInsurancePayerMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "One
U.S. Insurance Payer [Member]", "label": "One U S Insurance Payer [Member]", "documentation": "One U.S. insurance payer." } } }, "auth_ref": [] }, "us-
gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total
operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses
which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-
gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel":
"Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Loss
from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } },
"auth_ref": [ "r121", "r769", "r962", "r963", "r964", "r965", "r966" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfOperatingLeaseCostDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Operating lease expense", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease
over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset
```

and accretion of lease liability." } } }, "auth_ref": ["r499", "r803"] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail"], "lang": { "en-us": { "role": { "totalLabel": "Total operating lease liabilities", "terseLabel": "Total operating lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r493"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail",
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Current operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r493"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetail",
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Non-current operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r493"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease assets with right of use, net", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r492"] }, "myo_OperatingLeaseRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://myomo.com/20240930", "localname": "OperatingLeaseRightOfUseAssets", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Operating Lease Right Of Use Assets", "label": "Operating Lease Right Of Use Assets", "terseLabel": "Operating Lease Right Of Use Assets" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfAdditionalInformationRelatedToOperatingLeasesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r503", "r803"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfAdditionalInformationRelatedToOperatingLeasesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining lease term (in years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r502", "r803"] }, "us-gaap_OperatingLeasesRentExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasesRentExpenseNet", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Operating Leases, Rent Expense, Net", "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income." } } }, "auth_ref": ["r123"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureAccountsPayableAndOtherAccruedExpensesSummaryOfAccountsPayableAndOtherAccruedExpensesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r62"] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Other Assets, Noncurrent, Total", "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r145"] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments", "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": ["r2", "r607"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": ["r9", "r10", "r156", "r159", "r164", "r188", "r479", "r480", "r485", "r586", "r607", "r946", "r947"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), net of tax:", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossTax", "crdr": "debit", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Other Comprehensive Income (Loss), Tax, Total", "label": "Other Comprehensive Income (Loss), Tax", "terseLabel": "Other comprehensive (loss)income", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss)." } } }, "auth_ref": ["r3", "r161", "r164", "r391", "r403", "r404", "r479", "r483", "r485", "r586", "r607"] }, "myo_OtherInternationalLocationsMember": { "xbrltype": "domainItemType", "nsuri": "http://myomo.com/20240930", "localname": "OtherInternationalLocationsMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Other International Locations [Member]", "label": "Other International Locations [Member]", "documentation": "Other international locations." } } }, "auth_ref": [] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Other Noncash Income (Expense), Total", "negatedLabel": "Other non-cash charges", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": ["r96"] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total other expense (income), net", "totalLabel": "Other Nonoperating Income (Expense), Total", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r91"] }, "us-gaap_OtherOperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingIncomeExpenseNet", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Other Operating Income (Expense), Net", "terseLabel": "Other expense, net", "negatedLabel": "Other expense, net", "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r882"] }, "us-gaap_OtherShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherShortTermInvestments", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Short-Term Investments", "label": "Other Short-Term Investments", "documentation": "Amount of short-term investments classified as other." } } }, "auth_ref": ["r115", "r591", "r592", "r944"] }, "myo_OtherWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://myomo.com/20240930", "localname": "OtherWarrantsMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentialCommonSharesIssuableDetail"], "lang": { "en-us": { "role": { "documentation": "Other Warrants [Member]", "label": "Other Warrants [Member]", "terseLabel": "Other Warrants [Member]" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r844", "r854", "r864", "r896"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r847", "r857", "r867", "r899"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [
"r847", "r857", "r867", "r899"] }, "myo_PatientsWithMedicareAdvantageInsurancePlansMember": { "xbrltype": "domainItemType", "nsuri": "http://myomo.com/20240930", "localname": "PatientsWithMedicareAdvantageInsurancePlansMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Patients with Medicare Advantage Insurance Plans [Member]", "label": "Patients With Medicare Advantage Insurance Plans [Member]", "documentation": "Patients with medicare advantage insurance plans." } } }, "auth_ref": [] }, "myo_PatientsWithMedicarePartBCoverageMember": { "xbrltype": "domainItemType", "nsuri": "http://myomo.com/20240930", "localname": "PatientsWithMedicarePartBCoverageMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Patients with Medicare Part B coverage.", "label": "Patients With Medicare Part B Coverage [Member]", "terseLabel": "Patients With Medicare Part B Coverage [Member]" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r871"] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [

```
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Investment in Jiangxi Myomo Medical Assistive Appliance Co. Ltd.", "terseLabel": "Cash consideration paid", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r18", "r418" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "negatedLabel": "Purchases of equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r93" ] }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireShortTermInvestments", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of short-term investments", "label": "Payments to Acquire Short-Term Investments", "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": [ "r92" ] }, "myo_PaymentsToSupplierFinanceProgramObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://myomo.com/20240930", "localname": "PaymentsToSupplierFinanceProgramObligations", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfChangesInTheCompanysSupplierFinanceObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Payments To Supplier Finance Program Obligations", "documentation": "Payments To Supplier Finance Program Obligations", "terseLabel": "Increase" } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r881" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r881" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r873" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r890" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r883" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r872" ] }, "myo_PerSalePriceOfWarrants": { "xbrltype": "perShareItemType", "nsuri": "http://myomo.com/20240930", "localname": "PerSalePriceOfWarrants", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails",
"http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Per Sale Price of warrants", "label": "Per Sale Price of warrants", "terseLabel": "Per sale price of warrants" } } }, "auth_ref": [] }, "myo_PercentageOfDirectBillingChannelRevenueInsuresRepresent": { "xbrltype": "percentItemType", "nsuri": "http://myomo.com/20240930", "localname": "PercentageOfDirectBillingChannelRevenueInsuresRepresent", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of direct billing channel revenue insures represent", "label": "Percentage Of Direct Billing Channel Revenue Insures Represent", "documentation": "Percentage of direct billing channel revenue insures represent." } } }, "auth_ref": [] }, "myo_PercentageOfDirectBillingChannelRevenuePayersRepresent": { "xbrltype": "percentItemType", "nsuri": "http://myomo.com/20240930", "localname": "PercentageOfDirectBillingChannelRevenuePayersRepresent", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of direct billing channel revenue Payers represent", "label": "Percentage Of Direct Billing Channel Revenue Payers Represent", "documentation": "Percentage Of Direct Billing Channel Revenue Payers Represent" } } }, "auth_ref": [] }, "myo_PercentageOfGrossProceedsFromSalesOfCommonStock": { "xbrltype": "pureItemType", "nsuri": "http://myomo.com/20240930", "localname": "PercentageOfGrossProceedsFromSalesOfCommonStock", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of gross proceeds from sales of common stock", "label": "Percentage Of Gross Proceeds From Sales Of Common Stock", "documentation": "Percentage of gross proceeds from sales of common stock." } } }, "auth_ref": [] }, "myo_PercentageOfTerminationFees": { "xbrltype": "pureItemType", "nsuri": "http://myomo.com/20240930", "localname": "PercentageOfTerminationFees", "presentation": [ "http://myomo.com/20240930/taxonomy/role/DisclosureLineOfCreditAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Termination fee", "label": "Percentage Of Termination Fees", "documentation": "Percentage Of Termination Fees" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r874" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r918" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r873" ] }, "myo_PreFundedWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://myomo.com/20240930", "localname": "PreFundedWarrantMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentialCommonSharesIssuableDetail" ], "lang": { "en-us": { "role": { "documentation": "Pre-Funded Warrant [Member]", "label": "Pre-Funded Warrant [Member]", "terseLabel": "Pre-Funded Warrants [Member]" } } }, "auth_ref": [] }, "myo_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://myomo.com/20240930", "localname": "PreFundedWarrantsMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-funded Warrants [Member]", "label": "Pre Funded Warrants [Member]", "documentation": "Pre-funded warrants." } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r70", "r320" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r70", "r675" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "totalLabel": "Preferred Stock, Shares Issued, Total", "terseLabel": "Preferred stock, shares issued", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r70", "r320" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "terseLabel": "Preferred stock, shares outstanding", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r70", "r675", "r694", "r1083", "r1084" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance", "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance", "totalLabel": "Preferred Stock, Value, Issued, Total", "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r70", "r597", "r804" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r945" ] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassifications", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r937" ] }, "myo_ProceedsFromAtTheMarketOfferingNetOfOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://myomo.com/20240930", "localname": "ProceedsFromAtTheMarketOfferingNetOfOfferingCosts", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from sale of pre-funded warrants, net of offering costs", "terseLabel": "Proceeds from issuance under at-market sales facility, net of offering costs", "label": "Proceeds From At The Market Offering Net Of Offering Costs", "documentation": "Proceeds from at the market offering net of offering costs" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from
```

```
Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ProceedsFromIssuanceOfSecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSecuredDebt", "crdr": "debit", "presentation": [ "http://myomo.com/20240930/taxonomy/role/DisclosureLineOfCreditAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt issuance costs", "label": "Proceeds from Issuance of Secured Debt", "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt." } } }, "auth_ref": [ "r19" ] }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Maturities of short-term investments", "label": "Proceeds from Maturities, Prepayments and Calls of Short-Term Investments", "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": [ "r17", "r92" ] }, "myo_ProceedsFromSaleOfCommonStockInPublicOfferingNetOfOfferingCosts": { "xbrltype": "sharesItemType", "nsuri": "http://myomo.com/20240930", "localname": "ProceedsFromSaleOfCommonStockInPublicOfferingNetOfOfferingCosts", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Proceeds from sale of common stock in public offering, net of offering costs", "label": "Proceeds from sale of common stock in public offering, net of offering costs", "terseLabel": "Proceeds from sale of common stock in public offering costs, shares" } } }, "auth_ref": [] },
"myo_ProceedsFromSaleOfCommonStockInPublicOfferingNetOfOfferingCostsValue": { "xbrltype": "monetaryItemType", "nsuri": "http://myomo.com/20240930", "localname": "ProceedsFromSaleOfCommonStockInPublicOfferingNetOfOfferingCostsValue", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Proceeds from sale of common stock in public offering, net of offering costs value", "label": "Proceeds from sale of common stock in public offering, net of offering costs value", "terseLabel": "Proceeds from sale of common stock in public offering costs, value" } } }, "auth_ref": [] },
"myo_ProceedsFromSaleOfPreFundedWarrantsNetOfOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://myomo.com/20240930", "localname": "ProceedsFromSaleOfPreFundedWarrantsNetOfOfferingCosts", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of pre-funded warrants, value", "documentation": "Proceeds from sale of pre-funded warrants, net of offering costs", "label": "Proceeds from sale of pre-funded warrants, net of offering costs" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Net proceeds from common stock offering", "terseLabel": "Proceeds from exercise of warrants", "label": "Proceeds from Warrant Exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r952" ] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Product revenue", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r777" ] },
"srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueByMajorSourceDetail",
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r216", "r551", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r760", "r777", "r814", "r816", "r817", "r820", "r822", "r980", "r981", "r989", "r1051", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1080", "r1081" ] }, "us-gaap_ProductWarrantyAccrualClassifiedCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductWarrantyAccrualClassifiedCurrent", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureAccountsPayableAndOtherAccruedExpensesSummaryOfAccountsPayableAndOtherAccruedExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Warranty reserve", "label": "Product Warranty Accrual, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r62", "r982", "r983" ] },
"srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueByMajorSourceDetail",
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r216", "r551", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r760", "r777", "r814", "r816", "r817", "r820", "r822", "r980", "r981", "r989", "r1051", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1080", "r1081" ] },
"myo_ProfessionalFeesAccruedCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://myomo.com/20240930", "localname": "ProfessionalFeesAccruedCurrent", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureAccountsPayableAndOtherAccruedExpensesSummaryOfAccountsPayableAndOtherAccruedExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued professional services", "label": "Professional Fees Accrued Current", "documentation": "Professional fees accrued current." } } }, "auth_ref": [] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total", "terseLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r141", "r155", "r158", "r168", "r174", "r180", "r188", "r191", "r192", "r256", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r413", "r423", "r425", "r428", "r429", "r455", "r477", "r589", "r605", "r648", "r696", "r715", "r716", "r791", "r792", "r832", "r948", "r986" ] }, "us-gaap_ProgramRightsObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProgramRightsObligations", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfChangesInTheCompanysSupplierFinanceObligationsDetails",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "periodEndLabel": "Ending", "periodStartLabel": "Opening January 1", "totalLabel": "Program Rights Obligations, Total", "label": "Program Rights Obligations", "terseLabel": "Finance program obligations", "documentation": "Total amount of obligations related to rights to programming, including, but not limited to, feature films and episodic series, acquired under license agreements." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "totalLabel": "Property, Plant and Equipment, Net, Total", "terseLabel": "Equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r7", "r505", "r590", "r603", "r804" ] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Credit losses", "terseLabel": "Bad debt expense", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r167", "r269" ] }, "us-gaap_PurchaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseObligation", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Purchase Obligation, Total", "label": "Purchase Obligation", "terseLabel": "Purchase obligations maximum amount", "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r871" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r871" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails",
"http://myomo.com/20240930/taxonomy/role/DisclosureLineOfCreditAdditionalInformationDetails",
"http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r291", "r292", "r293", "r294", "r341", "r349", "r376", "r377", "r378", "r385", "r460", "r525", "r534", "r550", "r620", "r622", "r636", "r665", "r666", "r725", "r727", "r729", "r730", "r732", "r755", "r756", "r772", "r776", "r787", "r796", "r797", "r801", "r802", "r816", "r825", "r976", "r988", "r1028", "r1041", "r1042", "r1043", "r1044", "r1045" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails",
"http://myomo.com/20240930/taxonomy/role/DisclosureLineOfCreditAdditionalInformationDetails",
"http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r291", "r292", "r293", "r294", "r341", "r349", "r376", "r377", "r378", "r385", "r460", "r525", "r534", "r550", "r620", "r622", "r636", "r665", "r666", "r725", "r727", "r729", "r730", "r732", "r755", "r756", "r772", "r776", "r787", "r796", "r797", "r801", "r802", "r816", "r825", "r976", "r988", "r1028", "r1041", "r1042", "r1043", "r1044", "r1045" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassifications out of accumulated other comprehensive loss", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r10", "r15", "r162", "r479", "r484", "r485", "r607", "r946" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r839", "r849", "r859", "r891" ] }, "myo_RegulatoryAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://myomo.com/20240930", "localname": "RegulatoryAssetsAbstract", "lang": { "en-us": { "role": { "label": "Regulatory Assets [Abstract]", "documentation": "Regulatory Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails",
```

```
"http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Related Party", "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited
to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate
family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r222",
"r348", "r515", "r516", "r594", "r602", "r668", "r669", "r670", "r671", "r672", "r693", "r695", "r724" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions
[Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails",
"http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Related Party", "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is
not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of
immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [
"r222", "r348", "r515", "r516", "r594", "r602", "r668", "r669", "r670", "r671", "r672", "r693", "r695", "r724", "r1037" ] }, "us-
gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactions" ], "lang": { "en-us":
{ "role": { "terseLabel": "Related Party Transactions", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party
transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity
and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r512", "r513", "r514", "r516", "r517", "r645", "r646", "r647", "r700", "r701", "r702", "r721", "r723" ] }, "us-
gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr":
"debit", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role":
{ "totalLabel": "Research and Development Expense, Total", "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation":
"Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of
research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired
in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r388", "r757", "r770", "r1046" ] }, "us-
gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ResearchAndDevelopmentExpenseMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "Research and Development [Member]", "label": "Research and Development Expense [Member]", "documentation": "Primary financial
statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": {
"en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r840", "r850", "r860", "r892" ] },
"ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" }
} }, "auth_ref": [ "r841", "r851", "r861", "r893" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": {
"en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r848", "r858",
"r868", "r900" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit",
"presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted
cash", "label": "Restricted Cash", "totalLabel": "Restricted Cash, Total", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not
limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [
"r938", "r953", "r1047", "r1050" ] }, "us-gaap_RestrictedCashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RestrictedCashAndCashEquivalentsAbstract", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureSummaryOfCashCashEquivalentsAndShorttermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Restricted
Cash and Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestrictedCashAndCashEquivalentsMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureSummaryOfCashCashEquivalentsAndShorttermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Cash and
Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions.
Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily
convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } },
"auth_ref": [ "r144" ] }, "myo_RestrictedCashMember": { "xbrltype": "domainItemType", "nsuri": "http://myomo.com/20240930", "localname": "RestrictedCashMember",
"presentation": [ "http://myomo.com/20240930/taxonomy/role/DisclosureSummaryOfCashCashEquivalentsAndShorttermInvestmentsDetails" ], "lang": { "en-us": { "role": {
"label": "Restricted Cash (Member)", "documentation": "Restricted Cash (Member)" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentialCommonSharesIssuableDetail" ], "lang": { "en-us":
{ "role": { "terseLabel": "Restricted Stock [Member]", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive
sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r25" ] }, "us-
gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember",
"presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentialCommonSharesIssuableDetail" ], "lang": { "en-us":
{ "role": { "terseLabel": "Restricted Stock Units [Member]", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to
stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-
gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestrictedStockValueSharesIssuedNetOfTaxWithholdings", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Net
settlement of vested restricted stock units to fund related employee statutory tax withholding", "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings",
"terseLabel": "Net settlement of vested restricted stock units to fund related employee statutory tax withholding", "documentation": "Value, after value of shares used to
satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax
withholding obligation." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserveTranslationAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "RestructuringReserveTranslationAdjustment", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Restructuring Reserve, Foreign Currency Translation Gain (Loss)", "label": "Restructuring Reserve, Foreign Currency Translation Gain (Loss)",
"documentation": "Amount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve." } } }, "auth_ref": [ "r977", "r978" ] }, "us-
gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit",
"crdr": "credit", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": {
"periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
"totalLabel": "Retained Earnings (Accumulated Deficit), Total", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit", "label": "Retained Earnings
(Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r73", "r107", "r600", "r630", "r635", "r644", "r676",
"r804" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember",
"presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "lang": { "en-
us": { "role": { "terseLabel": "Accumulated Deficit [Member]", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } },
"auth_ref": [ "r137", "r177", "r178", "r179", "r181", "r188", "r190", "r192", "r260", "r266", "r278", "r397", "r398", "r409", "r410", "r411", "r414", "r422", "r423", "r435", "r438",
"r439", "r442", "r453", "r489", "r491", "r626", "r628", "r649", "r1083" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueByMajorSourceDetail",
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Revenue
from Contract with Customer, Excluding Assessed Tax, Total", "verboseLabel": "Total revenue from contracts with customer", "terseLabel": "Revenue", "label": "Revenue from
Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation
by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with
specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r119", "r120", "r205", "r210", "r211", "r213",
"r215", "r216", "r217", "r219", "r338", "r339", "r551" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue
Recognition", "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from
other sources." } } }, "auth_ref": [ "r698", "r759", "r765" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureLineOfCreditAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility
[Member]", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the
total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit",
"presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": {
"terseLabel": "Right of use assets obtained in exchange for lease liabilities", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
"documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r501", "r803" ] },
"ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1
Arrangement Adopted" } } }, "auth_ref": [ "r909" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement
Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r909" ] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
```

```
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails",
"http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from public equity offering", "label": "Sale of Stock, Consideration Received on Transaction", "verboseLabel": "Sale of stock consideration received on transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails",
"http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails",
"http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Sale of stock number of shares issued in transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails",
"http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Price Per Share", "terseLabel": "Price per share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Sales Revenue, Net [Member]", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r219", "r927" ] }, "us-gaap_SalesRevenueProductLineMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueProductLineMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Product Revenue [Member]", "label": "Revenue, Product and Service Benchmark [Member]", "documentation": "Revenue from specified product or service, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources." } } }, "auth_ref": [ "r928" ] }, "myo_SalesofprefundedwarrantsMember": { "xbrltype": "sharesItemType", "nsuri": "http://myomo.com/20240930", "localname": "SalesofprefundedwarrantsMember", "presentation": [ "http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails",
"http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Sales of prefunded warrants.", "label": "SalesOfPrefundedWarrants", "terseLabel": "Sales of prefunded warrants" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureAccountsPayableAndOtherAccruedExpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Accounts Payable and Other Accrued Expenses", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentialCommonSharesIssuableDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r25" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Potential Common Shares Issuable", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r25" ] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTable", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureSummaryOfCashCashEquivalentsAndShorttermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalent [Table]", "documentation": "Disclosure of information about cash and cash equivalent by type. Excludes restricted cash and cash equivalent." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Cash, Cash Equivalents and Short-Term Investments", "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments." } } }, "auth_ref": [] }, "myo_ScheduleOfChangesInTheCompanysSupplierFinanceObligationsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://myomo.com/20240930", "localname": "ScheduleOfChangesInTheCompanysSupplierFinanceObligationsTableTextBlock", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Changes In The Companys Supplier Finance Obligations", "label": "Schedule Of Changes In The Companys Supplier Finance Obligations [Table Text Block]", "documentation": "Schedule Of Changes In The Companys Supplier Finance Obligations [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r424" ] }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock-based Compensation Expense", "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]", "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit." } } }, "auth_ref": [ "r51" ] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan [Table]", "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r8", "r44", "r45", "r46", "r47" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name", "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r253", "r254", "r255", "r405", "r923", "r924", "r925", "r1019", "r1020", "r1021", "r1022" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_DisclosureInventoriesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventories", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r13", "r77", "r78", "r79" ] }, "us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Insurance Type and Tier Identifier [Axis]", "documentation": "Information by type of insurance coverage or layer of insurance that covers malpractice claims." } } }, "auth_ref": [ "r118" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r351", "r352", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Stock By Class [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r36", "r37", "r38", "r39", "r40", "r41", "r103", "r105", "r106", "r107", "r147", "r148", "r149", "r207", "r320", "r321", "r322", "r324", "r327", "r332", "r334", "r640", "r641", "r642", "r643", "r776", "r922", "r954" ] },
"myo_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://myomo.com/20240930", "localname": "ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Additional Information Related to Operating Leases", "label": "Schedule Of Weighted Average Remaining Lease Term And Discount Rate Table [Text Block]", "documentation": "Tabular disclosure of weighted average remaining lease term and discount rate related to operating leases." } } }, "auth_ref": [] }, "us-gaap_SecuritiesSoldUnderAgreementsToRepurchase": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuritiesSoldUnderAgreementsToRepurchase", "crdr": "credit", "presentation": [
```

```
"http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Securities Sold under Agreements to Repurchase, Total", "label": "Securities Sold under Agreements to Repurchase", "terseLabel": "Purchase agreement requires approval from shareholders", "documentation": "Amount, after the effects of master netting arrangements, of funds outstanding borrowed in the form of a security repurchase agreement between the entity and another party for the sale and repurchase of identical or substantially the same securities at a date certain for a specified price. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } } }, "auth_ref": [ "r110", "r153", "r154", "r175", "r176", "r725", "r727", "r730", "r732" ] },
"dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r834" ] }, "dei_SecurityExchangeName": { "xbrltype":
"edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label":
"Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r836" ] }, "srt_SegmentGeographicalDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Geographical", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r217", "r218", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564",
"r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r662", "r663",
"r664", "r726", "r728", "r731", "r736", "r743", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r761", "r778", "r806", "r807", "r808", "r809", "r810",
"r811", "r812", "r813", "r818", "r825", "r989", "r1051", "r1053", "r1054", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066",
"r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1080", "r1081" ] }, "us-gaap_SellingAndMarketingExpense": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpense", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, clinical and marketing", "label": "Selling and Marketing Expense", "totalLabel": "Selling and Marketing Expense, Total", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpenseMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "Selling, clinical, and marketing [Member]", "label": "Selling and Marketing Expense [Member]", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": [ "r88" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "General and Administrative [Member]", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total", "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense",
"documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r5" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
"presentation": [ "http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Number of shares, Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
"documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r369" ] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
"presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationScheduleOfGrantDateFairValueDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "Weighted-average dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r377" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation":
[ "http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationScheduleOfGrantDateFairValueDetail" ], "lang": { "en-us": {
"role": { "terseLabel": "Weighted-average risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r378" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "xbrltype": "percentItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
"presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationScheduleOfGrantDateFairValueDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "Weighted-average expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement." } } },
"auth_ref": [ "r376" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r351", "r352", "r354", "r355", "r356", "r357", "r358", "r359",
"r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Number of shares available for future grant", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [
"r49" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationScheduleOfGrantDateFairValueDetail" ], "lang": { "en-us": { "role":
{ "verboseLabel": "Number of options granted", "terseLabel": "Number of stock options granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r361" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationScheduleOfGrantDateFairValueDetail" ], "lang": { "en-us": { "role":
{ "terseLabel": "Weighted-average fair value per share of grants", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r371" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]", "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year." } } }, "auth_ref": [ "r50" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "xbrltype":
"percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Percentage increase in number of shares of common stock reserved and available for issuance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum", "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period", "terseLabel": "Committed to purchase", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": [ "r49" ] }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentialCommonSharesIssuableDetail",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367",
"r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379" ] }, "us-
```

gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationScheduleOfGrantDateFairValueDetail"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average expected option term (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r375"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining contractual term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r373"] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssued", "presentation": ["http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Shares, Issued", "terseLabel": "Share issued", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": ["r9"] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance, shares", "periodEndLabel": "Ending balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Stock award net share settled paid for withholding taxes", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestments", "crdr": "debit", "presentation": ["http://myomo.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCashEquivalentsAndShorttermInvestmentsMeasuredAtFairValueOnRecurri "http://myomo.com/20240930/taxonomy/role/DisclosureSummaryOfCashCashEquivalentsAndShorttermInvestmentsDetails", "http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Short-Term Investments", "totalLabel": "Short-Term Investments, Total", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": ["r114", "r115", "r944"] }, "us-gaap_ShortTermInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestmentsAbstract", "presentation": ["http://myomo.com/20240930/taxonomy/role/DisclosureSummaryOfCashCashEquivalentsAndShorttermInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Short-Term Investments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeaseCost", "crdr": "debit", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfOperatingLeaseCostDetail"], "lang": { "en-us": { "role": { "terseLabel": "Short-term lease expense", "label": "Short-Term Lease, Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": ["r500", "r803"] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r97", "r171"] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r134", "r147", "r148", "r149", "r174", "r196", "r197", "r199", "r201", "r207", "r208", "r256", "r297", "r299", "r300", "r301", "r304", "r305", "r320", "r321", "r324", "r327", "r334", "r477", "r640", "r641", "r642", "r643", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r661", "r675", "r697", "r717", "r737", "r738", "r739", "r740", "r741", "r922", "r954", "r961"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited", "http://myomo.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Equity Components", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r9", "r71", "r74", "r75", "r137", "r161", "r162", "r163", "r177", "r178", "r179", "r181", "r188", "r190", "r192", "r206", "r260", "r266", "r278", "r337", "r397", "r398", "r409", "r410", "r411", "r414", "r422", "r423", "r435", "r437", "r438", "r439", "r440", "r442", "r453", "r479", "r481", "r482", "r483", "r484", "r485", "r489", "r491", "r511", "r607", "r626", "r627", "r628", "r649", "r717"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Geographical", "label": "Geographical [Axis]" } } }, "auth_ref": ["r217", "r218", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r662", "r663", "r664", "r726", "r728", "r731", "r736", "r743", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r761", "r778", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r818", "r825", "r989", "r1051", "r1053", "r1054", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1080", "r1081"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited", "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "http://myomo.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r177", "r178", "r179", "r206", "r491", "r551", "r638", "r661", "r667", "r668", "r669", "r670", "r671", "r672", "r675", "r678", "r679", "r680", "r681", "r682", "r684", "r685", "r686", "r687", "r689", "r690", "r691", "r692", "r693", "r695", "r698", "r699", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r717", "r826"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited", "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "http://myomo.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r177", "r178", "r179", "r206", "r222", "r491", "r551", "r638", "r661", "r667", "r668", "r669", "r670", "r671", "r672", "r675", "r678", "r679", "r680", "r681", "r682", "r684", "r685", "r686", "r687", "r689", "r690", "r691", "r692", "r693", "r695", "r698", "r699", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r717", "r826"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r843", "r853", "r863", "r895"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock issued during period", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r9", "r70", "r71", "r107", "r640", "r717", "r738"] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total", "terseLabel": "Common stock issued upon vesting of restricted stock units, Shares", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": ["r9", "r70", "r71", "r107"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Common stock issued for the exercise of common stock options, Shares", "terseLabel": "Exercise of stock options, shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r9", "r70", "r71", "r107", "r362"] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total", "terseLabel": "Common stock issued upon vesting of restricted stock units", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": ["r9", "r107"] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": ["http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"], "lang": { "en-

```
us": { "role": { "totalLabel": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture, Total", "terseLabel": "Stock-based compensation", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r50", "r70", "r71", "r107" ] }, "us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Share Repurchase Program, Remaining Authorized, Number of Shares", "terseLabel": "Remaining capacity under its purchase agreement", "documentation": "Number of shares remaining authorized to be purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [] },
"myo_StockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://myomo.com/20240930", "localname": "StockWarrantsMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentialCommonSharesIssuableDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Warrants [Member]", "label": "Stock Warrants [Member]", "documentation": "Stock warrant." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets",
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Stockholders\u2019 Equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r71", "r74", "r75", "r99", "r677", "r694", "r718", "r719", "r804", "r833", "r956", "r974", "r1032", "r1083" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 Equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommonStockAndWarrants" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock and Warrants", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r104", "r173", "r319", "r321", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r333", "r337", "r444", "r720", "r722", "r742" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r486", "r518" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r486", "r518" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r486", "r518" ] }, "us-gaap_SubsequentEventsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsPolicyPolicyTextBlock", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for reporting subsequent events." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails",
"http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "presentation": [ "http://myomo.com/20240930/taxonomy/role/DisclosureLiquidity" ], "lang": { "en-us": { "role": { "terseLabel": "Liquidity", "label": "Substantial Doubt about Going Concern [Text Block]", "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern." } } }, "auth_ref": [ "r58" ] },
"myo_SummaryOfSignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://myomo.com/20240930", "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Summary Of Significant Accounting Policies [Line Items]", "documentation": "Summary of significant accounting policies.", "terseLabel": "Summary of Significant Accounting Policies [Line Items]" } } }, "auth_ref": [] }, "myo_SummaryOfSignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://myomo.com/20240930", "localname": "SummaryOfSignificantAccountingPoliciesTable", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Summary Of Significant Accounting Policies [Table]", "label": "Summary Of Significant Accounting Policies [Table]", "documentation": "Summary Of Significant Accounting Policies [Table]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r889" ] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxesPayableCurrent", "crdr": "credit", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Taxes Payable, Current, Total", "label": "Taxes Payable, Current", "terseLabel": "Income taxes payable", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r61", "r62" ] }, "us-gaap_ThirdPartyPayorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ThirdPartyPayorMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "O&P Providers or Third Party Payors [Member]", "label": "Third-Party Payor [Member]", "documentation": "Organization other than the patient (first party) or health care provider (second party) involved in the financing of personal health services." } } }, "auth_ref": [ "r989" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r881" ] },
"ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r888" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r908" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r910" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCashEquivalentsAndShorttermInvestmentsMeasuredAtFairValueOnRecurri
], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r317", "r332", "r443", "r474", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r608", "r793", "r794", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r805", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r969", "r970", "r971", "r972", "r1024", "r1027", "r1028", "r1029", "r1030", "r1031" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r911" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r912" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r912" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r910" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r910" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r913" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r911" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": {
```

```
"terseLabel": "Treasury Stock [Member]", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r42" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Treasury shares at cost", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r42" ] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValue", "crdr": "debit", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "periodEndLabel": "Treasury Stock, Value, Ending Balance", "periodStartLabel": "Treasury Stock, Value, Beginning Balance", "totalLabel": "Treasury Stock, Value, Total", "negatedLabel": "Treasury stock, 27 shares at cost", "label": "Treasury Stock, Value", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": [ "r42", "r43", "r71", "r74" ] }, "myo_TwoThousandAndEighteenStockOptionAndIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://myomo.com/20240930", "localname": "TwoThousandAndEighteenStockOptionAndIncentivePlanMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureStockAwardPlansAndStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2018 Stock Option and Incentive Plan [Member]", "label": "Two Thousand And Eighteen Stock Option And Incentive Plan [Member]", "documentation": "Two thousand and eighteen stock option and incentive plan." } } }, "auth_ref": [] }, "us-gaap_TypeAndTierIdentifierDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeAndTierIdentifierDomain", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Type and Tier Identifier [Domain]", "documentation": "Name of the type of insurance coverage or layer of insurance that covers malpractice claims." } } }, "auth_ref": [ "r118" ] }, "us-gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfAdoptionMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Accounting Standards Update", "label": "Accounting Standards Update [Domain]", "documentation": "Amendment to accounting standards." } } }, "auth_ref": [
"r135", "r136", "r137", "r138", "r139", "r140", "r180", "r181", "r182", "r183", "r193", "r220", "r221", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r277", "r278", "r286", "r397", "r398", "r399", "r400", "r401", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r419", "r420", "r421", "r422", "r423", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r475", "r476", "r488", "r489", "r490", "r506", "r507", "r508", "r509", "r510", "r511", "r552", "r553", "r554", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [ "http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails",
"http://myomo.com/20240930/taxonomy/role/DisclosureLineOfCreditAdditionalInformationDetails",
"http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r424" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "United States [Member]", "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCashEquivalentsAndShorttermInvestmentsMeasuredAtFairValueOnRecurrin
"http://myomo.com/20240930/taxonomy/role/DisclosureSummaryOfCashCashEquivalentsAndShorttermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "US government agency debt securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": [ "r766", "r784", "r1048" ] }, "myo_UnderwriterWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://myomo.com/20240930", "localname": "UnderwriterWarrantsMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation":
"Underwriter warrants.", "label": "Underwriter Warrants [Member]", "terseLabel": "Underwriter Warrants [Member]" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r907" ] }, "us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax", "crdr": "credit", "presentation": [ "http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label": "Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax", "totalLabel": "Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax, Total", "terseLabel": "Unrealized gains (loss) on foreign currency adjustments", "documentation": "Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective." } } }, "auth_ref": [ "r108" ] }, "us-gaap_UnrealizedGainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrealizedGainLossOnInvestments", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel":
"Unrealized gain (loss) on short-term investments", "label": "Unrealized Gain (Loss) on Investments", "documentation": "Amount of unrealized gain (loss) on investment." } }
}, "auth_ref": [ "r6" ] }, "myo_UnrealizedGainOnShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://myomo.com/20240930", "localname":
"UnrealizedGainOnShortTermInvestments", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": {
"documentation": "Unrealized gain on short-term investments", "label": "Unrealized gain on short-term investments", "terseLabel": "Unrealized gain on short-term
investments" } } }, "auth_ref": [] }, "myo_UnrealizedLossFromMarkToMarketOnShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri":
"http://myomo.com/20240930", "localname": "UnrealizedLossFromMarkToMarketOnShortTermInvestments", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel":
"Unrealized (gain) loss from mark to market on short-term investments", "documentation": "Unrealized Loss From Mark To Market On Short Term Investments", "label":
"Unrealized Loss From Mark To Market On Short Term Investments" } } }, "auth_ref": [] }, "myo_UpfrontLicenseFee1": { "xbrltype": "monetaryItemType", "nsuri":
"http://myomo.com/20240930", "localname": "UpfrontLicenseFee1", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Upfront license fee", "label": "Upfront License Fee1", "documentation": "Upfront license fee1." } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates",
"label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r30", "r31", "r32", "r128", "r129", "r130", "r131" ] }, "us-gaap_UtilitiesOperatingExpense": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UtilitiesOperatingExpense", "crdr": "debit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail",
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Utilities Operating Expense, Total", "label": "Utilities Operating Expense", "terseLabel": "Utilities operating expense", "documentation": "Amount of operating expense of regulated operation." } } }, "auth_ref": [ "r84" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang":
{ "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r877" ] }, "us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1", "crdr": "credit", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label":
"Warrant, Down Round Feature, Increase (Decrease) in Equity, Amount", "negatedLabel": "Deemed dividend on discounting of warrants", "documentation": "Amount of increase (decrease) in equity for down round feature triggered for warrant classified as equity." } } }, "auth_ref": [ "r334", "r336" ] }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WarrantsAndRightsOutstandingMaturityDate", "presentation": [
"http://myomo.com/20240930/taxonomy/role/DisclosureCommonStockAndWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants maturity date", "label": "Warrants and Rights Outstanding, Maturity Date", "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format." } } }, "auth_ref": [ "r1027", "r1028", "r1029" ] }, "myo_WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://myomo.com/20240930", "localname": "WarrantsMember", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentialCommonSharesIssuableDetail" ], "lang": { "en-us":
{ "role": { "documentation": "Warrants [Member]", "label": "Warrants [Member]", "terseLabel": "Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted",
"totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r195", "r201" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average number of common shares outstanding:" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [
"http://myomo.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Basic",
"totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r194", "r201" ] },
"ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label":
"Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r875" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481766/480-10-25-13" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
```

```
"45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-40/tableOfContent" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210",
```

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02-6(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481501/840-20-50-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r137": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef",

"Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-

```
50-18" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r334": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r336":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3A" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-
50-4" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-
20-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r343": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r344": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r345": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r346": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r347": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r348": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards
Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r353": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-
10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r357": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r358": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r359": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r360": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r361": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r362": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r363": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r364": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r365": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r366": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r367": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r368": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r369": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r370": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r371": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r372": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r373": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r374": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r375": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r376": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r377": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r378": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r379": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r380": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r381": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r382": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r383": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r386": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "35",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r389": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" },
"r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-
50-17" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
```

"Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-11" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r459": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/830/tableOfContent" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r523": { "role":

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r524": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r525": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r526": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r527": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r528": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r529": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r530": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r531": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-
50-7" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r535": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r536": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r537": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r538": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r539": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r540": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r541": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r542": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r543": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r544": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r545": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r546": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-
50-50-4" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r550": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-
65-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r554": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-
235-50-18" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r558": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r559": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932",
"SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-
235-50-23" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r563": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r564": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r565": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-
235-50-31" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r569": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r570": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r571": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-
50-5" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r575": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-
50-5" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-
50-8" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r582": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8",
"Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r583": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" },
```

"r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-
50-2" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r722": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-
45-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r726":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r727": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r728": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r729": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r730": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r731": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r732": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r733": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r734": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column C)(Footnote 6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r735": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r736": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r737": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-
50-2" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r741": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r745": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970",
"SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-
50-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r757": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
}, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)",
"SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r761": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40",
"Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" },
"r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef",
```

"Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483385/720-35-55-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r845": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r851": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r855": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r856": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r857": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r881": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r883": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r884": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r885": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r886": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r887": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r888": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r889": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r890": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r891": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r892": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r893": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r894": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r895": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r896": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r897": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r898": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r899": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r900": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r901": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r902": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r903": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r904": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r906": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r907": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r908": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r909": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r910": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r911": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r912": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r913": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r914": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r915": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r916": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r917": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r918": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r919": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r920": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r921": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r922": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r923": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r924": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r925": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards

Codification", "Section": "25", "Paragraph": "2", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481174/470-10-25-2" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 61 0000950170-24-122331-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-122331-xbrl.zip M4$L#!!0 (.B!9EEN0A;H%5D"/^J$P 0 ;7EO+3(P,C0P.3,P+FAT M;>RJ:U<;29H@-'GG5^1ZMJ>KSDO@N%]P5>VAL-WM'=_.V-O3[Q>?N$)V"4F3 M*6'3OWZ?R)1 8# 8))2@[-TI(V4],R*> ^_V7__WU:% JU=__M^__=LO_Q.AXOG+5V^+M_%+L>LGY7%\7M9^,*JG M52Q^VG_S<_%]."B'L?BOWS^\+IZ/_/0H#B<%*@XGD_'.TZ=?OGS9#JD'D^(G_W.1?P7O'@[C8!!/BI?ET Y}:0? %_ORM6[!,OUWL#@;% MA_RSNO@0ZU@=Q[#=/O1P N^MD\=;RW (6[V9/X1PGL+4XOQ]_H_O MW)XO.UN?WO[UF_O/[2]?G=]:?KWJN20O(X,\0WQ^^W T? N0KTI_^<_'I'HZ M.1G'IW C&K9WG]ZJ+B],$^R //VO-Z_W_6$\LNCBUNO)N#I_IG7TVP>CXZ?Y MRM.,$O-;IS4ZL'9\>G>RM6M>,,MP[F98*RP3J/JJ"&4# &!L%YX6OA@OG]UN/.'7J>_C=WK&PL2LW M=?$D+W_J]XXQPX\B(NUH>__ID;S2< #M$'P%CGA2^_?3KDTG\M.GG:<).G^:E/9X_]Q8W"25%/3@,QUR='MCHHASN%G4Y&_[,\&H\J0/_)L[$-_MF4? O%'K\]5G>&SJ,F:'M%.39DV81H3R>/R.4]7A@3S)U1K€Z2_EU)[\J5NV? M90AQV/QY1KY%"4?^\K/77$1L*!+<4\2%BL@0;9$PU%$:J21*/"F&]BB_)98[MN\#U0^;\+P?V8+;3KY,/,<$9? #84LZBY1S$IA{CQ'AF1'-)\.D:=#)KX){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|OH.%;#_.C= R#5,M;/HYOL M1S^MR@E\6K&:/XM*+$$4&2X ,@YI8C@0F:+(."L13C'18+SFQ'454JW0/Y45 MKT>^8: 7.&8<#, .:HB^ 6X:)_#WBZ_C&PBJ!\HT3:0L4H\PE@QQ@" RQBFD M8TR"2L-(Z*Z+]@/&=!=4>)LH3S@B+SE&G$B"K 1#W =JB#(F&-O+O8Y2GY=8 M>6#.A %+Y=1ZI#$5*,I@,;.-6L!"Z"KJ]*H9R,@?/1=?B\6AP#*SS_$W+TG^S MTOTN[5:5'1XT#. ,8UZ/[!:X]TRPGNP>5+&Y8QE6QH?\'NIE3 CZ^L5_+H^G1 MJHU(AP8=APXE8}> MDJY"]'9>L;=Q*,K!55S@/:PF8U5.E7H#N1"W5=P-QR!.[$@4CVMT21,N>RU, $L)J44!ISF#'<6K3L:S5]6 MW-@(G2QU(/.]!XXCM4':&H.H5X'H*(+T#Q4TZP] +0U("E-K&4:,< "2"@8$ M1,!(TQ2U2TIZT3D@+2L]4!5,Z685%HB2;E%W.=T#.8MHA+$> !U#?@U? XUI\S+W1ZTEXE)F#1FLAHP)CD8"\ MY"EZI TCR!&A1(I,Z08H$)XDFDW54G7MJR:NHP? C\Y_?.O\$1;^<.3UZ 3#\Z#Z?2F M5\/Q=%(W=Y 'XWUQ$L14$,C+ "'+"8:L=@9A3H&XN [*V:X"ZN;F#.@8.="CW?BB<$E(!U!H!,*X(F@?SB1"+)*1 \4:5CLG(/HE"?" M6\,T1SC>V,&X*4KQ9^9?8YX-PT=XQ:O3EYV\?.RBGXR M-R&-ZE!+ ^NZM>E M=8U?_?1!JX<{O[D{Y0NI$><4N*W##@6>0)<1UD7362_3C4+. MN2X^LU\ [?/,7D?C1GK>5]1Y#? 9XKF],-HM-%D"]L4HCRYQ&A%,*1E_PR7#3MT2#)[:R0'@]^5{(&O%[:?AZY=BXQW;F\ _:F+LAE%G>VD$N6GXUW+/CQ[@5)@46([*" IN18'YKJ8#?!<5]$C;X M[A4O/,H]8YF[2S>?)K F&@-MTN?:R4@(*"(1+!\34S94K;2<6DJP["H(;U)D] .>M(6K;R<#L.#Z>=@{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{\06>3T7 ME"%0F;2AB,>$D0F1(N]Q2DDS'_1#]TO?6V+?^9#7L@K(7'!.YYK,*!((UUQ4 M:RD!54EXS[G7S(C.^]@[J^.NPS,8C"0: VE904!,>!#]C$04'5BB(6$NU]%7.$(8;_VYR#-GFD1@H ,% CD PLSQ+0$NF@.0*53BHP7#ASG9TM MT[$0'EM>1H +5N5\## =6: [XDBYWA\@5[&:&VB2"ZEZKLC. ^US1[> _H>_(Q MSS]L!U#5OY\L7KE0"GU85NWW[^W). 7NTBXIH)2F0$!P\L1FZ%DQ +LBLF6@; M3=0$+G<5I@\KZ7,-Y1+' E3.J)%)+)#>+\@P!7W5()N:-P]1HVUD3N/L$NR:8 M$LRI, !3A8$)"RKA+X-1;B))"%>6T96[UG]8 BW.G+N+!/)4F>3:IBDZV_* M:>HPTL[%:!FA074N5'B-_=^DIDT.8_4*-EH- ;6L^S7G9_>8.]ZZ!=1$U-4Q* M'.%Q.,B2>[B;X:5B*FF+O9:&=-9@>=05,1Z,1L9Y0E'FBABE+\M"?>PC"#UG5$LKD%?9"@KP;(N=0\%XY:-WBJ;N!D*[KKU M]+? PG%O%2!Y\#7"DN1P MM0X ,DN0X8HZ:3UHO _5);OF/I1+,+SFA8D@"Q7R/N=V Q<$(!F'M-%1.2ZM M(YUCB9VAJS6Q0BD\B<$C%0@!D'&3%T7@P.HEQ M(2C^.%DBT),37J# (.9YJ&@6R3#$P@G-C7B$4H9T%78?CB$NL=?$R8,VS7T+(ME%NX4.1\P(A'IJE,TLKN5M)WMWHKLF>T.XHU(BFR=^QQ>6+!6B)85$CD^= {<9*9C64!.$>E=,B2N/KWDAVEZ.1]H M8X)8DU"R#€9O71X^GRCR.#IA+,%&=S;2L2J.7H)VLX,<#> ^)]49Y%*T!Q50# MB3@2&4HBL7NC>O(N-7C*'7SK/?Y #@;4@!DGLK/"8HT=*(&LLJZ]^.=R#EBO^^-CD"-B,5DSK,>;"#M2H ME%!,.58.DA(8<<- (&9T$10AKT37D+DKRLZ:#)@\4PZ[T)HM8,#D)K"1-P\B M@L:DD\:=RP? NBK*S)AIS&$##!8HN><1C,,@&^^JIQ!BD);&=H[&'OS\G=5$ M)H(WE@=X7, \(FY !=+:7(44HUHEK)D"MH3.RUN5Z;>R"Z0;*\Y\E0,DC6>JC)WFL_$-E M3^N=3,)OSIOX\GA3Q(Q0G@(26G, 9Y{[17! 7H5$J<+2^XWC30^3,"/F1@;M M49&%'*K.QK(!AFH<13:!#B]I<$()+@7L;"OD\K> MNV'\M'^60&1/5MJ[O3OJW7JB)I%G[6"D PGQ(D(@,@XHNBYUT19$[M,+?P MK,]U0%1@Q,%G*+$\PB&/9C9".A0 "-Q8FGCH%?:UMK-TF#K?0!R4PIQC3UR MF'B4@C,.1]!IDVKMG6I6T^8D:LLDCUD)S*H8@ !I[ABRW LOM?'BP>?7W_?$ MQF4%1Z,Q2L@<%.8$_J.(0H9H@62R#$15%(VV;&+C,O'2"6*PSCYAIQ&WR2*= MV\D9,! <8T:XT+G0S$.1S^MIZ&18CB/@02 Z)0T8M$[15W6W'8.%DUKI,4AI9,WL3)X0@;T>-83\Z(9_'; M&,.^W]OX_I1T>?"W?G(R.1FU(<{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

M(;ARS!%70%U:$B Q+!17EA+;W3DZG6N]L)X>320764PQE!Y%%(MV@LA&=>FLZZICC5=7X]93"11#C@E&"4D)\+13(.YW;_@BB>""">YNDZWN%EDL

*MC4/*8&/,X4&P'Q!G.=$D68&BY5'JF("#=C9O}).=3=:0O$=,"EP8@G3,+="E M3,@)FA# CQK&/0VLL]'!&!'(_3@8E,;# &CKQH>_7WP=/]HNK\2':$%Y1ECD M8AOI>|+5U2*%?3>*

*(#$G-BB0<4@7F9+6B -+WX%AK;CQ>3Q[=YOL[@UL7;]+ M,T/V?>6A/#A<$&2?P{JNOH ,>^0)Z"0&&4T@B D&,HPDDOLDFZR,J!A$"I)T MUAERHPP7H*I8Y3#U>SN^-O?*

TS@;TLKS+)#D?!&&D5C"_;-4-/DD.2!L4 MI:&[E+4AKMJKUW"'\/02&,R.&IEHHMDDQXU B2B.N<]-\[SWRD@3'%$F^>VE: MWTM@WP,-N(@$*,%&WG@<8Y<=PK<"R2U)WKN%JQY7?):.!*

*M,&*U"3971D6,N.8YXXIX1 61-(%>[%?OGE@Q=-;,3;6L]. <:,;AT$@%/D)O9< M.}!|LA25DA*=:,*NIYVF,Z3W?(AUS&7I(IF?Y{+ST;A!@$>~<0=HM%8FB83. M+G/G-#*<642-*

IY1@#;RU[R5.M:^#C:#:?_G%!F>8D9*C)/*XAD@PTM%X1!0"4CE M!H\/U0>PQG#)LG*F6)2!.J.0,3J/AZ/P%W8$$89IY,[P%#L;+NE8X< 2H<*| MJ7&;0!:IW"\@YSCKl'+S,V?*

DL}>T^[U'UC,'+C3YHEA.C# O$>*<<8<,1QC M9#&7G$B%F7GH\=6U.3'6D%S$B<,*>XL,"==4A=VX_Q/DMAEJ@3 MH-ZH@(@W.>-%9R[MK{'(U98"<:Y-K9!&5N=L'(0(Y*

*MX@WR+(ED=,1@7SY0"*T]"K;>N*87N,6.X"A:'Q$/.G?8D0)H+!FGF??).=#8A MH5/}Z,ND,J4##2FB((D!F(AL9TI'V]^.K1GK.C'[H:N,]%^8L3T1!:S:F3CE) M-*

*&=,FHB,=A(!K1@P\YDQWQN0B:!SI^"<$C9)O_KV\{0H5N>\;R M0)K.,2%WVV"&90$+-J<_VXZJW+?+@*TXBE8,_JW_?=R0I*+[<>HJ,]!8^>B5M\CCQSA7%=B<>MB8JBS@*X00H*

M#+1SJJ153:/I U.1.V(=0^]{^#:)F*N(;4=>&.,-@A$&4V(4\Z0LRHB'+"S MFBGO1'?+3+KGW%E-7BQ/@:FLH9F<<,==GDCNY$N*:8 M4@H!*Q$ @"XWW[4*

*2N$4M4%%0U@>$)Y]Y3>61%_FM1Y@*RD6@*K>)C7F4FL#(M.1-19,PHK:/P/?==>_F>8!)S!AJ/B4"H/%B,=*(.19=]:#[TE M^IF9Z&Y)&W4J*

<=9$=LF#NL:1\4M8KU3G:Z68GLO48?T(*KW2P*$8@)HX5 M:^<_D5 M79EFN+XRE'[687=XHE81{&Z"$K,>>))>4*>1U@8F00SNO..<2Z%&GL0(LM M87#D*7'D",N51*

!,&Q.HC$PIK2SW272VM6_75?KEZ8Y6!D>,_4,KZXZ.1F2" M%X@PJV4*F@?7W88.':"SU8R5$H[{%L<)>V!=+Q4R#H>$5C!F'$5/!&=+?_N

*MMtMK3>J@TQHDET01Z}SM!A#%:L^!U)A@AN-/8SIWL]## W1FORBV%[A M\UAVYQG8IED/BT+(1'4(H7,,]T=4AML5FGJ8T061M'$J.*1R.1S/A7'P!T4^*

*M"):H(T%VN);]._[*K'Y^B/6D*G6W&N;6AY)P)8G#"0,P6,S]P{#*,C EY).* MSH!1$+H[WJB3*5?OAO'3_EEBE3VYUFV]7):R68E5EDGOX(A'H>F3KE}$.BOG M.M+D,'90{)5G=-{BI-*

*906"$Y)Y%1C;SR(7*]+JE XJ&(-R"@#0*XA%Y_*\'L\!KT!861Y=XCH#+GM8PIQ=#3+LH0,G#A2*GKNN$G.=${3N*s[>N]MY{W =UE"TOY+'W0*

M)A.?)/G1ZG)4X\M(DYX,!/5*78V(>++.ICOW6Z}3-LE\!BT%(AFMS37P%N, M#0DQ[T%Q9E'1U1=I/Q#TC4GDT0 H&)*{WR2.M*8@0YEV8,;AY-F#2C-^-VPK MDE?J,;^"*

[>WZANT#Y_,1E&0WN-] X(9Y{1-S+FJ&,M-?AB+R ;0!<$]!KW0 MT$1\9_EN+I4_WXSNXY?1Q\/1M+,# (;6B_+@5]@^% M$RMJD\\S@35S,M?3FEQ*2Y!*P>I@O*

JRL]';,NKHZPGJ!&|)48A)'T-.7M,9 MCDXA3SGS1C"CNS4PL4QWED5V M(0WT#NK9LM*ME2+.8\Z1(#ECWN9TZR0H"DIA)A..N+LC@_;J&,K)2 ^N;46H7 M>>;Q:' ,W/+\3RN$*

J0QV3C5'KBVI,AH18PVTD;>V2A!GYG3(1U_/<:ITB2F M8)H]GE(;,Z[,,IE'9]H$VB,P \?MAF_-#4ML=2110=!FM(\H1TT@(Y+8#(

M+3=,/511O^:RG"4.OU8FCVP{@&D18V[IZ$";=@%Q%RW6,5"PD3{(SFN(""BC MO-:@N6*CFUP=D%N\'8/A(C$Z)=Y9M:C.,K)2\>;W^GE_]}T]C%O#YYH SVLZN_>#Y

MSO'_TD?.+_XHS/-??_.X&QXY?"B_[L#YC:.5CW7{\3#:T) 7'-)O_U84O\"__M13TY&0"[^!U4V2,#P/%&I0HI\|67C(M>/Z(L0T!]!+D1A/8[0X93YXEH!=4E_^*.P3#1S#$#^#AD]%X!{?

7DCTJ!R<[M'X&CU,7;^*7X,#JRP_F-LR?A9VY4PD1V4!X,=P8Q M3?+2ZK$=SA?E1X-1M?/ON/G?LR^'0 4(KONX S8!^E+9<;N0+ ^V&W6@0%E8M

MYWNX:IVPR"]EF!SNI'"&nXP$@OSS-BX!3&I_HZL/A%[W]@M'LK#O;-?' M:KD!)_J66__TJM7'%\+ 8^[U_L__@Q_!A>>/40]E_L:?KPZN.K%_O%[MOG*

*MQ8O_VOOK[MN_O"CVWKUY\VI__]6[MP_]9*Y%URM.YN^V/@0F,1D-MXKGVWO; M!<6"FZM.8[:K3-@[!/]15?PND]&I2AF!_'I/ZJV7I^\;7'>?4!WHF1_;>_ M$XF?_3BR7/N^!T)*

(+]}]~%/,M[^XGA]X-NP$A-]P-&STD-(WTO7E9R6Q=4EJ M9*+,L\^<1,{GIH9)2"%E"$R)\5,X_L04U;1#<4L:NY1S-,;N?$>&9%)N ML_N?:<_H!*74% M:Z A6"U40%*J/!1$-?*

*$OB1)F+EA,K#9N6:SA;U,P3F,U./D0QZ-J\1(H ^K(AFMS4JL(FP7'(.(X&S@&XGHXD;?>V&$/^/?S<*RV?7\$.+/1__W3[H>/+SZ_M_D?QX<7[=Q(\^N\|_?*

*=C_M/OV8_'Q70%.VD=0Q0K"BGP6ZGW7!/)MN<'+455,#F/QWW.T+.5H721'SC+GK1/5U M/[V"'@E341'C42 Y)4P9",3%)2*2$4,]4)Q7RZ+'|\UV7K1^H'/4N!/@&W0$*

*M,SG,/T/!GJ"3:"L4A]V S7X<3UH/'<-,*P)%4M*3G#J9&WCDWL^@-6'6-@(B M*DF:<%P6*%Z6M;>-#?\ 1OX1OZFX<OS,8E2M3F58LG)U=Z4A M$F^QRQES.*

!E&"%0MBHWO=#">X:.5M;RZ9YCR&LLZAW>)e.8@%,,>L3]Y&E+1&&I (#"EL%6CU MN9PWQMQAQ@CF3NTR"WUE@OFA"QGDO[5:2<@.4TN;OB)&J)2;(%!D-

*>BM,CAFG0&:)'0Y=/;=5O'[M[TT>ZU;H,E;.WI??+5^T@"Q&*7B#'B%K8O] MNS)T^O M^!G9QO3'?P4O$}?]ZI>GD^KBAF;Y. VN7 K3+W!:R%7L_K'3_!?E+R[9\W&L*

M)CD5,X8S@'"7H=#]\;S+190T5 G..=(R>U"$,!^,\4DEN1P1E>L! MJO',SFG2X_;-1BQ[HQ"_=:O4^8YQ-3K.SUF*W_!_;+S9F#UPDID)=P M'9Q;0*P$M.?{$2B77/@?

+8=+B&S>1&.]R4%T%-%-U$;Q@)%S B-.!4.:|@-6 M@E+,6FV]69(MJ-%^?35+^&T[@"W-,+HR&4XA;#@?5/+G^'''>]U\4#=.;?D

*M2EVN867%g"J:/HG_YE691U*WWC>1FF9W.-A_)8F<<#PI17VQ^V]{>+6=_9 MJB?&I1_Q.1VCH-$;&I)'A>'A=O1]N7(L5E5+A, MTCLJ0QC$*TY3WK>1>DNL ;CD*[\^H4\>Z39[_*

SB[D4V@1$M+R?W)*2K) 1$:*]Z-J,K###.Q/KG-0KFH9YW.'-MK@ !G*?C0B(*BT:<$88,D1HY1>%LN4J6WSE[^BH0T%4:*Y/#XN5@M)"YTKVS MIQ83)9U!JNE5*3U'#DX=!:N=*

*(\IC;)?DP)\=^A(-]Z,/JR2H?{Z-Z,AIV M^-B=3YH;8Y (1"+.*48Z48VH9W59SWF=TYJ.W?LC0WWKFJJ9H=^K=ZH-[:N MK3^.\#ET4V:**2UC[F?C@N$."'LDGRP,W1_#PS*

*M#O[_'RY@23/*TK_"U&YQ*D$Z\$0 MD/=Y.X0 %;H84/&#-V5Y#G.3.#]X>C8:<2|$RN(,)"]Q4,%P[F+.GG/_Y= M4Z*>U<7',(CC#,!9-NA6\6KH!]-HYLD>6D_%T_V>GSE+J> MIY3QJ4?*

3C1B_Q6^N?<\2/=#?HL7%1S>]5:- ?R\F@R>,UA\6?F#K^C]JXDL,,M+!*-Q-L_.8+[M?KK>7.V/\WO'^7:69-R@9_5J#W/;]0($$SP6OCF37BN.@-V8_SP&1G.%%%"D M(BZ7_@\%L?*

*CA+04&M1ZQAPH^%((?E(A.HZ8RVUYH\;(D201S958 M009FU)V;*LRX9LLT5QF>^,>[30=GBBP2EA0BDH,Q{RQ'>7XP4CCI)E44MAE MD?&+&<-NJGJ^B4IE=K{R@-3;?*

^R_*&9M3\+&B{!>?A@C9W;6;]+W>[]V+ZO MAKG%\!#@5]%2A'_4>2Q'Z!/Q"8!-MNYU5E%TT_DY^+0UD4J!V AU$ +N9& M'MEP_NJ!F,;%/GR[GQTQ#*53'*

M?"OLV,=&D22T:%K)U,5/\/#R@H:>@N93'XYR6=6\.GYR:"<7U_[%GE]E7F+[_MX]D>?MX]<@+*)3[3=HP-*A.ONG["#*']S*_PHKV+VG-Q3HFX6T2S2U!/"K"+8*

*MDWK[JNKLN[L?'17:R120%CF+AVJ%G)(,$>]5)#;Y='?W8QM@W3)M6%>RP{961 MY=*$3F[=3^9N:/J/>%WX_/[7M%,4LXY>&=AO1_//?#G,Y$&ZTGZ,G60R PH[M*B<3H,DX*

*$JK1DWS\|%)$4&5."E>91%N?1/R?&XGMBVPO\!MSIZQZ+3[,(4[M.1:SJL2I5HGWTL?@3#,WWUC#*Z/;MA!$[TTHK*3F&5035C'SV_.&W@<8Y=]$B SM!*

{D%$*@M!K"/6%BPN0>Y.3{04R:@*HON2[\M /3HT@OU$; 9>$LU%V] T=P M!"=;65.!QX%XSV=V4!Q4HR^3P_GE;5!<8K.V$%,Y,+KR-%D:.?1#\;.K5MA<

M)L_FMUU[P]7KF]^8M979S5>L=7YG.6RY(:$.T;G^M:ATW:)YRX/5[1]H((/B M,7V+N(3 V_(6%=?DQW]"Q;.XQ9OH#2K"[S-Y?X4)EJM+?WI].=/I3F[HZK;^ MK11]M%LM?C3+

*[4'N9R*1YI994,DU N\;70.+W M.5T.8UV?[]#>6#5H4DUO$6&^\V["#S9%52SC2%Y<;^3TEM9GXGB=)G4*&<)>N9& M'MEP_NJ!F,;%/GR[GQTQ#*53'*

M?"OLV,=&D22T:%K)U,5/\/#R@H:>@N93'XYR6=6\.GYR:"<7U_[%GE]E7F+[_MX]D>?MX]<@+*)3[3=HP-*A.ONG[

*{5X6_+!T7K..9{ZWE_,HY{R333/?%-FR+U1+6]E\\NXFEY3&-TMVCY M?VS,*MW\({4+AE5R7O?_/!&8&8;!R2;*A_^2IFM,7Z<@U|\]U>_[JY2WU$X]:WONUV\]W]#@ MG7#A;N)>OK5}\M/6J#}-MX<6;\HDI-;_'&8?&K/E[.R\Q1=S_C7O>7[,+_,E M'=#\O#'0GO/;^>)<9HO29MC.EG'ILHOD8A8N /XF.*VYQ),O5C=/?YVDT[!@H'@7? BDP.\OE^NV*.WE]JO{U_*XYOU3 MT,_J:7D/>3HO2YAXRC=^\7;V+$\7[T[#AZ?MU6?O0F[4IH)^$[=/+F[]*> 5C M/_F_UPLSJ?UP_4W+[^%,LO/WITMEB0+3^?E-#2R4,:0]TUT_M"G^>`0 M-0^ZXAMZV6QO{S!.+%N/JSK=R;CTF$JYN?SDZG,[Z+<+J;.1^`B .S9YR_P8[W\ M)7*A+/S>,H;)L3\/T\.`Q;/? ->F62EQ\|O4J+-A%*3,?:JHZ[:/L)F;\M MT"9%?)A2?IIE&>$9_/2?)S^=+#),?7SY_!'L'3%/]+P/SY%X7_\AKC_ M.'M7YN%\-Q[8\Y.7W[]X^>K%]Q/^Z=7)7W_|_KO7_(]7K_FOGUX\Q#:,_?*,O M7[^:G/PP.?GYQ=^^>_TCW^OD#Q\-VQ^WN-;/[@0M?;V;BAF6@'H%;>U>&M+Q MK;>W QO#LXNK>4W/+K]*"O%$_/[Z@M1FJ+Q;E*>+PBX%J^KU,UA&+Y>?_;LO M4\;_3A?393#PX>GU]3?E@I=?*

9_C;W:_1>$K.2]A^$_W7":?Z#4NNO\E_HDD MM95OZA)UB38MT5?:_^BKA5@W =E=SWSNDXJC_[+_B8QW@_G,V7 ?3K-_-2)C_Q[]\L)ARCE-P5X^B%[#-)(C MJ.M-*)O@FY..Y:L%DCN56AV$%#SV8BF];3E+K58N_#8^O;IVZ=OG\?6]&{! M.P0} (4AZ OGMQRQFE'GC%VS7X#0M\C7]LCNN^1OD?Z'NEVI. ^1OD>Z'7F\ M*.\;;6TCAGD'T-;VM_)KF5U\<]#.0X+ #9>?/0HR[49GP6-$^\<@[JY4BG8M M[EK#!R&U\-J!#Q0!C4[/SBH,0?IHJ D5Z;P9>^$$C%##B(4 M41<(I2#$((TJE2[)O#KK8[GM?IB?

O7W.'J9NXC^FVV^>7RQ8\#)_\3Z=7K2^ MO>\6B\+_RP^L=2S5NT<&,"4&)#4X5!W!.H+MXE)V!!L)P93SOBCT$(LH@%9I(,LN MF"FZ9L,0%5=`YV+4,M? CI=PHHWZ8,#+T@% [T@JD$)C M6\'N94,Y5^GJ?*!$E^-:E$]0?)4$!F&R9G.DG42.\PM! <%%"3MZ9H#,9 M7$EN"FF,=L6"EH8-4S$.?-3LG5X.C!T8UQ#-2^4AAV&/,/NVLOCC HK#.G;3Ij*@1]0#\ <.CAT<.SBN"XX2BW-59:A%,"0&AKS@ M2$/-A8R-1$&NI#,R9>5=K5"]YFM,8D"-68 G46)AX$S.=*_Q8/=*!\8.C(-4=QUZLND<(W7.^!W"TT@\2/S4P'HN63B#$XE4;PF8A"LQ0 MDIHY6(N:P.E!4Z..K9PD^&@VH1850VN&CMJT0-1'&QS8PO1BU.]=]*0\8MZ*U MRJ"*8).L@-(GH,0(0E1,[!Q7K"\]f<#5E_*H@*N@+C47"3E8=IZ2UM!.9?B? M,J!@B(^? E<-F/)9 THH1P'EX*!*^0*.B7KBDZ.'CU0E,C A8-SO>)T-E:W$7MVOQH2[KD8G;M?@@E_6@Q-UX'<,Z90N[MTZ*V_.+;[, _/UN<3\Y]UGK17:JR&X<0BY35!6R'0G:TN>@@%$!?,/BB>)>F< M,%@I7@>$E"V?5!6#4+++7C[7$_(=^3KRK9W45Q@I%@_&U0"89(1 M#&HRN91%DB::E=/(=:HH1D,^.1@O!KO);'U'OHY\'?D.'?ERT VOD&&+L0N5 ME$#:9- A%X]:61?K&'48HR&?

&;Q4@]4,++#HR->1KR/?H2-?(!T\6@V.?3S M$A%((H$50I*P'-C.%2*"=0HY1D,^'%"X0;G>++8#O&%'DF3]R_QLL9B\FY_Q MKWN&M1?^'7\A7Q+:.]9$;

(2W@*8]B.PE@T]%^FDD*.D1U=;,KF?EOSON(=,' M#A[-8(Z>0,+[P,>^E >*1QA+<)XLR.P*HU=>80 K-SJ$A)/N85/%%Q9U9[ZGC4\>BHE,)\4BX)(3[?

@DLZ[C&8H\9@1-42E;I:AJE:)EC4SB M2'@D<3!.#%)N,)P^9'NW'0P2WF@%38&R*A(Q2)!C#7 A2]X@A,H!->)[_\ M& F^L0!)#,*YP8ACC]C6+Y#<_VZL,7-

W)^_*)QO/9[],ROMWC=Y_\;1W;O4Z MZR[N@;@P78N[N%V+#W59CTS]E >*3]X:W,U$+ -_]X!(3H? M0E%2#%KXC5$>HHU[* T6H&J*5V1MPQ1A 0@41

M30".U(/(7)H<25A@XUB.7W5B,YPP-?!-'CE!]6-564H6ORNGI=/;+,$G\5Q-T MF3/D[_^OT@H?>L:P6Y,CMB:D@C 6(P03)2\![OT!2.'""{84.1'18Z7!=)V-X MM0O9F/QTO?-&

<791R$%2GZ30G=WC7LH#A2=GO8XY53!1M]%5E2 H&T!1+HQ, M(0BYXNRNDR[<##QQ'YN/[8/=T.3\>^E <*3\8++PLF,%1E8\-TX*M%*.@9 MF+)+HGE"#\\6;@:>:#

H!FDW2(UYR#K=X>E@EO) X4D;F0VC$"!F!>@, 05- M#%35BEJ52'Z45.%FX,D.EOQ@W+%W@_>2PJWD"]?29F5 ^E1T,F=\U?9RWWJA? M.VU\)]+K1'H/)-

+3Z*,@#4)9=I2MD$!6L55QOBJT/IND1*%&NR3W$"[^%W+.MCW.P;O0@-EGZMVC[EC8L? 6+(Q1"6U$!\49$-$+ V1D N.=#@G)*&]& M(67:-!:[

44KT^Y#-3H6=BSL6+A^AD)'8R,J*-E40&,+^(SL'!*C&ON$T<85 M+%R+$&IS6$B#0P&T[@2B/',R@@.F$A>$L4#3FK M1B&;WR 6N@&5&TAN,&5[,%AXS#,^-

XRN/0G;#4PW,"L&QGLL%3&#ETH!%N? M^U LZ=03#985YSM=9*P'TGEKBS*XF$FQ0L]2-%-2G>O,_IU]%M_BEWV1B@5 M@'SU@"%JB"$:6$[L*'58AVF,M.NHZ&<&

{UM'I^OHU]&OHU]'O{4+Z4M(V@<-.ME#P!DC?@;,910M5?1:TE45I(+ZR1:1T4_)0:CY8"`YU8[_'7XZ_"WOO-72PS9

M>7;^6OTKXQK$A.P!%F.SH9AL67'^ULFMC@I_T@SDVG^]Y&B]=.KME;'[/P7@-M,>A9#R-/VGEXN[C([_AT+>[B=BT^U&4],G&

[%A_DLAZ4N,=SLYNPR6SV:+7MS1^[2/HD_[#];N%>53[*V&K;4 5 F0I$3 &$]_QWXS5T8M02CY%Q3[4VDD'; MP^+N[LC7D.\CWV:1+T4;R3B.,UWSW1-$&N4H#!B4*%:8T<96[

IY#.#MW+0 MM,%"CZ- OMW8+AT,.Q@^(AAZI"1\-5 HEN8&1O!59K!..:4R^9N/MJ,4>HX.A M\S3H3;(K[!

<8]MJ.7MO13V+Z24P.3SSN93TR<,L6'^2R'IFX78L/F3B=BT^R&4]*"&_%.#<-> 4E>)69Q/+B.8.PAN]XL- MCR3,N<\AW:X=5&Y!Y'[./TK1$PECE1% -0; Z"+$-

LHZA>1B%N1RGAEOMDZ9 M^S4J7!{S7S${O#R;G5V?_[\LYP^B.+2#4/>?$;N7FVNDDJ@Q0'?/_Y]UH(. ML7L"L59D23:UX32BM+K2 C$RQ'J5B-"5=,.\AG4JZC<-L5*J08N.L0_#V/MO MLXZQ'6,[QG[#C96%?5)+4)U7K?24@#Q6L"DF46KS8_,8M?N;QE@M:3#&=(SM M&-LQMF/L3F&LM56(JM@35189+\E"J*X_*>VKD%5+%\=H"=@XQ@HUB#4ZX_=R M=XW<,3

]64O/E_]6[W.?,\^>%-_I]W>ROB?Z-JP"1L:!%I A3DVK=A."% MEZ2,EV6E#W9\,'7ZOF3X5YF?M44F)=65@^HZZSSJ'9LZ M-EURH!L?1D-OE&>><+T+(M5A:,0D0E_3@#

<,,,"IA7OE[^_@U,'IZ->R@,% M)RJRY&"[0DF^L!-4/,0:*C#\4)+5QN!6>O;7(C#ICM..*73'IH-99R@%/IJA% M-(G1)>O8 C0&&Y^3 ZVDDSKSB\J-PB>R,E.PQV&+S-'Y?*:\H%=(X$*

/[XR0GS(4PAAIT^X1[NG.Z###8 M8?#P89"]N*Q\R)"U4("U<+A+J4(R&(U3U80OD2G1.AD*^CE;K MNA& 13DXL<%!@!U@.:[V@.T NR; ZH.(+C]O&AV@5(T31A-D3(R\KE(HHR2> M-

P>PZ}(5=(3M"-L1MB/LQFEADO8IU Z.<_Q?D6@$ *8C)3G&RQI36LD1K%UU MO!&$E=X.4G:$W2AOPJV+E'ET7/A?=.EJ/H M9-F.C:HH8_2&0-O4[$U,0"TG'6LUQA=CG%BAAUR/@?

=ZP.X/\[.WS_GSIK,+ M-E57S3)GL\6?EWO]\GVOVTY_\?Y\'A@#I[,P__#C>7F[8!O7[F1^=GJZM'*7 M3#VC3.PEDH/1]Z?EV>6]UN.$CI\=/S=ON-G[*P9,;K-

W@@6)'T(Z@'4$/#D%5K!+5.!= M]"A*J=&J<&+8$;0C:$?0@T-0HZ*K*2F(5B-@21(H5@VU M%C19U"J<'(<:=^<15*A!&=L1M)=9/VB&W'6Z^9H8MR>=^^%J/UQ]D)'R)$R6

M@OUZU 18G8*8@=@4JMACG=9)V!%/O5\;GZOCSSV56^JX><@I*.)#;H!%'9T4/0 MWN'8 ; #X'AY#NU-#B9#MC$!*AF =,B@C#!2ZG*=-7*8D&63]>TH HAWT)KWJ M#H = #L'CH

8F5_3WN$*AH EJP9S*P 7Z27TCE-?L1$[Z@ J$@,)(^OEZ,C M8$? CH"C(:#@]%-K3-DMT6RL1.VX;, 9E.AD9SM M4KS?.=<{U_^^+.>3T[-%K_?=F-E13U3;9?GI(IZ6QS0\=SOA^!\;LT

W/XB] MMT%;:B/FMH@L,Y!W!E!DA(A@X\^V%(<"D5CY'49#WX[?QSEN-!;,^#V&K2__MT+(J;6_I_GT'V@ZTC\(XI)27VFE@;]&TX,%#5.B!BA+&2)<8-\?(%\//M&H0

MR@]";BV#W*&V0VV'V@ZU:S?%I40>B7$R2\>P:7+C'@K-4Q44*$@E5VH5ULE4 MCP^U9O!*^Q8W."JJ0VV'V@ZU'6I'%@O+ODT"8:CU5;%7&RN0J@&$,U9Z@RGE M.$9*?!-0:\D-.&6'VH?6)-2>AWR3@MTU4;X,.?$-./.19++=9%=HK__8[];L[M2_Z(4/L8"WT,XN[YGNU:W,7M6GRHRWIDXG8M/LAE/2AQUR_V?]@8\]P^G/J8 MOJ?

D26#9PB]EPA%P+//)6>5]J/8M1_"\+-V':,=WMV<;XX#[,\G?WRM(E'--9YANY_,1U6GZN'D[S42X_ MY--/O7]N.Q$0W;8 ?PZ+.9IP7#/)T],+#H1Z)\+!EQ(\4@O<@580W,;W:.+*

M8DL&8T(JKJ$(,T@_J)X76(A0]"N/X=?[BN\OTQ8W[=,?=++*G+VHIJ!%33ZA1*M4 U11#*)GY%H#%^@Y)^?PE;*P(_4%;M M!F_$8&X<"W)TE1"]0[H;B&X@1C40MD2*.E8PT4K

T(@MJTA)LF,HI*I*X/I MUFET>`P#82A'YZP!)Z4%9/L'A,,"BJ:*8TMU[9-8-A!F4M8. ^L3*NXANDM(+]Z ;B(0:BR%)$8&|Z>U_81V8#05I*<,A[O"]JBBM,:.NNT9VP7-F^6-6?C

M9<((Q;@,*+4!7]"!#<&R #F&U3'8(\JZ$6/($80VG@W$30V!W4!T]$-1#<0 M#V*:HUA1A0+)B-HB" ,A9_>LK8^YE]U=6,TE>R"@3!DA%=% A4BP"C9&'H;

M>&U*X#C!!N%':.#9IH%0;C!+(^&Z@=@N!U4O@;N)@VKRKLPOJ]TFX?Q\/HT7 MYZ&IQ?G9QU*X\[/T7V_XL\K\FXQ51W(DU,^BN[C[!W5V+>[B=BT^U&4],G&[

M^A_DLAZ4N+VZK5>W[5HH%B?UN[=ES@O__+GI M:9@OEI>P=69-*,L\WV])/W578HU;D2DFU ED1 4L(<$+PD<*ZB)FDV/#*&6$EP(XY1O0[HBAZC4XJX8)D0]YPK&(LM?#=LH

M$R)X5ZMS7K,5+YN0_W$,U8W3![JAZH;J&ZIN[';,4'F).J{GJ#8Y-E0JL:%* M$L@6*ZQ(-SN)*^DZ)7Z[:J@*6JVCU1!=ZQ@V3G PE0,(150ID>V173%48\C_ M.(9*];:IAQFJZQ-

$_KM5Z2U_O,/M*_[GJ"=0=ZU$_.UNOO;UEV]MG_QT>LY? MFVY]**_?E$E(Z>PMW\L'UN?)}(R5=;*L7N0MQ6_[91Y.)^_"_+R1^9WSV_GB MW_;%MC/VV7+L:FC,?

Q>S<)&;OD_J=!9F:5R50\:-K+5T_F7\N3TO=/03^KI^4]Y.F\+I7[*3^SB[>S M9WFZ>'<.:/CQMKSY[%W(K+/KY)^8Z6PI_-6Q,&^9]IO_<[$XG]8/U]^XO!;* M++#][=[:8+C]\7D[#^?

37PEK_OCWU1ECX<0,\OZ.6RQW7D]NT0GVV57@QKOYI M*_?FXTG[UO(TW!Q?O;L\Q?XL5[^>KG0E\?MH;)L3\/I\:`MQ;/?

>FC2EQ\O4J+I%BN82?,;J:HZ(:)MW+T=8H1L\T>L%VO[IQ^3IEU"\ M@Y^\^2GDV'RX\OG7Z++-A[!TM_XB(7_^!0+_]'P=%[>\"NLC/X/5OLQ@-[M?O+R^Q:_`]-?_UTXLUW=--

W.C+U2[F)S P?7[T M\]]>_"^^Y1____<7DKR>O7DW^\-'_/":SXZ&FIM=SVFHQS??W@YL&,\NV+Y-WY?\[/^KI!//Q.^O+TC-'7VW*$\7A8T\;-_U4UBE M/Y>?_;LO:ZQ^G2ZF<7HZ/?

P]/KZ&XJG+K].NR?>?Y31+Z2\Q*2_W3+9?*) ML7*-R]:XA+_*;,FKMB>4?B*U.C2A#G*E-B745XHCZ:NUD2/V=1U47N\@9?M8 M)VWO7B?]E4)-VCE"\

LG\L/9?!G.OGXS+V7R$__^S6+R@MVY;U:WINISZ4K? ME?Y.2O^2_,N\W=L)>C6L@/'?8'C\URY>-)2YM G M%#XV^NR1*O6-TS?.QXVC^\;9YL;9"R>E[YMN!%%; IV8PZIN!6 M_-

AUB"+&\UDS>*4'B!1:MH-L!]D.LKL+LJfZ5WR0$?^_#I-9N:0U",.?^'?G>%9I^2<;SB=BT^R&4],G&[%A_DLAZ9N%V+#W9)#TK<_M7G6S5D#RPJF<!)LDB[F\S)+'R;G\S!:-

,#JCNQ#;J1D2[*TGFA;-_9_!&W M-J-]-Q!D]%R6=5@B.@-%H@(,&,$+[R'+XF)"TB*NG,JN4_BRS 8_S09\%MJ MZVIC/K,:EZ_;MKR\R>]F^?5OF_2[CWOT93D_J;_#^\!DQ.Y^]FOLH

UN+A-V MR+NA_JO!+.7>_]N6DOY69"^CA^!5!B3DGXS+(-,%)R4A#A&^#1W8#F8!]Q[8ME317$.ORGIO51'$&A5$R6B)SD:.O(TB MCS+L8H==0[,&B^*@

/-1*D6..C'[]QG+?,IWF"\>_A.GL]CQDPOML\>9L?@X, M0&\GT]FOI2=H#[$277A1 `6R$ 41&!.3R#KK*E;F M_*Z3Y/UM(_^%]W$S3R>S'W_;MP]QS=%O,/&PHS6+W77O*.A1<&?=?

YW1:(B%M):LV/=VR"X=%@+#L_'L?&2!7AM*NDQ%<&*K>S0H]W;H,'83L*KSWWVW&VX^P& M>A!EBD59#<%][C9=R>#9FP!;,"D1>1-'Z4'G=OLZ-@\('14) 2 M Y\5$1P;SIYA*!"K-

E B^D+.D]&5>H%UDL,;1$&R&\SL'@P*]FKP.-5(;;$ZH*39XE1CV .WBBV.]2[7B"&M6)RQ2WG'*LSE4*&;GNZ M=SCL<+@KZ5Z#.@7K"5)KE\"@-7A-A*]ICY7041BTP7 8Y?

S'B/,]K1OQ]N. MMQO QV@IJ1C9E501D'2 2,1 %26ZJJ74FR\;']<(6 W"FJ/#Q>Y^=CCL<+BS M[F=D0'64"(I*%;!PB.]U*> 4)5')26-6&G7'+C8>MW18#HZ.+\'_\NQ M_/$.MZ_XGVL*

<(_9ZY]_S>_]*X(_%@"WF'C?G$W7_OZR[>V3WXZ/>>O3;<^ M@=-=ORB2D5E(>9A^FLU\FL]-S_]@PYU\S!O#;?IF'T\F[,+\<.]-OYXLS!/2 MF--GR]A<,[_N)B%BSQM/I7!+,S2E"\];G/-

+RYZ*)SOPC!_Z5.^E1'GZZR2= MA@6#U+OP2X'962[7U_!]M9>O:NM?,.4'^OXIZ&^UM+R'/V7)30!9:6X>#M[MEJ>+=Z?AP]/VZK-

W6(=>IT_Z*:7=W9UJB48=_@WC;EH6C]_OB%/?WGB/NQ%N6S+]&=CQ8ESIV5;N MS<>#PJN;G\Y.IS. ^BW/>!$_#Q?G9L\]?X,=Z^>OE0E^>%H;*LCT-I_\'Q,/ M?O>GCRIQ]+#E/*?

EZL6ST!S M&,_@I_\]^>EDF/SX\OD:\/G@1[#T #^_"J\ 3^0OD_TILP^Z4L_C&=\2_/TG^] M87%WXX$]/WGY_8N7KUY\I3%__?W'U_

MY^0/'TWK'[>H!H^ZV9MP2X_S^INO0*Y]=<,\OM/V*K!9/+M@ZS9]7_*SRT^6 M0CP1O[_VQGDU3\.[17FZ*.S#L 9?E7:!\4@[RZW0QC=/3Z?F'I]?OO]G.8_GA M&I\HJ7__*?

Q>27&)OW^ZY3KW!*6__V7VB5_G,GKB-=W_,O^$Y%]76;?&968] MV=9\DG>ZR:\4"]&VAE9^-75%>]Y*Y^CA2B;XQ4NE>I8[7=[W!!S.>^?_*1)UE M%/7ZS;RT&"M/7K((.:

F)W_!E,7GU!C9/7I5W;&ICF4^T5"9*%%R^D7_0IZQO M&TMM5U=A%3X'F'>IF>#K5NQO#*^*S_SL!=M&+IH\OOA&BJU?7:H_3^C9/.3E,,P=V8\[5VZ-

GD=+%VXO397;IL_SNT3^.CC???EROV?IHL M+N8?)]\ZXGSU.9V=7X-J^M@O,P75R%D=Q>VZBX<<99]]2;,RS<[!8[UZ7SW MEC?5>7\ZM[B7X5TI]NJ/Y^;\^,5S=-?[T+S=*P/Z?

M2IVG:MUB'YPI/(S^=_M%_]I,3W_,(H[>4WE-V+2]/8&RTUF3!\0;/7GV?/_3Q6]Z2MBX8#R5& 9C:B#TC N0DO:VN:NU7N#*0HHJ>*!!5'K!Q*WN*_M%D@G;

[/B*ZKXLA+M$B5/+LX7YV'6#ND_JS]:+%_]M 3MQY<_?*O;P@U2FT'8 M-2@^>?[?)ZWZM28[D/OU7ZN4UM*K(6YO.@,1_(@24 P4@!5[GG64<11M^B0F

MO\30!]\#4[>GV6E*]&&E$A4AFQ7$6Q0!%AEFV:1*_A;K"V.]'- M6G1C@?Z&U4B[PB,*1PCH+&:H?+:254)%*21KB76X,K4,'665:X%L)9NU;%B# M"B.2C1B43:@]K32HWEN-

[E:E[^W@M1A(W*Y3&UFK-3,]NZ&QFU8I:.0TA5WN M6!EEJ'(P1#DH+U@!9'5K*B4995RV7N052I60U:N& -?DW14PH7DS*]1VX#?MW9%I9Y I(Z'B* V\9^5!;P/XE

28:%T)P4@;5R9_K;5&FT$F.Z"]?=Q7!Z6# M3)97B\6.FS-^2*B!Q\]5!TX=!%\8;0F@: LO\4/[:2^NC+PZ^N_03SY_51!%@_Y M B5#@(@Y*4E>,NRM&\

<4%RS8L8>&8,%@%>PU+W=,:^Y*.LR(T1SX(,MX#6RJX.A85XVH5UQX&LJ[4HRX)0R@(0* MA,I7NQ #:Y@7Q>R42N!@/ U6WW_"P\,48ZQ3RK$Y)I95A&K->K^"W^8 MQB EYX.*

GQNIUA8V!A4LF!5-$DGM@YAQ7%4&+*/'L%A9K-A#0)%X3FT)FV3 MB-:GLGO&P+F[G=KO0AG,P<;3CQ >&YL*1Y05%*\28(T(WFL"(UV)V?GD4UW1 M\,:&E%6 TDA!4<0,P:* D$-

$X5")I%>(CQ(R$G]CS"?A]GYR?QO367NG@7_ M9L6 PL'IVU-"&UG$RRKY=E&]6#8T_O-2NL5>Y4*<2A((46OI0)':7M2RM9BFT@6>B5-I&+L2+@>3M^>INSKOP

MW9>YSO9GM$?R/M>\Y>)TD)(1H&KQ4HK>3O+#02V\,_+#TMPO$+^Q3=27_<$ M &?U((6VQ.X3]\W\.Q*-'\,`.^%=+'%; ^8[_LV097'>0A<.6MB'JY!4Z,_N'Q? M6[(U^Z^.8C!L\?

SN:U3,\OO@S-UCF4U$(,!K<=H.VU MQ-S_M+\+#'IADFAC13UVX-"O]!?KP="U<,) MOMV!\!WKOG8,77V1-3#"D12.6X5_"HZ=9:M4R$8;55;2*>MXU+N!=3U#09[N MQ"SGDU-

>J4W1"1\USO3'TQ)/?SP[_WAZ;=&M3H1),DH9#2C3VF=]BA"+M>"$_M4KZBM3X?"VT\H*%99D(.A+!@*Bj;@:U&0R"E5E->&5CBT MUXFG#AL*^RG' ^=P_!3FZ9+\;3*M):!&D

M9\\WQ@JH(D*.OH*6DFKQ&9-9&>]REC:./(:#']=[[:/.:,:?8LO8K@253(26FM>;ER6ND\=EXF61P#4\2,1Q8K M4"4#8QO- M&)O?X[*

F&4",:06*? O]&HM'ZM20LGO3,N194("N^V,9TJ@8L^+=@^[5V2Y[%3,X2FRWCAKU01R'I:R/X=E;H6OU M&AC>"%!@:B^,<71!V!2LQf R>RB%P(C(^FVR:

<5H0D$,.K/"2IMB];LW+,7 M WD_N#O.(N@U%IV"97>=<#!=LXWE'TFH 9H;[V$;)94VZID#5Q)7RIB+0VTRI MS67BH"FQVQN=+1P%5>,L&A^)=H^"Q6H[D#BLH&G3=;

[1HPA)09#86\)34PVK MP"K% 7 UFG E6S>B9!'CK-++) M=:(4S'.U.'I"\=A\[^(?E_![:>.]*U6UN3)2!]T_GEUX//T*:Z]ZX- L!42P$DLC>*X0=W@,_I_$@=R-9.F*:/+)42+ZX21LP1:1) -(0%

M#)FJLRDRYQ4B%E%$C<(W5B],+9B*[6P3L6J!6D;O+EE_0RZ%7&-V^H!A5-(_>6K$KD^1I6)<41N:1B M6#DWS:*E:,,"M3WC?%5ZC*!&$EFG=89 -0-BK&U9ZOFIV1LI"3<"AV+-

U)F MEQ*8$MOQE5/@EYZ5:T8QV.QR%BOGDH$D M16D]9&SQ=$0); \]>(4<4F)\C:L96"$U(('9G3@5S4C*&&(%5I25YV5\-VG'L M4YT5F1T!%P54E$4U@3V?P_ A#=S:\|+>_V(.L!

MNO!=-^"[\(0G?]R8ZI6G27;tQ_%'Y'3E2DL(%")$*C'HV!#@{J`!/.7"@C:MM ML..YLNMSMGV[!D+A(,D<5,3TN2)\|2(4JH+!>W@SS;G,GOIP#*<<\VI@U9"D"

MARBD@)SV8&5.P6F13#4;W&B?_]4QIPO?A=_D!E_3'B)L50]:#FL:CDW!3[4 M"!ZSR${7Y, MEQ7S'6NZ\%WX;F4^/2<,)] G<-X(P&0<1%T1B)+R7@67P\IID%?L,4MR8&UP M'

=9WTZ# @ACM%2NMDD*XU(M?+THR=B!T':VTK[?N_=[+/Z;P DYD6B] AG; M;$4-)).\0L;KH+SP>26!LXY+O2-@UV/BG?)EYX"F/Y[^>/KCV?G'TRN:,;]H MHA0Q>0Z4DLN #G;

[TM%01,B5HZGD5FN98Y:1VF"'8]IOK8H2@I(&R*2FA[MLP7*%V_MP%[/7A0HJ9W>'\\N/)X.A+<"H4'O<_4)(K9V:;D0?$8"$TUP,;<3 M[I4:\W7"]4,&PG[&\4"ZEU?

EW7EY&\O\@9POGR.&>]{:9.2SBWA:=@PS-OW>^U(G7F>MZK,28/19;@?)%6BY6.9UUL5I%=(N^) (/BGT24_|%'"%8P> M:UDE8;AG=^HW3Q;%H+ =+]J],L'IHQ%

[W1KH<\K*ZP)L$ 2@T+7Q(F;(,1MI M4B;7V!!"T+?1F6/&]HGJBK8510NR>&]9O?RRXD:.FWW'KP*JN88E5YU5]!C MR#X9*)YU#%/(X$M5T-IO3*@VW5)0.2]FC#.XH,_]ME?

JEM#XT#KSHPP&L$@'-M9(. FER0JE:OTLK)*AF+DE\';UIJ01G&PAH3V%R+1K;%6FX:U[P9G!ZK?^X8 M5>U14E(B)2(;049? =ML&T^L0*9!S#BU62.R%0$Z(24EO+)E

MA;!-1Z[Y_D:H)F#*#10%4? +IT%!V@AUXW'2L,!J/S?VHPI%*7%!%6XV-%) = M_AHL!)D$KZC264A98EX-$M91M&/GNCE&A7X,6CGG;[79LT9R<(&R\)3!59R ;_MIZBZ&-

PJ=Q.IE$16@=\D&6Q)[_#9)#:89)31466Y8;I4/RBO!GU"]_"FU.9A MUYS<\WQ#6K'/I6I=VBYME[9+VZ7MTNZUM%/T.]J$C-\+L(LP_3.3R %;W"O3; MD\(YH"PH09@B

5V4$*>)",'KK(/PT<65VC%AI&GC3XT-&E H ^2M!^F#XJLD MA[BK9Q"C4_^ZP1DQ6'U81 %[`4064B486UK4Y8X8?(5H8@%=;31)-=H)-XHR MC1I$.M=5:&=4*)D8J@B-

)E06P#:Q)4:56EM,.6/#."0C6RE@H M*^(5(N.UU.C8CR /35D?PQE33ALK*IC4.C-\0K:(M0U#\X7#09AOK$2&'$E6 MB6I6TX8VM(/()HM0999!96B")5QH?

KZC=45!L_:+LA=JA#.FGLXS9VE\=0PA4? MM06ML>T@7RsBXX"$\LCYETNC^?Q\PSG+GFU.;!QT0<"0(_C*3F_&6%T4;NA; M"O VR')_!Y]DH*V/3#W(%L4N?!>^"]^%[\+OO_[?

X(\FG.UIC-ZMU#IY_E9 M*B4O)G5^]G:R"*>E.:,I,X=U-GEW$4^GB5^H7E PV16SMO[KG_!%RS.%^TW MCQ%Z:91*2"?!6^W;\-\(T64#CHP-ID:E+3[$$WS[X>SIR96D5UG0'_A1O>(G

M=5)?77ES#PC K!IX-@\]Z;3IY&*V/E4.LI4)!"@21\W"5- R8LW>&Y-7NKSN MN1$7V^*WL;Z,X2P@=@=G/R_UPK1-+A_]3!7FXRR_U(*T?A%NLL6J;/EK549((

M%3!3*]=6'H+S"8)56@NC-:%^9,U8; M #ZUGY*/4:=HLUY)(@>DO.2;TM'Y-K/90+3"@2$L2#%636*7E$(/5N+@W+85 M8P_]QBY\%[X+?ZS&P&

(V3K()[JP"?"R0&A]M*YFH]F++,M:O"\|!)*%_"-9R]XTQ*A[A2S8,&)2;#U__7-^>9 VAM#1172:=44S3QRV.1YZ=A ML3BI_Q'F\S /[YG_K:G,>.WB=B

M!]H\NCXPWLHR7'0OMHLHJ7_+DGY?R+78L MV2%,RJI-F]%MD;K;(#W)^"Q&A\]2ZL.K4BN50;"[M;,@7B"[>-2,+++ &-M$GSX:0\]#&#/WWQ*XZAM]E$+O]<.2S84LB;"E

I'H@EYTS(>MQ(H!GEODI(K MNVHC]VGOG>@[<)W M*W.G41B938-K9\.HFY7A.&,Y/P5-E8*"M7EU$+(6')60+6!%TOQ.$;[SN%,?SS]\?3'L_,/9T\(=1Z%_*G(Z)F$$ERF"0B

M0HP'V\%,LK)8AV9UYKM&+RRU_+&.Z9:P)1C I^DMU;43';%W7#\4<=JL(B# M^LKTP(TL4[ZOMM[O3^>#H5KUO0'WU(^`!IUH_^M HB\@%)(*F6,Y\|>(XXZ

M;"CLIQP/G#GP4YBG-Q/=1PY\LSLC),S":ZB\58*D2 LA[IG69QN9("T4DXB MB_+1V Q95@68^^_7JFP;!%^\+E:D^. 9C7>@&FL]-VHP6AQ4B_E>,TOJBI9$ M#0K*#N]*SN)8VCQ""

_%95-4CCZ9M.%)[(+Q MR=:1=%B4%WNM2D7)2")FD/HS'L7&F)(T>Z-.4E(N- :>E0$6F&4HWI"PDM5/ M4-8?/@2J3Y]UGNCE&@I*%O&IE^^G5A*XTPM MK&YQJ?

F]SQTX;&0*-9@H10;1"R.38.-&65J^:"$=*##8H]JT(!$L- B (C9"/X(9TS(M+E;<^%ASJ^?@_=UHS7>^PF(_,&K6'T/PD?WD$12<2K;1%@N23&*;GBIXCXVV M1&0B-

,X(@%8PF"/U"1CI_VP'Y*T+1\+G_GQ_+O MET_EI'Y\|O_W]D0>SO!I!{?MD567[#:.7=SOYY_3\S9MRFMMM3LK;=Z=G'TJ9 MG(?W14^=^_K=2I$}+Z@>4[*+=TP\H19=1"%

U%)UYH2A+8*53\$-Z_MTK$;O=)\-)*R+#N)[fI;\VC;+L 7\|O)<(5! = OJC5@,QL$;%@"R'1 $;D M&&UNWDMVO6 M+#B/_^?;]J%VOBNK\ZAM]E+O}<.2S84LB;"E

I'H@EYTS(>MQ(H!GEODI(K MNVHC]VGOG>@[<)W M*W.G41B938-K9\.HFY7A.&,Y/P5-E8*"M7EU$+(6')60+6!%TOQ.$;[SN%,?SS]\?3'L_,/9T\(=1Z%_*G(Z)F$$ERF"0B

M0HP'V\%,LK)8AV9UYKM&+RRU_+&.Z9:P)1C I^DMU;43';%W7#\4<=JL(B# M^LKTP(TL4[ZOMM[O3^>#H5KUO0'WU(^`!IUH_^M HB\@%)(*F6,Y\|>(XXZ

M;"CLIQP/G#GP4YBG-Q/=1PY\LSLC),S":ZB\58*D2 LA[IG69QN9("T4DXB MB_+1V Q95@68^^_7JFP;!%^\+E:D^. 9C7>@&FL]-VHP6AQ4B_E>,TOJBI9$ M#0K*#N]*SN)8VCQ""

_%95-4CCZ9M.%)[(+Q MR=:1=%B4%WNM2D7)2")FD/HS'L7&F)(T>Z-.4E(N- :>E0$6F&4HWI"PDM5/ M4-8?/@2J3Y]UGNCE&@I*%O&IE^^G5A*XTPM MK&YQJ?

F]SQTX;&0*-9@H10;1"R.38.-&65J^:"$=*##8H]JT(!$L- B (C9"/X(9TS(M+E;<^%ASJ^?@_=UHS7>^PF(_,&K6'T/PD?WD$12<2K;1%@N23&*;GBIXCXVV M1&0B-

,X(@%8PF"/U"1CI_VP'Y*T+1\+G_GQ_+O MET_EI'Y\|O_W]D0>SO!I!{?MD567[#:.7=SOYY_3\S9MRFMMM3LK;=Z=G'TJ9 MG(?W14^=^_K=2I$}+Z@>4[*+=TP\H19=1"%

U%)UYH2A+8*53\$-Z_MTK$;O=)\-)*R+#N)[fI;\VC;+L 7\|O)<(5! = OJC5@,QL$;%@"R'1 $;D M&&UNWDMVO6 M+#B/_^?;]J%VOBNK\ZAM]E+O}<.2S84LB;"E

I'H@EYTS(>MQ(H!GEODI(K MNVHC]VGOG>@[<)W M*W.G41B938-K9\.HFY7A.&,Y/P5-E8*"M7EU$+(6')60+6!%TOQ.$;[SN%,?SS]\?3'L_,/9T\(=1Z%_*G(Z)F$$ERF"0B

M0HP'V\%,LK)8AV9UYKM&+RRU_+&.Z9:P)1C I^DMU;43';%W7#\4<=JL(B# M^LKTP(TL4[ZOMM[O3^>#H5KUO0'WU(^`!IUH_^M HB\@%)(*F6,Y\|>(XXZ

M;"CLIQP/G#GP4YBG-Q/=1PY\LSLC),S":ZB\58*D2 LA[IG69QN9("T4DXB MB_+1V Q95@68^^_7JFP;!%^\+E:D^. 9C7>@&FL]-VHP6AQ4B_E>,TOJBI9$ M#0K*#N]*SN)8VCQ""

_%95-4CCZ9M.%)[(+Q MR=:1=%B4%WNM2D7)2")FD/HS'L7&F)(T>Z-.4E(N- :>E0$6F&4HWI"PDM5/ M4-8?/@2J3Y]UGNCE&@I*%O&IE^^G5A*XTPM MK&YQJ?

F]SQTX;&0*-9@H10;1"R.38.-&65J^:"$=*##8H]JT(!$L- B (C9"/X(9TS(M+E;<^%ASJ^?@_=UHS7>^PF(_,

{!8%LM/^\C7URCZ47R4"R-MZ_6N|0F^GWP_^>=9$9YP572%(I0'VG'&D%ZCLSA@61E!%ZXU#Y-NK|3D!= M?X30%YG=.9CIEZ=?GGYY=GYY>A?@13J$-X2%Z##"6&G$F1;*

*(60*F#XA/KCDF MSFUD^DMG% 55 45#X1ZC<*E)BZ(TN;!;3"EN-/[.?F5%,L"$##XBXO%#;+AW2 M]+S>+\|\N+$\/A9="(4_>6<,<4BX;1)9:Y P5*& #Z!9HX&FC:.5MS*FG#87] M&*

<<=B\S^]WP<*X,[&K/?85<3DN81,!UM.)1;&AC K*1.:!*@2$>X1XF,-QM(HJ, M&:5U%%YL-'_9+BDQ,Z\!T>L=JH\"&I&,TGODC>,(!QFS>XW\KZ'$K-TP#D92-V?F-T9O=N+!'0$*

M6D_@N?]!UU@*9(!)RQ&@K(C8^;)PZ$DF4*Y&%AEC$(\TUGEA"2@Z#%$P@=@*_'#=K M//4E9I\R.F$@ A)\0%/GGA9OGB!W'-=+.8<&Q)MYN.)YO149]B=FG1:R/81Q2 M'I0R-&OS(!%-

!D"N^4=)&^+S=YQN5!E+!+X,RB&LG,K!&4199'0,R0G,3B#%8 M,,24;5<9TP--\0"SZ^EC.O]?L1\E9C_4$Q]C:*143TZJ0WIBKAKKUPK/CJOI MW(V&'KY),>?I5LORLLM/_*29-?F31S$^'

Z!8X54E&!(& H:8& 18X+Q8+ Y>L8DZ#2,!+8:L79HVZFKV"B;V&M/L)2';6/ MG5B_@PG"0&=+L7 M?'&VU:LEA\48A,$@/VX%&U>TT6+EK*5=3(4IM= M$((C1W,

[MT!3L"0E+C8ZCTP6932!G=!"\$?NGK-7I.$P%)0&S$H-1ZV-SE, M##,&A41 0"AL8MILHD4,TY'!1<1[Q!ES<(_'Rs&+0UE(E4F!F]2R1!!X;(,;ZB M-ET?

A]U/OH]\/_EG+@PT$T9[3I&2"K2"9 BRW@IDC>0,S%\GPT:UT@&B:IE I M@$X1\2)4KE BD<.$X]2<$9C%D3T&XZ?5R/; M-$?I'[:N[7AV5/^&:>;ZKN_O9]F8[G"#QP?UG9;;7_F6Q-0?

@S5UW:6S<5. MC\?R>0ABL/.6(.|R)P%)>*Z%(.)!4T0K*F"!J \U2%-9Y)<':X?F4W\$!- JD ME-7*V92"B@_A\R!$#;1^Z$"09RVYG_7D|UIM,90[!6)$ -[Y$,D"TSH/C"Z) MS$%,U]2-N,&[V[?

ZOBVP%^'\/.2,US2^[M&ZT[A?X[?]*[HQD:M^\>VO/C MI?RHHB;4! R&$\,YVMXC8X'5>+"!"^>3CIM9'#X+Z7Y(V0 MVG$L<]1]"#@A[@)%1@> 7FH=#6!>^[@1(+9%RGB87I(]05R?

(*@@QI24!(;.MH,+GY]&)63!;),B6LGPAH?F)H;;+A $ZYTXO1K?3IZ??"%+I$"R6"M @-^MZ%P@KG,(*K&.,+PQ8D1M5GTI*8&W$Y(@7OJM*GVO>=*WN\[*VAE$>FG@)

M8&EHKFO"(I+<4$1Q5$P&2A@VIZUU;I!Y%6-XP$Q?9+>'@'!R_>1[\+\L_@GG M\);D29(TNX0X(QH7B*/-J-NEZ1.U)2(27+)T]$ &A; M'%'TW&NBK(EVRS7RKU=S@*N!YK(O.K

KVI$E3$K0:A!3"FB+19I+=P6$0[#> M)(6-VLB;I;EPD_4)>1$,W$,-TCRD$C?,4B2@4\]D'H*TT_ 8#_7>L)RL0U=O" MO;3JI=5C2]O C&8*1$T2EB">V]I8

K\]V%/W=$/(^=VXB&N8V!];RD57],TG>. MV3FPI)>G7YY^>79^>7I=Y5)=Q<=-7 , ,61YS^C=GR$@5D$XT2,PPIGBC%LAM MK)HTTLI=<'K'\/13>TA&4I-*)*)3RX1C'5"

(KK4;&FB0E M(02[S3(!MS#;GC84]D=M=^P<\S%.9_'$Q?].[6/6,8,>T P;83)WH[AC]"/ M?.T4-9'.7 D|'QYP99$.EB+&E?:.2Z_"AH/7!2-#[OP@ \M-0;2$>S1'5C,

M"6\Y<_RNI:Z_6[5&#@!.4:X3C(+3 MVFDG!=L,M[@5O6VY"8T4/:'M%Z%)RXA+%NPPP#0NNIZLV,B" M3H:SJ A&CAFXAP6%C#($&^9T @6 X'E@.B>W/:KV+ ^2PJ2@.%).

M,.0IJ+T@6 52FGH7N&5V, 018QT)OX0APG.R1^Y;H@U7*$8:A%4\2%SVV+<<+HVW1^$3 3,=" ML2#3N7$6.9U;6 A-=-1>X?1@???X@\'T5+U/!HD

T6RDE,C:G%CA0>/3 M(@$F!JZ< Y3U?(/L$C6,1*/A'HP15W"YX9Z &-=:BL!M)!L^UZT;)-LJIKP_ME+#?^>$8I"%SA$THTX-S76"!MB4:.FY MT>^|[_+9G4'DK=&KC.:JU[>7YB>_&;

[@M?[2!?AT'"O0U28G,);37"1L/)G! MHT"|]F!P0[CLWQR<6]DP_%+Y7$OZ?_\PM9(C&D]"7 P&%B1_W:W'O|%P'.*W%XB]3*/X M#85A'0NRO("5FI^,7X9A,QW9TQ?YVY=3&

[(6N"*..&SW0#N?P2"W5>_S9O9 M.)TNWECN17$<7SDZ$;\OCXC.QM-2B#WON6UAH>^6(K :]>4:V3'J>,R6N!K MH V:T?W,.W>\//+J!C_@&5M/RX;W9YQV01S>V%'

M7^UI_*ORQ)HGOR8A<+>)0M7&"S=W<[J8])%K=>HOSJ/+0RQ!T===@,"&.FQC^>09U__2V.?YG&DV^.M-OJ<@.)N+-

BKH_>OWJS_^.9U!;]!//KEW>O#3_#'QT_PSZ]OWG_Z6!V]O8OI ML>7A5]\./_ZM>OO+T3\^5C\NQW>4PMGG,(EH>2@0Y& MGB]'(LG\RYQYF7[*H+Q ?[3X@;8SI&=-O%%$T&:

]DNE]!84^^2S?S@?W_!E MV S=< 1VPHO% 1<$*;2O4_A \S^M@G WSO>>7?9

<;O)=4QMRB\5QT%+.!"F50M%$B7BI+Y$ZC/BK/A:(6A["O>$@&E)&! M5J1'Q#NK[M_5;^RWYA9?UV-2<^5Y)M>8#TSKNOEU*J<\M13XW.D5196W(N M3,2@D@=/G0&10*&G (I)3V6&D5"0-></1L$]R<,CK+2<6DJPW%F8\ MUTNI-3<[U]0&%E T/E=O$1@!3#,D1%##$^"@XWW"SDPB"R 2"F& 8<9((LL$; MI)-5,8@4)&%{J5*.#GZ=ZPGF7!*HX=>//4(V&_K\T% 8BQFGH.*SEQ 7&"<-M^\MG/=WBR&+RH'2?1T#*)(;+!3+1@IX.5P+X$8>B2RYI $0[W9X@X(;>KK@<-M8*Y[&+RAEGXS9?Q2)WROI>?GG#%"=?V@F)L%XNX,6=Z;[+K6>ES)I-\/G-\C M-MXV[=PHJ~ I24R,C;5!)61E!/V?BH\LS+4?K6?)$(I-W'#QBZ2-4\$A9:E" MW&B-X!>?! L44>"='L;FO.]5/Q'Y-)+E;L:3&=,K,BA{2.\A02*TVT"ZU#0R M[C7"DCG$L0.#1C*%J+0:F^"L2W*C^@E\+J(T2,3@X1Y#D5->(NI)HB9RGCC? M$TC?GANH1_/^B&.W1<@SE9RWY#]Z0#,#YL[:,V-"ITf^A0W[!PY,$8-I!+W[1N\DN;V40CV M^- OC;X^ -XZ@4I$!%QQ*3"G 4IZ0T](BKTT*N5PC=1M&R6T*PNX/_FI%!@S+ M'G_OYP3G[O4Z+C7_GEXACXLK9=_1K?>$Y> %I1&>XS+T4W^.4^^) QE30.\" M?/#XB=|_5I\G.,E0:4IF/Y=>FN<:,3/3FZI&,?69]=L]^\:6R<[NM/61MNDUI)EQ@"SC>?9R88*T(0PIfY2A41NW61O)&V:38A01D7(^_MHK!(YX)*TG#*A:94$+-ER+J@:.]3M-M4? =14=>3Y(1@'%&%)>(Z"F0MC@@;RXP7E B[E33(;9L4V: 0DO70VX?K]N&Z M3T?,]>%B?;C83>T&JKQ-GB"2? 0)YCVR7,7<.)_!A,09T\@Z&Q"GC"(G T;8.6NI4(2GS1+BMXBGW? ZI@3%_M(''7M>U8]YHPA'& M5H%I"^:PH8*@:(;$CM(L"3-R[]P ,.9V\,&P;HC>_.11^'7_+6'(I#X6@T^9J; MF[^=U*]*G_5?)DT3FP]@4_K33_%ZG>:O,_Q':CA^FQCD&U!$>VE^U8OA#$;A M+Z61Q?)?9^M?NA N=Z#TJ6_WH&HW8996@KK%R^G%6[FZL\^DX5J\F)_#>TZJ; M4X#RIK*+I:17EFJ6K)XG0Ql#94_;KT>Q@8O'E5U;0mNX:@LX4&U^H+XQ8X M@V!@PTM>]+++JAL,FJ9YMA?D<85,-4C>'"IK'UZ0#X(.;L#E.WQM"?@8, MNCP9A$UNDSD)50*9,JD:>.PBHZ/R\[K.\7/=W3 *^"=G<10Z\?,&M@UNGMK3 M$F9W/(0ZM/U&88)O' \F<&<_F<^K&-5.LR#3F%%0P.I@S\"^^$3V &95 7 M+79^7QG%@@0? GC"JI\/D)8(%)%!&VLJ/.-/R?FH_1S2>A+AX^ \%B!>S^7=Q MWGQ[@=C+-.(K?4(!5*^(>'CV:GXQ?AF$S'=G3%_G;EU,;\EZM..'&[10Z?Q4& M*0Z?_ LV:YA.%\[GX(X#B^GDZ,LZ8KZPK8,O\35[N]+A>#;.-4^H;=G^;MU M\;[,WJ]UO6WWQ;#SV>3E^A>PK.W'9.;-//Z!- M,+<7=O35GC8O?_C+DB2Z)R]VL6A.90M7]&!S-[>[:?=O\- V/1K"6D6)6>6\ M3HWASE+/#F446.X.X#PRY&!F2SCOM/15>I'_2#?7A6K>Q=;9=F2,Y-\<_OX+U MSZF.V4(9 MI*4EB"A*2" OR)D17*>#=^[??I8&# MRX/,'YX _E1- %K/-8OJ/;/%7_5VTX_?AM6OIY.32?4K* 0PU^JP.89-MFFJ MP^ET-"P;PZO)0?7++!Q4/V9LR:>&%+_\[f\O4*9\0%[^-"BNDA9XC]._S,' M"RV"II"?]NH8% 7 INRW:.H3^Z\)=W"KA"Y4ZKG^/P7]G[=OIO^?UA&T8U@[=+%(%WKQG\B=]#T0C>-Y5PO61.5&#'_X$? \!C;^?E 9_L$%2N M=8?,4M? */#DL3UU.$5XP6Q_\"2NNGP8"O%7)X6**Q?A'4U\Q;F;,SR.E@)H/3\NH/[$=7IO"0K,\\9YIG2^,KD 5<_](I M5? A"*D+E-PPCPNUM-5Q\Q; I2O+\6=8B>-LQ'0?=ZIN]]?*$L.B3^LA;,84 M5+I): 8++1@H]TR#AK=-X,8:5GF:M>#]1]C[R4G\;;%IEZC'2Z4XOWFRK,.R M+J6/;?,151,'RD0KF^%UN9MGE;_M1@[OR[19F&5]"H^]rM_AD"-*83$&X5XQ M(L'2-B#V.=9(/1'*QUHQ?@N>O,"_W^+7^>)X'G^#O036R.MIL1.,ZXSSN9IF M=&MQ/Q7)N]$W#S8G6A5HI;8.PG:.3V M!(JCP@YEW* %+G/15P,.A(O_LC*>]8=>GG: M/5A2VMDI84]QCTAQ=&\I#HBB^'"*>;PTO9H5@ZXCR#,K_^MQ+-H$_#@M4CUD M7\G8SPJ9KMP(>[Q!V#WE[A;ELCV@W-&7NS:Z@H'4D^)ND.+8 M U) <<31E6EP8+""AQT6%M* [7D:#67(W\'N3AC$<7$1]|QQK|WCVWL)%,VQ6 MG21YU5J6G"P<,@TL4:R_#+-, RXN?)YBW?E8)O-ZJ9*7F-428E+"<-LSGCH"-M164GR4(>G9T[KY]93- NKBMLF:VFS4?L&>&3]YH^S'Z5XGF;'DY4A'=$O.L-MS;IWO^N'|G!]X1W;DV6YHSK_]#T0D<5UZO.R#:(MW++$2#6 MYX-J_4ANU$R6MZ[=EI_=V%$Y1,K/7!X% H$>_2|I,GWY(7_V)1/W4K3]#]@$ M-/QQ5@++I_^OA%>W.ERJLN?Y2O_GK4[X*OJ,,:;O MQ>NY/H_O^@D+7Z\X6<|\-[X>EO"N@H4G<=9[<'9$]OXXW /AF[FGXX5R>.DB MT%F #?L2.P%15$"@9KA^+.4\:'44%7)IF.6W'<&_0/KS5HG,T2' 8/.F!A;* MSI'F/M#F*\"XV(49-4"40!HA$ZM;9K(.UXBV-. SU1Z78Y75^(F.HW5C5PZI M6ES=.&4;MDDVY]H6\#??. <5M)YEBQS0OVDF?EB.@HIS,W]_L8W>:FG-9/0% MU-2J.BR91?&;S3RTCOTER*4-5E@.R8=9TN^B;<3.OBTJ7(?F#(+C(5Y4'C'MUS:LDZ$"9X4\F_/1E>B MS%H# 2[+QZ? +P]KVAM:.B/YX//R?>6R*V;=RZ]FDF56CX1\Q:USEW#JO#F==ZB%\LJWG%ZB>V^L/-HL,M'4X-TL*#)816>UL0#XW M<HODX<7\<1'P]_C3=?\#D5U!.SP]Q,A?@<$N5,69;I<--ML9? 5>M\!U>C;MX=|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}!6GR'<2GQ.AYWN],R* M7]^KW!K>H/FO[]T]=L0R'VZMY$%;\[=-?5L6;FR=(\4BS[Z1<,MD".E1>,* MY0? 5X;A+ZFI/:MTO_D=Z=-DG67]RX1=;4WGK%ZI#0$&Q5%4AJ&N&,&849 MTE9YXI35-&V$>=VF7^T6Z5'OV.%VB?>]FE"@N:5TTF<]R,=UB<&[<:,RH!'4! MZ%U9]#A^O.F&LSH;\QI.[JX!0OXT4_WC.VJ?AC]GUU7LU\&?OZ<3U,RH5ZK M*/;YZBLWA[]+>E.E0 Q5BB"<3$#<:(6, U3"!$O/O%0\;@1PW:,&_LJ< 7*. M4C?K3UD- V\=.57=7=\]JJ92VUU67V"F_0; *FU0]@;0 @;P+!R]9]W VU6Y MH"I$"1[IPCCRB'}4'TP@7XY&]A0D!+SD6PPOVQ=-O%%$Z3 ZKIK6^^]8TP9LX>_K7]9,_]K?0 4_E\)BOY[>^^WHW_^9=9?3%6 M=/%H64%SUQ_QN9[,QP%ULB65_RZ6+2LU7]K(N/S!I3#S)=:S?-[3 7<+YCL3 MUG:#6+59>'XS!&K(WY=#F"MGNXQ87(2P3F=5:2!5++=24"'\9^P? KH+2W/W2)1 M5[7KJX+!LIGT]>2:_3KJZ13_Z>]_ ->;S92*N\#1%2O;.BEF.[&V/7OU[4/ M/(4^)ROUW+55VMM1G>#)K?-M46Q.4WQ@$*.]B)U;O]4"-5TZ]5S3<\TUN8;U M7-- S3<\UO:QY=*YYFE/N^;B7/@]J41;'S*9)Z6$YDK^AJ7CAR.]M!BS88]B(M[A"_TY;5:Z/S2IFVZQ'A=1,C*;G,+GCP>+),DUXG@LMF^QI;W\|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} G>X M*L+(-G!1!HF>CG_^7/SM_^]MET;WQ:+Y8_]7>TUW<&L#!=YU M#NH"(P(70X-K2+C(DI.P6C3Y#*Y?N_&312+G_\7<.-%?78%X*[fZ^AQ@CV+ M\P\SF)H$<>:/.]L"T.\^{M/G"!%\9.2#_.YZE!_IR$?_ESZ.%G<($.N9\9 MAO)_'IMOF[B.AGM*3-0!?5M/ C,,V?Y]D2]%D'ND3?^AN4#L^+6\\2?EW2R| MSPL4L>8!3, ^#3KE0, ^9?8 4]P-81%-.^CFV7E-+>F,,(X)C9\4 3BV0(5EB@U M-&]M>UL'[G-^])%F6=*Q;!9'@/>-. <8'GS,TXMQM0OSU1)&<(%?S-<06?'N MO@@G]H1P1R=S#.2&9T.}%PRWGH!Y[$\X[= ^ YCS@/XR-M=O>)3[;8T:!XYOV> LW-OX.7?<"**3W_2 M[^U: :/_4YNRFG8W7S8)KO_*@,"9]DWJT4>CV!@ZRTI3V:%]LN^);GO3L" M\,6Z5VMI.)+MC!?EZ!X2LE\>NUT7I7(I59Y08VDB,DN#OHDDU!5JO I&ZUZE MY/OX, ^]2/?/>T2CW91H;0Q],<=/2R,E"# -A(M,%,)4"89DT*GU+>#[U'P^<++"!5FWZ%?.H-89^%G33MGF'FI?TI;F'P/P="'|-M2'(>/1C]!G&T'L71UK@=|OSE5W3]]Y'8*S]8BD%?Z5)5F/99SRZ$>UN9^EIY MR:RM6.\]!648]1B=(,.8TI8)M=.#N:P;H*TF0Q(IW/L5]5X6,W_-#6!<7%9# G_DQ<<>\I>'O$N[DP'7Q!E. MI8_,Q"&2*G7@5H\"LGQ9*0CWC(+WDD))7D7$NVQ2=R/>OP)A$&. M,3LN6=AVH^X6UUT,71VP)\\$W(S,+"IA2"RX"]FI#/(,LDFCB2#-T@6SES7\ MDY%GP?@7R[D.X/8586"L9(CNB$Y[OOVEU#4!@:A7O(@)V(OZZY((@R*'ENN M[(LAXN':=4PT;O7[ZKKZ6-F/P4S^+>=2#AYK.ZBHN+D.W2T'M&;OW*QRLNMS2C#[A_M')&8+.8@+O+??: M&'E3PJ+U[G?&L,8>W:#!LU;-6NJ;_ERA(?T1O.V\E?M(O-Y_- %7<;IXXU7-MKONVV[4K3ZY-!B"|?(/_")?"M-27K#M:+SNFE>RG)7R^1(CN]A:R7Y^M^MK|-MDANR5=9ZY8PLR,B&I_5C(@$$3536W+%2:[3TMS'6?G!+W!#1_.+7KP_!>W< M0T[|(F)1\|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|\G18-7Y)5<@ NB7E+2O&*2&G!*N%9S!Q"3D4XST0OIU,"149U M27S&X^4,9-G@6#",@?A=-2!6F"896TMF\N,CZC^?@:M5E0??DZ-8#1 *.Q M"TQ!R5PH%4EPR-6!..I8"809]R3C (RE5]Q7FTRM4(>HF256Y-/@[&=-1.$. MG(/[)>U56!O]/F"Z9!%?I#R_8:EOP=SM7_EXB<%%>:I]=E0SMA^6(Z/ E3Y6# U9OK1 M5S1?'*CNQ@+P%QI!?B:,/5\GKCUH!QAZ+&'D_O? KW+'P359C&9SN,QCI=2\ MB!.DO5A@8:1C+'BG Z-"@7<'OIPCLG!+@B^:>,VE=;RPW"^R:'F,-%/DF(> MP$MXXI**1!BKN!*!)\9[M="PG/G/Y3_;M9R?%[\B-/_0C<\O.#R;+YONVV:W M?OS?X=>T#V/#98Q-9P772+EFB$E9_S4I"+|+|_'+)F,BQ,--;Q+B+R)*S-]\ M5_E(Z1&7'_ZQFGP$N0+|_&61? UPAA7'$)X<[(Z0B5NA$4G%2ZF*,EKU4:W;.*.TUD1+KHQMFB&-6$5V\#1G M!9/^|%-NQT91B$MO/DYQ@"E'FJS#O7Y-*X;/+'6LMUBT*OGDK>DBK(0;7.(MC? +EK+8L5U=X,4/E7>MQBUU#@-,19?H86P(N_,P&]L^;6#2[GE76S>F\$D$B M#.%=F'KETAG63*RK]4"[?_F9RN_N.@&XMWJPZI9;M%X,7TM MQU_Y-AT(C6"(G M__>0[,*WH|=~%*7^)X'G^#O036R.MIL1.,ZXSSN9IF M=&MQ/Q7)N]$W#S8G6A5HI;8.PG:.3V M!(JCP@YEW* %+G/15P,.A(O_LC*>]8=>GG: M/5A2VMDI84]QCTAQ=&\I#HBB^'"*>;PTO9H5@ZXCR#,K_^MQ+-H$_#@M4CUD M7\G8SPJ9KMP(>[Q!V#WE[A;ELCV@W-&7NS:Z@H'4D^)ND.+8 M U) <<31E6EP8+""AQT6%M* [7D:#67(W\'N3AC$<7$1]|QQK|WCVWL)%,VQ6 MG21YU5J6G"P<,@TL4:R_#+-, RXN?)YBW?E8)O-ZJ9*7F-428E+"<-LSGCH"-M164GR4(>G9T[KY]93- NKBMLF:VFS4?L&>&3]YH^S'Z5XGF;'DY4A'=$O.L-MS;IWO^N'|G!]X1W;DV6YHSK_]#T0D<5UZO.R#:(MW++$2#6 MYX-J_4ANU$R6MZ[=EI_=V%$Y1,K/7!X% H$>_2|I,GWY(7_V)1/W4K3]#]@$ M-/QQ5@++I_^OA%>W.ERJLN?Y2O_GK4[X*OJ,,:;O MQ>NY/H_O^@D+7Z\X6<|\-[X>EO"N@H4G<=9[<'9$]OXXW /AF[FGXX5R>.DB MT%F #?L2.P%15$"@9KA^+.4\:'44%7)IF.6W'<&_0/KS5HG,T2' 8/.F!A;* MSI'F/M#F*\"XV(49-4"40!HA$ZM;9K(.UXBV-. SU1Z78Y75^(F.HW5C5PZI M6ES=.&4;MDDVY]H6\#??. <5M)YEBQS0OVDF?EB.@HIS,W]_L8W>:FG-9/0% MU-2J.BR91?&;S3RTCOTER*4-5E@.R8=9TN^B;<3.OBTJ7(?F#(+C(5Y4'C'MUS:LDZ$"9X4\F_/1E>B MS%H# 2[+QZ? +P]KVAM:.B/YX//R?>6R*V;=RZ]FDF56CX1\Q:USEW#JO#F==ZB%\LJWG%ZB>V^L/-HL,M'4X-TL*#)816>UL0#XW M<HODX<7\<1'P]_C3=?\#D5U!.SP]Q,A?@<$N5,69;I<--ML9? 5>M\!U>C;MX=|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}!6GR'<2GQ.AYWN],R* M7]^KW!K>H/FO[]T]=L0R'VZMY$%;\[=-?5L6;FR=(\4BS[Z1<,MD".E1>,* MY0? 5X;A+ZFI/:MTO_D=Z=-DG67]RX1=;4WGK%ZI#0$&Q5%4AJ&N&,&849 MTE9YXI35-&V$>=VF7^T6Z5'OV.%VB?>]FE"@N:5TTF<]R,=UB<&[<:,RH!'4! MZ%U9]#A^O.F&LSH;\QI.[JX!0OXT4_WC.VJ?AC]GUU7LU\&?OZ<3U,RH5ZK M*/;YZBLWA[]+>E.E0 Q5BB"<3$#<:(6, U3"!$O/O%0\;@1PW:,&_LJ< 7*. M4C?K3UD- V\=.57=7=\]JJ92VUU67V"F_0; *FU0]@;0 @;P+!R]9]W VU6Y MH"I$"1[IPCCRB'}4'TP@7XY&]A0D!+SD6PPOVQ=-O%%$Z3 ZKIK6^^]8TP9LX>_K7]9,_]K?0 4_E\)BOY[>^^WHW_^9=9?3%6 M=/%H64%SUQ_QN9[,QP%ULB65_RZ6+2LU7]K(N/S!I3#S)=:S?-[3 7<+YCL3 MUG:#6+59>'XS!&K(WY=#F"MGNXQ87(2P3F=5:2!5++=24"'\9^P? KH+2W/W2)1 M5[7KJX+!LIGT]>2:_3KJZ13_Z>]_ ->;S92*N\#1%2O;.BEF.[&V/7OU[4/ M/(4^)ROUW+55VMM1G>#)K?-M46Q.4WQ@$*.]B)U;O]4"-5TZ]5S3<\TUN8;U M7-- S3<\UO:QY=*YYFE/N^;B7/@]J41;'S*9)Z6$YDK^AJ7CAR.]M!BS88]B(M[A"_TY;5:Z/S2IFVZQ'A=1,C*;G,+GCP>+),DUXG@LMF^QI;W\|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} G>X M*L+(-G!1!HF>CG_^7/SM_^]MET;WQ:+Y8_]7>TUW<&L#!=YU M#NH"(P(70X-K2+C(DI.P6C3Y#*Y?N_&312+G_\7<.-%?78%X*[fZ^AQ@CV+ M\P\SF)H$<>:/.]L"T.\^{M/G"!%\9.2#_.YZE!_IR$?_ESZ.%G<($.N9\9 MAO)_'IMOF[B.AGM*3-0!?5M/ C,,V?Y]D2]%D'ND3?^AN4#L^+6\\2?EW2R| MSPL4L>8!3, ^#3KE0, ^9?8 4]P-81%-.^CFV7E-+>F,,(X)C9\4 3BV0(5EB@U M-&]M>UL'[G-^])%F6=*Q;!9'@/>-. <8'GS,TXMQM0OSU1)&<(%?S-<06?'N MO@@G]H1P1R=S#.2&9T.}%PRWGH!Y[$\X[= ^ YCS@/XR-M=O>)3[;8T:!XYOV> LW-OX.7?<"**3W_2 M[^U: :/_4YNRFG8W7S8)KO_*@,"9]DWJT4>CV!@ZRTI3V:%]LN^);GO3L" M\,6Z5VMI.)+MC!?EZ!X2LE\>NUT7I7(I59Y08VDB,DN#OHDDU!5JO I&ZUZE MY/OX, ^]2/?/>T2CW91H;0Q],<=/2R,E"# -A(M,%,)4"89DT*GU+>#[U'P^<++"!5FWZ%?.H-89^%G33MGF'FI?TI;F'P/P="'|-M2'(>/1C]!G&T'L71UK@=|OSE5W3]]Y'8*S]8BD%?Z5)5F/99SRZ$>UN9^EIY MR:RM6.\]!648]1B=(,.8TI8)M=.#N:P;H*TF0Q(IW/L5]5X6,W_-#6!<7%9# G_DQ<<>\I>'O$N[DP'7Q!E. MI8_,Q"&2*G7@5H\"LGQ9*0CWC(+WDD))7D7$NVQ2=R/>OP)A$&. M,3LN6=AVH^X6UUT,71VP)\\$W(S,+"IA2"RX"]FI#/(,LDFCB2#-T@6SES7\ MDY%GP?@7R[D.X/8586"L9(CNB$Y[OOVEU#4!@:A7O(@)V(OZZY((@R*'ENN M[(LAXN':=4PT;O7[ZKKZ6-F/P4S^+>=2#AYK.ZBHN+D.W2T'M&;OW*QRLNMS2C#[A_M')&8+.8@+O+??: M&'E3PJ+U[G?&L,8>W:#!LU;-6NJ;_ERA(?T1O.V\E?M(O-Y_- %7<;IXXU7-MKONVV[4K3ZY-!B"|?(/_")?"M-27K#M:+SNFE>RG)7R^1(CN]A:R7Y^M^MK|-MDANR5=9ZY8PLR,B&I_5C(@$$3536W+%2:[3TMS'6?G!+W!#1_.+7KP_!>W< M0T[|(F)1\|(_0V4_=_1MP$-'=6A>@VK]_Z'D1R!GV?KOL.9@90!N"O8GE3 MS=!JV6X> A68U!U6FSO\%L]'IU/5]"N.8XR MV*DIM@$;C79\YZ:34?4?) [$U@O#V:I>V/JF^8S/N_FA/5,1F^1-?@ '9[']SJ MK.XFXY6N&Z=V@**?QE7G!]1#%?#]9 &6%02LVCQX[&3=Y),K22\T<#7IM7GP M_98ON\ 6-Z!!GU?3)7PPG=YBU-H3)# *N%6L;B> ;.RZ+UV0YR?IC E2 =^ M_R_?Z&^^W-G=6D_T!$L]U33'=57"#B8!]PFZ;I5R>XBY]V*^Q\(^]:0%G9]1?=EG7;I[_]0D(A>.9W>E<1IW MI2@2!+.$\: ME5[P/@&-+"E1HQ*Q,G@DB6? $J"")R2$!)G>1LD?O ,#<\KNZ M1+^SRZ7-L&YO=/GL;$]^,5.G&'-Y,_WFH P#QAU5IP>,V\L994N]EMH3&$(G M4BE'O!8,8$'&&*WR1?>H<'@T27H]"8W4MO<$+0 7F;3)F*<7+LOI ^_M_?]4X;X>\SH--GC,_WIU'T&[;V P*Z],DP:SLL/=Z((*643"G0:S8@HE_+R4 ML&)T")KY3'N\Y,$)Y9U1Q$8?D+"K@+N=&3'!R<"D"LGT]M$?AUEA8RID6"@S M6)8!YH9I? 3TP%YA(3HE,,D>BWL+8A&WK,^*6^6\5;VS+DGXI((PQ!>!FY"] M(#X(+-?AE599JA+Z##!' G..LS&@] !S#W.@AY3S9HA_KF=NUEMJ\XNR#PWZ M^H+9,]*Q>T|\G18-7Y)5<@ NB7E+2O&*2&G!*N%9S!Q"3D4XST0OIU,"149U M27S&X^4,9-G@6#",@?A=-2!6F"896TMF\N,CZC^?@:M5E0??DZ-8#1 *.Q M"TQ!R5PH%4EPR-6!..I8"809]R3C (RE5]Q7FTRM4(>HF256Y-/@[&=-1.$. MG(/[)>U56!O]/F"Z9!%?I#R_8:EOP=SM7_EXB<%%>:I]=E0SMA^6(Z/ E3Y6# U9OK1 M5S1?'*CNQ@+P%QI!?B:,/5\GKCUH!QAZ+&'D_O? KW+'P359C&9SN,QCI=2\ MB!.DO5A@8:1C+'BG Z-"@7<'OIPCLG!+@B^:>,VE=;RPW"^R:'F,-%/DF(> MP$MXXI**1!BKN!*!)\9[M="PG/G/Y3_;M9R?%[\B-/_0C<\O.#R;+YONVV:W M?OS?X=>T#V/#98Q-9P772+EFB$E9_S4I"+|+|_'+)F,BQ,--;Q+B+R)*S-]\ M5_E(Z1&7'_ZQFGP$N0+|_&61? UPAA7'$)X<[(Z0B5NA$4G%2ZF*,EKU4:W;.*.TUD1+KHQMFB&-6$5V\#1G M!9/^|%-NQT91B$MO/DYQ@"E'FJS#O7Y-*X;/+'6LMUBT*OGDK>DBK(0;7.(MC? +EK+8L5U=X,4/E7>MQBUU#@-,19?H86P(N_,P&]L^;6#2[GE76S>F\$D$B M#.%=F'KETAG63*RK]4"[?_F9RN_N.@&XMWJPZI9;M%X,7TM MQU_Y-AT(C6"(G M__>0[,*WH|=~%*7^)X'G^#O036R.MIL1.,ZXSSN9IF M=&MQ/Q7)N]$W#S8G6A5HI;8.PG:.3V M!(JCP@YEW* %+G/15P,.A(O_LC*>]8=>GG: M/5A2VMDI84]QCTAQ=&\I#HBB^'"*>;PTO9H5@ZXCR#,K_^MQ+-H$_#@M4CUD M7\G8SPJ9KMP(>[Q!V#WE[A;ELCV@W-&7NS:Z@H'4D^)ND.+8 M U) <<31E6EP8+""AQT6%M* [7D:#67(W\'N3AC$<7$1]|QQK|WCVWL

*M|&G/^V./E^SIZ0|N/W\.@>>RL7PX3+'"U;U8?'3%38.C$6U@R"*1XBZ@,,_M#3!VM# V'/(<%/HXIW10Z$&A!X4>%/[U*_3U@8:R);N2&'CK.1))@R3!&$>B M+N(0:+SV4|O/+ROU MW94BKH.U>(:,:UB+P?T;W+|!H5^{0M_ #NHXCT8Q$E*11#H;2"C4$:IST=)+ M#Q?TW#_M>=="*$]FR)U)F1P)GDF0'QVI!>6'E(.Z?D7IL-!^%?*
NT*?;U7PI1,VD5.BK.Q8:/4@_3E_;5G/@>+\0SU9[8@PLXN("# M0K|VA;[>!139,IT%9J*\(>#(<\1($ER1YSK3W6G2G#[$VV-CY^18#_[>@%C'/Z4##8@TNR*#0
M@T*_=#B\=#\%&5B11P5SLOOC6G$\A*(+HGYS&U.]>>"%^_\,Z0[*%M+$=-P1LV=<%AT3#*%EENC@@AP!"UHW-'|;G>7%),+?:?*Q_10?.YFM?
#=B^#G7=7WS=;KQ0)&Y#=HP[?3>?S]FU%NHC^'YR_A M,,?3WU/^7U.'^]!(OXV7^:U/-RG.0^D[M.CA[Q\SV/1>:ZCM6R-.N&J?()5
MF$;=G(U^^'R>9TW>R2WO58\DEY0I:0E8*DFD-Y8$$QSQ/F5A@Y9)I'WHT?MX MFM-JFG\N5S5]EOI*$1M^\QRUYF&"<0>!P"EI)@U<.R\CN*+CB4122;||C9^X)W|C2^OB0#$X\-T|
(=_-+I7V=3SOOS#[-M>R6+RN?+CDJ9CBLE%*=]KM5;\M(@L$@9D9I8BG7?)3HE-%>_M"R/W463F2F:FJF&7P7S82HB@;*P4'59"\N-Z]BD=@&N?YQH%$URX3#*7_%S!-M2!*
<8(0;KHV1+GKM|K%V^VC 18T82ZH&X'J 6SL065QFIVL*\/|/,(=?E[9K MAC_D689++'T_W!:C20"=VZ(8MQ3X0NAD@3-'$T!9*=+9%++IW*>W)P40-_.M.#N?
SB|R_K,3NSV8"CY6SHZ=&';[#) U3.DK@*RB54K9&W!HBR:R4$$"+#9V6H|E0-,V)&WWZ=U.9LUJX6:=Q/:X7;AQLKZ5B9(=\Q(-4PI:\ MJ;AVC"LO
9^D(U(K<&>5]X0G+@HS41O6VT3_"=VGTCEU%C;845I2,SNT74] M7|Q+:,AJ0(S\=88'!21RV'[PB-1J,P[9Q<+XD;B(#NP 8+SWU!(^M@%?K=)N[!/B@Y5D(,]F'
JF%*7SY6E<)++Y$P3;9Q$ MP/+$!-^6(5\4Q&25UZD$;#1X9J_B8TV'E;$C#ID$__M,O/3+!,:7HP6&3W8(0O[M>C1G, G;)D$6[CC-C&3O =Z-
E,1*S0A7165E7,ZA9Q+NDX4%LY!6<;G6NVH5 M_/2]0=3429[L0]_,7!FV6 @!N0:IO3E(Q?"EI2.$U:RO/(>X-(DF,'&!PL6 M/J2YO[M|GZSL$R 7%VS,]!V0:TC3/EQ;OELU\(J\ /D[GS?#?
MG7I#J#A=A9 MMQ.B.,DE$=*BA:"..)8U$=E83[V(C):'IF;I]#QK_?N^5,^'[3VSRHR5'G8: M#(@U3.DK0"R38DQ21F(H_$38*=<|)OQ,|S4NR*,$:,?2VX ,[L"C)9V(=6(>B M@\F"NL!
<+TMRG_QNU=3K3,L>B-J+-PC|V&[#?O.2]+1 4@'Q-P$B=13I> MD; $(^Z*<)Y'\)V=2-)0G6OO.7"?]/'C :-<)o=E' .&26Q1R!SOS M92WB)Q5*.SV.U7R,A\6>MSAS:.?
VPS&"S4ZGFLM.36$BFC Z,@"WCA3Q#LEI/ B MB+|1V0-%V;KXP|.8(3V6THZIT4]IB*Y(5?,S10-V#M@Y8.>=*EPY97V4BA3! M(I$4S^,)+ BGPI@0C4Y1/0)+V]-
BIQQ.J!9.R@$[`Z|&5N_3H4+6<^YNHB2H]40&QHA7D1&K-)=,NEAXCU#@/C5ZOLIA>5F[ZJ;R.Z.N-%M. M[Y.W;=U_L8,;LB>M=#4RHW61IW^?S#+6Z/END=-D^2H*\]RF9_HYUF?
Z>3;Z MMJ7T8L38>(15)49_Q.1+..?>^7N7{WOYI7(LS?3<_:@9> MC$?5,:DL.Y,'LCW..X6D^7Z-V'1]U*./X$;E<:+$!U:.5?
S$"]V0Q_S1:G8|@MC<>|W;7[M#^N_1^:0HB)04'(BB.,F*:60K!^YKVMQ6ER)W0FF8B*$".9$X2EZ(APA3K:;3: M(9/6%5&:SSY@&6=T9G_)"TP4^__YV^P7H'K_?_%J.JG:H:,Y:]@J??
D[1P< MWV|&X.[BZ/Z#T=+"4P;!..C?)+@'0(=,:F ""!BNT M?*Q%EZ!+ZIL_1V&!V3J_1(&]QG#%6G521X,;|KYM4B"&Q.[#?:M M7QLJ0*SE@A]6?P4:B9.R]/S7]27Y<\Q-
+629<@$D2&!?SR9+>:|<\&/!R7BM@ M)GQOO>=DA+9ZOEHV2W@<(NHY3&Z=?)1 M.?VH3.?0$G@&%GDK.)TTH]73K]+ZGRB [Y?@62Y'_S9?!+9!B"+U*?-B
M3S/(Z1*E;S)/H_/I"K1AE@E(,<$/8XT'CDWJ1(Q!@0M)K#) _,= B2O>D:BC M*]K;F*._*G69ELQ8H.18 _XCX#BQ(&G$^,Q+I-Q%J0\M=?3(I.Y)P\]7OWP MJ.B*YSH\|P7#U=;/ 3%Z!
(A>%XCV(35*T#2#PF/MJ .;/Z^*)6+;X@OKR M%#]$@ RQ:UPBXD+,;1(/SZGVI/-_6KOB%Q?55IQW5N =(/PL?X* ',<3FP/@ M'?
^OPF#3FE5H)F!W05DBM>1&5X%/SZL()Y[A+|6LY1;3=R--|\ 3J/>5*: M^M SAVS"1)!VSU(.6F#/302"W#LY(YA!^/P6+SF@9[J3A[XIH8SEQB,>"QV7 M;|
[!X)/9|.7U0[[9J4;^3S*!3GY^0\3;,LV?28*)]-J#E9!79[.WX/">3_W% M&_SV[;E/.+NW=N!,VJ9VFU;H"<=/_ANF?E(NUF^L]Y(}ZV_KEG¥\.,"GQ[S+ M=O7=5<+ YUMF_QF_?|
[B8249'S,'C.],8KLV1)ZZT\U&H*[UDQEF+@CX38NN MAO7N%S"N[<=UIMO=0+Y Y|!XZ2=_T725C+Z,Y MT1W=NKLE;PUREX;W6O9YGZGX9YG# RP^)RF#(IR5N.7[.@*T45?\=-
||3M^$/WY9(FQ#EC(#WF6%_!{6#5P68.> MYP)T+#>O)F=[9:#:.6A#51R@:O&_%BIB<-B&BLWH#(N/HL7/U61?/L5W-*'X M|VI\VIB?
I,I2LU\]GX[7EGYR|/S*!5H!SDB#0Y!NZ@]:C+M.S_#0?%]ZTO'HP46SY:KLKB7LRN39NS!D9WC UL1PY@4#29 SB)]K3U)R3!+=73ZQ6,ST\$)X
MR0!0!7ZS1122F2Q"YNR*ZFT3NT_(L)U/_-%'W-=P\=UF>'|,NCTQK'E M&<=M9 JO[0+3=UMR!5U>1Z<@%\AOU6"SN>+9;<2W1>]D]%/LQ'&$'C)N%L(Z6SXUDU7@NXN
M\NW*)}1=/J=]K1F=1CDW,1,S4J4V)*I;E+BM@,9D3I@*F?T6MS|M9HNP-%>)')'3'S\|7|||@1H<;_>KF'YVS;2(3P>L"SE%0 M:P9,RXC1VF4'[G;D/6A@.OF MYL?
%_.RGIEEA&/5S>=^FB#%Y_R#>#>=P?J^(L_$#^@2|6DZYOL0-A#@IQ6N M,%24F-4.'G#';3."N!X73P$B\ED #DREHMW<,T|KSV7>OMZ/,&2*W$?
NG+X\17W_V2T$T5V.008B?;JZW14UW ;C)/I?O^SZ|Q9 MF_1OE@N/>3U2MT*U.?_:Z$U(G#ICE6,PFA^[O#=:T^O-.;3M^VO>#T\+>?UZ M3.I?IZ1IW4*WR.LQJ2MN[>+"=
(YY2;RV77,X*#Z_"H!^M\;BXT1$;8,$)}T<1 M$5PB@(6!.)D]*=F5PHIG2J3>1FK&4^14#5J<)M))2P('MREFJ[Q5*A31.VEQ M75#P5P_CLCK[MJX2@2Y]YZ$G\'D?'#L'2F_#)%%?
#0IN9B8Z@+C#U=.*;K@Z M]M%/IC7SU2IT6OA/LQO7PW |#52[#Y@ $G^;,W:;? *0N?>3K]Y|,:?27\M1 MBHNC!+H7,>5IG*2LB!F0*#1D,8*;&!4T)!P755E-3K.KI M'%,>=1@$#I
4?ACU-PN!KTI;&HWV)@3TW;M!UCUM2KMJW83W_[\6ONOAA# MA&$FYN:#@P>P9FU/ZH;<5IV:C3H=FU0D)0HO4I H DB%EP"H/C.2M+-*:#RF MW\M[WD4J.!^$$M',"[2PH.U-
GSI(>?#LZ[$%&^WXS2?N#S#Y^+"VGZ-U!W'G MZ-$YMY(+%FA.Q''<8)W 1P43 +ZN8>"D.LML,T-UHQ*KARXM(9:(A7?\)NC M!#U>AKZRX+U%E"T\^ 4|
$QP5S68=63KGN%VR_#/Y5WU%?SW\^G4+YKNZL[- MI=LB(K[PU1^,V?P(80#W,HJTZ757V1%A9%"%1X"B2PPP(-B2*#*@&X,;S7\ MJAEIB%1T^6$4BPH-/Y?_O X-
]BD/7U*$5P>5>"# M'!Q+C;G+%LMQVT2;)1 MW4Z%B9HVO|)E2:IQ\4<>/2OF9%2..*$A>HY@5;POGE"CF!#)B6+V[7:|\-Y\U MDY3;LP*_U],.?U\H\=Q__!9G9ACDJ(N?,8#/S?
$L..C\SRTES)RPG#M7B9 MDR(N__(ZC4F223//<^#95S"MP7D 6N,*JV(A\^(208"0CS>XY_&\U!CD-0Q M"/@Q2<%UGL MO>OAX@F9V1Q7_*;K1}5EUGB<^XM$-L@**X@TX A)
(03&1)FPX*@)Q7A%>Z2P MJ_&\VJBZC8GFO_C%?_CL;B\.'<-'HS4S97 #ND!#:N?CY_-+>+?Z@+L3N'MI MR0SP#J2\VJA#P%@!IO>(0@<0'&;6#1

*{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`RYO6;EK:M'8[,6G3VDW+F]9NK^L,ZTN;C]+WXU)>M;B=8@T]G5-],+>> M]>7^'6;3V9Y(#<$\=+((:Y('0+_](CMV[;MN"+QA;V< V0Y06IS3DD4>_", M8V$+C" FGN.';6@EH1O3A[/I,!GH.8ET86"&C]_O\S^'H358:, Z-K "5 I= M*R0>0 QQ?3<@C'H!\|6(6I8Z,IFSU8[$0'OPDY839(H%G DIBSF/"D\BS0YYP MQV$O"U:4^]9#=?41,5<=]GY[J-IEFS :!"GS&$DB.N$=*8DM)@@3L!\QW:H M35V^?B[5W4*5[3NF9VG#2AM6!^E&]UVV:*#4Y=&U"<612/\CFT2V6E$XI"S MxL\&D0K-T%\[@H>^N J6G9 7/# [2,1X2IPD\0/AB"!\;2_0\0)3IXY&JV=$ M"'"7I^A<%=F'%9-02$>]#A+N0(%SO&9:F:/X^PP_'=S-7PIPNA;60TGRT(M"L\37DPM]/\!!%F(7<,MEWB1%7F<)[Z=6KN(5SX+!.552/*'],HW?R6ZWIF& M/PU_&OYV G]>$(-+)EO@$K#>L OF BRG<@,2^&[L.L^U(1+N(@>[6!G1-F+7& M08V#V@O67O!53X$83VGH,T+E*5 <"*"_"4>CY, `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|\?"D?/:!===?]S%G9-DON<#C*?]ZA.[128?#SFSS]/[,>WVG$WM9 M4S!/5\03[_39VIY3SK#\G1:?\Q:?IT3220^5TK-1=4DM/9N9TCI9\5'Z]L$G MPE3TR:CZ\%.7P2AOC7^=%<:=8%7]9WU.?7SLH1>M%ZT/6D^I1M"K;NE^ST77 MG]!$E+,PH8* *D^(*QR'A(Z(24+]E*=1Z@IOI;KK\WNE/WI20Q>,-TDMD@O> M5]@Y=Z>QP,";NUC+IWR:K352'=22SQZI@MD7E%M@K&@K>Y^)C^)B/K M@K\#;F57XE[@G^7U0G66G_^5>-+YS09VW"KB=6K ?UXHQU^W M$Y@EO+ V&. <9@@3+C;Q0Z(+H5XDMR\FL>C)Y14_P9 M8UJO7,=\N

*M#NKD?]*FK!JF0L\Y2XN!9Y.<5\REV>O+U^GH>^";>VG(91 MNZ$9;EN_36_N(6]N0 /3WK;XY6$L7^_VYDTU'6KZ=$LGY#"6KW=[XSO_VU80*

*M.8R5ZXU^0FTYF]JF8T5:0Y_>YE(S\$+3#;>)L^Z MO-I6U/RD;D*9\S(#Z)[#^%\$7L/0\G-R\N.8KD5-&FY9.5SO[0'O+5AT86!:_MT5$K?KW=FSZ(U-7--S+9/Z6[:HTBKZ@/?6 M-_TP,KU@R\X'1]]^:,H;>97KAEKD*FK&_M4!^0[XZ:?Q,%EG]1=4@X_"K# MLH181D6+SEE6'"9,VW-,;S=!]^^K,JRYY,BYQ#9="W,O3KR_]6;:G7H#K>;") M9WH4NJ3@F6&*

__<2H8'3H9)K=IYG^B\24SH+83IZ%&K CW585%\>S M:R/)65W_Y_MW63I?2\B)9(@I^.2WK3+Z\-MsKE,3QD6IY)W^X%,;+>6C6<1O6[V68'=9$C=

*ML*KKK['X!=!5?2QW6D7P6]+NV#Y#;NKN\+_PTWOMU$RN=S# 1NL;N=N=^TX MI6J^08?;OGG>1NB MKH$A=B%;;!/8/8%]B>]R*$1N8L>OO)6=O&]6, ^P/;AJQ*$0]^X?*

*&9=']B&V7+ MS]9,O\!8=@?#!G0PENPX9<[ZL0TG*0<>7-6K&QBE;UXH>P5W71<3L 28[%"6 M59Qq@7[({7$!3L:01*S4T_/>W"]P-%N'6AUV(^N^D@W*9DV%86UM50DNVRYG*

M2%29,4\48]FK&2DB:H=0JKU:UX=YV(,WPKK6AP.WM"W23-DZS7X_T4+2P32 M9'MM8'8V71:[#9EQ_$.M@&55D+X1<'?;NFL$"0M T/GK;E1-S\SJ3OCYJV! M%]L+RJ:*PT!NS9YLKNJS//55GS8H"\I6Q ^,).(6E$V%$P2D>.)DV+X M&DRCKMFN*&!GA9"KQK6N$V.18L.S>KGI;U)VW0F!W'TO8=VZ;P\ZL*

*M*E>H8"Z28:8R/[V7R/^A"3HSS43.AWJ,1:DY:VJ/;7M!CV*!3!"":JCO0&DI M.1LVX5V>V%,UL7FO&E8ZFN5R+9-)5M?8\|?L5@/+8EPZW;4DU'P&G>1/2GP) M3!L;=DK-*

*75;34L(&O]XMNB[&]5S=+[YC44?7(^-?L ;9 7!AEA+!^D4C! '9 MN&P>*J> ^2!V&F JF/R)\;5RI2P8 C6 787-1_'&%G2^Y4OS=V+-_^IQ)O\5_ M=V!'R=;- +5M):=U4U9?*

*\+7P,YC4!,T$M!,ZG=!SRIQ#AGI_9B1(#,9F!O}I M-8!1[FE.BCV<<6GW=6_ +4QH3K18Y=J'S =U<9G.#0B:#0X/ MWG[HK0$%V!#"R:RO[P0X/ MWG[HK0$%V!#"R:RO[P0X/ MWG[HK0$%V!#"R:RO[P

*M,4TX#54GBX]!M$(R,D=I$NLX2A8N6-#M_<[)K^-T^.*Q=#=F(FC[!(&1A@$B-M8HGB##D'J?)'8/%C$)L:V03%$QO&5R|4N1_>H>[T3]-E!Q-2(?J@W0OHT=!IO-MZ]Y8M-J62L'DQO'/JCETPSW06[+FO@X3\|IRV!}SVYP>?$_J>I\41,&ID;P2SN7+TKG;BA!M3JT\4E(W2H@H40HK:6!U^R*B4=^BN7L_YR-D,^|_"LOD6IS9H/R5$QK>BR6+D(MG:1)}#9D46;MOD4#H#;-6_*,O+!*"H.M-\/C\'3',,T7,N1CX5;2+YPK!HE\@ATGV/+MKM??-MJNA?,&SPO4M:NI+W/RI;BLO')W-OL=-Y)W_^(6UR7[|C[OT>[!-&784K^KOMY|/+7"+/3EDZ[J&T€>'F*B-.O:)P&WA&CA9\MYB3VM8&R++&K6%\1,&'U\M>Q.-8[4A6B&0EIQ!@%&/AN!)'QXU5V=YHZ7+-/NJ!P\x++<+^#I*0)[VY##3JEBZK0?V'9@4S U^.E 1YT":]_9 MIT-!]05Z-"U%3V*2!-.7Q4$G9\,4AQU]DDOR(R] Y%X94IL"Y:NPI8,"6ZS]-M%A.53ZJ'Y-,H/,,H LV<[?A2'@\ROT2OS G.N2NQ31!0H<*4=U@O*/F'K){IF) MB2G@5C$%]-T/+@?6,]TL8?BWNR)#&5:9N^-^S,B7?L7=_2,NI#;5F-=,4S*3M. HTM)P6 [3XWXOM79A\P'L] MS*9(;A?.1^W]C6;6TG9!*_1$U#XMP ^P !4B+4TX0589Z068VYJSFYQHK5*

MD4)0@]_K!7'M%G-BVYX6Y_N=Y$T]+P&, I,P]Q!;XW)1M77?+%C;4.!GJ>#A(M|)$]Y0\#L^ MXEXS>FL]^"PSS_6[G<#>@DJ7>0M1U'=C]+TG:,,'&^5YM3<0PH'2H+9 ->]"©MFC_I&5#;+0)O>X5: +,*[]D(P @,S#SYG,@ MH;'L?VSZ]>P\XJ@"Y4\!,O/G\|Q\"\,=@€V&.I+E#63)3 0-2K);/DBW/ZC70 MNZ^SV8M|<3]HU>Y?[OC,5,3"%Z%?34?!5@)>"@I0SV+$1UNAC%-62'%[P] 9. MLL.+<0BMFS>U"88 M2=UR/H%#+K5T26'BV"_TC!D>]@X:.YF H00@%_@+Rl8(T#N(-M#HXLR<$4@;3'%@S85H"UYY*] {]9PF*^%|GTL#@;_H"LQL=NB*;,,R$*/$^>@ M'+W;98G_FO]V-PTT;RSE@OX 8T5RVL 3@}T4R>,0ZS,TA;O:4W>>>7SO{FR9 M{UM|$[/+INA 'UVAD]VE>UG?DVWV;'+O\Y4'GSTOI,VA$!:UX]2EL]8-.TB9=!{G/K.3^,%HAF1&3KL0-ARU H&W' M=="ZQDMGXBR;.K["C"P5$&7"")%)#+8V8MU@3!<.]IQUH.OA-OS M4POL6[XX1,+X]SAX=8$61SCK2W#3V\.8_97&-.$HYF|=O.QR1\]O9162/K2Y_M)=+/X3(E.3_0BT]G MEYMV?HE4&GCQO=1=9;\SI^+%RU^\NV(|;W,VX.'31U.$/8WRP[3(,K-8X,$?MB1'C_C\!S)!S4|IQKOS?)RUH;%-@{A!8[O2025-M Z+(-/.U%$SUEK](OW-T+8L(60GBO M0-A(9^V&SR@A<=.,?9XQ@L(.P7T='@,7N>I1QJ?"_W_^L.1%-H^.;?|^&QE3 MELF+%*"YR P^\4Ff;8-"@"GLY=^)O 75Y%AA26;^3PVGTUBPV7N$L7=<"9& M[^Y0AR LKY!A7!9P=>=#$"RGQ,M^J](DR4">'3Z#YK)M(JX!E&BX=.P-A99G$ MH[*/C#I5F)I-L=Z!RH<)YX7+$[JWY0#Z,Z>R9 MYBC?""G{D;YKN_2VVKASD2/=P|FI[L_:+>B-@C>>9BM'#?^/G$-E3(B.M:[C7NQKW$2I.1M3$)LB^:A$/=Q1!9HK[.+5YB&UE*VF7IZYL%QNW-M[$NU/MP66DGO1MWX_$MT$$JD$TL*'3-(D0TZ),3DFF 5QU@X9=HHW(QX H5" MX%7B]DOXV/K)@EYK9X;!FV/)>JR9L#.TH3-9EZ=!B$8W1MSY7%,08NQ:%WV<-M24UY'J/N<.%C93K1U"AY2289V0T*)4(^P7A;^0I^%O>1)H+!#N(C$N&98'BC-MN<%1RXH T2L.,2R/^JT."!+U>2*D",'Z$*N;^N'_A6SO4$Y&PL?0'$)OJHRD!F M2W:8,,#H<00I%/,:9=[P%)2NZ_A4"DQ\>GC%VEWTS&'K.8IY+T&N3P%XO^<-MAD2>B!-&9 SR4CV 3H"5WA+{AC=|Z!L[X-^FXA77*P2V(GM#GD,?%GI9S3 M"@L)$K;0\?@UA=|?Z=N$M&*NN)-1I2IO>-M\S9PMX(?*)075>'I??]>N:CU!GM\N03K)@E?;$Q0-.)ISK*\E8NG47Z*8/9J-M-R N?!Y+E\(A4>W.I+RJ01V]"OS]JP,JR[(R@Z.:[-8=O:D&+=<.4ZZ^VL@) M?+7S/_G^TU;]=\'7>0- V)[^/7#Q?=XW6>U%!70IGE]8#DL2^)N8KES?L+K#4 MD@;]7,M)-"'+KL#%,K] Y(1E':N6.ZQGKE 51>6; 8"4>R;^0,O)H"*F8UG>7+F<=\N$%9%9IQ 5OP,"4)*OH';,(4^=?0=E@PL#>XH6\0 MR>'*=2?K3?B,`"7I+\1]]XF)*N7I;)%8FX.+(1/EEP#A<>CP'?25&^ZG^"A3 M=, V_Y-&=+_X',)?BE;2&BB#Y3M1-M5'>++LIXPU!*+E-I;@2=I;@=':R:#R(<1?]O8EE>1G$"L^(?4*$4 #$[T7--Z M,7H(:4YO^/N:PMTWC_(EDQY?3][>XE\]KFG5<-V(U=,N9T_OF>*]K$K6 M10R,S]ULPPHY2+UV@<-FKHCS\L?2ZWS^'/8[2_&S>>NI>\?PBC//*1*F(F(L6MU]TCYKY{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`M [I=#SAM,A(4ET#ZL4T89H=XTX8A*?-H0U;T:AOT5!V*=Q@^-9 /R[ZO*TE, MW 9&##2-R;D98T5E#Y>XH5S\PB%\Y'Y1);>W!^<|Z/0-'N.V\/?\;-<1*A;P M"!\ 7T7@NRT$>LCGL[^5@49*-M WB&P 6QH0W 4O*2M6+TR'F?(&)P46IYB M@!BF]6KP[.ELL;389;-)]B3[*V9?DN7'>F1Y&^OWEOL(9,; ^*)]A2-^6_1; MWZ @_A,8I0=],I)%Z)MM70A#=!^-]?!67GXE[>0+12)O5S50TD0-,T?:3?@P MEG^WE]!\WLD"C+L-!#K@U_F!F>8K^SUA?61[MALL?O.(M0LJ1Q66YCL])_Z(£$L: M/NKV;OLY; TZ>Q-5R/E:S(9N6GYYR6W8Q>;#L6V<SZ3N+8SU%V=J6T0%(0NB M(UZZ58Z,4"VH+'V\^"9B[G4K*KB)5G/)1AN3'-E+M#5/K^EKUL M6K+$_++-]LKHEOX6&!GH{@30QG50TI.5Y"9J/A1:>NV0%KK>Q_XY1[^W(>(-M/FS8E)@'"K=5?H!Z9LBVI(K6_)(XF^5WN=R>]K&-*!CT MLFO>9GWJ?@O[3'>]_\P0#+LLRE]2K,HW@,AA4Y=+[>A2N- E3]=@YXP7#NL M-J5);EU5B+\EF7N-L^QR(S'*,+(E_X]0/'A6UL&_Q],J78*D3E@BL2!A)AZ*.."M*Y;'+@PG,6_6MS+>F%HA=],9$APS1V0IL"4+1U_#+A4L^7RB V0!E{G0.S*AP M/<0]305;7/9B4

*SUPTY.QI8%+,D_5!LF;[RX=_3VZ>BC$X,KC!Y78[@T=A*7FL"+%Z((E^A0N-MI,D4+4F*>WX15RY;UW7E&_-T]F?@3E*)*

D3DWZDN#MPB9(S'&PIM5B]1:./A@9:W7T'3SIB.Z%=I6$=?/(0R77]!HA?A*C;^-M*3F'QZ+"FD\,QB32-N3,.V-MI;[H.$E,YWD;YBX;)$&\BJ?SB8T9WBAJR1!$

M]BN&B[>LV(=8O<[P*3%-0_9,.:>5F1$N.5X4M74)Q<8C8P-NGCAAV5]Z%=?>_M3+!%K)"D$@!51,6"}0KGUU%B\]>VGW5OYWR\!]N&QK;!$O@6^KLX'7& %=-]*

*MZGN4(B5C#,>]68&Y*U)KY@*5&KDN<_A/P8K%\.W4",8>E9J;Z[A5]LL[FAR1-M]EVL\P24(#"P2AT1PK(C'DLUQLA07-*

*+U1H]'!P\N;1,5\3LL_A?;%^O*3/S:ENV_,1$A%7PN8<.8P[NAI M3;6NI;%Y\8LQ-.RP+^)HFT4F72]!H7A$)=;+WK^G5.RTG+XJZ_'^U1-%8!S?*

M#R90&3;$3__ZCL\W[8Z7O_D2)0Y8Y>Q!\Y6Z#36YM,[$'_74B9$6VNX?NK0\M!4_W[GKW/-R_;U@>',VV-1Z<:,#QY.K0=3Z\'-,NL?I"?Z.BW1-M0%/7];7VPL+A-*

V]W2G"3&UGDL:.%U6:[(J2+^/8'@^U?F-(E-I8XL$N?T?G-M!5VMQ02<%C[!TT"BC7%!SCM5$T:P4X'E),X1#)8B>"2M\005/_L S:5.V7_TK%HG/IS-[S]"(WK>KW6-4>!1<3 M(FJ-*

*89<7#1>2RGSA0KD(!:AIV4W+[KWD,YV6Ol) T-#$1 5Q\F9.:]-;>X^U M=H3U HACU-W1#9+P,70U4T!N^FZ)!K3 H$%_GY,BM!3?8RE;>=]H,=*Z&/>?*

*M3\MK6E[OHPA,OEEK<%35;0!P6!P|E^ ; FKLL)""GKD&YR[%&].''G!;D.R_(-M7=^T3/\X3B|U9&W=[.SBU-QPU2C/8T"PS[AIY@ZL)D4SI#@0[\H-.$URQGZ=-M!$X**

(R=@TNV]XL8MH07P8$]G:*?%8Q^O$B4,3(TQHD-MU_S. RSYE1"]\,$3@)263*CILHM0)Z.2X',,X0;*M<.%S"25I-!GUN-[8<$ M"RJ-

/5@Q4,_@=C;^S%'QQ]$^(E\RC32U]=CE!KZ4U+">'IG+B#8]P/4G-M3,*)LB:2'LK5%9S)F:/,U7K]B@=%C.EWFD$H<&\3+8_1_>AP'AR$8%B9"VQJ0

M@)${[[9KLJTKUX&=RTI&26^)7Y5O:C+YF>G6&I?IOXIEM#2M-V6TX62T$>3 M%'Z03!\6R'BOVPMRO!7DNFTRY35)7909^ZE&6F>$6\XYJ.954N/'#55J!FL-MHF-*

L8:/NZ&TY="8'ZQ, Z]RI4X>5=. ,;3I'@\^2$2+/L-_/;?$;?>#YLZ!Z MAM.ABTZ_08%0))<6<4L86Y2Z6M>P$W'W#%*? J<;]F-*BSJ%=3E:C28*I1O@*

*M_WP=B_\3$]H%%,6'ZJ_1&D.OT=*$]SS)[0V.R8]/Z*U6U&F7($F',0[0Q%B'#P MK^?&Z&EA7)!H7W-*X^ACP_,\""V<"];+&74.=^39=CQ:+Z#N'2MP1-6W<+LA8 M*SDBY]9@RZT'J*

*\^]WL3G'7#UZ]U-L?]Q!^#U]G#YOWD9[:%U\]JCS;0_\M)?]6@,B$:,;$1YB!&;/LAIA5F^LR=XN)NZMHLD*Q%FG;HWZ3NJ T(>H2&OF/:*

MX:6,1PY^0^:/N,YG1(TTR@_P"A_9=]O("VY)!>><=0:"V_C%GC'T,XGLV(H5 M%V3]A"Y,1.*P"U25@?X)DU/O-K 3H]JI'4Q!-KP2YPQ-";]GR? /RF4$S?<*!N,A9;9>89C_,*8ML*?*

GRD7!^,DN1C[GVP2;ZEJ^&1OIU%^ MF-8P,$ L(ME?BIV2'K#I-!K!-*/G.E2A?9C.!A9<;=[)PBE=.B2*4V3O&, M(D=CIL58SJ>.DTFW':S;.&7*(B MIV,"IGISBY4\3C-M:/?*

*RK'/'OK#FEGWMKNU7JX*EB6?\A1{G$\(1>6IQ M_^,%09&#*V,]SKKORKI^Q:OOE_^D .7[7[WT1"PV::I*F(2M1QL5Y,E4\Q.(."V M!V[+(1A:!7)O $ MOW1QKBPV;B#Y$3OQ'N1'\@/XI*

Z3OXD$N@4#MZ6$.H7D;Q[ECTK#JO@+P;A[MU]NO)0N_,Q6//;+8%>6U:G+/3&1CC63FV ,)TX?OMD""':,,"ZZM?1H""EXA MW@@"TE&6-_R\$][431]B\'TE0F>

2\#)@;T"3Z;W1 /PN#G68:[%3.#-N1 MBKRQ5+!F)PP'TUCL[EI0K! EARW0Y//!98U?I@:?!"VC0I*\!K) G(L![&%/ MPP206I3GLD5< H"59SO/FRW0/ENXF\B8-*

*!1RUUOYMT3T)_7J1+4Y9M[27#9U MM<87QZ!,V8R"IN45,RY#P-45$>U#U&:16; (M M\,4UBK>*,GXQ,>46K5J[@VE-R09$3G%AV0!9G32](*7U(M(]9'UG?/:W,E M0#;N4\]B4*

Z@24+K"F&U7!'F,[%P5H!^#E]7U@9&QYH1U?8"?C9G?! A1L8 M9P"SK?HT"Z_W(*8A;?P.KW5;=.K8L+]Y!.FLF+@H=HB=.7;GU:9IM!UM7L[3 M-85C#B.9'B.4U[T*

*%.K2B5]HV]=WQ!^U+A9D)C&M=*PTW\>]e9>]D+ M#0<9#U/O>SJ;G2=*87+XI;9 KI 0U<;FP:MB#U#K;W5B!@V>"-T3$B=$76,*

M!39\%>:3A8LE$@J8L#;P*+D*7V!K\^K\4.D&; MA;&-\5Z/CBD<'P)K]7].9*EBZMUN(T]6]PM)\<3,9XYU*OJ&'DNT%0]M[5B M_/BI> ^E;HLO8R14_:*

*2"B$P@$MAOMW.Y*5ZZ?.GF?/38YC.,4 .;55P&P.[* MF&?'-FKPK\.M5A]PLCT MMD>=.EX>FPD=@?(WHC1'#<74G,=>4P]$.5L K=@M6=&Z&.5%OK](R#VSK0DX)+OK0MV0Q*

*MF;V-7YEIY88R4G*06D%]'XZSU+ ^U4D]W63>O/#&5ZI#X9B/O&H7I'=UX^O7(MJ4]WG>?/TFO+==,EC -X,/%&]&T^-+==B7]R7/PAE=5B,EX!G*

*MTF,5EGOVY19:6.%A5]XI/%7TB_0B<&=E^[HCVRON:5N5W_O_;GP?M(B%8 M)-M+M+]7#K2S!SU>M6S^1.D[*6S2 "ZNBT%54\,8MWSO@6EP\(P/PZRP36!+ MW-*OH\B#X*6*

*:D)N:O\5\3D."@PW^YB=&D??R*FJKS=NDV0]A672:D%G?*]T M_&B%V$?AD DHM2%RA&GE!>UBT2>MS;/W''(/H]I7X]59")*V' O'\IGUU MN*F\#0VN-VJZ+I:T% LNAL2L.9U!/:*

<"WN(@O^;!-%3;80/.X$UIBTNEN$R& M.VI+T284?9B%2'EN\R7C0(,"BHQYW=3]KI7N(BF8E[X6?7@PBR$4#Z/G,@L*

M&X$X9VP>U=V"4N%/SMZW3=Y#3lK5$#EU!8+&@YT%SEI>'YX50(! MZ;N5+]6E8^N9BE:>E!:67;-XIHV8GM7"MHO?O^.58NW'I3EGB_&^%%K);IRT

M^Z6S9B9CU8XODW2U^6WD=XRD74+VU#^CJf@%)S2"FV/A'U:!;-S1L<1=)$&O MV[_U+0-;,+?,2+!;"I\/"O01'-'"UJR!%' ,R,!(Y]'!&326?$I C;>SG\D- MQ16"G!-[+W+YS$O9\S8=*

*<=KMX#Y((_*LR\L(?AGR$MQQAI>?O#O^./QJ"=7E M*X=&(XK9]<916] ,;JS:M^&3,,E=_:(89#$68'N6QL*2>]7P %@:M/?*

*VO3M4AENE'C>]4Y]9996#8";PY153L&%7TB_0B<&=E^[HCVRON:5N5W_O_;GP?M(B%8 M)-

*MK*J5B0";42T3K25@9.NV;I5^-O&Q9+"?AAAW4Z'XR!@Z0N/A^XEZ68,]]$V2-MI.^3XG,1O&?: KW9W\(A2U$28;.K>(1K^*33R??!E1DA*/·'8@DT>CGSR%"?·M3!1D(I\)X$H);F$0*D%X7/*<^>;.X(&/IZ5U;ZVR(0%!AE8+!O2(HX@QZP/·M-KX^E/=S91U%,2 ;7S*7CR"O"1.&Z@%U)'3ZRZK"':X+3Z)RIQQ#1GJ)I'J)·MLDON\!MC2I1S-T!J;YB#OIXGT8$L.D5R;Z2B=+"W/5]T2/7A=_YIK;I[%&Q^_MRN;C>9?'$BG-9E[_#(TPL3DW,SP;'5RZ2##51[4J$%/55Y;(RUDB]H/B\\Z0·M"7]@W!^+X7H;Y=-(&^!]?UP!/RE(DN<;&A"!7O1;*86BOR1>;)_>'L'17FT]·MZE\Y*,M,+\(9F_,V3]PG,JLPNH8->-+'%WH_IJ3C>UP3L-/UUUX&_-[>7SE]·MX/1!%2HQ[DE^Y6_^;U=x=&^S1.{M.899/@)YD[KAM6_LP34SCM^#\83M-'·M$2O,]&YW_'H00#E4(%/]DBG@H:IQ8·G,ELIYRW8O@,(WINUAl\Y4,/.U=-TV·M1(]RUMP^]OPPC)\<9!·A7]R.>]/;?]_/+._+V"=0GXCLX$S#Z3P][(PD\$BP4JTC15S <^;·0ILI·MAY=@A>'4- X,8@*$','90Z\=[,A[+0MR)H\#V;.RS^F]IU;+A[5QMPMOZ(?,J·M3Q%%QR>7D@8FA8T64LPBJ56&ZA%0@?.K4\EQK&_1CZ@_4ZV+TBS_ZPF=F.Q·M-D>RP>,;['&Q_]:T)5#9\Y1> FPH<)+4+4"0N!·#MFN1$RP*%WSF6F*GH,XP9·M(.4Q1(QVI>S+·<[D69#<,*?=;0:Z2MV=KM0==16Z7:?N;ND7QP#\-,M4R$F& M5A\%50H3O1$-A"H#2!$@&THA%Z':N.4ZV*39*BV:?%Y+V32E"@\0.-\7.))H4.M,1$#WQT9_GWNLZH='P,3#/("?+K^%%0'(:'TJN1Z5U|> D·MSZL4SWA"\589.>.D$O!_J4Y6:N\1'!?DB&-·>26'IP3!C7^0*O|[@128?>6N0M·M>N%L&T.7CZN5]<&O1·M^//(·S.>>.^V0Z4%(.L8F&0Z37XM92HYRYGOB"EQ6·M+KF2=<7=@0U(6#S+&PS!##O@\Z@X1QJ;UU5N<,OF@02CX&?R4AIR2K*0UUX?·MC%93>BMKV=U]TOW,:SD"VSDO;;U#,U(0Y8ZR$;(D^,7V=9&/.LIGE3·M(hH7]2L·M0/#'!=DJ29EN:FM5/#*!=@\Z9EN:GOOFEZ&TV*#$YZ3)A·MVM=FXC#5?GVF_=[P5A.=\$1'H_K<*.>K5YXL-#.@V@<@4X$?7]68IT=[$+%Y·MIFOW32(L\Y4Y-A3WQ^.1E.E9,,XA9,N5@>1%,#H ^GAJ]7.2>[N·ML]·I6C "+H#XK!X^"=C#B+(6$^.P,>!E*YD!S·M[H4DL-RK5OH9_I(KHH&>>_E>0;/*"Q%Y/X5HGQS/HA)G0M·F+$I(?IM1@#% M=QEUD$R#_;YP2@(X'&GUN)\[W+3(·]'XPM[K7·M&.O4%FUZ6C.[='6NU*U;;MZ6*U45>LUA6KI9:%1Z@W#&0[T"")@#4'4'E:Y] (R:H!1C1N,*6·!AAH80]MAQQ(:T.FK_&.Q&9I&0XXV00I@V.Z78@%*:'M7RM.9LE&+#!2!#BZ*C1=P;P2@SSZ#4]KLZG=8W#BPOT1Z6?(U&K/Z=1PD9X.D·MI4TMK=+YE@ETQ/Y,KB0RM·I8+'%BY"L "[T;OE·N&;6'F$S·M$TBGN362!_U(ZXS_%S0CHX54K·MV82E=+76KYW;-]$P7C*1T.W9X#S4C:]C"/T6LSR9@KD!]>PDS9#·.DB; 6X2·M"E30X!F^"BB1=ES;1A"H^%F0C Z, C]XMZ2(\!3](6L,"<6VA%,Z/]MDKOV#IZ+1@AVZP$BG%H"@4·M+]!V5C2?+2F9YZT+]>4$ &X[%[_6D*BUFN?;[,1>)\'V(3-$H[O@#;.1I·M·M4>'#_]@TK?G%&C'.(".D·3HS%NX!DHO9L# MD:*<[_"<5)\:&IRXFI5UR<'SX GVY·MY5%NCMC0XVE!^\"1EQLT\?Y=61Y/9FXX)C!#M<>P=]0[.CQX9AP.;&%QU.L? M/JL,.\X2''Z].T"'+$"0QM=7X-/Q4I3GDQ8"K,_Y41·M5?"+=_(G!6/<;I]ZTMI&^!EVIX!%F2&WVI#0/XIP<(0F\,RT?GFP6G\,U [KPAD^K48.AV,.2H4CY2·MA[$PN>V9>·AGY'=M.\V%+'_CN=Z,;WFW4O!>_>O: M$OSI1#]JFB=_"HLH+?8*[X?YXLC?6MYKO^*9[O]55TN#]7H_\A\.@']-OT.-^K^;_]B^6 PVE=1·MOW\XO,N%_9·OT_*K1MJ/1L/I.-S?.XPG·[T%^H?ZI^AH[VC_X&!T.!B.)X.;·MC[2VKML-]F',!R.9O+7ZBG]W>97'DU<59;MN15'MH"MJH[=%T^=*8"\U]]_5"XX-ZG"O

M/F=16\BK44"Z@16I.DNJLNDXK6R/OBOAF[%[\;J =.,%;<>><@6B.[;/>Z&,<7 M$7FZTW^L?GO06"X0&\1#*%X&]>VX9=HAW$]SCE0?'DQ|5

M^!E+F_65'2%>04!SI,\\S^$RY@!=3(@!OWQlN5U;V(F$X'B";^M>ZR/+0;XXF M;&}]]<^5MV>UP#@ONGVENU[HD1Y=#E

M"H%!D;T",%/E#700L6$!A9)@LH,,IZ+Q6/*) ^<[2,TUY=GKV@*LV8QQ ;K@W MKPBB6W-X5+4>3.!#N]2%[J>&QJF4,5'M,; ^;GQON6&A;M%(OT-Z4@M61Z BL M%FE-TEH\WY_0D/E:N6&= S0.C",YI$@$SML2_ZZ9$ 4K-$MT2@4&BN8K)>|\%<9^U}>,/OVBNLR[.2"\%<9TU3=H1#*8T(M]H1 MWE\ *.7RR5>,%%7I:?!" 2S0N8>_D]D\|,,O\E?U"\;\D62:.!KLU-[&X0.^4*# Mn>*M.<3@+V$G7"#\P@H$-J%"KD! = _?.RPWCFS)9GD>WQ]LMJ=-%&QX;/]^L M5AK*-AK6\O;4',OV5)"\I- 56!GF,Q.G0?PE69PKQ)Y%%9]]! 0?

JRU$FBU;K2T5 R[?L\/;RQ,BV4G|9K M;C)7ECYC/5I0..QJ0P5EDP%-(0L9%[/@AQ 8WS4$5 X-4@##D-HA**C3&V5 M5A.#70PJRA\LN @FBJ^=%&=T$4F(336;@<5!C,;>V""75S8?7@#L;;JO>VJX ML4\K W

*&*9_:=3A&1*"W%B]I(U33"1,?/9Y@1BTVZ<5V\3;[J/7A(:_M_Z")W?&VK1C17?'.%XT8#@3+-*_J4BZMBM$W,U-B.X0:V3B<^1>O(S$7K@6*

MI>D@$;S+RN6*A6?)PI4H,LVL&/\,,TKVX/'HE,N8+@*PNO@*N]M+8A^.AZO2 MX*G!^,H*^ (U9OD8@O/Q\+"IO"C/R9X$RQ.(6.24CXJM3,Q>PAOAJ<<.$)19

*M,12Z@=98<^620W5<0\[9[4H MF??>[13YJB'G4/0#NYV\MH+$L8Q>(J8WB74 MH]2Y?8|= MD(#1>'P+7EJD'\13IE0G37IA<)?M!FN!OK5Y\$+YR3PY@^4FY' MH=F8YFU<@EUBD)+YAXGI,1:1)\N6/'l/FZ6)!8.WD"M=N0I5OX=OI3T?-)&GF MSUJUZ.N20MYG"<#:)>Y6!.^ZO*0W)&D|"X*KR MH5!Y@DPB"0E[0O\E*+L,7NXO0<-*

:TD=%I5"1+]1O8=1WL2H7ZJG>AB^1:H!Q MDO)<4R(UZFY.[J,4.CX)1. M!]QKKD:F7(A !SV/(;1",Z6Q(R M6)!/(@U$#Y +_R);6,D#[>02YH>G#2@E@"H1>@QH(%

%X<:AO\T#^"^.9C[/ MHX4T6BV+MA,.1-(?>@=EZ=\C IH/CS;?L#XAE&G#^P9M.19O!%D\7K]9_':MFH^D@1'/GXR0!#YP6)V!<*C+WSWO*.FI]PK@JB(NF9D M>?*

SJ.?!"AF.C503]H^^.R8$!#[L7KPO6M+LY#SI$WH8+_EXF4 I8]^"2Y(R MV)0KH'>)1)^6#+:,EAH5.&:Y>,ZH"2Q\% MB=VES6H-51_E=*?_TC69-*

%,NY7A9(EENN&,K8%I;RIS'H2UMI)\R@=-%Y&$ M8]_Q3#F'\(QC;^D926Q4M!'4 J#/O>_%GEB2JR:HIOK2;]W5TNJ@M[CE0>B MGA\=@N"2A;63]FA*LG<4&A,\D"$&GZOL*R[Z>[&GH<+O)2^UI>ISF0F1E37, M>/%2?E"$F/1VY_;+H)*2]0+5H@ND^N"5]D4O2'5SG,S6E:=V!--4,:V5;?-D M=[VKWKQ4)60R>]T278 ,SUCW^L^*.'S(1|_MG971 1+1;'EH 35MBCE8-*

*SL) M)"E+8G>WX6?"/L3P+95_ZS1N4CKCO>L%BS5V8UXJL\E;%:YB^=0G:R34B0'M ?D-O M4{Q,.T>DNTS#C%$;_|~UGZP[U-21W*RI2JL-GO2PUI7>]ZQI,><;*

*M3%>>OV(XDNTAM$ZO@E?C**+;&$D*1\)0V1(7K).0@B$[=M!"BICH1W#YOB4 MB_?5\E?A^!^&277^W@0^W@F7\F7LNP9B9RBBEI8 DUK[?QFF"$Z7#1+;?FF5*

MCUR86+;T]BR.PHCID>Q@8S>0M^BR5IS<7.CR=F%<+5"$76MMPGB_5D2QGN=M W(X^WWSK;KM9FN':;$[0PZNI-)E95ZT#HZ1PTRQ>.6F<(.?%3NEN3V6&2IW M-*

7HXU$#).A>RV@^33/W*+9HP5-\XTCIA4"V)NU[PC97]=*'NZDY ^(]Y* M#.@J(!M-K3$D.H2SZ#@<^<5BKH"#!0[N=@7/;GKD<,-)#X3I@6\8(BCB !8 M*AL'-Z"_I,- D?-*

*J*0FFYWE0398F9[ZQJ!4:R@AH#L$7%#:AFQ#1A^Y6^92G:-G<5'YU/WJ0)%B&65HN0GR)7 M+F-41$$+\"GVG0[8]XYWCSZ]MR8F&&+1+F>:P#9!@@3O@5;UKAB&A,%I?|\<*

*MBW^O _F"!Q:"I@%>@:GO2A1K0V KJD?T3O4)";1(=8MDOSSH0$%W:UU;.GU8 MFIO(@_QC M+B7P\T;(;2+3\A9'LV56CNR(@P*9XT).5I"<#BCE0@ M(t,%SUDC)XJC@.Y*

*LM8EI;.>LWPP9C(G4K.2-X*4K64Z+,PIF\B<<<-Wl.V!C M(C(!:$>_=9)Z)VFYDPX27UGU%$OB7AZUSV#-7UAEGB*Z51!^1\,.7)TR*,+A MZOC*L*%[O A6OH#U,*

[=DBCQ2!\=/R3+R@<1+E H 7'-/[#,R(V?@N3[Z$F+ M%@#[BAX-5AR+HD@:.G46$/9;)KL,]8#E9A\'1DD%3_KZ1!=XJ M8000IT[\1?FD"=;?+?

*15Z!A9/*R.;3))4ZD%42ZI(GG26;.4AO6&(/`M(OUM94_V/S=CR*SLG4O2O/@U[IG\XO>;'R@L-S 1(%!O99NHDM*$"F*%L65 M:PVA1)"'Q.:\SCEA-_'?BK$WYM76?*

P0L<|=/VTK!]_K2P6)UR52Q3^_M ; M#N8KPYF#W#^15PQW(/VB$T2^<2TZ[5QEB_A+,UT$S;^ZC8B+R'>NANWOH\|=/?Y9)>Z(+/@-))PAZL1+T8HEWN=:L M-Z2ZXZ*CZC*

[%J.O>B[RHB,;DTC-"?P/JSD1)L$@W1!>,B=:,UKI=43!3D\P$ MDE!UQ;4?CHXHCKOHPJ?W.H?9M$!?+)5Y$L<7%ZV(-DA(H M.#,?

*3M3<;9V:ON5IGOU":\EV.HG!MLR4IFT0.N0+#>*M4J) ?&%2F]2- [^3 M\U2,'NXS-7ZA2K)M#X.:%*X&*"606,Z3"R3_7>:;A!VD^$&<(?ZDSA)*>;)5*

*M2>;X%D)/5DL6;QE0=G;Y"*M%Y,JL^,Q+" "$RMMD5ITEG5^"23}OO?_>>2CD M&M#=O?-RPSBFGD-X2|*

*M.302O(7Q$]2WVSP1"S$%IEDB^R]>_Z(#ZYT;ZSOGABM*UM"3Z.PV=##'7Q&%4 MC_6N^Y3T0N0_<0\R/$2HWX>P%=:VE65P?@L\+G0%CL$=.U/1E'S4POP(NV& MVX'?)K1_?A*

M$D5?P0>4%'WMU>EEEC>Y6[XJGLK+V%IG+ W:QTM,J0R?,IE>E% >+,/(+&\D MSY;M,"/8B\7PU\I$3#,;4S@W2?!K3USE\BA,J)7=<'4J'Q4@(T0WIZYS5T

*M.1RSJ\""^E"EJXHGM43&6+.X>)GI'A MT:1,ZBW@+_#981H!V.E+SUQF*ST(% 1#92HDIL*81TYL#SJ-,EQ(@-8%?YTA MO6ZZ8.IWS"-+>/P7R-*

4KYD8[3UC@3$@,5>%PU!%07<+L,R,(T1!S-\N)OT, M"G@TVD(?#J^]\S5/$BF?'Y&IJ U"ANIEAB%1-A(W^2<5!I,;\,5?+ J50RW M>)-*

*)TZ1NN15&T:Y%#C,WF+S5/&&.GH@*B%AS.XNS,C&BVC!:CWLZ-4>&2NT M*>+19,[@8NNV(^]F^A(HO4V?H"%)%]CD.1.4X",P) ^?[U%.KI;_5*

*MFOW96&);0G&8[+;$VCI;)KDR=T'(Y6[QLTGAEQV4Z2).(JZ1283Q45<9P=5 M8<\$1ZE]?8$UUY4!%@KF*@6A!<3>6\13N0WN'"&(&$%2N>51$$*S.@HN,L=<*

*ML/$@(^#B%=.%QVZH7ME(-8V'-2;$'(L)V0AZ^ 'H"DQ"G=TSNHD+ZF@=IY@O [ESY9\[68\=I1[.1 M&H(HLB <76P0(*CS48#@[:*

M#$16]P6AP4FS<#@&$9?. ^7"^MNF2F^1MFO8P M9)F8]V/^YRIQ(,#^2UDR;23&BNL@UBIH&.64I4J4!Z22A?&//>.64@P$";D0 M;9Q7;Q-O9 &2_[_7N?;]\(.4L%B_C#N\]

*GP<0EG&HZ@4-.G;;"0MNS=25WG,D#A^KFN8?KVZG_9\ITBQ^C[WM"&0G2Q\(2&92;7(DPD?9Y&5#EZU3*M@DD5P4P!!70$NC=I(.CX["N M_IDG..6HK8I3K#K]S27?*

*&ZN9UTZ97]C)O*7X9"FPE!6;$_1LP]J4..BUV(H; M{(!)V)WY]QB4$%DN(.P*P"'#)^K D*H_Q*$I9(^\;$ H[0HV 5^LS$AI/2TP MJ^331'DT>%]P1:L*DTZ; W:8)-"C.(GV,&++.(_V W12!D*

*HO,L*AO#"&AZC MS=D@Q1W4%HIQ@#>KQ)-E9\!%MO.=A3

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~!<%8 M:C.TW[]BC8%,0WECC"#2:R>PMEN,MK$)-(]D&Q.FM+& 44 M07(8/!Q%U0(VD]':P4BZ;Z1Y<]Q"-=*!VD'(H_?;P6@=?C]N"SG8.\OSD!N3 M#HTU@;21 XN$E9U2@V6,N&$YW]52"\&@V"D:5H)XA;@6>\A4 ;6&UO+>-<7)5F&@%DDOS_C-;(O!!OU"8N<0C*QAL!D*HA\!0CHA&5J.G$CN+ M\MU+Z/\5 @*!Y4&&+$^11#36G9FQ>BD%0VTOO9Y@=ZCU]1"F$IKE*""A6(S0!7;9Q:KAZ3"1 -+E0N%/0BKDH[3C M^Q^.Y6T_G8>C0=9QI6[" B1T^9&T!(S"97_GUH\X~CZ7PCN3L9O?ON.RA6 MA0.114QO)A@!DJ !$9,(2NY16M>?1@7<~GB#G!LE$(+PRF+&H$:B.=#-',G M9^D#M8SU10I8O8.]$^V#&F]7NY6,0 (H,)S GSA33S7 J/DJ1@!?+OY6]?Q& M#H[ZJG-_RA[\O*$K>TZ[8+V5X&Y-%9^G(_+9_W<04:<=\G"OWQC"6]W7E+: MG;"H!B;'$Y8S AWWG.+*F3GN%]'.F\4U&*A/-P+<-!+C%Q__?N?1$ 5^R7+^_M2". X'5[_K%9<^@?#;]1Q>M1VS:2]XHU74,[%[WW++<@=CO.\CHLM1C1*D<]. MY:/U^.L(6$|=FP+0."_,8+|\$M\8L["D997RP@H.!X7I97#_OS]FT)*7 M^O?<+'_2'0ZZ4&_P>?IT ^AZT]~6_IJ_<:?OO_IQ^__&%]?ON?OCW^D&'@F M_R?-14_'+%Q+]Z<7OSMOX>%^,O7!'6+_\|3}4#H.(N\@C;1O?.{?G%_-A;A1 M/V4X.XPV:/RI^/O > &{6B!O/SAO4.M:0&KCAMXDX+]T)QMED=]V2C#E=]6\V;'VNP^6^ ->3GNWWR7L\'B#P-MBG&^ M9[1U@%]X(21&=Q FXQ?M>P>B*^V<.B@ M^(3>A?B*?'9+]$8A-HNC!MT@KU5497^%0<-NC^=!K.ZO,&K0#=[L$=X2?O(5 M^Q_AK@Z1_-'#;O@SJP[$V+-XM]6APS(CA42+!*F>231K\[A?+#',O?CQD6,Q* MV_M4<V#.Y.$'\ M/T0-RR(=*AOFC=6\V1\;;/8'+9N%_@I+O/(_O+JMYD;]V"C-DUYBZK[SUF)Y M53!<'VY9{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f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{/D)PHNC? ,RR6P&28:^0'FAO^E%Q&Q2+[8MS/ GG-I,7 U^\PS M3^]NH\)U+7EF9H$LOCNJBI9Y7CGE1Y+O*(MQ]&72.&KV)M8YYN:&LE.>P9ZP MY8>6:Q*VFN&GZH6 M-"!C)CALQ^D5A/AI(ZZ>TGC3*FK%_ MB9.G6S2-VUZC$D@T"^KJRX(S$ZJK9_HG!D/-@@C5#3U<_O_G29-8_,&?$\75 M"]9.(Z5FSP O8*Q3-/W$T.2A+3PMDB%*P2[!#TR;!1EUXE!D8.TOD\9:L\LG M$!JZ19-I"%TU^F%(=)A%U&X(S?PWZC()10(A[U*K. M,B%IO>'549EI EB*ET8VPQPPI-=%--J<[===?E/Y;.9^Y. (5XO!ER M7UM;F^I;.XO@V&Z06&5/LXBHZA)Y"5.<17Q*EXCCM0J9MM?OE.BA6C%I%A;R M#€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

E1P$CP;!!-PE9ELM-81=<8I&/[92K!+#WT^G+GD:<+4L>) M]HRPL(Z]>*P!CL@'RSV 5$+DC72!+<8+KRD'XSB8DZFS(OR0\INU]VL#G;DG*-M?V0S-/I*,5]39>&56FXV!.DXN'>L-OI,FN)?RHP:+:&UXJ_@007R7GJUP>*;8?2*8@GL-50L>D.VL+<)f['>+EN?(1-6(512>?_,U-M.@4AJ<^5RH6<+5;'](Y%,+M<7ODLWK41[G@SS=&0LNHMHC1!Z11]'6ZPO\?6 M/FZF^N8Z6[H_8;<;T7!H0A9Z"I/>=!\O=S<.C@(GI&_(B(!)7XRT;&HSS<$-M1!8Y[JSC?3UAAX@5>61@?R9]H$/Q5A,&H M*Q)9U!5HRUFK)XVO-M!H;N L+!#,]31HK<2!@UXJC&3QX[M8;PI&F&O@#Pl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`I<2/LQ)0?H6^,R",(= F#6=A[QW,"6D/Q M'-0=2Z ,E^$"KR;3[C-D1/L0*T@1(+>A&=1.\\U$&I&LM="/$FC&I4-+&,.5Y$MI>962_1QL>(C5M9GR@@=(\M-M'Q.^;>$C-69"[B;8U'PJA23]E5#[ZN^+FM%(-AL?Z"7A? &^6+AJMSSZ PMH[ M6!S#V6KF(> Z83(W&VS3@W>$F0 =[_"#&5Q^,_DE-%G`&-2ZW/_-`V$ &WW MN0=E[W@LG]70X7OA'V]FG+AS+30,&2#Z#A; [0D1KR4@N<<2TQL3W%4QL+#=C M(;[@VM0Z^>V^(&BW ;j5L=UHS#@$YH'\[%N[8.W-;F_+C.Y)47*)\7@DP,=V MZVZA3\WA9F.A_G+46M6+=T1[OOXI*I1\)"7W== IV/5*P&YO'\RA0.T";C)D= .M61FOHS?T;5.SE%6R0X\3I28_W(<==#C MXR'V!/2!LQ],>SX*#H.10]SH\:AU08P<&:.U8]8(CHP^T_&C:K9!0TLCA;W1' M.$Z@&I/_D[U"GI=B!P\YGTV#7(%K[(&'OYB&ASZ]G7K[(^*MI2.C5F=<'!O]F M)@8Y?KP^H/_)-.A:+;L!>=!#CO%[-595>\&*5%?/&3,TJ2PL0 MO(3^^O>= [Y)#"6[^%=!RBN*"PRHFR+RWAVI]M>K-?1/J+5]PK{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|=.89:1$!53:LFXT#=/=O&TY-TM\T9]2CITKH? R2/=5H(O6H7VIY+10>.OJXC 0WLAO1%W)&B D0@BJ0(SG0>@%);(1+!"(:@_;(X;_U0DI>P5&@X!P2W0XES4WPO2)+ MU6LU$IS(WL>ND=(O&QTR&+@7NX_$R6 ROOK7235%%_]4'7J2-%_,_:PZ7ZL MI1TYCTQ&[G!7K G+'WG-S9[(4=U=9S+^AJ,X@1(^\OJ<_1 7K+'7ABT%QSS7.!C2/"+;MN]\Z^("-CD@3]G=(TMH^O*=PE< M/]95(JL&Z[7@Y[R0IY;VU=F'.@W$? 41A5B._[$/U]WF\DY_SP,YY8#KP>DZZ MZB/IZIRI-+_I7&G79[3='IE2>8ZK?):(V(AF8O MO1PU@NZ"FN8 &K1[9.8KQI:6K$]

*[TF'LY'R$+,1HP@:H?"Q\XX*.%$|6Z,J,A;&9\2+Z>WFL_ MP-]^#.+(#3;4*1JF[XE198^UJ+B,GN_,<'C4.3&MI\QCQ=U993%EV*/,W M,.O)[_\#4$L#!!0 (.B!9EDG ON%F"U(%O@M9E[YMBMY>_RNYG PGLU%\A,"HDYAEIM@(YS<5_?G+6M[YTJF0K3=_4'5CK)?:3QM9 M%$K/4_%-LYY62E.R(#5?^%1,IE\&+85:]F-TPHDW33H>7BD]_251NJ!UFEQ. M:Z7[OA.T-,8IKXQ.+572]R5-,I-.G/]%M67&%F03O(&26=./?QKM6832R;CQ MTVARU#8-,:6L5;5)?U(U.?$CK<1'4TO="V;&>U-#UM/:)}}2_#WG:=GQQQ/-365L^FH<_DWOG_8]MABTS53$LNV3YMSC@NOU0F7*BPC+K2-.=,'DF\-?I5?5BTG\@}[\AZ5:1<\B(0 M'UKK6]PWX8WXV%8D)IO'^'9BZ?O[*IS'Y/N!^"#;2GP,$=I=\"ZHUHM;4CNFP[L"MQD!EQ;33K_EH&X0G4RE7(^DBN8J7\ M A-T#>7!0!ZW@6FFP#27Z%:(;+/OAA<#BLM/@()$]33D2ZRLRN])YU188$Z'<\^D ,%"\)F&_8Q QN*IJAY(N0.Y(-8PM0MTT8(FVM@@"@81" H,X%>W+I%J*LS,KUN+$T5\Y;SC"27T:[8>5@+_RN-^;6M2|&:,^' MXJ<#=WWU:GTQGGP[=5V0N\S"Z\B42-]XQ9Y\+Z2ES#/$0&5(U_"M(EJY1; ML#B+U>0YA%^+I3+*^-;I&/]UE0Q>(TU.15X[<098E40@A\#8Z@X9KL.W(P NX+//SYV XX1>2R=:=W8:[,""J-$7V-ZW% %C 2^4"+4"*M=!B'JY\=Hz>R34MQS(? = _>^"-^@(BQL5R6V.%.10OI@:..94H.15/ $5DU2@ M2]8/1(9[1DUI,.R./BA"$E M;=&'%X:3,E.5\AM.27>19; ')(0@1YP>B.X5-X%=+69'U]5U8 M%/1= 7NF//A+ 4$!6HGNO1TFWN%TV3^TW V&#[ ))R&3YZWE:.PQ_EW#UL9Y M-.1<$)>P$"-UNU=Q=E^?$L#"2C\2[VO'}4QA?\9;~]UN+3N/=BVDVR9(YH@ M1"H">0:7=,2VP2[LAJINLW8D/_CU7GHD^IYGC7WUZ!H[?-PH>N0.=HN9N64? M.[MUS<%_0-*\50_M;),HBKRQ;INHP@N,66.C[XD^Q9V902YD@4+!PC#*&2 & MJG),A?C-M5F_,NCG5F$"81&T.@_[NO.75$SS1IBKC_!|% ;PUB17A&AU269;MU^YWG#6B-D_Y(U0MX0;/\VF^$$8Z.K/N)V|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

gaap:SellingAndMarketingExpenseMember 2024-01-012024-09-30 0001369290 us-gaap:RetainedEarningsMember 2022-12-31 0001369290 us-gaap:CommonStockMember 2023-03-31 0001369290 myo:UnderwriterWarrantsMember 2024-01-012024-09-30 0001369290 us-gaap:CommercialPaperMember 2024-09-30 0001369290 stpr:DEus-gaap:SalesRevenueProductLineMemberus-gaap:GeographicConcentrationRiskMember 2024-07-012024-09-30 0001369290 myo:ClinicalAndMedicalProvidersMember 2024-07-012024-09-30 0001369290 us-gaap:RetainedEarningsMember 2023-09-30 0001369290 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-012023-09-30 0001369290 myo:PreFundedWarrantsMember 2024-03-31 0001369290 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0001369290 2024-01-012024-03-31 0001369290 2024-01-192024-01-19 0001369290 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-012023-09-30 0001369290 2024-07-11 0001369290 us-gaap:TreasuryStockCommonMember 2024-03-31 0001369290 us-gaap:EmployeeStockOptionMember 2023-01-012023-09-30 0001369290 us-gaap:DirectorsAndOfficersLiabilityInsuranceMember 2023-06-30 0001369290 us-gaap:CostOfSalesMember 2024-07-012024-09-30 0001369290 us-gaap:DirectorsAndOfficersLiabilityInsuranceMember 2024-04-012024-06-30 0001369290 myo:AccumulatedComprehensiveIncomeMember 2023-01-012023-03-31 0001369290 us-gaap:TreasuryStockCommonMember 2022-12-31 0001369290 us-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0001369290 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-09-30 0001369290 myo:OtherInternationalLocationsMemberus-gaap:SalesRevenueProductLineMemberus-gaap:GeographicConcentrationRiskMember 2023-01-012023-09-30 0001369290 country:USus-gaap:SalesRevenueProductLineMemberus-gaap:GeographicConcentrationRiskMember 2024-01-012024-09-30 0001369290 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001369290 myo:DirectToPatientMember 2023-01-012023-09-30 0001369290 us-gaap:TreasuryStockCommonMember 2024-09-30 0001369290 us-gaap:CommonStockMember 2024-09-30 0001369290 2024-01-19 0001369290 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0001369290 myo:JiangxiMyomoMedicalAssistiveApplianceCoLtdMember 2022-03-28 0001369290 us-gaap:CommercialPaperMember 2023-12-31 0001369290 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001369290 myo:AccumulatedComprehensiveIncomeMember 2024-04-012024-06-30 0001369290 myo:PreFundedWarrantsMember 2023-03-31 0001369290 us-gaap:RetainedEarningsMember 2023-12-31 0001369290 us-gaap:CommonStockMember 2023-12-31 0001369290 us-gaap:MoneyMarketFundsMember 2023-12-31 0001369290 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001369290 myo:PatientsWithMedicareAdvantageInsurancePlansMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0001369290 us-gaap:ProductMember 2023-01-012023-09-30 0001369290 myo:DirectToPatientMember 2024-01-012024-09-30 0001369290 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0001369290 myo:AccumulatedComprehensiveIncomeMember 2022-12-31 0001369290 us-gaap:SellingAndMarketingExpenseMember 2023-07-012023-09-30 0001369290 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0001369290 myo:AccumulatedComprehensiveIncomeMember 2023-06-30 0001369290 us-gaap:CommercialPaperMember 2023-12-31 0001369290 myo:ClinicalAndMedicalProvidersMember 2023-01-012023-09-30 0001369290 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30 0001369290 us-gaap:LicenseMembermyo:OtherInternationalLocationsMemberus-gaap:SalesRevenueProductLineMemberus-gaap:GeographicConcentrationRiskMember 2023-01-012023-09-30 0001369290 us-gaap:CommonStockMember 2024-01-012024-03-31 0001369290 myo:AccumulatedComprehensiveIncomeMember 2023-12-31 0001369290 us-gaap:CommonStockMember 2024-06-30 0001369290 us-gaap:SellingAndMarketingExpenseMember 2024-07-012024-09-30 0001369290 stpr:DEus-gaap:SalesRevenueProductLineMemberus-gaap:GeographicConcentrationRiskMember 2023-01-012023-09-30 0001369290 country:USus-gaap:SalesRevenueProductLineMemberus-gaap:GeographicConcentrationRiskMember 2023-07-012023-09-30 0001369290 myo:RestrictedCashMember 2024-09-30 0001369290 myo:OneUSInsurancePayerMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0001369290 2024-04-012024-06-30 0001369290 2024-08-31 0001369290 myo:ClinicalAndMedicalProvidersMember 2023-07-012023-09-30 0001369290 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001369290 us-gaap:EmployeeStockOptionMember 2024-09-30 0001369290 us-gaap:TreasuryStockCommonMember 2023-12-31 0001369290 myo:OtherWarrantsMember 2023-01-012023-09-30 0001369290 myo:RestrictedCashMember 2023-12-31 0001369290 us-gaap:CostOfSalesMember 2023-07-012023-09-30 0001369290 us-gaap:RetainedEarningsMember 2023-04-012023-06-30 0001369290 country:CNus-gaap:SalesRevenueProductLineMemberus-gaap:GeographicConcentrationRiskMember 2023-01-012023-09-30 0001369290 us-gaap:MoneyMarketFundsMember 2024-09-30 0001369290 2023-01-012023-09-30 0001369290 myo:OneInsurerMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0001369290 myo:TwoThousandAndEighteenStockOptionAndIncentivePlanMember 2024-09-30 0001369290 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0001369290 myo:DirectToPatientMember 2023-07-012023-09-30 0001369290 us-gaap:CommonStockMember 2023-01-012023-03-31 0001369290 us-gaap:RevolvingCreditFacilityMembermyo:LoanAndSecurityAgreementMember 2024-07-112024-07-11 0001369290 myo:OneUSInsurancePayerMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-09-30 0001369290 2023-01-012023-03-31 0001369290 myo:AccumulatedComprehensiveIncomeMember 2024-03-31 0001369290 2023-04-012023-06-30 0001369290 us-gaap:RetainedEarningsMember 2024-03-31 0001369290 us-gaap:CommonStockMember 2024-03-31 0001369290 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001369290 myo:ClinicalAndMedicalProvidersMember 2024-01-012024-09-30 pure shares iso4217:USD shares myo:Insurer myo:Customer iso4217:USDfalse0001369290--12-31Q3 0010-Qtrue2024-09-302024false001-38109MYOMO, INC.DE47-0944526137 Portland St.4th FloorBostonMA02114617996-9058Common Stock, $0.0001 par value per shareMYONYSEAMERYesYesNon-accelerated Filertruefalsefalse3024587066226756871306019946623729387238265833835131803507968569598850147041441365098337500004669626635545613251757942054409123702854457-9693080927276464646492923348989350163128711458156892075865029523048274212719855050000017649209207586507952320482742144847752262031159067559126957553-2024369-5961384-5798371760201123003185553020530467060980701240998407602041709318555196115-881533-1982660-5642829-5602256848764635628081985204-966409-2029016-5923648-5687461379505153795051535266361352666361373593663735936627537357275373 57-0.03-0.03-0.06-0.06-0.16-0.16-0.21-0.21-966409-2029016-5923648-5687461256354-47072311939-52640492-77412686025684 6-47846312065-51780-709563-2076862-5611583-5739241271350612715105840239836 69-9693080927-6464898935054725715421813545986364598771224730908147631387631383005443 1-3132028832028863842638423842-3835632-3835632287898232881115222704714 51-10076644127-6464108997576368016 3-63-91893-91893774730777-8623-8623-1121607-1121607302013543021111430314138888-10188804827-6464967771142828 4-4324185324185256846256846-966409-9664093024418230251117544953957 34-10285445727-6464929233477506357775951050714322 7-8878324427-6464635936528216638561316907413173614777361609468309261553562064012206401217102717102765788657886442954-2644295209225302092100954887109015-9142753927-6464963199116744169499 18-8165-8147280061280061-71357-7135716341634-1014150-1014150210902921101012267833929 2-9244168927-6464882003233241354133345412915047291558819200001178801033928103392810099130313303943303 94-47846-0-47846-2029016-2029016265154622652105506182-8554-9447070527-6464110231 11-5923648-5687461114346136416552580781513118520052571262 60-9984019659230105 3-8418049271111635262559615731939010061495143958416640-19797189579521419782021 37-74944-366675-3528202346095 33-6655632-3817020548275752098667595814140000004998771141511613180-4324017459877166236337631383097940088147-1995005162409971342664 12-6610126369156578068713065345967699767569117470508186 0-91952126860 Note 1 — Description of Business Myomo Inc. (“Myomo” or the Company”) is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro ® myoelectric upper limb orthosis product is registered with the U.S. Food and Drug Administration as a Class II medical device. The Company sells its products directly to patients, to Orthotics and Prosthetics (“O&P”) providers around the world, the Veterans Health Administration, and distributors in Europe and Australia. The Company was incorporated in the State of Delaware on September 1, 2004 and is headquartered in Boston, Massachusetts. Note 2 — Liquidity The Company incurred net losses of approximately $5,923,600 and $5,687,500 during the nine months ended September 30, 2024 and 2023, respectively, and has an accumulated deficit of approximately $102,850,000 at September 30, 2024. Cash used in operating activities was approximately <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$6,660,000 and $3,817,000 for the nine months ended September 30, 2024 and 2023, respectively. The Company’s historical losses and cash used in operations are indicators of substantial doubt regarding the Company’s ability to continue as a going concern. Based upon its current cash and cash equivalents, as well as the availability under its credit line (see below) and the future expected cash flows, the Company believes that its available cash and cash equivalents will fund its operations for at least the next twelve months from the issuance date of these financial statements. The Company has historically funded its operations through financing activities, including raising equity and debt. On July 11, 2024, the Company entered into a Loan and Security Agreement with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, which provides the Company the ability to borrow up to $4.0 million against eligible accounts receivable. Availability under the credit line, which is undrawn as of the issuance date of these financial statements, is approximately $0.9 million. See Note 7 - Line of Credit for further discussion. On January 19, 2024, the Company completed a registered direct equity offering, selling 1,354,218 shares of common stock and 224,730 pre-funded warrants to purchase common stock at $3.80 per share, or $3.7999 per pre-funded warrant, generating net proceeds after fees and expenses of approximately $5.4 million. On August 29, 2023, the Company completed a public equity offering, generating proceeds after fees and expenses of approximately $3.9<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New

Roman;min-width:fit-content;"> million, selling 5,413,334 shares of common stock and 1,920,000 pre-funded warrants to purchase common stock at $0.60 per share or at $0.5999 per pre-funded warrant. On January 17, 2023, the Company completed a public equity offering, generating proceeds after fees and expenses of approximately $5.7 million, selling 13,169,074 shares of common stock and 6,830,926 to pre-funded warrants to purchase common stock at $0.325 per share or at $0.3249 per pre-funded warrant. See Note 8 – Common Stock and Warrants for further discussion. Financing activities, such as the line of credit and the recently completed registered direct equity offering, are enabling the Company to sustain its operations. Management's operating plans are primarily focused on growing revenues in its direct billing channel by serving an increasing number of Medicare patients and training O&P providers in the United States, which will enable them to provide the MyoPro to their patients, which is expected to result in further revenue growth in 2025 and beyond. Based on the final fees published by the Centers for Medicare and Medicaid Services ("CMS") for the Company's products, which became effective on April 1, 2024, if its supply chain is able to meet its volume requirements without disruption, the Company is able to compensate for additional advertising spending in the second half of 2024 above its original plan, expected payments are received and there is no increase in days sales outstanding in the fourth quarter, the Company believes it can achieve operating cash flow breakeven on a quarterly basis in the fourth quarter of 2024. In addition, the Company believes that it has access to capital resources through the use of its line of credit, possible public or private equity offerings, exercises of outstanding warrants, or other means. Based on the Company's latitude as to the timing and amount of certain expenses, its current cash position, availability under its line of credit and operating plans, the Company believes that the substantial doubt is alleviated as of the issuance date of these financial statements. However, there can be no assurance that the Company will be successful in implementing its operating plans.
5923600568750010285000066600003817000400000090000013542182247303.83.799954000003900000541333419200000.60.5999570000013169074683092603250.3249
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Note 3 — Summary of Significant Accounting Policies Interim Financial Statements The accompanying unaudited condensed consolidated financial statements and notes are representations of the Company's management, who are responsible for their integrity and objectivity. These statements have been prepared in accordance with United States generally accepted accounting principles ("U.S. GAAP") for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) that are considered necessary for a fair presentation of the condensed consolidated financial statements of the Company as of September 30, 2024 and for the three and nine months ended September 30, 2024 and 2023. The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the operating results for the fiscal year ending December 31, 2024, or any other period. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and related disclosures of the Company as of December 31, 2023 and 2022 and for the years then ended, included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. Basis of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary Myomo Europe GmbH. All significant intercompany balances and transactions are eliminated. Comprehensive Income (Loss) Comprehensive loss includes all changes in equity during a period, except those resulting from investments by stockholders and distributions to stockholders. The Company's comprehensive loss includes changes in foreign currency translation adjustments and unrealized gains and losses on short term investments. There was a reclassification, which management does not consider to be material, out of accumulated other comprehensive income (loss) to other (income) expense related to realized gains or losses on short-term investments in the three and nine months ended September 30, 2024. There were no reclassifications in the three and nine months ended September 30, 2023. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America require management to make estimates and assumptions that affect certain reported amounts and disclosures. These estimates and assumptions are reviewed on an on-going basis and updated as appropriate. Actual results could differ from these estimates. The Company's significant estimates include deferred tax valuation allowances, valuation of stock-based compensation, warranty obligations and reserves for slow-moving inventory. Cash, Cash Equivalents and Short-Term Investments The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents consist principally of deposit accounts and money market accounts at September 30, 2024 and December 31, 2023. The Company considers all investments with an original maturity of greater than three months but less than one year to be short-term investments. There were no instruments classified as short-term investments as of September 30, 2024. Short-term investments as of December 31, 2023 consists of commercial paper, U.S. Treasury Bills and short-term corporate debt securities, which were classified as held-to-maturity, and certificates of deposit totaling approximately $1,994,700 as of December 31, 2023. The Company determines the appropriate balance sheet classification of its investments at the time of purchases and evaluates the classification at each balance sheet date. Under the new lease, the Company's provided a security deposit to the landlord in the form of a letter of credit for $375,000. The Company has collateralized the letter of credit with cash in a separate bank account, which is accounted for as a long-term restricted cash on the condensed consolidated balance sheet as of September 30, 2024.   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.72%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30,
2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31,
2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Cash, cash equivalents, and restricted cash </td> <td style="vertical-align:bottom;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Cash </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">850,544</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,231,871 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,772,131 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,893,387 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 746,048 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Restricted Cash </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 375,000 </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,997,675</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6,871,306 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"> <td style="background-color:#cff0fc;vertical-align:top;"> Short-term investments </td> <td style="background-color:#ffffff;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:#ffffff;vertical-align:bottom;"> </td> <td style="background-color:#ffffff;vertical-align:bottom;"> </td> <td style="background-color:#ffffff;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:#ffffff;vertical-align:bottom;"> </td> <td style="background-color:#ffffff;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> US government agency debt securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,497,099 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> <span style="min-

width:fit-content;"> </td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 497,563 </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,994,662 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Accounts Receivable and Allowance for Credit Losses The Company reports accounts receivable at invoiced amounts less an allowance for credit losses. The Company evaluates its accounts receivable on a continuous basis and, if necessary, establishes an allowance for credit losses based on a number of factors, including current credit conditions and customer payment history. The Company does not require collateral or accrue interest on accounts receivable and credit terms are generally 30 days. At September 30, 2024, and December 31, 2023, the Company recorded an allowance for credit losses accounts which was immaterial to the condensed consolidated financial statements. Joint Venture On March 28, 2022, the Company invested cash consideration of $199,000 for a 19.9% ownership stake in Jiangxi Myomo Medical Assistive Appliance Co. Ltd. (the “JV Company”), a company headquartered in China that is majority-owned by Beijing Ryzur Medical Investment Co., Ltd. (“Ryzur Medical”). The JV Company will manufacture and sell the Company’s current and future products in greater China, including Hong Kong, Macau and Taiwan. The Company accounts for its investment in the JV Company under the equity method because the Company exerts significant influence over its management. The investment was fully written off as of December 31, 2023, due to the recording of the Company’s share of the losses of the JV Company in prior periods, which were recorded to other expense (income) in the condensed consolidated statement of operations, the Company has no obligation to fund any losses incurred by the JV Company. Revenue Recognition The Company accounts for revenue under ASC 606, “Revenue from Contracts with Customers” and all of the related amendments (Topic 606). Revenues under Topic 606 are required to be recognized either at a “point in time” or “over time,” depending on the facts and circumstances of the arrangement and are evaluated using a five-step model. Generally, the Company recognizes revenue at a point in time. The Company recognizes revenue after applying the following five steps: 1) Identification of the contract, or contracts, with a customer, 2) Identification of the performance obligations in the contract, including whether they are distinct within the context of the contract, 3) Determination of the transaction price, including the constraint on variable consideration, 4) Allocation of the transaction price to the performance obligations in the contract, and 5) Recognition of revenue when, or as, performance obligations are satisfied. Revenue is recognized when control of these services is transferred to our customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. Product Revenue Increasingly, the Company derives its revenue from direct billing. The Company also derives revenue from the sale of its products to O&P providers in the United States and internationally and the Veterans Administration (“VA”). Under direct billing, the Company recognizes revenue when all of the following criteria are met: (i) The product has been delivered to the patient, including completion of initial instruction on its use, (ii) Collection is deemed probable and it has been determined that a significant reversal of the revenue to be recognized is not deemed probable when the uncertainty associated with the variable consideration is resolved. As an example, the Company will record revenue if it is notified that insurance intends to pay and a payment amount is provided, and (iii) The amount to be collected is estimable using the “expected value” estimation techniques, or the “most likely amount” as defined in ASC 606. For revenue derived from certain payers, including CMS, where the Company has demonstrated sufficient payment history, the Company recognizes revenue when it receives either a pre-authorization from the payer, or, in the case of Medicare patients, when the Company has gathered appropriate medical documentation from the patient that demonstrates compliance with the Company’s inclusion criteria, control passes to the patient upon delivery of the device in an amount that reflects the consideration the Company expects to receive in exchange for the device and the claim has been submitted to the payer. These payers represented 93% and 69% of direct billing channel revenue during the three months ended September 30, 2024<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-

family:Times New Roman;min-width:fit-content;"> and 2023, respectively. These payers represented 88% and 61% of direct billing channel revenue during the nine months ended September 30, 2024 and September 30, 2023, respectively. During the three months ended September 30, 2024, revenues from patients covered by Medicare Part B were recorded at the time the device was delivered and the claim submitted to CMS for an amount that was expected to be received from CMS and supplemental insurance payers, as applicable. Depending on the timing of product deliveries to customers, which is when cost of revenue must be recorded, and when the Company meets the criteria to record revenue, there may be fluctuations in gross margin. During the three months ended September 30, 2024 and 2023, the Company recognized revenue of approximately $2,440,900 and $1,324,300, respectively, and during the nine months ended September 30, 2024 and 2023, the Company recognized revenue of approximately $2,185,300 and $2,305,500, respectively, from third-party payers for which costs related to the completion of the Company's performance obligations were not recorded in the current period. For revenues derived from O&P providers and the VA, the Company recognizes revenue when control passes to the customer in an amount that reflects the consideration the Company expects to receive in exchange for those services. Revenues may be recognized upon shipment or upon delivery, depending on the terms of the arrangement, provided that persuasive evidence of an arrangement exists, there are no uncertainties regarding customer acceptance and collectability is deemed probable. The Company has elected to record taxes collected from customers on a net basis and does not include tax amounts in revenue or cost of revenue. License Revenue If a license to the Company's intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when the license is transferred to the customer, the customer is able to use and benefit from the license, and collectability is deemed probable. On January 21, 2021, the Company entered into a definitive agreement with Ryzur Medical to form the JV Company to manufacture and sell the Company's current and future products in greater China, including Hong Kong, Macau and Taiwan (the "JV Agreement"). Under the JV Agreement, the Company is entitled to receive an upfront license fee of $2.7 million. As of September 30, 2023, the final portion of the initial license fee has been paid in full and recognized as license revenue. In addition, the Company is entitled to receive a guaranteed minimum payment for purchase of MyoPro Control Units for a period of ten years from the effective date of the JV Agreement. The Company will recognize revenue on these amounts upon invoicing of the JV Company as long as the collectability is deemed to be assured. Contract Balances The timing of revenue recognition may differ from the timing of payment by customers. The Company records a receivable when revenue is recognized prior to payment and there is an unconditional right to payment. Alternatively, when payment precedes the provision of the related services, the Company records deferred revenue until the performance obligations are satisfied. The Company had approximately $32,000 of deferred revenue as of September 30, 2024, and approximately $8,500 of deferred revenue as of December 31, 2023, the outstanding deferred revenue is expected to be recognized by the end of the fourth quarter of 2024.</p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Disaggregated Revenue from Contracts with Customers</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table presents revenue by major source:</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:78.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:40.718%;box-sizing:content-box;"></td> <td style="width:1.282%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.743%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.282%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.743%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.282%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.026%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.282%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.641%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">For the Three Months
Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">For the Nine Months
Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Direct to patient</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,431,751 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span style="color:#000000;min-width:fit-

content;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,501,958</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,491,584 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,245,345</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Clinical/Medical providers</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,775,835</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,527,565</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,991,158 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,474,510</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">License revenue</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,764,920</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total revenue from contracts with customers</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 9,207,586 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,079,523</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 20,482,742 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 14,484,775 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table> Geographic Data The Company generated 88% of its total revenue from the United States and 12% from Germany for the three months ended September 30, 2024. The Company generated 78% of its total revenue from the United States, 19% from China and 3% from Germany for the three months ended September 30, 2023.<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times

New Roman;min-width:fit-content;">   During the nine months ended September 30, 2024, the Company generated 85% of its total revenues from the United States, 14% from Germany and 1% from other international locations. During the nine months ended September 30, 2023, the Company generated 72% of its total revenues from the United States, 14% from Germany, 13% from China, and 1% from other international locations. Excluding license revenue during the nine months ended September 30, 2023, the Company generated 82% of its product revenues from the United States, 16% from Germany and 2% from other international locations. Cost of Revenue In conjunction with the adoption of ASC 606, there are certain cases in which the Company will expense costs when incurred as required by ASC 340-40-25. In certain cases, the Company ships the MyoPro device to O&P providers, or provides the device directly to patients, pending reimbursement from third-party payers, after which revenue is recognized. For the three and nine months ended September 30, 2024, the Company recorded cost of goods sold of approximately $107,200 and $140,800, respectively, without corresponding revenue. For the three and nine months ended September 30, 2023, the Company recorded cost of goods sold of $32,800 and $76,900, respectively, without corresponding revenue. Direct billing fees paid to O&P providers for services they provide in conjunction with patient evaluations are expensed as incurred as required by ASC 340-40-25, as a cost of obtaining a contract. These costs are recorded as sales and marketing expense. Internal costs incurred and fees paid to O&P providers to measure, fit and deliver the device to patients are expensed to cost of revenue. Advertising The Company charges the costs of advertising to operating expenses as incurred. Advertising expense amounted to approximately $1,043,700 and $822,500 for the three months ended September 30, 2024 and 2023, respectively, and approximately $2,680,600 and $2,360,400 during the nine months ended September 30, 2024 and 2023, respectively. Foreign Currency Translation The functional currency of the Company’s foreign subsidiary, Myomo Europe GmbH, is the Euro. Foreign exchange translation gains and losses from the Euro to U.S. dollars are included in other comprehensive (loss) gain. The Company recorded a gain of approximately $256,400 and a loss of approximately $47,100 during the three months ended September 30, 2024 and 2023, respectively, and a gain of approximately $312,000 and a loss of approximately $50,500 during the nine months ended September 30, 2024 and 2023, respectively, which are included in accumulated other comprehensive income in the condensed consolidated balance sheet. Transaction and translation foreign exchange gains and losses from a foreign currency to the functional currency are included in cost of goods sold in the consolidated statements of operations. Such amounts were immaterial for the three and nine months ended September 30, 2024 and 2023, respectively. The balance sheet is translated using the spot rate on the day of reporting and the statement of operations is translated monthly using the average rate for the month.   Net Loss per Share Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding, plus potentially dilutive common shares. Restricted stock, restricted stock units, stock options and warrants are excluded from the diluted net loss per share calculation when their impact is antidilutive. The Company reported a net loss for the three months ended September 30, 2024 and 2023, and as a result, all potentially dilutive common shares are considered antidilutive for these periods. Potential dilutive common shares issuable consist of the following at: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.72%;box-sizing:content-box;"></td> <td style="width:1.26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.38%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.38%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Stock options </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 23,246 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24,982 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,234,357 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,621,935 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 668,250 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 668,250 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,925,853 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,315,167 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> </tr> </table> Due to their nominal exercise price of $0.0001 per share, a total of 7,721,519 and 8,750,926 outstanding pre-funded warrants as of September 30, 2024 and 2023, respectively are considered common stock equivalents and are included in basic weighted average shares outstanding in the accompanying condensed consolidated statements of operations as of the closing dates of the Company's public equity offerings in January 2023, August 2023, and January 2024, respectively. Income Taxes The Company reported a net loss for the three and nine months ended September 30, 2024 and 2023, however records a tax expense. The nature of this tax expense is the difference between the effective tax rate and statutory rate due to tax provision for a its wholly-owned foreign Myomo Europe, GmbH. Recently Adopted Accounting Standards In September 2022, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2022-04, “Liabilities - Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations”, that requires entities that use supplier finance programs in connection with the purchase of goods and services to disclose the key terms of the programs and information about obligations outstanding at the end of the reporting period, including a rollforward of those obligations. The guidance does not affect the recognition, measurement or financial statement presentation of supplier finance program obligations. The new standard’s requirements to disclose the key terms of the programs and information about obligations outstanding are effective for fiscal years, including interim periods, beginning after December 15, 2022, except for the requirement to disclose a rollforward of obligations outstanding will be effective for fiscal years beginning after December 15, 2023. The Company adopted this new standard on January 1, 2024, which did not have a material impact on its financial position and results of operations. In October 2023, the FASB issued ASU 2023-06, “Disclosure Improvements, Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative”, that adds 14 of the 27 identified disclosure or presentation requirements to the Codification, each amendment in the ASU will only become effective if the SEC removes the related disclosure or presentation from its existing regulations by June 30, 2027. The Company currently complies with these disclosure requirements as applicable under Regulation S-X or Regulation S-K and will adopt these new standards depending on timing of when they become effective, which is not expected to have a material impact on its financial position and results of operations. In November 2023, the FASB issued ASU 2023-07 “Segmented Reporting - Improvements to Reportable Segment Disclosures”, ASU 2023-07 focuses on the requirements to disclose its significant segment expense categories and amounts for each reportable segment. ASU 2023-07 will becoming effective in the calendar year 2024 year-end financial statements. The Company will adopt these new standards when they become effective, which is not expected to have a material impact on its financial position and results of the operation. In December 2023, the FASB issued ASU 2023-09, “Accounting Standards Update, Income Taxes (Topic 740: Improvements to Income Tax Disclosures”. ASU 2023-09 focuses on income tax disclosures around effective tax rates and cash income taxes paid. This amendment in the ASU will become effective for public companies as of December 15, 2024 and effective to all other companies as of December 15, 2025. The Company will adopt these new standards when they become effective, which is not expected to have a material impact on its financial position and results of operations. Interim Financial Statements The accompanying unaudited condensed consolidated financial statements and notes are representations of the Company’s management, who are responsible for their integrity and objectivity. These statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) for interim financial information pursuant to Regulation S-X. Accordingly,

they do not include all of the information and disclosures required by U.S. GAAP for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) that are considered necessary for a fair presentation of the condensed consolidated financial statements of the Company as of September 30, 2024 and for the three and nine months ended September 30, 2024 and 2023. The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the operating results for the fiscal year ending December 31, 2024, or any other period. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and related disclosures of the Company as of December 31, 2023 and 2022 and for the years then ended, included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.

Basis of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary Myomo Europe GmbH. All significant intercompany balances and transactions are eliminated.

Comprehensive Income (Loss)

Comprehensive loss includes all changes in equity during a period, except those resulting from investments by stockholders and distributions to stockholders. The Company's comprehensive loss includes changes in foreign currency translation adjustments and unrealized gains and losses on short term investments. There was a reclassification, which management does not consider to be material, out of accumulated other comprehensive income (loss) to other (income) expense related to realized gains or losses on short-term investments in the three and nine months ended September 30, 2024. There were no reclassifications in the three and nine months ended September 30, 2023.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America require management to make estimates and assumptions that affect certain reported amounts and disclosures. These estimates and assumptions are reviewed on an on-going basis and updated as appropriate. Actual results could differ from these estimates. The Company's significant estimates include deferred tax valuation allowances, valuation of stock-based compensation, warranty obligations and reserves for slow-moving inventory.

Cash, Cash Equivalents and Short-Term Investments

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents consist principally of deposit accounts and money market accounts at September 30, 2024 and December 31, 2023.

The Company considers all investments with an original maturity of greater than three months but less than one year to be short-term investments. There were no short-term investments classified as short-term investments as of September 30, 2024. Short-term investments as of December 31, 2023 consists of commercial paper, U.S. Treasury Bills and short-term corporate debt securities, which were classified as held-to-maturity, and certificates of deposit totaling approximately $1,994,700 as of December 31, 2023. The Company determines the appropriate balance sheet classification of its investments at the time of purchases and evaluates the classification at each balance sheet date.

Under the new lease, the Company's provided a security deposit to the landlord in the form of a letter of credit for $375,000. The Company has collateralized the letter of credit with cash in a separate bank account, which is accounted for as a long-term restricted cash on the condensed consolidated balance sheet as of September 30, 2024.

	September 30, 2024	December 31, 2023
Cash	$ 1,231,871	$ 5,772,131
Money market funds	850,544	4,893,387
Commercial paper		
Cash, cash equivalents, and restricted cash	$ 2,082,415	$ 10,665,518

space:pre-wrap;min-width:fit-content;">— </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 746,048 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Restricted Cash </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 375,000 </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,997,675</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6,871,306 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"> <td style="background-color:#cff0fc;vertical-align:top;"> Short-term investments </td> <td style="background-color:#ffffff;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:#ffffff;vertical-align:bottom;"> </td> <td style="background-color:#ffffff;vertical-align:bottom;"> </td> <td style="background-color:#ffffff;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:#ffffff;vertical-align:bottom;"> </td> <td style="background-color:#ffffff;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> US government agency debt securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,497,099 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 497,563 </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,994,662 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 0199470037500The Company has collateralized the letter of credit with cash in a separate bank account, which is accounted for as a long-term restricted cash on the condensed consolidated balance sheet as of September 30, 2024.   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.72%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.92%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30,
2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31,

</br/>2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Cash, cash equivalents, and restricted cash </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Cash </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">850,544</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,231,871 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,772,131 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,893,387 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 746,048 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Restricted Cash </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 375,000 </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,997,675</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6,871,306 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"> <td style="background-color:#cff0fc;vertical-align:top;"> Short-term investments </td> <td style="background-color:#ffffff;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:#ffffff;vertical-align:bottom;"> </td> <td style="background-color:#ffffff;vertical-align:bottom;"> </td> <td style="background-color:#ffffff;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:#ffffff;vertical-align:bottom;"> </td> <td style="background-color:#ffffff;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> US government agency debt securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,497,099 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-

color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 497,563 </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,994,662 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>850544123187157721314893387074604837500006997675687130601497099497563019946624p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Accounts Receivable and Allowance for Credit Losses The Company reports accounts receivable at invoiced amounts less an allowance for credit losses. The Company evaluates its accounts receivable on a continuous basis and, if necessary, establishes an allowance for credit losses based on a number of factors, including current credit conditions and customer payment history. The Company does not require collateral or accrue interest on accounts receivable and credit terms are generally 30 days. At September 30, 2024, and December 31, 2023, the Company recorded an allowance for credit losses accounts which was immaterial to the condensed consolidated financial statements. Joint Venture On March 28, 2022, the Company invested cash consideration of $199,000 for a 19.9% ownership stake in Jiangxi Myomo Medical Assistive Appliance Co. Ltd. (the "JV Company"), a company headquartered in China that is majority-owned by Beijing Ryzur Medical Investment Co., Ltd. ("Ryzur Medical"). The JV Company will manufacture and sell the Company's current and future products in greater China, including Hong Kong, Macau and Taiwan. The Company accounts for its investment in the JV Company under the equity method because the Company exerts significant influence over its management. The investment was fully written off as of December 31, 2023, due to the recording of the Company's share of the losses of the JV Company in prior periods, which were recorded to other expense (income) in the condensed consolidated statement of operations, the Company has no obligation to fund any losses incurred by the JV Company. 1990000.199 Revenue Recognition The Company accounts for revenue under ASC 606, "Revenue from Contracts with Customers" and all of the related amendments (Topic 606). Revenues under Topic 606 are required to be recognized either at a "point in time" or "over time," depending on the facts and circumstances of the arrangement and are evaluated using a five-step model. Generally, the Company recognizes revenue at a point in time.   The Company recognizes revenue after applying the following five steps: 1) Identification of the contract, or contracts, with a customer, 2) Identification of the performance obligations in the contract, including whether they are distinct within the context of the contract, 3) Determination of the transaction price, including the constraint on variable consideration, 4) Allocation of the transaction price to the performance obligations in the contract, and 5) Recognition of revenue when, or as, performance obligations are satisfied. Revenue is recognized when control of these services is transferred to our customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. Product Revenue Increasingly, the Company derives its revenue from direct billing. The Company also derives revenue from the sale of its products to O&P providers in the United States and internationally and the Veterans Administration ("VA"). Under direct billing, the Company recognizes revenue when all of the following criteria are met: (i) The product has been delivered to the patient, including completion of initial instruction on its use, (ii) Collection is deemed probable and it has been determined that a significant reversal of the revenue to be recognized is not deemed probable when the uncertainty associated with the variable consideration is resolved. As an example, the Company will record revenue if it is notified that insurance intends to pay and a payment amount is provided, and (iii) The amount to be collected is estimable using the "expected value" estimation techniques, or the "most likely amount" as defined in ASC 606. For revenue derived from certain payers, including CMS, where the Company has demonstrated sufficient payment history, the Company recognizes revenue when it receives either a pre-authorization from the payer, or, in the case of Medicare patients, when the Company has gathered appropriate medical documentation from the patient that demonstrates compliance with the Company's inclusion criteria, control passes to the patient upon delivery of the device in an amount that reflects the consideration the Company expects to receive in exchange for the device and the claim has been submitted to the payer. These payers represented 93% and

69% of direct billing channel revenue during the three months ended September 30, 2024 and 2023, respectively. These payers represented 88% and 61% of direct billing channel revenue during the nine months ended September 30, 2024 and September 30, 2023, respectively. During the three months ended September 30, 2024, revenues from patients covered by Medicare Part B were recorded at the time the device was delivered and the claim submitted to CMS for an amount that was expected to be received from CMS and supplemental insurance payers, as applicable. Depending on the timing of product deliveries to customers, which is when cost of revenue must be recorded, and when the Company meets the criteria to record revenue, there may be fluctuations in gross margin. During the three months ended September 30, 2024 and 2023, the Company recognized revenue of approximately $2,440,900 and $1,324,300, respectively, and during the nine months ended September 30, 2024 and 2023, the Company recognized revenue of approximately $2,185,300 and $2,305,500, respectively, from third-party payers for which costs related to the completion of the Company's performance obligations were not recorded in the current period. For revenues derived from O&P providers and the VA, the Company recognizes revenue when control passes to the customer in an amount that reflects the consideration the Company expects to receive in exchange for those services. Revenues may be recognized upon shipment or upon delivery, depending on the terms of the arrangement, provided that persuasive evidence of an arrangement exists, there are no uncertainties regarding customer acceptance and collectability is deemed probable. The Company has elected to record taxes collected from customers on a net basis and does not include tax amounts in revenue or cost of revenue. License Revenue If a license to the Company's intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when the license is transferred to the customer, the customer is able to use and benefit from the license, and collectability is deemed probable. On January 21, 2021, the Company entered into a definitive agreement with Ryzur Medical to form the JV Company to manufacture and sell the Company's current and future products in greater China, including Hong Kong, Macau and Taiwan (the "JV Agreement"). Under the JV Agreement, the Company is entitled to receive an upfront license fee of $2.7 million. As of September 30, 2023, the final portion of the initial license fee has been paid in full and recognized as license revenue. In addition, the Company is entitled to receive a guaranteed minimum payment for purchase of MyoPro Control Units for a period of ten years from the effective date of the JV Agreement. The Company will recognize revenue on these amounts upon invoicing of the JV Company as long as the collectability is deemed to be assured. Contract Balances The timing of revenue recognition may differ from the timing of payment by customers. The Company records a receivable when revenue is recognized prior to payment and there is an unconditional right to payment. Alternatively, when payment precedes the provision of the related services, the Company records deferred revenue until the performance obligations are satisfied. The Company had approximately $32,000of deferred revenue as of September 30, 2024, and approximately $8,500 of deferred revenue as of December 31, 2023, the outstanding deferred revenue is expected to be recognized by the end of the fourth quarter of 2024.</p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Disaggregated Revenue from Contracts with Customers</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table presents revenue by major source:</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:78.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:40.718%;box-sizing:content-box;"></td><td style="width:1.282%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.743%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.282%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.743%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.282%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.026%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.282%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.641%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">For the Three Months
Ended September 30,</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">For the Nine Months
Ended September 30,</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Direct to patient</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,431,751 </td><td style="white-

space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,501,958</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,491,584 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,245,345</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Clinical/Medical providers</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,775,835</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,527,565</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,991,158 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,474,510</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">License revenue</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,764,920</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total revenue from contracts with customers</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 9,207,586 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,079,523</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 20,482,742 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 14,484,775 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Geographic Data The Company generated 88% of its total revenue from the United States and 12% from Germany for the three months ended September 30, 2024. The Company generated 78% of its total revenue from the United States, 19<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New

Roman;min-width:fit-content;">% from China and 3% from Germany for the three months ended September 30, 2023,   During the nine months ended September 30, 2024, the Company generated 85% of its total revenues from the United States, 14% from Germany and 1% from other international locations. During the nine months ended September 30, 2023, the Company generated 72% of its total revenues from the United States, 14% from Germany, 13% from China, and 1% from other international locations. Excluding license revenue during the nine months ended September 30, 2023, the Company generated 82% of its product revenues from the United States, 16% from Germany and 2% from other international locations. Cost of Revenue In conjunction with the adoption of ASC 606, there are certain cases in which the Company will expense costs when incurred as required by ASC 340-40-25. In certain cases, the Company ships the MyoPro device to O&P providers, or provides the device directly to patients, pending reimbursement from third-party payers, after which revenue is recognized. For the three and nine months ended September 30, 2024, the Company recorded cost of goods sold of approximately $107,200 and $140,800, respectively, without corresponding revenue. For the three and nine months ended September 30, 2023, the Company recorded cost of goods sold of $32,800 and $76,900, respectively, without corresponding revenue. Direct billing fees paid to O&P providers for services they provide in conjunction with patient evaluations are expensed as incurred as required by ASC 340-40-25, as a cost of obtaining a contract. These costs are recorded as sales and marketing expense. Internal costs incurred and fees paid to O&P providers to measure, fit and deliver the device to patients are expensed to cost of revenue. </p>0.930.690.880.61244090013243002185300230550027000003200085 00<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table presents revenue by major source:</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:78.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:40.718%;box-sizing:content-box;"></td> <td style="width:1.282%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.743%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.282%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.743%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.282%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.026%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.282%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.641%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> <p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">For the Three Months
Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> <p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> <p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">For the Nine Months
Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> <p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> <p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"> <p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> <p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> <p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"> <p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> <p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> <p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"> <p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> <p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> <p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"> <p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> <p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> <p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Direct to patient</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,431,751 </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,501,958</p></td> <td style="white-space:nowrap;vertical-align:bottom;"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,491,584 </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">   </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,245,345 </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> <p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;">Clinical/Medical providers </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,775,835 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,527,565 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,991,158</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,474,510 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> License revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,764,920 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total revenue from contracts with customers </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,207,586</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,079,523 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">20,482,742</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14,484,775 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>7431751350195815491584924534517758351527565499115834745100500000176492092075865079523204827421448477508.880.120.780.190.030.850.140.010.720.14
style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Advertising The Company charges the costs of advertising to operating expenses as incurred. Advertising expense amounted to approximately $1,043,700 and $822,500 for the three months ended September 30, 2024 and 2023, respectively, and approximately $2,680,600 and $2,360,400 during the nine months ended September 30, 2024 and 2023, respectively. 1043700822500268006002360400 Foreign Currency Translation The functional currency of the Company's foreign subsidiary, Myomo Europe GmbH, is the Euro. Foreign exchange translation gains and losses from the Euro to U.S. dollars are included in other comprehensive (loss) gain. The Company recorded a gain of approximately $256,400 and a loss of approximately $47,100 during the three months ended September 30, 2024 and 2023, respectively, and a gain of approximately $312,000 and a loss of approximately $50,500 during the nine months ended September 30, 2024 and 2023, respectively, which are included in accumulated other comprehensive income in the condensed consolidated balance sheet. Transaction and translation foreign exchange gains and losses from a foreign currency to the functional currency are included in cost of goods sold in the consolidated statements of operations. Such amounts

were immaterial for the three and nine months ended September 30, 2024 and 2023, respectively. The balance sheet is translated using the spot rate on the day of reporting and the statement of operations is translated monthly using the average rate for the month. 2564004710031200050500 Net Loss per Share Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding, plus potentially dilutive common shares. Restricted stock, restricted stock units, stock options and warrants are excluded from the diluted net loss per share calculation when their impact is antidilutive. The Company reported a net loss for the three months ended September 30, 2024 and 2023, and as a result, all potentially dilutive common shares are considered antidilutive for these periods. Potential dilutive common shares issuable consist of the following at: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.72%;box-sizing:content-box;"></td><td style="width:1.26%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:13.38%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.26%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:13.38%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Stock options </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 23,246 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24,982 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Restricted stock units </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,234,357 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,621,935 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Other warrants </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 668,250 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 668,250 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Total </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,925,853 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,315,167 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td></tr></table> Due to their nominal exercise price of $0.0001 per share, a total of 7,721,519 and 8,750,926outstanding pre-funded warrants as of September 30, 2024 and 2023, respectively are considered common stock equivalents and are included in basic weighted average shares outstanding in the accompanying condensed consolidated statements of operations as of the closing dates of the Company's public equity offerings in January 2023, August 2023, and January 2024, respectively. Income Taxes The Company reported a net loss for the three and nine months ended September 30, 2024 and 2023, however records a tax expense. The nature of this tax expense is the difference between the effective tax rate and statutory rate due to tax provision for a its wholly-owned foreign Myomo Europe, GmbH. <p style="font-size:10pt;margin-

top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Potential dilutive common shares issuable consist of the following at: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.72%;box-sizing:content-box;"></td> <td style="width:1.26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.38%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.38%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Stock options </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 23,246 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24,982 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,234,357 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,621,935 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 668,250 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 668,250 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,925,853 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,315,167 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>232462498212343571621935668250668250192585323151670.000177215198750926 Income Taxes The Company reported a net loss for the three and nine months ended September 30, 2024 and 2023, however records a tax expense. The nature of this tax expense is the difference between the effective tax rate and statutory rate due to tax provision for a its wholly-owned foreign Myomo Europe, GmbH. Recently Adopted Accounting Standards In September 2022, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2022-04, "Liabilities - Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations", that requires entities that use supplier finance programs in connection with the purchase of goods and services to disclose the key terms of the programs and information about obligations outstanding at the end of the reporting period, including a rollforward of those obligations. The guidance does not affect the recognition, measurement or financial statement presentation of supplier finance program obligations. The new standard's requirements to disclose the key terms of the programs and information about obligations outstanding are effective for fiscal years, including interim periods, beginning after December 15, 2022, except for the requirement to disclose a rollforward of obligations outstanding will be effective for fiscal years beginning after December 15, 2023. The Company adopted this new standard on January 1, 2024, which did not have a material impact on its financial position and results of operations. In October 2023, the FASB issued ASU 2023-06, "Disclosure Improvements, Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative", that adds 14 of the 27 identified disclosure or presentation requirements to the Codification, each amendment in the ASU will only become effective if the SEC removes the related disclosure or presentation from its existing regulations by June 30, 2027. The Company currently complies with these disclosure requirements as applicable under Regulation S-X or Regulation S-K and will adopt these new standards depending on timing of when they become effective, which is not expected to have a material impact on its financial position and results of operations. In November 2023, the FASB issued ASU 2023-07 "Segmented Reporting - Improvements to Reportable Segment Disclosures". ASU 2023-07 focuses on the requirements to disclose its significant segment expense categories and amounts for each reportable segment. ASU 2023-07 will becoming effective in the calendar year 2024 year-end financial statements. The Company will adopt these new standards when they become effective, which is not expected to have a material impact on its financial

position and results of the operation. In December 2023, the FASB issued ASU 2023-09, “Accounting Standards Update, Income Taxes (Topic 740: Improvements to Income Tax Disclosures”. ASU 2023-09 focuses on income tax disclosures around effective tax rates and cash income taxes paid. This amendment in the ASU will become effective for public companies as of December 15, 2024 and effective to all other companies as of December 15, 2025. The Company will adopt these new standards when they become effective, which is not expected to have a material impact on its financial position and results of operations. Note 4 — Inventories Inventories consist of the following at: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.72%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30,
2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31,
2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word,"> <td style="white-space:pre-wrap;vertical-align:top,"> Finished goods </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom,"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,367,375</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 321,484 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word,"> <td style="white-space:pre-wrap;vertical-align:top;"> Work in process </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center,"> 74,859 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,589 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word,"> <td style="white-space:pre-wrap;vertical-align:top,"> Parts and subassemblies </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,941,279 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,475,434 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Inventories, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,383,513</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,803,507 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Inventories consist of the following at: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.72%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30,
2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31,
2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word,"> <td style="white-space:pre-wrap;vertical-align:top,"> Finished goods </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom,"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,367,375 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;">

</td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">321,484</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Work in process</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">74,859</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,589</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Parts and subassemblies</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,941,279</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,475,434</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Inventories, net</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,383,513 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,803,507 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table>13673753214847485965891941279147543433835131803507 Note 5 — Fair Value of Financial Instruments The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820, “Fair Value Measurement” (“ASC 820”), which defines fair value, establishes a framework for measuring fair value, and establishes disclosures about fair value measurements. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: • Level 1 — Quoted prices available in active markets for identical assets or liabilities. • Level 2 — Observable inputs other than quoted prices included in Level 1, such as quotable prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. • Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use significant unobservable inputs. The carrying amounts of the Company’s financial instruments such as cash and cash equivalents, accounts receivable and accounts payable, approximate fair value due to the short-term nature of these instruments. Cash equivalents consist of money market funds that limit their investments to only short-term U.S. Treasury Securities and repurchase agreements related to these securities. Short-term investments primarily consists of commercial paper and U.S. Treasury Bills and are carried on the condensed consolidated balance sheets at amortized cost which approximates fair value. Cash equivalents measured at fair value on a recurring basis at September 30, 2024 were as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.07%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> In Active
Markets for
Identical Assets
or Liabilities
(Level 1) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Significant
Other
Observable
Inputs
(Level 2) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Significant
Unobservable
Inputs
(Level 3) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Cash equivalents </td> <td style="vertical-align:top;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,772,131</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,772,131</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,772,131 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,772,131 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Cash equivalents and short-term investments measured at fair value on a recurring basis at December 31, 2023 were as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.98%;box-sizing:content-box;"></td> <td style="width:1.299%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.176%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.419%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.176%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.299%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.176%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.299%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.176%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> In Active
Markets for
Identical Assets
or Liabilities
(Level 1) </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Significant
Other
Observable
Inputs
(Level 2) </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Significant
Unobservable
Inputs
(Level 3) </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Total </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,893,387 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span style="color:#000000;min-width:fit-

content;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,893,387</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Commercial paper</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">746,762</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">746,762</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Short-term investments</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,994,662</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,994,662 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> Cash equivalents measured at fair value on a recurring basis at September 30, 2024 were as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"> <td style="width:50.07%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> In Active
Markets for
Identical Assets
or Liabilities
(Level 1) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Significant
Other
Observable
Inputs
(Level 2) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Significant
Unobservable
Inputs
(Level 3) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Cash equivalents </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;"> </td> <td style="vertical-align:top;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,772,131</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,772,131</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,772,131 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cash equivalents and short-term investments measured at fair value on a recurring basis at December 31, 2023 were as follows:</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.98%;box-sizing:content-box;"></td> <td style="width:1.299%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.176%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.419%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.176%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.299%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.176%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.299%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.176%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">In Active
Markets for
Identical Assets
or Liabilities
(Level 1)</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Significant
Other
Observable
Inputs
(Level 2)</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Significant
Unobservable
Inputs
(Level 3)</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Total</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Money market funds</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,893,387 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,772,131 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table>

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 746,762 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Short-term investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,994,662 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 746,762 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr></table>577213157721315772131577213148933874893387467627467621994662 1994662 Note6 — Accounts Payable and Other Accrued Expenses Accounts Payable and Other Accrued Expenses consists of the following at: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.72%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30,
2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31,
2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Trade payables </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,301,550</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,073,405 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued compensation and benefits </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,598,932 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,964,487 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued insurance </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 240,575 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="color:#000000;white-space:pre-wrap;min-width:fit-

*content;">95,680 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued professional services </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 54,533 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 52,202 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Warranty reserve </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 159,531 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 231,108 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Customer deposits </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,857,565 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,114,979 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 235,390 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 354,083 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,448,076</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,885,944 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Accounts Payable and Other Accrued Expenses consists of the following at: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.72%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30,
2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31,
2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Trade payables </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,301,550</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,073,405 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued compensation and benefits </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,598,932 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-*

space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,964,487 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued insurance </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 240,575 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 95,680 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued professional services </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 54,533 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 52,202 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Warranty reserve </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 159,531 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 231,108 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Customer deposits </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,857,565 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,114,979 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 235,390 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 354,083 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,448,076</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,885,944 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>13015501073405259893219644872405759568054533522021595312311108185756511149792353903540836448076485944 Note 7 — Line of Credit On July 11, 2024 (the “Effective Date”), the Company, entered into a Loan and Security Agreement (the “Loan Agreement”) with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (the “Bank”). The Loan Agreement provides for a revolving line of credit whereby the Company may borrow up to $4,000,000 (the “Revolving Line”), which Revolving Line may be increased to $5,500,000 at the Bank’s sole discretion upon the occurrence of certain events. Amounts advanced by the Bank are based on 80% of “eligible accounts”, which includes all receivables in the United States, reduced by aged amounts and customers and insurance payers with concentrations in excess of defined limits, among other deductions. The outstanding principal amount of any advance shall accrue interest at a floating rate per annum equal to the greater of (i) 8.50% and (ii) the “prime rate” as published in The Wall Street Journal for the relevant period plus one-half percent (0.50%). The Revolving Line is secured on a first priority basis by all of Company’s assets other than intellectual property and certain customary exceptions. Any newly formed or acquired subsidiary of the Company or any guarantor under the Loan Agreement, will either join the Loan Agreement as a co-borrower or become a guarantor under the Loan Agreement. As determined by the Bank in its sole discretion, The

Company intends to use the Revolving Line for working capital and general business purposes. The Revolving Line terminates, and any outstanding principal amount of all advances made thereunder, and any accrued and unpaid interest thereon, become immediately due and payable on the two year anniversary of the Effective Date. The Company must also pay Bank (i) a commitment fee of $20,000, (ii) an "Anniversary Fee" of 0.50% of the Revolving Line and (iii) an "Unused Revolving Line Facility Fee" of 0.50% per annum of the average unused portion of the Revolving Line. In addition, upon termination of the Loan Agreement or the Revolving Line prior to the two year anniversary of the Effective Date, the Company must pay a termination fee of 1.00% of the Revolving Line, subject to certain exceptions. The Company recorded approximately $199,500 in debt issuance costs during the nine months ended September 30, 2024 in conjunction with entering into the Loan Agreement, which includes the commitment fee and the Anniversary Fee. The Company capitalized the debt issuance costs and is amortizing them on a straight-line basis into interest expense over the term of the Loan Agreement. Debt issuance costs to be amortized over the term of the loan are included in other long-term assets. Approximately $0.9 million was available to be drawn under the Loan Agreement as of September 30, 2024. No amounts were drawn under the Loan Agreement as of September 30, 2024.
4000000055000000.800.0850.005200000.0050.0050.01199500900000 Note 8 — Common Stock and Warrants On January 17, 2023, the Company completed a public equity offering, selling 13,169,074 shares of common stock and 6,830,926 pre-funded warrants at $0.325 per share or at $0.3249 per warrant, generating proceeds after fees and expenses of approximately $5.7 million. As of September 30, 2024, 5,801,519 pre-funded warrants remain exercisable. Each pre-funded warrant is exercisable for one share of the Company's common stock at a nominal exercise price of $0.0001 per share.
On August 29, 2023, the Company completed a public equity offering, selling 5,413,334 shares of common stock and 1,920,000 pre-funded warrants at $0.60 per share, or at $0.5999 per warrant, generating proceeds after fees and expenses of approximately $3.9 million. Each pre-funded warrant is exercisable for one share of the Company's common stock at a nominal exercise price of $0.0001 per share. All of these pre-funded warrants remain exercisable at September 30, 2024. On January 19, 2024, the Company completed a registered direct equity offering, selling 1,354,218 shares of common stock and 224,730 pre-funded warrants at $3.80 per share, or at $3.7999 per pre-funded warrant, generating proceeds after fees and expenses of approximately $5.4 million. Each pre-funded warrant is exercisable for one share of the Company's common stock at a nominal exercise price of $0.0001 per share. All of these pre-funded warrants were exercised during the nine months ended September 30, 2024.   As of September 30, 2024 there were 7,721,519 pre-funded warrants outstanding.   On August 2, 2022, the Company entered into an ATM Facility with Alliance Global Partners on ("AGP"). Under the ATM Facility, the Company may sell up to an aggregate of $15 million of the Company's common stock from time to time and shall pay to AGP cash commissions of 3.0% of the gross proceeds of sales of common stock under the ATM Facility. There were no sales under the ATM Facility during the three and nine months ended September 30, 2024 and 2023, respectively. In conjunction with the public equity offering in August 2023, the Company reduced the amount available to sell under the ATM Facility to $1,000. In May 2024, the ATM Facility expired and has not been renewed.
  No shares of common stock were issued through the exercise of stock options during the three and nine months ended September 30, 2024 and September 30, 2023, respectively. During the three and nine months ended September 30, 2024, 42,828 and 980,173 restricted stock units vested, respectively. During the three and nine months ended September 30, 2023, 10,099 and 199,163 restricted stock units vested, respectively.
131690746830926O.3250.32495700000580151900.000154133341920000O.60.599939000000.000113542182247303.83.799954000000.000177215191500000000.0300001000 <span style="color:#000000;white-space:pre-wrap;font-

weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 9 — Stock Award Plans and Stock-Based Compensation As of September 30, 2024, there were 491,770 shares available for issuance under the Myomo, Inc. 2018 Stock Option and Incentive Plan (the "2018 Plan"), On January 1 of each year, the number of shares of common stock reserved and available for issuance under the 2018 Plan will cumulatively increase by 4% of the number shares of common stock outstanding on the immediately preceding December 31 or such lesser number of shares of common stock determined by management in consultation with members of the Board of Directors, including the compensation committee of the Board of Directors. On January 1, 2024, 1,085,401 shares were added to the share reserve under the 2018 Plan. Recipients of awards of restricted stock units typically sell shares in the open market to cover their individual tax liabilities and remit the proceeds to the Company, which offsets withholding taxes paid by the Company. In certain circumstances, stock awards may be net share settled upon vesting to cover the required employee statutory withholding taxes and the remaining amount is converted into shares based upon their share-value on the date the award vests. In such instances, these payments of employee withholding taxes are presented in the statements of cash flows as a financing activity. There were no stock awards that were net share settled during the three and nine months ended September 30, 2024. There were no restricted stock units that were withheld as part of net share settlement transactions during the three months ended September 30, 2023 and 16,744 restricted stock units were withheld during the nine months ended September 30, 2023. Share-Based Compensation Expense The Company accounts for stock awards to employees and non-employees based upon the fair value of the award on the date of grant. The fair value of that award is then ratably recognized as expense over the period during which the recipient is required to provide services in exchange for that award. The Company attributes the value of stock-based compensation to operations on the straight-line method such that the expense associated with awards is evenly recognized over the vesting period. The Company recognized stock-based compensation expense related to the issuance of stock option awards and restricted stock units to employees, non-employees and directors in the statements of operations as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:77.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:41.563%;box-sizing:content-box;"></td><td style="width:1.259%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.235000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.259%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.235000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.259%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.416%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.259%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.516%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;text-align:left;"> For the Three Months Ended </td><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;text-align:left;"> For the Nine Months Ended </td><td style="vertical-align:bottom;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Cost of goods sold </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">22,805</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24,222 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> <span style="color:#000000;min-width:fit-

content;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">35,601</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 66,815 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 30,599 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11,362 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 63,562 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (24,056 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Selling, clinical and marketing </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 41,925 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50,984 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 95,237 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 142,432 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> General and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 228,856 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 243,826 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 358,180 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 596,322 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">324,185</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 330,394 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">552,580</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 781,513 </td> <td style="white-space:nowrap;vertical-

align:bottom;border-bottom:2.25pt double #fffff03;"> </td> </tr> </table> As of September 30, 2024, there was approximately $9,200 of unrecognized compensation cost related to unvested stock options that is expected to be recognized over a weighted-average period of 0.79 years. As of September 30, 2024, there was approximately $2,511,100 of unrecognized compensation expense related to unvested restricted stock units that is expected to be recognized over a weighted-average period of 2.50 years.</p>4917700.041085401016744<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company recognized stock-based compensation expense related to the issuance of stock option awards and restricted stock units to employees, non-employees and directors in the statements of operations as follows:</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:77.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:41.563%;box-sizing:content-box;"></td> <td style="width:1.259%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.235000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.259%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.235000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.259%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.416%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.259%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.516%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#fffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">For the Three Months Ended</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">For the Nine Months Ended</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#fffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#fffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cost of goods sold</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 22,805 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">24,222</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35,601 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 66,815 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#fffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 30,599 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11,362 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:right;">63,562 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (24,056 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Selling, clinical and marketing </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 41,925 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50,984 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 95,237 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 142,432 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> General and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 228,856 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 243,826 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 358,180 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 596,322 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">324,185</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 330,394 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">552,580</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 781,513 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>228052422235601668153059911362635622405641925509849523714243222885624382635818059632232418533039455258078151392000P0Y9M14D2511100P2Y6M Note 10 — Commitments and Contingencies Litigation The Company may be involved from time to time in legal proceedings, claims and assessments arising from the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. During 2022, a former employee who was terminated in 2021 brought an age discrimination claim against the Company. During the fourth quarter of 2023, the Company settled the claim with the former employee. The Company deemed it probable that its insurance company would pay its share of the claim. As a result of this assumed gain contingency, the Company reduced its accrual to an amount that is not expected to be covered by insurance, and recorded a liability of approximately $55,000 for severance and legal expenses as of December 31, 2023. The settlement was paid and all insurance proceeds were received during the three months ended March 31, 2024. There is no other material litigation against the Company at this time. Operating Leases The Company has a non-cancelable sublease agreement for its corporate headquarters in Boston, Massachusetts, which expires in January 2025 and a lease agreement for office space in Fort Worth, TX. which expires in December 2025. In August 2024, the Company entered into a new lease agreement for its new corporate headquarters and manufacturing facility in Burlington, Massachusetts, which the Company expects to begin occupying by the end of 2024, with a term of approximately <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New

Roman;min-width:fit-content;">88 months following the rent commencement date. The Company has the option to extend the new lease for an additional five years, subject to certain conditions being satisfied. Under the new lease, the Company provided a security deposit to the landlord in the form of a letter of credit for $375,000. The Company has collateralized the letter of credit with cash in a separate bank account, which is accounted for as long-term restricted cash on the condensed consolidated balance sheet. Termination options are either not included, or have expired, for the Company's other existing operating leases. Certain arrangements have discounted rent periods or escalating rent payment provisions. Leases with an initial term of twelve months or less are not recorded on the condensed consolidated balance sheets. We recognize rent expense on a straight-line basis over the lease term. As of September 30, 2024, operating lease assets were approximately $467,000. The amount and the maturity of the Company's operating lease liabilities as of September 30, 2024, are as follows:

  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.95%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:9.962%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:9.962%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:9.962%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.563%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2024 </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">144,610</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2025</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">102,841</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2026</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2027</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Thereafter</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Less: Imputed interest</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Present value of lease liabilities</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$ </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr></table>

</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"> Total future minimum lease payments </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 247,451 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Less imputed interest </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 12,822 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"> Total operating lease liabilities </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 234,629 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> Included in the condensed consolidated balance sheet: </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Current operating lease liabilities </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 29,165 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Total operating lease liabilities </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">234,629</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><div style="font-size:11pt;font-family:'Calibri',sans-serif,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">For the three and nine months ended September 30, 2024 and 2023, the total lease cost is comprised of the following amounts: </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.95%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.962%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.962%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.962%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.563%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">For the Three Months
Ended September 30,</p></td> <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">For the Nine Months
Ended September 30,</p></td> <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Operating lease expense</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 87,836 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">263,506</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 367,613 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Short-term lease expense </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"> 1,615 </td> <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,884 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Total lease expense </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">89,451</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 116,314 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">268,390</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 367,613 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The following summarizes additional information related to operating leases: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.95%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:9.962%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:9.902%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.362%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.022%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Weighted-average remaining lease term (in years) </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.54 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.20 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Weighted-average discount rate </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 23.3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 23.3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> </table> Major Customers For the three and nine months ended September 30, 2024 and 2023, there were no customers which accounted for more than 10% of product revenues. For the three and nine months ended September 30, 2024 and 2023, a U.S. insurance payer represented 19% and 22% and 36% and 40% of product revenues, respectively. For the three and nine months ended September 30, 2024, patients with Medicare Part B coverage represented 55% and 44% of product revenues, respectively. For the three and nine months ended September 30, 2024, approximately <span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-

content;">24% and 27% of the Company's product revenues, respectively, were derived from patients with Medicare Advantage insurance plans. For the three and nine months ended September 30, 2023, approximately 59% and 59% of the Company's product revenues were derived from patients with Medicare advantage plans, respectively.   At September 30, 2024 and December 31, 2023, one insurance payer and its affiliates accounted for approximately 25% and 56% of accounts receivable, respectively. Supplier Finance Program Obligations The Company finances its Directors and Officers Insurance policy, which requires the Company to make a down payment, followed by equal payments over a defined term. During the year ended December 31, 2023, the Company completed its payment obligation associated with its 2022-2023 policy and entered into a new policy covering the twelve-month period ending June 2024. Under this financing arrangement, the Company made a down payment of approximately $29,000 during the three months ended June 30, 2023 and made nine equal monthly payments of approximately $27,000, starting in July 2023. During the nine months ended September 30, 2024, the Company completed its payment obligation associated with its 2023-2024 policy and entered into a new policy covering the twelve-month period ending June 2025. Under this new financing arrangement, the Company made a down payment of approximately $39,000 during the three months ended June 30,   2024, and is making nine equal monthly payments of approximately $39,000, starting in July 2024. Changes in the Company's supplier finance obligations were as follows: </p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.311%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.624%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.624%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">For the Nine Months Ended September 30,</p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance January 1</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 142,217 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 56,603 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Increase </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 128,692 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Expensed </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (80,109 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (132,988 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance March 31, </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span

style="white-space:pre-wrap;min-width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">62,108</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 52,307 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#fffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Increase </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 349,909 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 375,824 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Expensed </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (78,593 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (155,076 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance June 30, </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">333,424</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 273,055 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Increase </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 63,478 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 29,809 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#fffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Expensed </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (121,512 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (80,538 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance September 30, </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">275,390</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 222,326 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> No assets are pledged as security under this arrangement. 55000The Company has a non-cancelable sublease agreement for its corporate headquarters in Boston, Massachusetts, which expires in January 2025 and a lease agreement for office space in Fort Worth, TX, which expires in December 2025. In August 2024, the Company entered into a new lease agreement for its new corporate headquarters and manufacturing facility in Burlington, Massachusetts, which the Company expects to begin occupying by the end of 2024, with a term of approximately 88 months following the rent commencement date. The Company has the option to extend the new lease for an additional five years, subject to certain conditions being satisfied. Under the new lease, the Company provided a security deposit to the landlord in the form of a letter of credit for $375,000. The Company has collateralized the letter of credit with cash in a separate bank account, which is accounted for as long-term restricted cash on the condensed consolidated balance sheet. Termination options are either not included, or have expired, for the Company's other existing operating leases. Certain arrangements have discounted rent periods or escalating rent payment provisions. Leases with an initial term of twelve months or less are not recorded on the condensed consolidated balance sheets. We recognize rent expense on a straight-line basis over the lease term.P88MThe Company has the option to extend the new lease for an additional five years, subject to certain conditions being satisfied.375000467000The amount and the maturity of the Company's operating lease liabilities as of September 30, 2024, are as follows: <table style="margin-left:auto;border-spacing:0;table-

layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.95%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:9.962%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:9.962%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:9.962%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2024 </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 144,610 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2025 </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 102,841 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> 2026 </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> 2027 </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Thereafter </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"> Total future minimum lease payments </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 247,451 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Less imputed interest </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:middle

sizing:content-box;"></td> <td style="width:7.962%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.962%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.563%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:top;"> </td> <td colspan="6" style="vertical-align:middle;text-align:left;"> For the Three Months
Ended September 30, </td> <td style="vertical-align:middle;text-align:left;"> </td> <td style="vertical-align:top;"> </td> <td colspan="6" style="vertical-align:middle;text-align:left;"> For the Nine Months
Ended September 30, </td> <td style="vertical-align:middle;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Operating lease expense </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">87,836</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 116,314 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">263,506</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 367,613 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Short-term lease expense </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"> 1,615 </td> <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Total lease expense </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">89,451</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 116,314 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">268,390</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td>

<td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 367,613 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>878361163142635063676131615048840894511163142683903676l3 The following summarizes additional information related to operating leases: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.95%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:9.962%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:9.902%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.362%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.022%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Weighted-average remaining lease term (in years) </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.54 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.20 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Weighted-average discount rate </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 23.3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 23.3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr>
</table>P0Y6M14DP1Y2M12D0.2330.23300000.190.220.360.400.550.440.240.270.590.59110.250.562900027000390003900039000Changes in the Company's supplier finance obligations were as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.311%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.624%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.624%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> For the Nine Months Ended September 30, </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance January 1 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">142,217</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 56,603 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Increase </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td

style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 128,692 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Expensed </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (132,988 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance March 31, </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">62,108</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 52,307 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Increase </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 349,909 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 375,824 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Expensed </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (78,593 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (155,076 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance June 30, </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">333,424</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 273,055 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Increase </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 63,478 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 29,809 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Expensed </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (121,512 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (80,538 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance September 30, </td> <td style="white-space:pre-wrap;vertical-align:top;"> <span

style="white-space:pre-wrap;min-width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">275,390</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 222,326 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table>14221756603012869 2-80109-132988621085230734990937582 4-78593-155076333424273055634782980 9-121512-805382753902223 26falsefalsefalsefalse